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ABSTRACT
Type 1 interferons (IFN-a/ps), are innate cytokines possessing important 
immunomodulatory and effector roles in the innate and adaptive response. They are 
transiently induced to very high levels during the initial stages of many viral 
infections. However, regulation of IFN-a/p production during persistent viral 
infections is not well understood. This project aimed to address these issues using the 
murine lymphocytic choriomeningitis virus (LCMV) infection model.
Initial objectives were to develop assays that would allow characterisation of the 
IFN-a/p response during chronic LCMV infection in vivo and in vitro. Cell-based 
reporter gene assays were developed to measure EFN-a/p activity, along with a series 
o f real-time quantitative reverse-transcriptase polymerase chain reaction assays to 
detect mRNA transcripts of IFN-a/p, and their utility was evaluated.
Analysis of IFN-a/p production during acute and chronic LCMV infection indicated 
that there was an early burst of IFN production following infection, but only a low 
level of IFN-a/p production could be detected during the chronic phase o f LCMV 
infection despite ongoing viral replication. Persistently-infected mice exhibited 
reduced numbers of splenic CD1 lc+ plasmacytoid dendritic cells (DC). These animals 
were able to produce IFN-a/p in response toll-like-receptor (TLR) stimuli. Inoculation 
of influenza virus elicited less IFN-a/p production than was observed in uninfected 
mice, but this may have been due to impairment of influenza virus replication in 
persistently-infected mice.
In vitro LCMV infection of DC and fibroblast cell lines induced very little IFN-a/p 
production. Persistently-infected animals made normal IFN-a/p responses to TLR 
ligands but produced lower levels of IFN-a/p upon infection with Sendai virus than 
uninfected cells.
There are several pathways by which IFN-a/p can be induced. These results suggest 
that the intracellular response to RNA viruses may be impaired in LCMV-infected 
cells, although persistently-infected cells still retain some capacity to respond to 
external TLR stimuli.
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Glossary of abbreviations used in the text
pi microlitres
pm microgram
2’5’ OAS 2,5’ oligoadenylate synthetase
AP-1 Activator protein 1
APC Allophycocyanin
APCs Antigen presenting cells
BHK Baby hamster kidney
BM-DC Bone marrow derived dendritic cells
BVDV Bovine diarrhoea virus
C Cytoseine
CARD N-terminal caspase recruiting domian
CARDIF CARD adaptor inducing IFN-P
CAT Chloramphenicol acetyl transferase
CBA Cytokine Bead Array
cds Coding sequence
CNS Central nervous system
cpm Counts per minute
Ct Threshold cycle
CTL Cytotoxic T lymphocyte
Cy5 Cytochrome 5
DC Dendritic cell
DMEM Dulbecco’s modified Eagle’s medium
DNA Deoxyribonucleic acid
dsRNA Double-stranded ribonucleic acid
EBV Epstein-Barr virus
ELISA Enzyme-linked immunosorbant assay
EMCV Encephelomyocarditis virus
FACS Fluorescence activated cell sorter
FAM 6-carboxyfluorescein
FITC Fluorescein isothiocyanate
Flu Influenza PR8
G Guanine
GAS y activated sequence
GFP Green fluorescent proterin
GM-CSF Granulocyte-macrophage colony stimulating factor
GP LCMV surface glycoprotein
GP-C Glycooprotein precursor
HA Haemagglutinin
HBV Hepatitis B virus
HCV Hepatitis C virus
HIV Human immunodeficiency virus
HPRT Hypoxan thine ribosyl-transferase
HPV Human papilloma virus
hsp Heat shock protein
HSV Herpes simplex virus
i.c Intra-cranial
i.p. Intra-peritoneal
i.v. Intra-venous
ICSP IFN consensus sequence binding protein
IFN Interferon
IFN-R Type 1 IFN receptor
IFN-R Type 1 IFN receptor
IFN-a Interferon alpha
IFN-a/p Type 1 interferons
IFN-P Interferon beta
IFN-y Interferon gamma
Ig Immunoglobulin
IGR Intergenic region
IL Interleukin
IPS-1 IFN-P-promoter-stimulator
IRF Interferon transcription factor
ISG Interferon stimulated gene
ISRE IFN-stimulated response element
JAK Janus kinase
k/o Knock-out
LCMV Lymphocytic choriomeningitis virus
LCMV Arm Lymphocytic choriomeningitis virus Armstrong strain
LCMV Cl 13 Lymphocytic choriomeningitis virus Armstrong Clone 1 13 isolate
LCMV Docile Lymphocytic choriomeningitis virus Docile strain
LPS Lipopolysaccharide
Luc luciferase
M mole
m.o.i. Multiplicity of infection
mAb Monoclonal antibody
MAP Mitogen activated protein
MAVS Mitochondrial antiviral signalling molecule
MCMV Murine cytomegalovirus
MDA5 Melanoma differentiation associated gene 5
MEM Modified Eagles medium
MGB Major groove binder
MHC Multiple histocompatability complex
min(s) Minute(s)
ml millilitres
mM Micromole
MyD88 Myeloid differentiation marker 88
N.U Neutralizing units
NDV Newcastle disease virus
NF-kP Nuclear factor kP
NK cells Natural killer cells
NKT Natural killer T-cells
NOD Nucleotide oligomerization domain
NP Nucleoprotein
nt nucleotide
p.f.u. Plaque forming units
PCR Polymerase chain reaction
PD-1 Pregrammed death-1 receptor
PE Phycoerythrin
PML Promyelocytic leukaemia protein
PolylC Polyinosinic acid: Polycytidylic acid
PRD Positive regulatory domain
PRR Pattern recognition receptor
R848 Resiquimod
RIG-I Retinoic acid inducible gene I
RNA Ribonucleic acid
RNase Ribonuclease
rpm Revolutions per minute
RPMI Roswell Park Memorial Institute
RTqPCR One step revese transcriptase quantitative polymerase chain reaction
RT-PCR Reverse transcriptase polymerase chain reaction
SOCS Suppressor of cytokine signalling
SPF Specified pathogen free
ssRNA Single-stranded ribonucleic acid
STAT Signal transducer and activator of transcription
TAK TGF-P activated kinase
TAMRA 6 - c a r b o x y - N ,N ,N  ’ ,N ’ ,-tetramethylrhodamine
TANK TRAF-associated NF-k|3 activator
TBK-1 TANK binding kinase-1
TCR T-cell receptor
TGF-p Transforming growth factor-p
Th T helper
TIR TLrAl -1 receptor
TLR Toll-like receptor
TNF Tumour necrosis factor
TRIF/TICAM-1 TIR-domain containing adaptor-inducing IFN
U Units of biological activity
UV Ultraviolet
VRE Viral recognition element
VSV Vesicular stomatitis virus
VZV Varicella zoster virus
CHAPTER 1
INTRODUCTION
1.1 Overview of immune activation in response to infection
Humans and other vertebrates are exposed from birth to a sustained barrage of 
organisms that pose a continuous threat to their well being. In mammals, evolution 
has given rise to two types of immunity, innate and acquired, that act in concert to 
protect the host ffom both external dangers in the form of invading pathogens, as well 
as internal threats in the form of aberrant host cells that may go on to become 
malignant cancers. Protection ffom cancer or infection by a pathogen is a multi-step 
process that depends upon interactions between multiple cell types of the immune 
system which need to occur in the proper sequence of events, location and temporal 
order so as to clear or control the infection with minimal damage to the host.
All vertebrates posses anatomical defences such as the carapace, epidermis of the skin 
or the mucus membranes of the gastro-intestinal lining that serve as a physical barrier. 
When an infectious agent successfully penetrates these defences and gains entry into 
the tissues or bloodstream, its presence is first detected by sentinel cells of the innate 
immune system. The innate arm, which includes neutrophils, eosinophils, 
macrophages, complement, fibronectin, dendritic cells (DC), natural killer (NK) cells, 
natural killer T cells (NKT) and mast cells is activated to mount a “non-specific” 
response that combats the infection and triggers the induction of an adaptive immune 
response, which may be required to eliminate the infection altogether. Cells of the 
innate immune system, such as dendritic cells, macrophages, monocytes, neutrophils 
and NK cells, do not require contact with specific antigens in order to be activated 
(Janeway and Medzhitov 2002). Instead, pattern recognition receptors e.g. the Toll­
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like receptors (TLR) (Vasselon and Detners 2002), the mannose receptor (Milone and 
Fitzgerald-Bocarsly 1998) lectin receptors and cytoplasmic helicases such as retinoic- 
acid-inducible protein I (RIG-I) and melanoma differentiation associated gene 5 
(MDA5) recognise specific molecular patterns common to large groups of infectious 
agents and distinguishable from self. Slightly different responses are mounted 
according to the receptors triggered (Janeway and Medzhitov 2002), and the 
responses are usually optimized to eliminate the type of pathogen encountered. Innate 
activation, maturation and defence occur within minutes of detection and last for up to 
72 hours, or sometimes more. The innate cells do not usually retain specific 
“memory” afterwards. The innate immune system therefore either clears the infection 
or controls it until more specific, potent and long lasting responses can be mounted by 
the adaptive or acquired immune response.
Unlike the innate immune response, the adaptive response is antigen-specific, and 
develops by clonal selection of CD8+ T-, CD4+ T- and B-lymphocytes from a vast 
repertoire of lymphocytes bearing antigen-specific receptors that are generated via 
gene rearrangement. Acquired immunity is responsible for the elimination of 
pathogens in the late phase of infection as well as the generation of immunological 
memory. However, the innate immune response is able to trigger and modulate the 
activation of the adaptive immune response. Thus, both arms of the immune system 
must be able to interact with each other in order to develop effective and long lived 
immunity against a given pathogen.
1.2 Innate and adaptive responses triggered by viral pathogens
Vertebrates are susceptible to infections by viruses, bacteria, fungi, prokaryotic and 
eukaryotic parasites and helminths and are able to tailor an immune response that is
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appropriate to the type of pathogen encountered. As this project investigated aspects 
of the host response to lymphocytic choriomeningitis virus (LCMV), the primary 
focus of this review will be the immune response to viral pathogens.
Infection by viruses is associated with exposure to viral components such as virion 
surface glycoproteins and viral nucleic acids e.g. single (ss) and double stranded (ds) 
ribonucleic acid (RNA) (Alexopoulou et al. 2001; Diebold et al. 2004; Yoneyama et 
al. 2004). Viruses may induce changes in the host cells they infect, such as a reduction 
in surface multiple histocompatibility complex (MHC) expression. Virus infections 
are frequently associated with apoptotic cell death and lytic infections may also lead 
to release of intracellular contents such as heat-shock-proteins (hsp) into the 
extracellular environment (Basu et al. 2000). These signs of infection are detected by 
sentinel cells o f the innate immune system, including the Langerhans cells or 
plasmacytoid or myeloid DCs in the tissues and bloodstream: ssRNA is believed to 
activate TLR7 (Diebold et al. 2004; Lund et al. 2004), dsRNA to activate TLR 3 
(Alexopoulou et al. 2001) and DNA to activate TLR 9 if CpG motifs are present 
within the sequence (for DNA viruses) (Krug et al. 2004; Lund et al. 2003); viral 
glycoproteins are recognised by lectin receptors while hsp 70 activates both TLR 2 
and TLR 4 (Asea et al. 2002). Sentinal cells both mediate effector activities and help 
to drive the activation of other components of the innate (and adaptive) immune 
response, for example, type 1 interferons produced by plasmacytoid DCs helps to 
activate cell types including DCs, NK cells and T and B cells.
Once activated, the innate response combats the infection directly via a variety of 
mechanisms including non-cytolytic pathways involving the actions of cytokines such 
as type 1 interferons (IFNs) and interferon-y (IFN-y) and via lytic pathways e.g. NK 
cell lysis of cells via perforin and granzyme-dependent mechanisms, as well as via the
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activity of lytic cytokines such as tumour necrosis factor (TNF)-a (Kawai and Akira 
2006; Le Bon and Tough 2002). The innate response also acts through cell-cell 
interactions e.g. the interaction of DCs with T cells and via secretion of cytokines e.g. 
type I IFNs, interleukins (IL)-12 and IL-15, to stimulate a predominantly type 1 
adaptive response, including activation of cytotoxic CD8+ T cell and Thl CD4+ 
helper T cell responses and the production of antibodies of a Thl-associated isotype 
appropriate to neutralise virions and eliminate virus-infected cells and clear the 
infection. CD4+ T cells play a crucial role in the developing adaptive immune 
response by producing cytokines that direct immune function, sustain cytotoxic T 
lymphocyte (CTL) activity when required and potentiate CD8 T cell memory 
generation (Le Bon and Tough 2002; Pulendran and Ahmed 2006). CD8 T cells 
express T cell receptors (TCRs) that recognize specific 8 to 9-amino-acid-long 
peptides derived from viral proteins bound within a cleft in host MHC molecules 
expressed on the cell surface. Binding of the TCR to the peptide-MHC complex 
coupled with the appropriate maturation/activation signals activates the T cells, 
switching on a program of activation and proliferation that allows the activated CD8 
T cell to clear the specific viral infection, usually through cell contact-dependent lysis 
of virus-infected cells and by production of antiviral cytokines such as IFN-y (Roitt et 
al. 2003).
Different effector pathways or cell subsets play different roles in the control of 
different viral infection (Haller et al. 2006). For example, while type 1 IFNs are 
critical for early control of many viral infections, the activity of the NK cell subset is 
especially required to control herpesvirus infections (Yokoyama et al. 2004). CD8+ T 
cells play a key role in eliminating many established viral infections. CD4+ T cells 
mostly provide help to CD8+ T cells but are important in clearing persistent
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infections. Antibodies help to contain viral spread and are important for clearance of 
viral infections in the central nervous system (CNS) but their main role is frequently 
to mediate protection and reinfection.
1.3 Components of innate immune activation
There are many mechanisms for innate recognition of pathogen components, 
including Toll-like receptors, intracellular helicases such as RIG-I and NOD, C-type 
lectin receptors, mannose receptors, NK cell receptors and Fc receptors. Many of 
these receptors have evolved to become specialized (although not restricted) to 
recognizing particular subsets of pathogens and to stimulate the most appropriate 
response. As the study investigated the type 1 EFN response to LCMV, this review 
will focus on the the best characterized pathways for induction of type 1 EFN in 
response to viral pathogens, namely activation through the toll-like receptor and the 
intracellular helicase pathways.
1.3.1 Toll-like receptors in innate immunity
The family of TLRs are a series of transmembrane proteins that are highly conserved 
in many species, from the worm C. elegans to mammals. The prototype receptor, Toll, 
was first described in the fruit fly Drosophila, where it is involved in the development 
of embryonic dorsoventral polarity but also, more relevantly it was found to be critical 
for appropriate initiation of anti-fungal response in flies (Hashimoto et al. 1988; 
Lemaitre et al. 1996). TLRs play an important role in early host defence against 
pathogens. So far, 10 members of the TLR family have been identified in humans and 
12 in mice (Akira and Takeda 2004; Akira et al. 2006; Medzhitov 2001). Each type of 
TLR recognizes a distinct subset of ligand(s). Synthetic ligands for all of the types of
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receptors and some of the biological ligands for most of the TLRs have been 
identified.
All TLRs are type 1 integral membrane proteins which share a structural template 
consisting of extracellular domains containing varying numbers of leucine-rich-repeat 
(LRR) motifs and a cytoplasmic signalling domain that is homologous to the 
signalling domain of the interleukin 1 receptor (IL-1R), known as the TLR/IL-1R 
(TIR) domain. They thus activate same signalling adaptors used in IL-1-mediated 
signalling (Bowie and O'Neill 2000). The 24-29 amino acids in the LRR motif are 
arranged thus: XLXXLXLXX, sometimes with conserved residues,
X0XX0XXXXFXXLX (F=phenylalanine, L=leucine, X=any amino acid, 
0=hydrophobic residue). The LRR domains are composed of 19-25 tandem LRR 
motifs; each LRR is folded into a (3 strand and an a helix connected by loops. As these 
receptors are germ-line encoded, there is a limit to the heterogeneity of ligands that 
can be recognized by TLRs. Recognition via TLRs is therefore focused on generic 
components of microbial pathogens which are difficult for the microorganism to alter. 
In line with this, biological ligands, or pathogan associated molecular patterns 
(PAMPs) so far identified for all the TLR members (listed in Table 1.1 and adapted 
from (Akira and Takeda 2004; Akira et al. 2006)) are components essential for the 
survival of the pathogen, ranging from structural molecules, e.g. peptidoglycan, LPS 
and mannan, to viral nucleic acids encoding genetic information. It should be noted 
that some TLRs also recognize host-derived components, such as single-stranded (ss) 
RNA or hsps.
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Table 1.1 TLRs and their currently identified ligands (adapted from Akira et al, 
2006)
Receptor Ligand Organism Species
TLR1/TLR2 Triacyl lipopeptides Bacteria Bacteria and mycobacteria
TLR 1/2 Soluble factors Bacteria Neisseria
TLR2 PG Bacteria Gram-positive bacteria
TLR2 Porins Bacteria Neisseria
TLR2 Lipoarabinomannan Bacteria Mycobacteria
TLR2 Phospholipomannan Fungus Candida albicans
TLR2 tGPI-mutin Parasite Trypanosoma
TLR2 Hemagglutinin protein Virus Measles vims
TLR2 ND Virus HCMV, HSV1
TLR2 and TLR4 Glucuronoxylomannan Fungus Cryptococcus neoformans
TLR3 dsRNA Vims Viruses
TLR4 Lipopolysaccharide (LPS) Bacteria Gram-negative bacteria
TLR4 Mannan Fungus Candida albicans
TLR4 Glycoinositolphospholipids Parasite Trypanosoma
TLR4 Envelope proteins Vims RSV, MMTV
TLR4 Heat-shock protein 60, 70 Host
TLR4 Fibrinogen Host
TLR5 Flagellin Bacteria Flagellated bacteria
TLR6ATLR2 Diacyl lipopeptides Bacteria Mycoplasma
TLR6/TLR2 Lipoteichoic acid Bacteria Group B Streptococcus
TLR6/TLR2 Zymosan Fungus Saccharomyces cerevisiae
TLR7 Broprimine - Synthetic compound
TLR7 Loxoribine - Synthetic compound
TLR7/8 Imidazoquinolene (R848) - Synthetic compound
TLR7 and TLR8 ssRNA Vims RNA vimses
TLR9 CpG-DNA Bacteria Bacteria and mycobacteria
TLR9 Hemozoin Parasite Plasmodium
TLR9 DNA Vims Vimses
TLR 11 Flagellin Bacteria Uropathogenic bacteria
TLR 11 Profilin-like molecule Parasite Toxoplasma gondii
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The structure of human TLR3 was recently elucidated and it suggests, contrary to 
previous predictions that the extracellular LRR domain would form a horseshoe 
structure with the ligand binding to the concave surface, that the ligand, which is 
negatively charged dsRNA, is more likely to attach to the convex surface of the 
domain (Choe et al. 2005). However, some TLRs are able to recognize PAMPs with 
different structures. For example, TLR4 is activated by structurally unrelated 
molecules like LPS, the plant diterpene paclitaxel, the fusion protein of respiratory 
syncytial virus, fibronectin and heat-shock proteins (Akira and Takeda 2004; 
Kawasaki et al. 2000; Kurt-Jones et al. 2000; Vabulas et al. 2002). This may be due to 
the presence of adaptor proteins such as MD-2 which interact with selected TLRs to 
provide the flexibility of recognition (Shimazu et al. 1999).
TLRs can be divided into several subfamilies, each of which recognizes related 
PAMPs -  in general, lipids are recognized by TLR1, TLR2, and TLR3 whilst nucleic 
acids are recognized by TLR3, TLR7 and TLR9.
In the host, TLRs have a wide tissue distribution and are expressed on both immune 
cells such as dendritic cells, macrophages, mast cells, neutrophils, B cells, T cells and 
other cell types such as fibroblasts and epithelial cells. Expression is modulated 
rapidly in response to pathogens, certain cytokines and environmental stresses. As 
some of the biological ligands are expressed by the host, e.g. ss RNA, sequestration of 
TLR into distinct subcellular compartments where the host molecules would not be 
normally present is used to allow discrimination between host and pathogen. For 
example TLR7 is sequestered in the endocytic compartment, while host mRNA is 
typically localized in the nucleus. As viral replication and transcription in the host cell 
often occurs outside the nucleus but within the cytoplasm, ssRNA encountered by
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TLR7 in the endocytic compartment would be likely be virally derived (Barton et al. 
2006; Diebold et al. 2004).
Signalling via the TLRs on innate cells can trigger direct antiviral activity and 
promote the induction of further innate and also an adaptive immune response. For 
example, activation of TLR 3 or 9 on human NK cells by dsRNA or CpG in the 
presence of IL-12 leads to secretion of high amounts of IFN-y and TNF-a while IFN- 
a  secreted in response to TLR3, TLR7 or TLR9 activation upregulates interferon 
responsive genes with direct antiviral activity such as 2 ’5’ oligoadenylate synthetase 
(OAS) (Banchereau et al. 2000) and also mediates the activation of innate subsets 
including DCs and NK cells and promotes the development of the adaptive immunity. 
Triggering of distinct TLRs on DCs elicits different cytokine-production profiles and 
different immune responses (Pulendran 2005; Pulendran and Ahmed 2006).
1.3.1.1 TLR signalling and its activation during viral infection
TLRs and the IL-1R share common signalling pathways. Stimulation with their 
ligands recruits TIR-domain-containing adaptors including myeloid differentiation 
marker 88 (MyD88) and TIRAP to the receptor, leading to the formation of a complex 
of IL-lR-associated kinases (IRAKs), tumour necrosis factor receptor-associated 
factor 6 (TRAF6) and interferon regulatory factor (IRF)5 (Takaoka et al. 2005; 
Taniguchi et al. 2001), as outlined in Figure 1.1. TRAF6 functions as an E3 ubiquitin 
ligase enabling it to catalyze the K63-linked polyubiquitin ligase complex of UBC13 
and UEV1A. This activates the TGF-p activated kinase (TAK)1 complex, resulting in 
the phosphorylation of IkB  kinase (IKK)y/ nuclear-factor kB  (N F - k B ) essential 
modulator (NEMO) and activation of IKK complex (Mizukami et al. 2002; Takaesu 
et al. 2000). Phosphorylated IkB  undergoes K48-linked ubiquitination and Figl
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Figure 1.1 Pathways involved in the transcriptional activation of type 1 IFN gene expression following virus infection and viral counter­
acting strategies
Overview of the signalling pathways leading to type 1 IFN production so far described are explained. Abbreviations are explained in the text, 
(adapted from Kawai and Akira, 2006)
to-o
Common viral strategies to block type 1 IFN induction include a) sequestering viral components from PRRs, b) impairing signalling pathway of 
the PRR, c) blocking activation and translocation of IRFs.
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degradation by the proteosome, allowing NF-kB to translocate into the nucleus to 
initiate the expression of proinflammatory cytokine genes (Deng et al. 2000). 
Simultaneously, TAK1 activates the mitogen-activated protein (MAP) kinase 
cascades, leading to the activation of activator protein (AP)-l, which is also critical 
for the induction of cytokine genes (Wang et al. 2001). TLR4 triggers the MyD88- 
independent, TIR-domain-containing adaptor-inducing IFN (TRIF/TICAM-1)- 
dependent signalling pathway via TRIF-related adaptor molecule 
(TRAM/TIRP/TICAM2) to induce type 1 IFNs (Hoebe and Beutler 2004; Yamamoto 
et al. 2002).TRIF activates NF-kB and IRF3, resulting in the induction of 
proinflammatory cytokine genes and type 1 IFNs. TRAF6 and the death domain 
serine/threonine kinase RIP1 induce NF-kB activation and TRAF-associated NF-kB 
activator (TANK)-binding kinase (TBK1) or inducible IkB kinase (IKK-I) 
phosphorylate IRF3, which induces the translocation of IRF3.
Biological ligands for TLR 3, 7 and 9 include viral nucleic acids and these are thus 
likely to be the main TLRs responsible for type 1 IFN production in response to viral 
infections. There is a certain level of redundancy and overlap in the potential for 
TLR-mediated activation of type 1 IFN, as a virus could possess ligands for several 
TLR species, e.g both ssRNA and dsRNA may be generated during RNA virus 
infections. Furthermore, other TLR, such as TLR2, may also be involved in 
recognition of viral components. TLR2 was thought to be mainly involved in 
recognition of bacterial pathogen as peptidoglycan is its main biological ligand, but 
was recently also shown to be activated by viral glycoproteins such as the 
paramyxovirus glycoprotein (Oldstone 2006) while it has been suggested that the 
haemagglutinin (HA) of influenza viruses of the H2 subtype may activate innate B 
cell lymphocytes through an orphan TLR (Marshall-Clarke et al. 2006).
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As briefly outlined above, TLR7, 8 and 9 signal through MyD88 to form a complex 
with IRAK4 and TRAF6 and also IRF7. IRF7 becomes phosphorylated by IRAK-1, 
translocates into the nucleus and activates expression of multiple IFN-a genes. This 
leads to autocrine induction of IRF7 and IRF8 which ultimately generates a positive 
feedback loop for high production of IFN-a subtypes and IFN-|3 (Asselin-Paturel and 
Trinchieri 2005; Tsujimura et al. 2003). This pathway is critical for induction o f type 
1 IFN in plasmacytoid DCs during the initial stages of a viral infection. Robust 
production of IFN-a/p via this pathway in plasmacytoid DCs is largely due to high 
pre-existing levels of IRF7 protein in the cytoplasm which helps kick-start the 
pathway and amplify the response to the initial danger signal. IRF7 serves as the 
master regulator of type 1 IFN production (Honda et al. 2005a). Other cells do not 
usually express IRF7 in a constitutive manner and the reason plasmacytoid DCs are 
such rapid producers of type 1 IFNs may stem from the presence of constitutively 
high levels of IRF7, coupled with expression of the appropriate TLRs, namely TLR7 
and TLR9, that allow this DC subset to sense a viral pathogen and generate a swift 
and appropriate anti-viral innate response. Also, it was recently noted that within 
plasmacytoid DCs, ligand-bound TLR9 (and presumably also TLR7) remain active in 
the endosomal compartment for a longer period compared to other cell types, where 
after activation, ligand-bound TLR9 is rapidly translocated to lysosomes for 
degradation. This would again serve to amplify the type 1 IFN response in 
plasmacytoid DCs.
The MyD88-dependent pathway controls the expression of genes required for 
inflammatory and adaptive immune responses, such as IL-6, IL-lp, tumour necrosis 
factor (TNF) and IL-12p40 (Kaisho et al. 2001; Kawai et al. 1999; Kawai et al. 2001).
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IRAK-1 also induces phosphorylation of IRF7, which dimerizes and translocates into 
the nucleus where it induces type 1 IFN gene expression.
1.3.2 Recognition of intracellular infection by RNA helicases
Most cells in the body contain intracellular sensors that upon infection with an RNA 
virus, detect viral components, usually single or double stranded RNA and activate 
IRF3 and NF-kB which in turn activate IFN-P expression. Infected cells initially 
secrete IFN-P and IFN-a4 but then the positive amplification feedback loop 
upregulates expression of other IFN-a subtypes.
Fibroblast cells lack expression of TLR3, 7 or 9. Instead, these and most cells in the 
body express two cytoplasmic helicases, RIG-I and MDA5, that detect intracellular 
infection via the presence of dsRNA, a common replicative intermediate during viral 
replication and transcription. RIG-I and MDA5 apparently bear non-redundant roles 
but may have specificity for certain vimses (Kato et al. 2006; Yoneyama et al. 2005). 
RIG-I and MDA5 both recognize polylC, a synthetic dsRNA analogue; however, 
RIG-I recognizes in wYro-transcribed dsRNA while MDA5 does not (Kato et al. 
2006). Likewise, studies using RIG-I and MDA5 knock-out mice have shown that 
RIG-I is essential for production of type 1 IFN in response to influenza vims, whereas 
MDA5 is critical for picomavims detection.
RIG-I and MDA5 are related, containing two N-terminal caspase recruiting domain 
(CARD)-like regions and a C-terminal DExD/H box RNA helicase domain 
(Andrejeva et al. 2004; Yoneyama et al. 2005). It is proposed that interaction between 
the helicase and its ligand dsRNA induces a conformational change which allows the 
CARD domain to interact with CARD-like domains of downstream signalling 
partners, one of which was independently isolated by a number of research groups and
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is known variously as interferon-p-promoter-stimulator 1 (IPS-1), mitochondrial 
antiviral signalling molecule (MAVS), virus induced signalling adaptor (VISA) or 
CARD adaptor inducing IFN-P (CARDIF) (Kawai et al. 2005; Meylan et al. 2005; 
Seth et al. 2005; Xu et al. 2005) (in the rest of the thesis the protein will be referred to 
as IPS-1).
Marques et al have put forward a theory that these helicases discriminate between self 
(microRNAs) and viral dsRNA according to the type o f end structure of the RNA 
rather than the sequence; 2 nucleotide (nt) overhangs on the 3’ end of short lengths 
(-21-27 nt) o f duplexed RNA activated the helicases, while blunt ended duplexed 
RNA of similar length, which are structurally analogous to self-microRNAs, did not 
substantially activate helicase activity (Marques et al. 2006).
As shown in Figure 1.1, the adaptor IPS-1 bridges the triggering of the helicases with 
NF-kB activation -  IPS-1 too posses a CARD-like domain that binds activated RIG-I 
or MDA5 but it is able to interact through its C-terminal domain with FADD and 
RIP1 which are able to activate NF-kB and turn on transcription of pro-inflammatory 
cytokines, including IFN-P and other interferon stimulated genes. IPS-1 is a 
mitochondrial associated protein, which localizes to the outer mitochondrial 
membrane through its C-terminal transmembrane domain. It has been suggested that 
this may keep the interacting RNA-sensing helicases close to sites of viral replication 
inside the cell.
Direct activation of type 1 IFN is also mediated by IPS-1; it activates IRF3 by a yet 
unidentified mechanism, which is believed to involve recruitment of two hep kinase 
(IKK)-related kinases, Ik k 8 and TBK-1, known to phosphorylate IRF3 and IRF7. 
Phosphorylated IRF3 and IRF7 then translocate into the nucleus to upregulate IFNa/p 
expression (Kawai et al. 2005; Seth et al. 2005). This would suggest that the TLR and
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RIG-I signalling pathways converge at the level of I k k e  and TBK-1 and that both 
pathways evolved for a similar purpose -  rapid upregulation of type 1 IFN.
A similar CARD-dependent signalling pathway exists for the detection of foreign 
lipid molecules. Nucleotide oligomerization domain (NOD) proteins represent another 
set of cytplasmic pathogen sentinels. NODI and NOD2 are believed to recognize 
bacterial components. Like RIG-1 and MDA5, the NOD proteins contain N-terminal 
CARD domains and signal upregulation of NF-kB and corresponding IFN a/p 
amplification.
Another helicase, LGP2, has been identified that shares sequence similarity with RIG- 
I in the helicase domain but lacks the CARD signalling intercellular region. It has 
therefore been proposed that LGP2 may act as a negative regulator of the RIG-I and 
MDA5 signalling (Rothenfusser et al. 2005; Yoneyama et al. 2005).
It has been suggested that a viral DNA-specific helicase also exists, which induces 
production of type 1 IFN via the IPS-1 and TBK1/ I k k s  pathway (Stetson and 
Medzhitov 2006). The protein has yet to be identified, but its existence is highly likely 
as previous experiments showed that herpes simplex virus (HSV) induces type 1 IFN 
in a both TLR9-dependent and TLR9-independent manner (Malmgaard et al. 2004).
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1.4 The Type 1 IFN Response
1.4.1 Overview
Interferons (IFNs) were first identified in the 1950s on the basis of their ability to 
protect cells from virus infection (Isaacs and Lindenmann 1957). IFNs belong to a 
large family of cytokines that exert pleiotropic effects, especially in the generation of 
antiviral immunity. They are part of the class II family of cytokines that also 
encompasses IL-10 and IL-10 homologs (IL-19, IL-20, IL-22, IL-24, IL-26) 
(Donnelly et al. 2004; Kotenko et al. 2003; Pestka et al. 2004). IFNs are further 
grouped into two major classes based on their biological activity, antigenicity and the 
cell types from which they are secreted (Le Page et al. 2000a): type 1 IFNs (IFN-a, - 
p, -5, -e, -k , - uj ,-x and (also called limitin)) which are stable at pH 2.0 and type 2 
IFN (IFN-y) which is inactivated at pH 2 (Boxaca M 1967).
Type 1 IFNs are derived from a single ancestral gene. The multiple IFN-a genes are 
believed to have arisen through repeated gene duplication and recombination; subtle 
modifications of their promoter and regulatory sequences allow them to be 
differentially expressed depending upon the cell type, stimulating agent and 
environment (De Maeyer and De Maeyer-Guignard 1998). IFN-a and -p are the best 
studied members within the type 1 IFN family. In mice, there at least 10 distinct IFN- 
a genes clustered within the Ifna locus on chromosome 4 that encode biologically 
active EFN-a subtypes. These are intronless genes with a high degree of homology 
(80-95%) that produce proteins of 16-27kDa which are 166 residues in length and are 
sometimes glycosylated (Doly et al. 1998; Le Page et al. 2000a; van Pesch et al. 
2004). In contrast, only one gene {IFN-P), also intronless and located on chromosome 
4, encodes the IFN-p protein. IFN-p is a glycosylated protein of 28-35kDa containing
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166 amino acid residues. All type 1 IFNs signal through a common receptor, the type 
1 IFN receptor (IFN-R).
Some type 1 IFNs are species or cell specific e.g. IFN-5 is found only in porcine 
species, IFN-x is expressed in ruminants such as cattle, sheep and giraffes (Liu et al. 
1996), limitin is only expressed in mice while IFN-k is only expressed by 
keratinocytes.
A subset of type 1 IFNs appear not to function primarily as anti-viral cytokines. IFN-5 
and IFN-x, termed trophoblast IFN, are important during pregnancy, where they are 
expressed at high levels by the trophoblast as an antileukocyte protein to allow proper 
implantation of the ovum. Additionally, trophoblast IFN has been reported to posses 
immunosuppressive effects against CD4+-lymphocytes. IFN-tn and IFN-e are 
expressed by humans and are also reported to play a role in maternal recognition of 
pregnancy, suggesting they may be the human equivalent of IFN-x. Promoter analysis 
of the bovine IFN-x gene indicates that while expression may still be induced by 
viruses, it also contains elements for trophoblast-specific expression (Cross and 
Roberts 1991). Thus, unlike IFN-a and -(3, these IFNs have limited anti-viral activity 
and likely have a physiological role as pregnancy hormones. As this study focuses on 
the antiviral effects of interferon, the term type 1 IFNs will be used in the rest of the 
text to denote IFN-a and IFN-p, whose antiviral activities have been most 
investigated.
Type II interferon or IFN-y is encoded by a gene on chromosome 10 in mice and 12 in 
humans. The IFN-y gene contains 3 introns; it encodes a protein of 143 amino acids in 
length. The translated protein, which has a typical molecular mass of 20-25kDa, 
shares little structural homology with the type 1 IFNs. IFN-y is mainly secreted by
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NK cells and activated, mature cytotoxic T cells again in response to viral infections. 
IFN-y binds to a single receptor, consisting of two chains, IFNyRl and IFNyR2.
A new class of interferon-like molecules have been recently described in a number of 
species including humans and mice; these cytokines, which are distantly-related to the 
classical type 1 IFNs (15-19% amino acid identity with IFN-a) are grouped under a 
new interferon type, IFN-X, of which 3 subtypes have so far been identified - IFN-X, 1, 
IFN-X2, IFN-X3 (also known as IL-29, IL-28A and IL-28B). Unlike other members of 
the IFN family, which in humans are intronless genes located on a locus on 
chromosome 9, the genes encoding IFN-X subtypes contain introns and are clustered 
on chromosome 19 (Sheppard et al. 2003). These cytokines, which may be 
provisionally termed type III IFNs, signal via a separate cell-surface receptor 
composed of two chains, IL-28Ra and IL-lORp (Donnelly et al. 2004). While the 
IFN-X proteins are structurally related to the type 1 IFN proteins, their genomic 
organization shares many similarities with the IL-10 family, leading some researchers 
to hypothesize that these cytokines may represent an evolutionary link between type 
IFNs and the IL-10 family (Sheppard et al. 2003).
Within the context of immunity, type 1 IFNs are known to induce potent anti-viral 
effects as well as anti-tumour activity and apoptosis. Furthermore, they are important 
mediators in the modulation of the adaptive response. Type 1 IFNs mediate their 
activity via the upregulation of effector molecules that directly influence protein 
synthesis, cell growth and survival. Microarray analysis has shown that signalling of 
type 1 IFNs through the IFN-R modulates expression of hundreds of genes (Baechler 
et al. 2003; Der et al. 1998).
Studies in mice treated with neutralizing antibodies against IFN-a and IFN-P or in 
mice with an EFN-R knock-out (k/o) phenotype showed impaired upregulation of type
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1 IFN when exposed to viruses, indicating that constitutive expression of type 1 IFN 
appears to be a pre-requisite for enhancement of type 1 IFN production after viral 
infection (Hata et al. 2001). Pre-existing levels of type 1 IFN are also needed for 
efficient induction of IFN-y signalling.
Type I IFN can be produced by most cells if they are virally infected, and is also 
produced by specialised cells of the innate immune system in response to stimuli 
associated with viral infection (Doly et al. 1998), (Biron 2001). It used to be thought 
that IFN-a is mainly secreted by peripheral blood leukocytes (plasmocytoid DCs, 
other DC subsets, macrophages, monocytes and lymphoblastoid cells e.g. B 
lymphocytes) while epithelial and fibroblastic cells are the main secreters of IFN-p. 
However, it now appears that all cell types secrete all subtypes of IFN-a or IFN-p, if 
only in varying proportions. Viral infections are believed to be the most potent natural 
inducers of type 1 IFN. IFN-mediated protection occurs within hours of viral infection 
(Le Page et al. 2000a).
1.4.2 Pathways leading to production of IFN-a/p protein
Type 1 IFNs are among the earliest cytokines secreted by the host following viral 
infection. They can be produced so quickly, as reviewed above, because the 
transcription of type I IFN genes can be activated by a host of pathogen sensing 
receptors located inside and outside the cells, via a number of intracellular 
phosphorylation pathways that are parallel, convergent or completely independent of 
each other, but that ultimately result in translocation of the transcription factors NF- 
k B ,  IRF3 or IRF7 into the nucleus where they bind IFN-a or -p genes to initiate 
transcription (Beutler et al. 2006; Doly et al. 1998; Honda et al. 2005b; 
Theofilopoulos et al. 2005).
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Type 1 IFN genes contain multiple independent promoter elements, termed positive 
regulatory domains (PRD or viral recognition elements (VRE) which are recognized 
by multiple transcription factors (Civas et al. 2002; Doly et al. 1998; Goodboum and 
Maniatis 1988; Leblanc et al. 1990; Mamane et al. 1999; Sato et al. 2001b; Taniguchi 
et al. 2001). The protein coding sequences of all the type 1 IFN genes are not 
interrupted by introns (Kelley et al. 1985; Kelley and Pitha 1985a; b; Shaw et al. 
1983; Vodjdani et al. 1985) thus doing away with the need for post-transcriptional 
processing, enabling speedy transcription and translation of the proteins.
IFN-P and IFNa-4 are produced initially, then they upregulate both their own 
production and that of other IFN-a subtypes by a positive feedback mechanism (Le 
Page et al. 2000a) through activation of the transcription factors IRF3 and IRF7.
The ‘first wave’ of type 1 IFN is often insufficient to control a viral infection. 
However, in order to generate the ‘second wave’, categorised by transcription of 
additional subtypes of IFN-a, the cell requires IRF7, which is one of many antiviral 
proteins synthesized in response to the first wave of IFN-a4 and IFN-p, thus 
generating a positive feedback loop. The same kinase complex, TBK1 IkB kinase e 
(Sharma et al. 2003) is responsible for phosphorylation of both IRF3 and IRF7 and 
they themselves, along with pathogen sensing receptors such as TLRs and RNA 
helicases, are also IFN-inducible proteins, as are the ISGF3 components STAT1 and 
IRF9 needed to mediate production of IFN-stimulated antiviral proteins. All of these 
are therefore produced in response to the first wave of IFN production, and constitute 
both a positive feedback loop that not only induces and amplifies type 1 IFN secreted 
through the second wave, but also amplifies induction of anti-viral proteins (Mamane 
et al. 1999; Platanias 2005; Theofilopoulos et al. 2005). Failures in the activity of any 
of the key intermediary proteins will result in either complete abolition of type 1 IFN
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production or a partial response with no ability to generate the second wave of IFN 
production. For example, when challenged with a respiratory viral infection, mice that 
lack STAT1 are only limited to production of the immediate-early IFN subtypes IFN- 
a4 and IFN-P and cannot mount positive feedback or express other IFN-a subtypes 
(Marie et al. 1998). Here, impaired IFN production in concert with impaired IFN 
responsiveness contributes to the exquisite sensitivity of STAT1-deficient mice to 
viral infection.
1.4.2.1 IRFs in type 1 IFN production
IRFs are transcription factors possessing a helix-tum-helix-DNA binding motif (Sato 
et al. 2001b; Taniguchi et al. 2001). At least nine type 1 IRFs have been identified 
(IRF1 to 9), which under normal conditions are resident in the cytoplasm. All IRFs 
characterised so far contain a conserved N-terminal binding domain which recognizes 
a consensus DNA sequence known as the interferon stimulated response element 
(ISRE) (Darnell et al. 1994; Tanaka et al. 1993). They are activated by 
phosphorylation, and gaining of the extra phosphate moiety allows the IRFs to 
translocate into the nucleus and initiate transcription of IFN-P and IFN-a subtypes. 
Lymphocytes express IRF3, IRF4 and IRF5 constitutively. Additionally, in 
plasmacytoid DCs, IRF7 is also constitutively expressed (Honda et al. 2005a; Prakash 
et al. 2005). Other IRFs are ubiquitously present and are themselves induced by type 1 
IFNs.
Studies in mice lacking expression of selected IRFs demonstrated the importance of 
these signalling molecules to the development, regulation, and function of the innate 
and adaptive immune system. IRFT ' mice had defective NK cells, NKT cells and 
intraepithelial y5+ T cells, believed to stem from the lack of IL-15 (Ogasawara et al.
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1998; Ohteki et al. 1998). Additionally, these mice were unable to mount Thl 
responses as T cell signalling was also dysregulated, affecting CD8+ thymocyte 
development and positive and negative selection (Lohoff et al. 1997; Matsuyama et al. 
1993; Penninger et al. 1997; Taki et al. 1997). When IRF2 expression was deleted, 
NK cell development and Thl differentiation were again impaired, indicating that 
IRF1 and IRF2 both may be needed in a non-redundant fashion in order to allow 
normal NK and T cell development (Lohoff et al. 2000; Lohoff et al. 2002). IRF-4' '  
mice suffered splenomegaly, lymphadenopathy, reduced humoral responses and 
serum Ig levels, and defective Thl and Th2 differentiation (Lohoff et al. 2002; 
Mittrucker et al. 1997). Mice that lacked IRF8 were unable to respond to signalling 
via TLR3 and TLR9 (Schiavoni et al. 2002; Tsujimura et al. 2004; Tsujimura et al. 
2003). Furthermore, plasmacytoid DCs were absent in lymphoid organs and there was 
a reduction in the number and activation state of CD8a+ DCs.
At least 4 members of the IRF family were initially believed to play a role in 
regulating type 1 IFN production. These were IRF1, IRF3, IRF5 and IRF7 (Barnes et 
al. 2001; Darnell et al. 1994; Mamane et al. 1999; Miyamoto et al. 1988; Nguyen et 
al. 1997; Taniguchi et al. 2001). However, further studies indicated that IRF1 and 
IRF5 were not essential for IFN-a or IFN-p gene induction. Type 1 IFN production in 
IRF l 7' embryonic fibroblasts (MEF) after infection with Newcastle disease virus 
(NDV) was not markedly different to that observed in normal MEF (Matsuyama et al. 
1993). Similarly, MEFs from IRF5‘‘ mice infected with virus or stimulated with 
dsRNA produced normal levels of type 1 IFN (Takaoka et al. 2005). However, IRF5 
is thought to be of importance in regulating pro-inflammatory cytokines via an 
MyD88-TRAF6-NF-KB dependent manner. Although some of the pathway remains to 
be uncovered, what is thus far known is that cytoplasmic IRF5 interacts with MyD88
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and TRAF6 and becomes activated through a mechanism that is not yet clear. 
Activated IRF5 then translocates into the nucleus where it interacts or co-operates 
with activated NF-kB to switch on transcription of pro-inflammatory cytokines such 
as TNF-a, IL-6 and IL-12. This conclusion was made following observations in mice 
which were deficient in IRF7; while they were unable to produce IFN-a or IFN-p in 
response to TLR-activation, they were still able to produce normal levels of IL-12 and 
IL-6, suggesting these cytokines are induced in an MyD88 and NFkB -dependent but 
IRF7-independent manner (Honda et al. 2005a).
1.4.2.2 IRF3
IRF3 is expressed constitutively in a variety of cells where it is present in the 
cytoplasm as a monomer (Lin et al. 1998b; Lin et al. 1999; Sato et al. 1998; Suhara et 
al. 2000; Wathelet et al. 1998; Yoneyama et al. 1998). IRF3 has potential 
phosphorylation sites in the C-terminal region (Ser385, 386, 398, 402 and 405, and 
Thr404 of human IRF3) however, to date, only one site has been conclusively shown 
to be phosphorylated (Ser386) (Mori et al. 2004; Servant et al. 2003). Phosphorylation 
induces homodimerization and activation, which enables the dimerized proteins to 
translocate into the nucleus where they form a complex with a co-activator p300/CBP 
(Hiscott et al. 1999; Suhara et al. 2002). The complex then binds the PRDI or PRDIII 
sequence on the promoter region of the IFN-a or IFN-p genes (Lin et al. 1999; 
Servant et al. 2003; Suhara et al. 2000). Other non-IFN genes such as RANTES and 
IP 10 have also been reported to be induced by IRF3. IRF3 phophorylation is 
mediated by TBK1 and IKKs kinases (Sharma et al. 2003) and as such occurs as a 
consequence of activation of TLR4, TLR3 or RIG-I/MDA5 (see Figure 1.1). IRF3 is
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therefore an important adaptor in the initial production of type 1 IFN during the early 
stages of viral infection.
1.4.2.3 IRF7
Like the other IRFs described, IRF7 is found as a monomer in the cytoplasm. 
Activation requires phosphorylation of the C-terminal serine residues, followed by 
dimerization (Lin et al. 2000; Marie et al. 1998; Marie et al. 2000; Sato et al. 1998). 
Sharma et al demonstrated that IRF3 and IRF7 were phosphorylated by the kinases 
IKKs and TBK1, which are themselves activated by viruses or dsRNA acting through 
TLR3/TLR4 or RIG-I/MDA5 (Fitzgerald et al. 2003; Sharma et al. 2003). In murine 
IRF7, Ser437 and 438 are the primary targets for phosphorylation; although other 
residues have been identified, namely Ser425-426, Ser429-431 or Ser441IRF7, as 
possible partners (Caillaud et al. 2005). Additional phosphorylation is needed to fully 
activate IRF7 in virus-infected cells, suggesting that it serves as a main transfer 
molecule for type 1 IFN-mediated signalling from uninfected or infected cells. 
Activated IRF7 subsequently induces production of IFN-a subtypes and IFN-p 
(Nakaya et al. 2001; Sato et al. 1998; Sato et al. 2000) (Marie et al. 1998).
Honda et al provided evidence of IRF7 being the essential regulator of type 1 IFN 
production in all cell types, including plasmacytoid DCs and conventional DCs, with 
IRF3 being dispensable for IFN-a production by viral activation of TLR7, TLR8 or 
TLR9 (Honda et al. 2005a). Studies they carried out with knock-out mice showed that 
in MEFs generated from IRF7 deficient mice, IFN-a/p expression was more severely 
impaired after infection with vesicular stomatitis virus (VSV), HSV and 
encephelomyocarditis virus (EMCV) than responses in IRF3‘ ' MEFs. Viral infection 
o f IRF7 and IRF3 knock-out mice further suggested that IRF7-deficient mice do not
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produce much serum IFN and are more susceptible to viral infection than IRF3- 
deficient mice. The IRF7-dependent pathway may therefore be a critical regulator of 
type 1 IFN production, able to promote IFN production in IRF37' cells. In contrast, in 
IRF7* ’ mice with normal IRF3 expression, the absence of IRF7 abolishes the type 1 
IFN response. The authors of the study hypothesized that IRF7 may be present in low 
levels in uninfected cells, probably synthesized in response to low levels of IFN-a 
pre-existing in the cell. This low-level IRF7 or IFN-a/p production occurred in the 
absence of functional IRF3. By contrast, while IRF3 contributes to type 1 IFN 
induction, it may need to interact with IRF7 to function. In other words the 
homodimers of IRF7 or heterodimers of IRF7 and IRF3, rather than IRF3 
homodimers may be responsible for inducing IFN-a/p in MEFs infected by viruses. 
Once the initial activation of IFN genes is achieved by IRF7 (and IRF3), the positive- 
feedback regulation becomes fully operational, wherein IFN-induced IRF7 
participates (Honda et al. 2005b).
The importance of feedback and the role of IRF7 were investigated by Kalinke’s 
group (Barchet et al. 2002), who conducted studies measuring IFN-a production by 
splenocytes lacking the IFNR in response to VSV or ultraviolet (UV)-inactivated 
HSV. They could not detect any difference in the levels of IFN-a induced nor 
upregulation of IRF7 in the spleen of IFNR+/+ and IFNR7’ mice, and so concluded that 
early IFN production in vivo did not require IFN feedback amplification or IRF7 
(Barchet et al. 2002). However, others have suggested that the route of infection may 
influence the responsive cell type and hence the results obtained (Levy 2002). 
Systemic infections (e.g. intra venous (i.v)) may lead to efficient activation of splenic 
plasmacytoid DCs while peripheral infections may only target localised responsive 
cell types. In accordance with this hypothesis, Prakash et al reported that when using
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an RNA virus infection model inducing a localised as opposed to systemic infection 
by targeting the lungs, they found that IFN production correlated with IRF7 
production in the lungs of normal mice, and ST ATI deficient mice that were unable 
to upregulate IRF7 exhibited very impaired type 1 IFN production (Prakash and Levy 
2006). Analysis of the tissue distribution of IRF7 showed that most mouse tissues 
expressed IRF7 in an induction dependent manner, i.e. not constitutively, except for 
plasmacytoid DCs which had very high pre-existing levels of IRF7 protein and 
consequently were able to respond rapidly to virus infection by robust production of 
multiple IFN-a species (Marie et al. 2000). These observations emphasise that 
differential regulation of IRF7 expression constitutes the underlying mechanism of 
positive-feedback regulation in peripheral tissues and is an important element of cell- 
type specific differences in IFN production.
In addition to secreting normal levels of pro-inflammatory cytokines IL-12 and IL-6, 
IRF7-deficient mice exhibit normal activation of other adaptors such as NF-kB, JNK 
and p38 (Honda et al. 2005a). This implies that IRF7 has a specialised role in 
regulating only type 1 IFN transcription within the MyD88-dependent cytokine gene 
induction program activated by TLR signalling. The function of the cytoplasmic 
molecular complex anchored by MyD88 in the activation of NF-kB/MAP kinases is 
therefore under separate control and signalling, so that arm may be modified without 
affecting the regulation of type 1 IFN induction.
Studies with IFN-p'7' mice have confirmed the role played by IFNp in the induction of 
the overall IFN response. In IFN-p'7' mice, the expression of various IFN-a transcripts 
and IFN inducible genes (2’-5’OAS) were much lower compared to heterozygous or 
wild type control after viral infection, rendering the k/o mice more susceptible to 
vaccinia infection (Deonarain et al. 2000). Subtypes of IFN-a are also important in
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viral control. IFN-a2, -a5, -a6 and -a8 subtypes were found to be induced 
specifically in response to NDV infection by IRF7-mediated activation (Levy et al. 
2003b; Marie et al. 1998).
1.4.3 Type 1 IFN Signalling
1.4.3.1 The type 1 IFN receptor
Type 1 IFNs have direct antiviral effects and also regulate the activation, proliferation 
and differentiation of multiple cell types, thus affecting both innate and adaptive 
immune responses. IFNs are signalling molecules and achieve their diverse effects 
through activation of a single cell-surface receptor, the IFN-R, triggering intracellular 
signalling pathways that result in upregulation of the transcription of IFN-inducible 
genes. The IFN receptor is broadly expressed at low levels, (between 200-6000 copies 
per cell) and binds IFNs secreted into the extracellular environment with high affinity 
(dissociation constant of 10‘9-10'10) (Theofilopoulos et al. 2005).
While multiple subtypes of type 1 IFN exist, they bind and activate a single receptor, 
the IFN-R. One explanation for this incongruity may be because all the genes in the 
type 1 IFN subset are thought to be derived from a single ancestral gene, amplified 
through gene duplication and recombination events over time. The receptor is 
composed of two separate chains, IFNAR-1 and IFNAR-2. In humans and mice, 
IFNAR-1 consists of 590 amino acids, and has a mass of ~66kDa. The extracellular 
N-terminal of the molecule contains two 200 amino acid domains, as seen in other 
members of the class II cytokine family. The locus encoding IFNAR-1 contains 11 
exons and is situated on chromosome 21 in the human genome (Benoit et al. 1993; 
Lutfalla et al. 1992; Lutfalla et al. 1990; Uze et al. 1990). IFNAR-2 is 331 amino 
acids in length, with a mass of ~51kDa. NMR studies of its extracellular portion
45
indicate it folds into two fibronectin type III domains orientated perpendicularly to 
one another and linked by an a-helical ‘hinge’ (Chill et al. 2003).
IFNAR-1 contains two IFN binding sites which is postulated to contribute to the 
diversity of biological responses elicited by different IFN-a subtypes (da Silva et al.
2002). There is biochemical evidence which suggest that the IFN-a and IFN-p 
subtypes engage the receptor chains differently, e.g. IFN-a2 and IFN-p utilise 
different regions of the IFNAR-2 for signalling, triggering different signalling 
responses, leading to distinct effects on cell function (Chill et al. 2002; Chill et al. 
2003; Domanski et al. 1998). NMR studies have suggested that the N-terminal 
binding domain of IFNAR-2 is flexible, allowing it to adapt to the different structures 
of its various ligands and that binding (to IFN-a2) causes ‘tightening’ of the entire 
chain, increasing its rigidity. This increase in receptor rigidity may initiate the 
intracellular IFN signalling cascade (Chill et al. 2002). Interestingly, a single aromatic
• Rtryptophan (W) side-chain in the binding site on IFNAR-2 ( W100) may be 
responsible for specific recognition of IFN-p. Mutation of the RW100A position 
abolishes IFN-p activity, while IFN-a activity decreases only 4-fold (Piehler et al. 
2000).
Attachment of type 1 IFNs to the IFN-R activates the Janus kinase signal transducer 
and activator of transcription (JAK/STAT) pathway, activating IFN stimulated genes, 
as illustrated in Figure 1.2. (Grandvaux et al. 2002; Le Page et al. 2000a; Nguyen et 
al. 2002b).
1.4.3.2 Classical JAK-STAT signalling pathway
Each chain of the IFN-R interacts with a member of the Janus activated kinase (JAK) 
family in the cytoplasm (Damell et al. 1994; Ihle 1995; Platanias 2005) Figure 1.2
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outlines a schematic representation of the JAK-STAT signalling pathway. IFNAR1 
interacts with tyrosine kinase 2 (Tyk2) while IFNAR2 binds JAK1. The initial 
signalling step involves attachment of a monomeric type 1 IFN molecule to the 
binding sites of the IFNAR-1 and IFNAR-2 chains of the receptor on the extracellular 
end of the chains, bringing both chains in close proximity to form a heteromeric 
complex. This induces structural rearrangement of the cytoplasmic ends of the chain 
resulting in ligand-induced receptor activation (Chen et al. 2004; Damell et al. 1994; 
Ihle 1995; Platanias 2005; 2003). This promotes autophosphorylation and activation 
of the associated JAKs, which in turn allows recruitment and activation of the 
transcription factor signal transducer and activator of transcription 2 (STAT2) to the 
IFNAR-2 chain, followed by STAT1 (Stark et al. 1998). Both STAT2 and STAT1 are 
activated through tyrosine kinase-mediated phosphorylation. Phosphorylated STAT1 
and STAT2 are released, then associate with IRF9, also known as p48, (which is not 
phosphorylated) to form a complex called the IFN-stimulated gene (ISG) factor 3 
(ISGF 3). The complex translocates into the nucleus and binds genomic DNA at 
promoter regions containing IFN-stimulated response element (ISRE) sequence 
motifs to initiate gene transcription. The genes transcribed include those encoding 
IFN-p and IFN-a as well as IRF7 and IRF3 (Levy et al. 2003a), proteins which 
promote autocrine induction and amplification of type 1 IFN expression. Additionally, 
activated STAT1 is also able to form homodimers of STAT1:STAT1 which is also 
able to translocate into the nucleus. These homodimeric complexes bind to genomic 
DNA at promoter regions containing the y-activated site (GAS) sequence motif to 
initiate gene transcription. Individuals with non-functional STAT1 succumb to viral 
infections, which likely reflects the importance of STATs in controlling viral infection 
through IFN signalling pathways (Dupuis et al. 2003).
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Figure 1.2 Activation of IFN-stimulated genes via the JAK/STAT pathway and 
viral counteracting strategies
Type 1 IFNs exert their biological functions by binding to the IFN-R, a cell surface 
receptor consisting of two chains, IFN-R 1 and IFN-R2. This activates a series of 
transcription factors and kinases that make up the JAK/STAT pathway, which leads to 
induction of IFN-stimulated genes (ISG). The products of the pathway set up an 
antiviral, antiproliferative and immunoregulatory state in the cells (adapted from 
Honda et al, 2005). Unsurprisingly, this pathway is often targeted by viruses as a 
means to downregulate the antiviral effects of type 1 IFN production. Common viral 
strategies include d) preventing attachment of secreted type 1 IFN molecules to the 
IFN-R receptor and e) interfere with the activity of transcription factors of the 
JAK/STAT pathway.
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While type 1 IFN-mediated signalling occurs mainly through the STAT2 and STAT1 
adaptors, other STAT and IRE adaptors are also recruited into this pathway under 
certain conditions and in various cells (Meinke et al. 1996; Stark et al. 1998; van der 
Zeijst et al. 1983). These include STAT3, STAT4 and STAT5. However, STAT1 has 
been reported to pre-associate with STAT3 and STAT5, which may explain why 
STAT3 and STAT5 were found to be involved with type 1 IFN signalling complexes 
(Stancato et al. 1996). Conversely, the presence of IFN-a may inactivate STAT1 and 
STAT3 (Kirkwood et al. 1999).
1.4.4 Negative regulation of type 1 IFN expression
Excessive levels of type 1 IFN are detrimental to the host, and have been implicated 
in autoimmune disorders, toxicity, excessive inflammation and immunopathology. 
Even in non-toxic doses, prolonged systemic exposure to type 1 IFN may not be 
desirable. In patients with hepatitis C virus (HCV), long-term treatment with 
recombinant IFN-a is not without side effects, which may include autoimmune 
disorders such as insulin-dependent type 1 diabetes or rheumatoid arthritis; depression 
was another side effect. Patients with the condition systemic lupus erythematosus 
(SLE or lupus) often have increased levels of serum IFN-a that coincide with disease 
exacerbations (Bengtsson et al. 2000).
Mechanisms have therefore evolved within the host to downregulate type 1 IFN 
expression. As such, expression of type 1 IFN is typically followed by appropriate 
activation of ISGs as well as repression of further IFN activity and expression. Some 
of these mechanisms that negatively regulate type 1 IFN signalling include receptor 
internalization and degradation, induction of phosphatases to promote 
dephosphorylation of JAKs and STATs, expression of suppressors of cytokine
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signalling (SOCS) (Fenner et al. 2006; van der Zeijst et al. 1983) and repression of 
STAT-mediated gene activation by protein inhibitors of activated STATs (PIAS) 
called small ubiquitin-like modifiers (SUMO) E3 ligases (Liu et al. 2004; Shuai
2003).
Within the human IFN-p gene, cis-acting elements of the IFN-p promoter such as 
negative regulatory domain (NRD)I and NRDII have been characterized as being 
involved in the constitutive repression of gene expression, while positive regulatory 
domains (PRDs) mediate both induction and repression (Whiteside et al. 1994) (Liu et 
al. 2004). Interplay of the binding of the activator as well as repression factors is 
necessary in regulating expression of type 1 IFN genes as well as for the differential 
expression of the IFN-a gene family.
The first IFN gene transcriptional repressor to be discovered was IRF-2, isolated by 
its homology to IRF-1 (Harada et al. 1989). IRF-2 binds PRDI and PRDIII within the 
viral regulatory element (VRE)-B of the IFN-p gene and also recognises the IRF 
elements present in other virus-inducible genes such as EFN-A (Au et al. 1992; Au et 
al. 1993) (Figure 1.3 A). This was confirmed when mice deficient of IRF-2 expression 
produced higher levels of IFN-A and IFN-p mRNA upon viral induction (Matsuyama 
et al. 1993). Furthermore, IRF-2 competes with the transcription factor IRF-1 for the 
IRF-binding site in the promoter region. Expression of IRF-2 is constitutive in many 
cell types and is believed to play a role in maintaining the gene repressive state before 
viral induction occurs. Type 1 IFNs up regulated in response to viral infection also 
induced IRF-2 expression and thus also repressed type 1 IFN gene expression post­
induction (Harada et al. 1989; Lin et al. 1999; Whiteside et al. 1994).
Another repressor of genes containing PRD promoters is the IFN consensus sequence- 
binding protein (ICSP), which is a member of the IRF family (IRF9). Expression of
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A) IFN-p promoter
PRDIII PRDI
PRDIV PRDII
B) IFNa4 promoter
DNRE
Figure 1.3 Regulatory elements of the IFN-/5 and IFN-A gene promoter
A) Interaction of regulatory activators with the human IFN-(3 gene promoter after 
virus induction. Transcription factors NF-k/3 binds to PRDII while IRF-1, IRF-3, 
IRF-7 bind to PRDI and PRDII domains on the human IFN-/3 promoter to 
upregulate IFN-/3. However, these domains can also be occupied by repressors of 
the human IFN-/3 promoter e.g. IRF-2, ISCBP bind to PRDI and PRDIII, while 
PRDI-BF1 binds to PRDII, thereby preventing IRF-7 and IRF-3-mediated 
upregulation of EFN-/3 transcription (adapted from Doly et al, 1998). (All 
abbreviations are defined in the text).
B) Positive and negative regulation of type 1 IFN expression by Pitxl is dependent 
upon the promoter elements on the IFN-a subtype gene. Pitxl attaches to the 
DNRE region and also binds to an IRF(3 or 7) attached to the promoter region of 
the IFN-a gene to prevent the IRF complex from initiating transcription of the 
gene. However, attachment of Pitxl to the DNRE does not repress the IFN-A4 
promoter because here, the EFN-o4 promoter contains an additional IRF binding 
sequence in between the DNRE and the VRE, that enables IRF3 bound to Pitxl to 
attach to, preventing Pitxl from interacting with IRF3 and IRF7 bound to the 
VRE-4 promoter sequence. In contrast, the IFN-al 1 promoter sequence lacks the 
IRF binding site, so the only IRFs available for interaction with Pitxl are IRF3 or 
IRF7 bound to the VRE-11 promoter and this therefore prevents expression of 
IFN-al 1 (adapted from Island et al, 2002).
DNRE
IFNal 1 promoter
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ICSP is restricted to cells of lymphoid/macrophage lineage where it is constitutively 
present (Driggers et al. 1990; Nelson et al. 1993; Weisz et al. 1992). Evidence from 
viral infection of ICSP7* mice suggests that it may have a limited role in repressing 
IFN-a/p genes as there was no marked increase in the levels of IFN-a and IFN-p in 
selected tissues of virally-infected knock-out animals (Holtschke et al. 1996).
Negative regulation of PRDI-containing genes is also mediated by vims responsive 
element B (VREB)-PRDI-BFI (Keller and Maniatis 1991). This is constitutively 
expressed at low levels but can be virally inducible and is thought to be a post­
induction repressor of the IFN-P gene.
IRF4 reduces type 1 IFN production by down regulating TLR signalling (Negishi et 
al. 2005). It competes with IRF5 for MyD88 and is probably part of a host response to 
control expression of pro-inflammatory genes, as IRF4 knock-out mice have high 
levels of pro-inflammatory cytokines and are hypersensitive to DNA-induced shock. 
IRF7 is associated with Epstein-Barr vims (EBV) latency and is also able to repress 
transcriptional activation by both IFN and IRF1 of an element containing an ISRE 
(Zhang and Pagano 2001).
Another target for repression of expression of ISGs is the transcription factor NF-kB, 
which is responsible for the activation of transcription of ISGs. NF-kB is activated by 
phosphorylation via the JAK/STAT pathway, and the gain of the phosphate moieties 
enables the protein to translocate into the cell nucleus to initiate transcription of ISGs. 
Kp inhibitory proteins (IkB) modulate NFicB/Rel activity on up-regulation of IFN-p 
gene in response to viral infection (Beg and Baldwin 1993). IkB inhibits NF-kB 
activity by sequestering the protein in the cytoplasm and expression of IkB is also 
upregulated during viral infection, increasing the rate of sequestration.
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The promoter region of certain IFN-a subtypes also contains specific cis-acting 
repressor elements which may contribute to differential expression of these a  subtypes 
during viral infection. A distal negative regulatory element (DNRE), which was first 
discovered in the IFN-al 1 gene subtype which is present in the genome but not 
expressed, has since been identified in the promoter region of IFN-a4. The DNRE 
sequence is considered a silencer region as it antagonizes the inducibility of the VRE 
promoter upstream of IFN genes. Silencing of IFN-al 1 gene is mediated by the 
transcription factor PitX which has dual role as an activator or silencer of type 1 IFN 
gene expression. PitX blocks IFN-al 1 induction by attaching to a DNRE region, 
associating with the translocated IRF3-IRF7 heterodimer and abolishing their 
transcriptional activity (Island et al. 2002) (Figure 1.3 B). While the DNRE element 
may be responsible for the permanent repression of the IFN-al 1 gene, its role in IFN- 
a4 regulation is more complex as the presence of an IRF binding region close to the 
DNRE acts as a antisilencer to override the effect of bound Pitxl. IRF3 binds the IRF 
region, and Pitxl associates with this IRF3 rather than IRF3 on the IRF3/IRF7 
complex.
The presence or absence of silencer and anti-silencer elements could play a role in 
the differential expression of IFN-a genes. Expression of IFN-a subtypes after viral 
infection is also affected by variations in the sequence of the VRE in their respective 
promoter regions, which would affect how well the promoter is recognized by the 
corresponding DNA-binding factors or the related transcription activators (Civas et al. 
2002).
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1.4.5 Effector activities of type 1 IFNs
1.4.5.1 Direct antiviral effects of type 1 IFNs
IFNs-a,-(3 and -X on their own do not posses any antiviral activity - they are important 
messengers that activate transcriptional of genes that encode direct antiviral activity. 
Type 1 IFNs released from infected tissue cells can help contain the spread of virus 
infection by upregulating expression of these proteins and creating an antiviral state in 
surrounding infected cells (Goodboum et al. 2000; Le Page et al. 2000a; Mamane et 
al. 1999).
Type 1 IFNs activate the expression of several hundred IFN-stimulated genes (ISGs) 
(Der et al. 1998). A subset of the ISGs whose production is up regulated by type 1 
IFNs have direct antiviral effects. Three IFN-activated antiviral pathways are 
particularly well characterised. These comprise the protein kinase PKR, activated by 
dsRNA, which suppresses cellular protein translation and promotes apoptosis; the 
enzyme 2’5’-OAS that produces short 2,5’ oligoadenylates that activate RNAse L, 
which destroys viral and host RNA (Doly et al. 1998); and Mx proteins, which are 
GTPases that are necessary for control of orthomyxovirus infections (Amheiter et al. 
1996; Hefti et al. 1999; Pavlovic et al. 1999).
Other antiviral ISGs include ISG20, promyelocytic leukaemia protein (PML) and 
guanylate-binding protein 1 (GBP-1) (Anderson et al. 1999; Espert et al. 2003; Regad 
and Chelbi-Alix 2001; Taylor et al. 2000), as well as P56 and RNA-specific 
adenosine deaminase 1 (ADAR1) (Guo et al. 2000; Hui et al. 2003; Samuel 2001), 
two antiviral proteins reported to limit replication of HCV (Taylor et al. 2005). 
Additionally, NF-kB and ATF-c-Jun are activated in response to various stimuli in 
order to regulate the expression of genes relevant to inflammation.
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1.4.5.2 Activating effects of type 1 IFN expression on the innate immune system
Type 1 IFNs have activating effects on many innate immune system cell types, thus 
indirectly contributing to antiviral effecter functions of the innate immune system and 
also helping to promote the induction of the adaptive immune response. IFN-a 
directly augments NK cytolytic function by inducing the lytic pathway, leading to 
secretion of perforin and granzyme B. IFNy production is also up-regulated, 
augmenting development of Thl-type adaptive responses as well as further activation 
of the innate response, e.g. macrophage activation (Le Page et al. 2000a).
There is also evidence that type 1 IFNs upregulate gene expression of TLRs 1 , 2 , 3  
and 7 in primary human macrophages after infection with influenza A and Sendai 
viruses (Miettinen et al. 2001)
DC maturation is directly triggered and promoted by type 1 IFNs. They stimulate 
migration of DCs into lymphoid tissues where they can interact with T cells. 
Simultaneously, they increase the expression of MHC class I on the surface of DCs, 
thus increasing antigen presentation, and also increase the expression of co­
stimulatory molecules such as CD80, CD83, CD86 and CD40 that are important in 
DC:T cell communication (Biron 2001). Type 1 IFNs appear to preferentially induce 
maturation and functional expression of co-stimulatory molecules from myeloid 
CDl l c+ DCs over plasmacytoid CD 11c' DCs (Ito et al. 2001), although they are 
required by plasmacytoid DCs for survival (Kadowaki 2000).
Type 1 IFNs have been reported to induce expression of various chemokines in DCs. 
In vitro generated monocyte-derived immature DCs, generated in the presence of 
GM-CSF plus IL-4 and then stimulated with type 1 IFNs upregulated CXCL9, 
CXCL11, and CXCL10 (the latter also upregulated in type 1 IFN stimulated DCs 
matured in GM-CSF + type 1 IFNs) (Padovan et al. 2002; Parlato et al. 2001). Each of
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these chemokines binds the CXCR3 receptor expressed by activated T- and B-cells 
and by plasmacytoid pre-DCs (Celia et al. 1999a; Loetscher et al. 2001; Shields et al. 
1999) indicating that DCs stimulated with type 1 IFNs may promote recruitment of 
these cells into specific regions of the lymphoid tissue or into peripheral sites of viral 
infection or inflammation. Additionally, DCs generated by culture in GM-CSF plus 
type 1 IFNs constitutively express CXCL19 and DC-CK-1 (Parlato et al. 2001), two 
chemokines involved in the recruitment of naive T cells and therefore may be critical 
for initiation of immune responses (Adema et al. 1997). Type 1 IFN stimulated DCs 
also secrete IL-15, which in turn promotes DC maturation, suggesting type 1 IFNs 
may activate an autocrine stimulatory circuit involving IL-15 (Mattei et al. 2001).
1.4.5.3 Type 1 IFN as a modulator of the adaptive immune response
Type I IFNs are an important link between the innate and adaptive immune response 
(Kadowaki 2000). They not only help to activate DCs to become potent stimulators of 
T cell responses, but also by inducing cells of the innate immune system to produce 
cytokines such as IFN-y and IL-12, they bias the response induced in a Thl direction. 
Recent studies have shown that the use of type 1 IFNs as an adjuvant for soluble 
protein antigens results in stimulation of strong T cell responses, and that mice 
lacking the IFN-R respond poorly to complete Freund’s adjuvant. This suggests a 
model for adjuvant responses where detection of viral/bacterial components (via TLR 
and other PRR) induces type 1 IFN production that primes DCs to become optimal 
antigen presenting cells which in turn activate and maintain Thl-type, CD8+ and 
CD4+ T cell responses and the production of antibodies of isotypes with good 
antiviral effecter functions (Le Bon et al. 2003; Le Bon et al. 2001; Le Bon and Tough 
2002). Additionally, type 1 IFNs may also act directly on T or B cells to enhance
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antigen-specific immune responses (Le Bon et al. 2006a; Le Bon et al. 2006b). During 
MCMV infection, production of low levels of IFN-P appears to be required for T cell 
survival (Banks et al. 2005).
Type 1 IFNs may also play an important role in the maintenance of memory T cell 
responses, by stimulating the production of cytokines such as IL-15 that drive low- 
level turnover of memory-phenotype T cells (Tough et al. 1996).
Type 1 IFNs also regulate the activity and/or expression of other cytokines ((Le Page 
et al. 2000b; Pestka et al. 2004; Theofilopoulos et al. 2005; Tough 2004). Basal 
expression of type 1 IFNs increases the signalling of IL-6 by providing docking sites 
for ST ATI and STAT3 on the IFNR1, which may bring it into close proximity with 
the gpl30 chain of the IL-6 receptor (Mitani et al. 2001). The presence of type 1 IFNs 
also upregulates expression of transforming growth factor p (TGF-P), IL-1 receptor 
agonist and TNF (Brassard et al. 2002). Conversely, STAT6 activity is downregulated 
by IFN a/p through secretion of IL-4 which in turn induces expression of SOCS-1 
(Dickensheets et al. 1999). IFN-a/p also antagonizes expression of another anti-viral 
cytokine, IL-12, although it upregulates transcription of the IL-12 receptor’s p2 
subunit in CD4+ T cells (Biron 2001; Trinchieri 2003).
1.4.5.4 Systemic vs. local IFN induction and action
Most cells use the intracellular helicase pathway to detect viral infection and respond 
with type 1 IFN production. These are cells likely to be the first host cells infected 
upon initial exposure to the virus. Here, production of type 1 IFN is dependent upon 
activation of pre-existing IRF3 and upregulation of IRF7 (Kawai et al. 2005; Seth et 
al. 2005). It can be thus argued that IRF3 may be important in generating localized 
type 1 IFN reponses early in an infection as a means to control viral spread and clear
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the infection. However, IRF7 is absolutely critical for control of systemic infection 
coupled with high viral load, as in this scenario, plasmacytoid DCs are major 
contributors to type 1 IFN production and the principal pathway for type 1 IFN 
induction in these plasmacytoid DCs is the TLR7/ TLR9-MyD88-TRAF6-IRF7 
pathway and not intracellular IRF3-mediated induction.
In such a situation, activated plasmacytoid DCs migrate to T cell zones of secondary 
lymphoid organs to help prime naive T cells (Colonna et al. 2004; Nakano et al. 
2001). Thus the type 1 IFNs secreted by these plasmacytoid DCs may act locally to 
induce maturation of other DCs in the vicinity and ultimately aid the priming of CD8+ 
T cell mediated adaptive immunity. It may be likely that systemic vs. local induction 
of type 1 IFN, which seeks to employ different IRFs for induction of type 1 IFN, 
represents a host-derived mechanism to discriminate between a mild viral infection, 
one which only affects a limited part of the body and can be controlled by local 
antiviral responses, from a more virulent infection needing a systemic response and T 
cell mediated clearance.
1.4.5.5 Negative regulatory effects of type 1 IFN
In addition to their immunostimulatory effects, type 1 IFNs may also have negative 
regulatory effects on their ability to modulate cell proliferation and survival. For 
example, as well as stimulating T cell responses, type 1 IFNs have an anti­
proliferative effect on T cells. The mediated effect is thought to depend both on the 
levels of type 1 IFN present and the timing of the exposure of T cells to type 1 IFNs 
during the immune response. The anti-proliferative effects of type 1 IFNs may be 
critical to proper functioning of adaptive immunity. If left unchecked, excessive 
proliferation of T cells may lead to immunopathological damage. T cells become
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refractory to IFN (by down regulating IFN-R) upon activation as a means of resisting 
apoptosis (Dondi et al. 2003). Studies on the effect of pre-existing levels of IFN-P on 
the functions of DCs found that IFN-p plays a dual role in shaping the T cell response, 
crucially, the timing of the exposure to IFN-P determined whether it promoted or 
inhibited generation of a functional T cell effector response (Nagai et al. 2003). When 
immature DCs were exposed to IFN-P and then matured, the matured DCs primed T 
cells which lacked IFN-y production, and downregulated levels of TNF-a and LT, 
cytokines normally associated with a Thl profile. Furthermore, pre-existing IFN-p 
reduced DC secretion of IL-12 which is needed for T cell expansion, and down- 
regulated expression of IL-18. Pre-existing IFN-p also elevated IL-10 levels in 
differentiated effector Th cells, thus dampening the cytotoxic immune response. 
IFN-a/p is also able to exert inhibitory effects on B cell development and survival. 
Bone and spleen cellularity were found to be depleted in IFN-a treated mice and B- 
lineage cells were reduced by more than 80%, especially levels of CD19+ pro-B cells 
(Lin et al. 1998a). Furthermore, type 1 IFNs may inhibit apoptosis of mature B cells. 
Hahmn et al (2005) also report that continuous expression of type 1 IFNs may 
suppress maturation of bone-marrow DC precursors.
1.5 Cellular components of the innate immune response
1.5.1 Dendritic cells
Dendritic cells were first described in 1973 by Steinman and Cohn (Steinman and 
Cohn 1973; Steinman et al. 1974; Steinman et al. 1980). They are sparsely distributed 
cells of hemopoietic origin. There are numerous types of DCs in the peripheral tissues 
such as the skin and in the blood and lymphoid tissues, the lineages between which 
are unclear. Phenotypic analysis has demonstrated that DCs are a highly
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heterogeneous population. Many subtypes of DCs have been described with 
overlapping functions. In the spleen of mice, DC can be classified into three main 
subsets: Ly6C' B220' CD8a* C D llb+ C D llc+, which may be further subdivided on 
the basis of CD4+/' expression (myeloid DCs), Ly6C' B220' CD8a+ C D llb ' C D llc+ 
(lymphoid DCs) and Ly6C' B220+ CD1 lb ' CD1 lc'° (plasmacytoid DC). The CD1 lc+ 
lymphoid and myeloid DC subsets are together termed conventional DCs. 
Additionally, another subset of conventional DCs, termed interstitial DCs, have been 
isolated from the lymph node (Villadangos and Heath 2005), while yet another DC 
subset, defined by CD205 expression, is found only in the lymph nodes that drain the 
lungs, kidney and liver (Belz et al. 2004). Langerhans cells, which are present in the 
skin, comprise yet another DC subset.
Splenic conventional DC subsets do not appear to traffic through peripheral tissues 
before reaching the secondary lymphoid organs, but instead may be derived from 
precursors that traffic directly to the spleen and lymph nodes via the blood 
(Villadangos et al. 2001). The development pathway of plasmacytoid DCs remains 
controversial. It has been variously suggested that they are generated from a common 
myeloid precursor that is able develop into any DC subset (del Hoyo et al. 2002; 
Wilson et al. 2003), that plasmacytoid DCs are generated from a committed lymphoid 
precursor (Grouard et al. 1997) or that plasmacytoid DCs may be a subset of 
lymphoid cells undergoing programmed conversion into myeloid cells (Comeau et al. 
2002; Zuniga et al. 2004). What has been established is the requirement for Flt3 
ligand in the development process of DCs in general and specifically for plasmacytoid 
DC generation, as Flt3L k/o mice lack plasmacytoid DCs and posses reduced numbers 
of myeloid and lymphoid related (CD8a+) DCs (Brawand et al. 2002; D'Amico and 
Wu 2003; Karsunky et al. 2003; McKenna et al. 2000). Granulocyte-macrophage
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stimulated factor (GM-CSF) may also be required as it enhances plasmacytoid DC 
migration from the bone marrow (Arpinati et al. 2000; Pulendran et al. 2000).
DCs in the spleen possess a high turnover rate, of about 2-5 days and even quicker 
upon activation (Kamath et al. 2000). As analysis of the blood did not reveal large 
influxes of replacement DCs or their precursors (O'Keeffe et al. 2003), it is likely that 
the source of replacement precursor cells are pre-DC precursors that seed the spleen 
and lymph nodes directly from the bone marrow (Villadangos and Heath 2005).
The frequency of DC belonging to each subtype may differ in different mouse strains. 
Using a plasmacytoid DC specific antibody, 120G8, Asselin-Paturel et al (Asselin- 
Paturel et al. 2003) analyzed the frequency of this population in the spleens of 
different strains of mice. They found that the frequency of 120G8+ plasmacytoid DCs 
was lowest in C57BL/6 mice (6.7% of total splenic DCs) and highest in 129Sv mice 
(27.8% of total splenic DCs). In contrast, the frequency of the splenic CD8+ DCs 
subset among total DC was higher in C57BL/6 strains than in 129Sv (20.2% vs. 
2.6%). Such differences could affect the ability of the specific strains to overcome 
infections by distinct pathogens.
1.5.1.2 Role of DCs in antiviral innate immunity
DCs are often the first cells of the immune system that responds to a pathogen due to 
both their location and their ability to sense the presence of a pathogen directly, e.g. 
via PRRs or by detecting the presence of cytokines released by other cell types in 
response to infection, e.g. the release of type 1 IFNs. All DCs have strong phagocytic 
ability, being able to internalise soluble proteins, microbes and pieces of dying cells 
from the extra cellular environment. They also sample the environment by 
macropinocytosis, forming large pinocytic vesicles in which extracellular fluid and
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solutes are sampled (Sallusto et al. 1995). DCs also express receptors that mediate 
adsorptive endocytosis, including lectin receptors like the macrophage mannose 
receptor and DEC-205, as well as Fey and Fee receptors (Sallusto et al. 1995);(Jiang 
et al. 1995). Direct recognition of the pathogen is accomplished through the 
expression of a variety of pattern recognition receptors outside and inside the cell. 
Each splenic DC subset expresses a unique combination of TLRs, as outlined in Table
1.2 overleaf:
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Table 1.2 Types of TLRs expressed by different splenic DC subsets (adapted from 
(Edwards et al. 2003))
DC subset
Relative levels of TLR mRNAs expressed
1 2 3 4 5 6 7 8 9
CD l 1 chiLy6CloB220'CD4+ +++ +++ -/+ + +++ + + + + + + + + + + + +
CD1 lc hiLy6CloB220'CD8a+ +++ +++ + ++ -/+ ++ - + + + + +
CD l 1 cmLy6C,oB220'CD4' 
CD8
+ + + + + + + + + + + + + + + + + + +
CD l lc dimLy6ChiB220+ + + + + + - + + + + + + + + + + + + +
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Upon encountering a non-self component/antigen, the previously quiescent DCs begin 
their activation or maturation process, characterised by migration out of their resident 
environment coupled with upregulation of the chemokine receptor CD62L, which 
allows entry into secondary lymphoid organs such as the lymph nodes and the spleen 
(Celia et al. 1999a; Nakano et al. 2001; Tough 2004).
Activation is accompanied by production of a range of cytokines tailored to combat 
the pathogen. During viral infections, production of type 1 IFN or IL-12 by DCs are 
key to the initiation of inflammatory, innate and adaptive responses (Akira and 
Hemmi 2003; Akira et al. 2001; Trinchieri 2003). Also, secretion of cytokines and 
chemokines at the site of infection serves to recruit more monocytes and DCs from 
the blood, thereby alerting and amplifying the innate response (Banchereau et al. 
2000; Shortman and Liu 2002).
DCs possess direct anti-viral activity, via secretion of type 1 IFN leading to 
inducement of an anti-viral state. A subset of dendritic cells have been recently 
described that displays strong NK cell-like activity (Chan et al. 2006).
Cytokine production by pathogen-activated DCs also regulates the anti-viral activity 
of other innate cells, such as NK cell function. Human and murine plasmacytoid DCs 
secrete type 1 IFN and IL-15 which promote NK cell cytolytic activity and cytokine 
production and prolong their survival (Ferlazzo et al. 2003; Walzer et al. 2005a). 
During MCMV infection, interactions between murine NK cells and CDl lb ' 
conventional DCs have been shown to be integral to NK cell activation (Dalod et al.
2003). Engagement of the cell surface receptor NKG2D on NK cells and the NKG2D- 
ligand on the surface of MCMV-exposed CDl lb+ DCs provided the signals necessary 
to override the inhibitory signals provided by MHC I engagement to activate NK 
cytotoxic functions (Andoniou et al. 2005). Furthermore, NK cell capacity to produce
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IFN-y was reliant upon the polarized secretion of IL-12 and IL-18 released by the 
C D llb+ DC subset. Finally, adoptive transfer of MCMV-activated C D llb+ DCs 
resulted in improved control of MCMV infection, indicating that these cells 
participate in controlling viral replication in vivo (Andoniou et al. 2005). It should be 
noted that this NK-DC crosstalk is bi-directional - immature myeloid DCs physically 
interact with NK cells while the DCs supply NK cells with proliferative and survival 
signals such as type 1 IFNs and IL-15 (Moretta 2005), while cytokines such as TNF- 
a, IFN-y and GM-CSF produced by NK cells can influence the progression of DC 
maturation.
1.5.1.3 Mechanism of type 1 IFN induction in splenic DCs
In many viral infections, DCs have been identified as the major type 1 IFN producer 
during early infection. The range of PRRs expressed on different DC subsets enables 
many components of the same virus to be detected, e.g. viral RNA/DNA by TLR 
3/7/9 or RIG-I/MDA5 receptors, viral glycolipid by TLR 4 or DEC 205 and viral 
glycoproteins by TLR/lectin-type receptors (Haller et al. 2006). This, coupled with the 
means to signal for type 1 IFN via a number of adaptor molecules, such as MyD88, 
TBK or NF-kB, gives a level of redundancy in the system. This helps to ensure 
efficient type 1 IFN responses even if one component of the pathway is disrupted by 
the virus. Differential expression of TLRs on different DC subsets means that each 
subset is induced to produce type 1 IFN in response to a unique subset of stimuli. For 
example, plasmacytoid DCs are believed to have evolved to respond very rapidly to 
viral pathogens as they express TLR7 and TLR9 in the endosomal compartment 
(Beutler et al. 2006; Bowie and Haga 2005; Malmgaard et al. 2004) which serve to 
detect the presence of viral genomic components. Plasmacytoid DCs also possess the
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intracellular RIG-I and MDA5 helicases but preferentially induce type 1 IFN via TLR 
signalling, a mechanism that probably evolved to allow swift and early production of 
type 1 IFN without the need for intracellular viral replication to occur in the 
plasmacytoid DCs. This means that plasmacytoid DCs can respond to the presence of 
infection themselves without becoming infected. As described earlier, plasmacytoid 
DCs are primed to produce high levels of IFN-a/p in the initial stages of infection to 
combat viral infections (Celia et al. 1999b; Colonna et al. 2002; Edwards et al. 2003; 
Siegal et al. 1999). Furthermore, plasmacytoid DCs consistently express lower levels 
of co-stimulatory molecules and are reported to be poor APCs compared to the other 
subsets, thus suggesting they may have evolved to be specialized type 1 IFN 
producing cells, rather than APCs (Asselin-Paturel et al. 2001; Grouard et al. 1997). 
Conventional DCs preferentially express TLR3 and can sense viral and other dsRNA 
molecules in the endocytic compartment. They can thus respond to viral RNA from 
viruses with dsRNA genomes or dsRNA derived from uninfected cells provided they 
are taken up in the endosomal compartment (Schulz et al. 2005), again without the 
need to be infected themselves. However, conventional DCs can also produce type 1 
IFNs in response to being infected. Experiments in which infected conventional DCs 
were infected with RNA viruses Sendai or VSV indicate that, in spite of differences in 
the route of entry, both viruses preferentially induced production of type 1 IFN via the 
helicase pathway and not the TLR3 activated signalling (Kato et al. 2005). The 
presence of TLR3 in conventional DCs may be predominantly used to recognize viral 
double-stranded RNA released from virally infected apoptotic cells sampled from the 
environment.
In summary, the combination of TLR expression and the capacity to sample the 
environment around them confers DCs (especially plasmacytoid DCs) with the ability
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to initiate the first wave of type 1 IFN production even before they are intracellularly 
infected, unlike other cell types which can only respond to the presence of a virus 
when it enters the cytoplasm. This is a useful ability should the invading pathogen 
posses a means of blocking type 1 IFN induction in the cells it infects as this first 
wave of type 1 IFN secreted by the DCs can then activate antiviral genes and 
paracrine induction of type 1 IFN via the IFN-R JAK/STAT signalling pathway on 
the other cell types which, in the absence of DC-secreted type 1 IFN, would be 
susceptible to infection by the pathogen, and not be able mount a subsequent type 1 
EFN-activated antiviral response if the infecting vims induced impairment of the type 
1 IFN pathway.
1.5.1.4 Modulation of adaptive immunity by DCs
Perhaps the most important Junction of DCs is to transfer and translate cues from their 
surrounding microenvironment in order to inform and ‘educate’ the adaptive immune 
response. The ability to transfer an antigenic ‘snapshot’ of their environment is 
achieved via their antigen sampling and migratory capacities, which enable DCs to 
travel to lymphoid organs and expose circulating T cells to peripheral antigens that 
they would not have otherwise encountered. Additionally, DCs have the ability to 
translate environmental cues for the benefit of the host by possessing the capacity to 
activate different types of adaptive response or silence the adaptive immune response. 
As professional APCs, DCs are able to prime pathogen-specific adaptive responses 
and also tolerise the T cell response to self antigens. The specific role played by DCs 
(as activators or silencers) in host immunity depends upon the activation status, 
location as well as their cytokine expression profile. The range of cytokines secreted
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is also subject to temporal constraints, namely different cytokine subsets are 
expressed during each stage of DC development and maturation.
In the absence of pathogens or a danger signal, DCs are present in tissues, lymphoid 
organs and the circulation in an immature, inactivated state (Henri et al. 2001; Wilson 
et al. 2003). In in vitro experiments, these immature DCs which express low levels of 
co-stimulatory molecules, do not interact productively with CD8+ T cells (Albert et al. 
2001). Unless DCs are in some way activated or licensed to produce immunity, the 
stimulation of T cells by DCs, will, by default, lead to tolerance. ‘Inappropriately’ 
activated DCs, for example, DCs induced to mature by TNF-a and prostaglandin E2, 
are able to stimulate CD8 T cell proliferation but this leads to tolerance induction as 
the cells are eventually deleted. In order to be ‘licensed’, DCs must receive another 
signal, which can be delivered from CD4 T cells, via interaction of CD40L with 
CD40 on the mature DC cell surface (Celia et al. 1996; Schoenberger et al. 1998), 
although signals via type 1 IFN appear to overcome the requirement of CD4 T cell 
help (Le Bon et al. 2003). Licensing has been reported to require direct stimulation by 
pathogen associated stimuli (Sporri and Reis e Sousa 2005).
A possible mechanism for DC-mediated self tolerance in vivo has been put forward, 
based upon the observation that the vast majority of DCs in the spleen are in an 
immature state and thus express very low levels of co-stimulatory molecules; their 
role may be to establish peripheral tolerance during steady state while maintaining 
their capacity to respond to infections reaching the organs (Naik et al. 2006). 
Migration of tissue DCs into the draining lymph node occurs constitutively at a low 
level. These DCs have engulfed host cells and therefore present naive T cells with 
self-antigens, but as they are in an immature state, the T cells are not active and so 
peripheral tolerance to self antigens is maintained. Therefore, mature but quiescent
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DCs induce tolerance while activated, licensed mature DCs induce immunity (Reis 
2006; Shortman and Heath 2001).
These biochemical signals, which determine the fate of naive T cells, are referred to 
as Signal 1, 2 and 3.
1.5.1.4.1 Signal 1
Signal 1 refers to the physical interaction between pathogen peptide-MHC complexes 
expressed on the surface of the DC and antigen specific TCRs expressed by T cells (at 
the immunological synapse). This is believed to occur mainly in the lymphoid organs 
such as the spleen or the lymph nodes. Immature DCs, which are present in most 
tissues, possess several features that allow them to be specialized at antigen uptake. 
They are able to sample the antigens in their environment by phagocytosis and 
pinocytosis, forming large pinocytic vesicles in which extracellular fluid and solutes 
are sampled (Reis e Sousa et al 1993; Albert et al, 1998, Inaba et al, 1998). They also 
express receptors such as the mannose macrophage receptor (Engering et al. 1997; 
Sallusto et al. 1995), DEC-205 (Jiang et al 1995), Fey (Sallusto and Lanzavecchia
1994) and Fee (Maurer and Stingl 1995) receptors that enhance adsorptive 
endocytosis. Unlike other cell types, captured antigen can be process by both the 
MHC class I (cytotoxic) and MHC class II (helper) pathways (Banchereau and 
Steinman 1998). These different mechanisms dramatically increase the amount of 
antigen available for presentation. Immature DCs also contain MHC class II rich 
compartments, to which exogenously-acquired antigens are targeted (Kleijmeer et al.
1995). After peripheral encounter with infection or antigen, DCs are induced to 
mature, reducing antigen uptake, increasing expression of MHC molecules on the cell 
surface and upregulating expression of co-stimulatory molecules and subsequently
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migrate to lymphoid organs such as the spleen. This results in influx of matured DCs 
with high expression of the MHC class I and MHC class II molecules on the cell 
surface into the T cell zones of the lymph node and spleen (Itano et al. 2003; 
Lanzavecchia and Sallusto 2001). In mature DCs, MHC class Il-peptide complexes 
are stably expressed on the surface for days providing a window for prolonged CD4+ 
T cell stimulation (Celia et al. 1997a; Pierre et al. 1997; Winzler et al. 1997). 
Furthermore, the morphology of mature DCs alters to become cells with multiple long 
dendrites that can simultaneously engage multiple naive CD4 and CD8 T cells (Miller 
et al. 2002).
All cell-cell interactions occur within defined structures of the spleen or the lymph 
node. Destruction of the lymphoid architecture in some cases disrupts adaptive 
immunity (Deonarain et al. 2003; Koch et al. 2005). CD8+ T cell interactions with 
DCs occur in three successive stages: transient serial encounters during the first 8 
hours in which the T cells decrease their motility and upregulate activation markers; 
formation of long-lasting stable T cell:DC conjugates and secretion of IL-2 and EFN-y 
by T cells; and finally T cell migration at ~48hrs coinciding with onset of 
proliferation and reduction of DC contacts (Mempel et al. 2004).
1.5.1.4.2 Signal 2
Signal 2 refers to the accessory signals delivered to the T cell via co-stimulatory 
molecules e.g. through engagement of CD80 or CD86 on the cell surface of a licensed 
DC with CD28 on the T cell surface (Keir and Sharpe 2005) and CD40. DCs must be 
matured, via interactions with pathogen components, inflammatory mediators such as 
LPS, TNF-a or via CD4+ T cell, in order for signal 2 to be delivered. In the absence of 
Signal 2, interaction between DC antigen-peptide MHC with naive T cell TCR
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(Signal 1) inactivates or tolerises the T cell by anergy, deletion or turning it into a 
regulatory cell, plasmacytoid DCs may also bring about tolerance via activation of 
regulatory CD4 T cells (Kawamura et al. 2006).
1.5.1.4.3 Signal 3
Signal 3 refers to signals from DC and other environmental sources to T cells that 
determine type of effector cell the T cell will become, for example differentiation into 
T helper 1 (T h I )  cells or Tr2 cells or cytotoxic T lymphocytes (CTL). Cytokines and 
other molecules secreted by various DC subsets define the milieu in which T cells 
proliferate. Expression of IL-12, IL-18 and IFN-a, which biases CD4 T cells towards 
a pro-inflammatory ThI cell fate, and production of Notch ligands which promote 
differentiation into Tr2 effecter cells, are examples of DC-mediated Signal 3.
It has been suggested that interaction with different DC subtypes may affect the 
outcome of the effector functions of the matured T cells. This proposal arises from the 
observation that each DC subset expresses a unique combination of TLRs and 
cytokine profile, which would then enable each subset to be optimised to promote 
distinct effector functions. For example, it has been reported that the CD8a+ and the 
CD8a' DC subsets differentially prime Thl vs. Th2 responses (Maldonado-Lopez et 
al. 1999; Pulendran et al. 1999). In addition, ony CD8a+ DCs are reported to be able 
to cross-prime CD8+ T cell responses. Furthermore, treatment with LPS preferentially 
induced IL-12p70 production in the CD8a+ DC subset (Dillon et al. 2004; Pulendran 
et al. 2001), and finally the CD8a" CD4a+ DC subset could not be induced to produce 
IL-12p70 in response to a range of innate stimuli (Agrawal et al. 2003; 
Manickasingham et al. 2003). However, while the subsets may be genetically 
programmed to differentially regulate the quality of the T cell response, these subsets
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also exhibit a large degree of functional flexibility in response to environmental cues, 
as evidenced by reports that challenge the above hypothesis with observations that the 
same population of DCs could stimulate either Thl or Th2 responses depending upon 
the stimuli it encountered (Boonstra et al. 2003; Huang et al. 2001; Vieira et al. 2000; 
Whelan et al. 2000).
In addition to educating and activating the cytotoxic T cell response, DCs have also 
been shown to modulate anti-viral B-cell development by secreting IL-6, which 
induces human B cells to differentiate into antibody-secreting plasma cells. Also, B- 
cells activated by plasmacytoid DCs preferentially secrete IgG instead of IgM, 
suggesting they may specifically target memory B cells (Jego et al. 2003).
1.5.1.5 Cross presentation
As mentioned above, DCs posses the ability to present exogenously acquired antigens 
on MHC class I molecules, a process termed cross-presentation (Heath et al, 2004). In 
most cell types, MHC class I molecules only present antigens present in the cytoplasm 
to ensure that only virally infected cells are recognized and destroyed by CTLs. 
Antigens from a variety of sources can be presented to CD8+ T cells in this manner, 
but this process is especially important in generating CTL responses against targets 
that do not or can not infect professional antigen presenting cells such as DCs. These 
include immunological relevant antigens such as antigens acquired through uptake of 
apoptotic cells, virally-infected cells and tumour cells (Heath et al 2004). However, it 
appears that not all DCs are able to cross present, as recent reports suggest that cross­
priming primarily occurs via the CD8a+ subset (Belz et al. 2005; Schnorrer et al. 
2006) and may be promoted by activation of TLR3 (Schulz et al. 2005)
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1.5.2 NK cells
NK cells play an important role in controlling many viral infections (Biron and 
Brossay 2001; French and Yokoyama 2003; Lodoen and Lanier 2006). They are cells 
of lymphoid origin that are present systemically, in the blood, spleen and lymphoid 
organs and in tissues (Yokoyama et al. 2004). NK cells are important in the control of 
tumour growth and viral infections, particularly in the control of herpesvirus 
infections, exerting their effects mainly through mediating lysis of malignant or 
virally infected cells and through production of antiviral cytokines such as IFN-y 
(Biron et al. 1996; Kagi et al. 1994; Loh et al. 2005). In humans, NK cells constitute 
about 15% of peripheral blood lymphocytes. In mice NK cells constitute about 2.5% 
of splenic leukocytes and about 5-10% of peripheral blood. Typically, murine NK 
cells are defined by expression of CD 122, NK1.1 and DX5 (Yokoyama et al. 2004) 
Activation of NK cell effector functions is controlled by the balance of signalling 
through activating and inhibitory NK receptors (Lanier 2003; Moretta and Moretta
2004). The receptors are able to recognize normal cells of self origin through their 
surface expression of histocompatibility complex (MHC) molecules; in normal cells, 
activation of these receptors inhibits activity of NK cells, protecting the uninfected 
cell from lysis (Vivier et al. 2004). Virus infected or malignant cells often experience 
changes in protein expression, and often express MHC class I at reduced levels 
therefore they are less able to maintain suppression of NK cell activity, rendering 
them more susceptible to NK cell cytolysis (Cerwenka and Lanier 2001; Smyth et al.
2005). Triggering of NK cell lysis is also promoted by the interaction of activating 
NK cell receptors with ligands such as viral glycoproteins and stress-induced 
molecules on the surface of target cells.
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NK cell activity is enhanced by the presence of cytokines such as IL-12, IL-15, IL-18, 
IL-21 and IFN-a/p (Nguyen et al. 2002a; Okamura et al. 1998; Orange and Biron 
1996; Smyth et al. 2005). Activated NK cells are induced to secrete cytokines such as 
IFN-y and TNF-a and are also able to mediate destruction of target cells by perforin- 
dependent binding of pathways and by death receptors such as Fas and TRAIL-R on 
target cells to induce apoptosis (Sato et al. 2001a; Smyth et al. 2001). Additionally, 
NK cells modulate other components of innate immunity by secretion of cytokines or 
signals that induce either maturation or apoptosis of dendritic cells and help to 
promote the development of Thl-type T cell responses (Andoniou et al. 2005; Della 
Chiesa et al. 2006; Gerosa et al. 2002; Gerosa et al. 2005)
1.5.3 Macrophages
Macrophages are myeloid lineage cells with a wide tissue distribution. Monocytes 
which circulate in the blood differentiate into macrophages upon migration into 
tissues. These are phagocytic cells, which play an important role in controlling early 
bacterial and fungal infections. Macrophage mediate pathogen clearance by a variety 
of means -  for example, they express pathogen recognition receptors such as the 
mannan receptor or CD 14 that recognizes distinct sugars on bacterial cell surfaces and 
enable binding and killing of the bound pathogen (Aderem and Underhill 1999; Stahl 
and Gordon 1982; Tobias and Ulevitch 1993). Alternatively, macrophages are able to 
promote complement activation or phagocytosis that result in removal of the 
pathogen.
In addition to their role in the clearance of bacterial or fungal pathogens, macrophages 
may also help control viral infections, as studies in macrophage-deficient mice 
suggest they may be unable to clear viral infections (Karupiah et al. 1996; Seiler et al.
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1997). Activated macrophages have been reported to produce IL-1, IL-6, IL-12 and 
TNF-a that enhance recruitment of lymphocytes to the site of infection as well as 
promote their functional activation (Salazar-Mather and Hokeness 2003).
1.6 Evasion of the innate immune system by viruses
1.6.1 Overview of viral immune evasion strategies
Many vimses have evolved strategies for interfering with host immune responses to 
promote their survival within the host. Such strategies may facilitate the duration of 
acute infections or permit the establishment and maintenance of chronic infections. 
These viral immunoevasion strategies may target both the innate and adaptive 
immune response, with innate cytokine responses DCs, NK cells, T cells and antiviral 
antibody responses all being evaded by different viruses (Ambagala et al. 2005; 
Andrews et al. 2005; Lodoen and Lanier 2006; Pollara et al. 2005). Immunoevasion 
strategies may be divided into tactics employed to avoid normal host 
immunosurveillance mechanisms or impair the host immune response. Tactics used to 
avoid normal host immunosurveillance include establishing latency, where, after the 
productive, acute phase of viral replication, vims remaining in the infected cell 
downregulates protein replication completely or to levels too low to be detected by 
the host response. Examples of viruses that can establish latency are HSV (latent in 
sensory neurons), varicella zoster vims (VZV) (latent in dorsal root ganglia) and 
Epstein-Barr virus (EBV) (latent in B cells). EBV is not fully latent in cells, as a 
single protein the Epstein-Barr vims nuclear antigen (EBNA)-l is expressed to 
maintain the viral genome, but this protein is unable to elicit a T cell response. Human 
papilloma vims (HPV) is another vims that becomes latent, but during latency
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expresses only low levels of viral proteins, thus avoiding detecting by the immune 
response (Frazer et al. 1999).
Another strategy employed by viruses is to infect cells in immunopriviledged sites, 
which are areas of little immune surveillance (Tortorella et al. 2000). Such areas 
include the central nervous system (CNS), the kidney, salivary glands and the anterior 
chamber of the eye. Examples of such viruses include HSV, VZV and measles virus 
which have tropism for the CNS, and are protected from CTL clearance low levels of 
MHC expression on cells of the CNS and by the blood brain barrier which limits 
trafficking of immune cells.
A number of viruses practice antigenic variation as a means to escape from host 
immune responses. Rhinoviruses and influenza viruses constantly alter the structure 
of epitopes of the dominant surface proteins haemagglutinin (HA) and neurominidase 
(N) such that strains quickly become unrecognizable by neutralizing antibodies 
generated by past infection with previous strains, permitting re-infection to occur. 
Such changes are termed antigenic drift (Tortorella et al. 2000). Antigenic variation is 
also employed to evade the CTL response. Mutation in viral CTL epitopes can 
abrogate epitope-specific responses by modifying peptide processing or transport, 
altering peptide binding to MHC class I or peptide interaction with the TCR, as 
discussed in more detail below. Antigenic variation is a strategy especially favoured 
by RNA viruses, including HCV, HIV, influenza and LCMV (in laboratory settings) 
in part because the proofreading mechanism of RNA polymerases is less efficient than 
DNA polymerase leading to higher error rates in the RNA genome (Elena and 
Sanjuan 2005). Thus each round of replication leads to an ever increasing number of 
genetic variants within the host, such that the virus exists as a quasi-species, and these 
variants are then subjected to selection pressure for fitness including the potential to
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escape immunosurveillance. Other mechanisms of antigenic variation include 
reassortment and recombination of the viral genome (Hay et al. 2001).
Apart from avoiding the host’s immune responses, certain viruses are able to impair 
immune functions in order to establish an infection. In the case of some viruses, 
infections may be associated with generalised immunosuppression; in many virus 
infections impairment occurs in a more restricted manner.
Measles virus is able to infect T cells, B cells, monocytes and DCs in vitro, and 
induce syncytium formation or apoptosis, therby destroying key immune cells (Joseph 
et al, 1975) with a knock-on effect on other immune responses as a result of reduced 
T and B cell function (reviewed in (Borrow and Oldstone 1995; Schneider-Schaulies 
et al. 2003) thus inducing a state of transient profound immunosuppression.
Dendritic cells are critical for both early innate responses and priming of T cells, and 
as such, activity of these cells is often subjected to impairment. Plasmacytoid DCs are 
often targeted as they act as viral sentinels and a source of type 1 IFN in peripheral 
sites of infection (Bautista et al. 2005; Freigang et al. 2005; Liu 2005; Rinaldo and 
Piazza 2004). There are several mechanisms by which viruses may interfere with DC 
function, but general strategies include alteration of the differentiation or signalling 
pathways, or modulation of DC effector functions in order to block induction of host 
T cell responses (Flano et al. 2005; Majumder et al. 2005; Walzer et al. 2005b)
NK dysregulation is another method of evading the innate immune system. Viruses, 
such as HCV and HIV that go on to generate a persistent infection, and even other 
viruses, like vaccinia which cause acute infections, have evolved means to modulate 
NK cell functions (Meier et al. 2005; Reading and Smith 2003). Viruses are able to 
interfere with either NK receptor-mediated recognition of virus infected cells by 
expressing homologs of MHC class I or modulating MHC expression on infected
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cells, interfere with the release of NK-activating cytokines such as type 1 IFN, affect 
the intracellular activation pathway by antagonizing NK receptor functions and inhibit 
effector functions by blocking production of granzyme or Fas ligand (Domer et al.
2004)
In T cells, multiple viruses are known to inhibit the MHC class I restricted antigen 
presentation pathway of infected cells to avoid recognition by CD8+ T cells 
(Ambagala et al. 2005; Lilley and Ploegh 2005; Lybarger et al. 2005; Yewdell and 
Haeryfar 2005). HIV-1 impairs the T cell response by replicating in CD4+ T 
lymphocytes, rendering targets for destruction (Tortorella et al. 2000).
Also, several viruses are able to inhibit the presentation of lipids to CD la-restricted 
T cells (Renukaradhya et al. 2005; Sanchez et al. 2005).
It is not uncommon for viruses to target more than one arm of the host immune 
response, or to employ multiple strategies for evading a given antiviral effector 
mechanism. For example, EBV escapes immunosurveillance by becoming latent in B 
cells, but the EBNA-1 protein which is expressed during latency is also able to avoid 
detection by CD8+ T cell through interference of the antigen processing pathway to 
impede presentation by MHC class I molecules, reducing the surface MHC expression 
on infected cells.
HSV becomes latent in neuronal cells which are immunopriviledged because they 
express low levels of MHC class 1 molecules (Abendroth and Arvin 1999).
Herpes viruses and poxviruses express a variety of virally-encoded proteins which are 
soluble forms of immune receptors as a way to ‘mop up’ secreted cytokines and thus 
dampen the immune response, including soluble forms of TNF and IFN-receptors 
(Alejo et al. 2006; Couty and Gershengom 2005; Nicholas 2005; Rosenkilde 2005; 
Sodhi et al. 2004). Certain viruses have evolved mechanisms to inhibit activation of
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the apoptotic pathway in infected cells to reduce the availability of antigen for cross­
presentation (Bowie et al. 2004; Boya et al. 2004; D'Agostino et al. 2005) or prevent 
cross-presentation by inhibiting phagocytosis (Cheung et al. 2005; Watts and 
Gommerman 2005).
Finally, many viruses also interfere with production of antiviral cytokine, type 1 IFNs, 
which is discussed in more detail in the next section.
1.6.2 Viral evasion of the type 1 IFN response
Many viruses have developed strategies to counteract the biological functions of type 
1 IFN: these include viruses that cause both acute as well as persistent infections.
Both DNA and RNA viruses have evolved means to down regulate the IFN-response.
The multitude of strategies that viruses employ to evade this arm of the host immune 
response illustrates its importance in host defence. Interference mechanisms have 
been identified that cover the whole spectrum of the IFN response in infected cells. 
The strategies employed may include blocking IFN induction or expression, 
preventing activation binding of IFN to the IFN-R by means virally encoded soluble 
receptors, blocking the intracellular signalling pathways involved in the IFN response 
directly down regulating transcription of ISGs with antiviral activity by interfering at 
the transcriptional level and possessing resistance to the antiviral effects of ISGs.
To evade type 1 IFN responses, some viruses use non-structural viral proteins that are 
otherwise non-essential for growth or replication. For example, while inactivated 
influenza viruses are good inducers of type 1 IFN, infection with live influenza virus 
inhibits the subsequent induction of IFNs by inactivated virus (Lindenmann 1960). 
Deletion of these non-essential genes results in type 1 IFN induction in the host and 
renders the virus susceptible to the consequent anti-viral effects (Ferko et al. 2004;
79
Talon et al. 2000b). Other viruses employ proteins that have additional functions in 
viral lifecycle to evade the type 1 IFN responses. For example, the phosphoprotein P 
constitutes an essential component of the viral polymerase complex in some RNA 
viruses. However, the P protein can have another role in dysregulating the IFN 
response. The P proteins of rabies, bomavirus and Ebola virus have been reported to 
inhibit activation of IRF3, mainly by interfering with TBK-1 mediated 
phosphorylation of IRF3 (Basler et al. 2003; Schlender et al. 2005; Unterstab et al.
2005).
Signalling via the PRRs is responsible for alerting the host to the presence of a viral 
pathogen and thus often presents a target for interference. The activation pathway 
may be disrupted by preventing recruitment of appropriate adaptor proteins or 
interfering with the phosphorylation of the adaptors (Boehme and Compton 2004; 
Bowie and Haga 2005; Finberg and Kurt-Jones 2004; Netea et al. 2004).
Viruses may prevent detection through host PRRs by concealing viral ligands that 
may potentially activate such receptors. For example, the NS1 protein of avian 
influenza prevents IFN induction by binding to and sequestering dsRNA (Femandez- 
Sesma et al. 2006; Garcia-Sastre et al. 1998; Talon et al. 2000a; Wang et al. 2000)). 
Paramyxoviruses express V proteins that bind dsRNA and sequester them from the 
dsRNA-sensing helicase MDA5, preventing induction of type 1 IFN (Andrejeva et al.
2004)
The signalling pathway downstream of the PRR is also targeted. The NS3/4 A protein 
of HCV also interferes with the RIG-1 pathway (Foy et al. 2005) by enhancing 
degradation of membrane bound IPS1/MAVS complexes (Loo et al. 2006; Meylan et 
al. 2005).
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Other viruses may block transcription of IFN-a/(3 by impairing the activity of the IRFs 
that activate transcription. Aside from the P proteins of rabies, bomavirus and Ebola 
virus mentioned above, the viral protein E3L expressed by vaccinia blocks 
phosphorylation of IRE 3 and prevents up-regulation of ISGs (Smith et al. 2001) and 
the NS3/4A serine protease expressed by HCV disrupts IRF3-dependent signalling by 
inducing cleavage of TRIF (Foy et al. 2003). Human herpes virus 8 (HHV-8), the 
causative agent of Kaposi sarcoma expresses homologues of IRFs (vIRFs) that either 
mimic the activity of cellular IRFs or exert a dominant-negative effect (Burysek et al. 
1999a; Burysek et al. 1999b; Li et al. 1998; Lubyova et al. 2004; Lubyova and Pitha 
2000; Zimring et al. 1998). A more global approach is applied by the NS protein of 
Rift valley virus, which prevents IFN production by inhibiting host cellular 
transcription (Billecocq et al. 2004; Le May et al. 2004).
Even when type 1 IFN is successfully produced, other strategies are applied that 
prevent the secreted cytokines from activating the EFN-R to initiate transcription of 
antiviral genes. Poxviruses posses a massive viral genome that encodes soluble IFN- 
binding proteins that compete with the IFN receptor for the secreted type 1 IFNs 
(Alcami et al. 2000; Symons et al. 1995). By ‘mopping up’ the type 1 IFNs produced, 
they permit viral spread by preventing induction of the autocrine IFN amplification 
loop and the establishment of an antiviral state in the surrounding uninfected cells.
The JAK/STAT signalling pathway is also targeted. Aside from sequestering viral 
nucleic acid, the V protein of paramyxoviruses also enhance proteosomal degradation 
of the IFN transcription factor STAT1 by promoting the ubiquitylation of the protein 
thus impairing JAK-STAT signalling pathway in the same cells (Didcock et al. 1999; 
Garcia-Sastre 2004; Precious et al. 2005; Ulane et al. 2003). The NS1 protein of the 
Rift Valley virus activates SOCS-1 which inhibits signalling by interacting with IFN-
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R1 and may also block Tyk2 phosphorylation of STAT1 (Fenner et al. 2006; Haller et 
al. 2006). In order for this to be effective, SOCS-1 must be activated to engage IFNR1 
very early in infection. Anti-sense segments of RNA encoding the NS proteins are 
packaged into infectious virus particles which can be immediately transcribed into NS 
mRNAs upon entry and uncoating in the cytoplasm, giving the virus a head start in 
blocking the JAK-STAT pathway (Ikegami et al. 2005). A similar approach is also 
adopted by HSV-1, which activates SOCS-3 to down regulate STAT1 and JAK 
phosphorylation (Yokota et al. 2004).
The consequence of activation of the type 1 IFN pathway is the production of a host 
of genes with antiviral functions. These genes are also targets for certain viruses. The
• IPK. • •NSl gene product of influenza virus activates a host protein P58 which in turn 
inhibits the activity of PKR, reducing the activity of this antiviral protein. HSV 
secretes a product, infected cell protein 0 (ICP0) in the initial stages of infection 
which can both interfere with the JAK/STAT signalling pathway as well as directly 
down regulate transcription of ISGs. The virus also produces a PKR inhibitor, Usl 1. 
Viruses may also suppress IFN gene expression by global inhibition of host gene 
transcription (Ahmed et al. 2003; Billecocq et al. 2004; Femandez-Sesma et al. 2006) 
(Thomas et al. 2004). Lytic viruses especially adopt this approach as it not only 
inhibits production of antiviral cytokines, but also expression of apoptotic factors and 
thus prolong the lifespan of the host and the number of progeny virions that can be 
produced from a single infection event. Diversion of host transcription machinery for 
the purpose of viral replication also enhances the rate of production of progeny 
virions. Poliovirus, vesicular stomatitis virus and bunyaviruses have been reported to 
adopt this strategy (Curiel et al. 1993; Femandez-Sesma et al. 2006; Weber et al. 
2002; Yalamanchili et al. 1997; Yuan et al. 1998).
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Finally, as the IFN-response is the initial signal that sets off a cascade of events, 
virus-mediated inhibition of one component of the pathway will affect the regulation 
of distant signalling or effector molecules, thus interference at the early portion of the 
circuit amplifies the resulting inhibitory effects. So inhibition of the JAK-STAT 
pathway will suppress production of all IFN-inducible proteins, which not only 
include proteins with direct antiviral activity but also proteins essential for proper 
sensing of viral components such as RIG-1, MDA5 IPS-1/MAVS, IRF-3 and IRF-7 
(Haller et al. 2006; Takaoka and Yanai 2006). Furthermore, the ‘second-wave’ of IFN 
production will be reduced, leading to contraction of the IFN response and promotion 
of viral infection and spread. These observations suggest that type 1 IFNs are a 
critical weapon in the immune response against these viruses that has helped to shape 
the evolution of these pathogens.
1.7 Immunity during persistent viral infections
There are instances where neither the innate nor the specific adaptive response is able 
to clear a vims infection completely. The vims is instead maintained in the host, and 
may persist for the lifetime of the host.
The levels of ongoing viral replication vary in different persistent infections. Some 
vimses remain latent for the lifetime of the host with occasional or sporadic 
reactivation, e.g. HSV-1, whilst others establish a latent infection with low levels of 
ongoing viral replication, as observed in cytomegalovirus (CMV) and EBV infections 
(reviewed in (Ahmed et al. 1997)). Alternatively, there may be high levels of ongoing 
viral replication. This requires that vims replication is sufficiently non-cytopathic to 
allow replication levels to be tolerated by the host, as is the case with hepatitis B vims
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(HBV), HCV and LCMV infections, or that a renewable cell type is infected, as is the 
case with HIV and lactic dehydrogenase virus (LDHV).
Where there is constant (especially high level) viral replication, antigens and virally 
infected cells will constantly be present and encountered by the host immune system. 
The effect this has on the host innate response which is normally activated by the 
presence of infection, is not fully understood. Studies carried out in a variety of 
persistent infections have indicated that although innate responses may be highly 
activated in the acute phase of infection, this is a transient response that is not 
sustained over time. Instead, a much lower level of ongoing innate activation, or in 
some cases abnormalities in the innate response are observed in the context of chronic 
infection.
Analysis of the type 1 IFN response in the acute and chronic phases of infections with 
viruses that readily establish persistent infections has revealed a strong type 1 IFN 
response in acute infection that is not subsequently maintained (Abbate et al. 2003; 
Abel et al. 2002; Su et al. 2002; Thimme et al. 2002). A recent study of endogenous 
levels of IFNa/(3 and ISG mRNAs in the livers of chronic HCV patients found that 
the levels of type 1 IFNs were significantly downregulated in comparison to levels in 
non-infectious liver diseases (Abbate et al. 2003). The situation is similar in HBV 
infections where type 1 IFNs are produced at a lower level in chronic HBV infection 
(Bertoletti and Gehring 2006). The mechanisms involved are not well understood; 
although viral interference with IRF3 activation/functions has been implicated in 
impairment of IFN production by non-cytopathic bovine viral diarrhoea virus 
(BVDV) and HCV (Baigent et al. 2002; Foy et al. 2003).
In HIV infection, type 1 IFN is transiently upregulated in the serum in the acute phase 
of infection, but declines to undetectable levels prior to the peak in viral replication
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(von Sydow et al. 1991). Again, the mechanisms involved are not well understood. 
The number of DCs present in peripheral blood is known to decreased from acute 
infection onwards (Pacanowski et al. 2001; Soumelis et al. 2001). PBMCs from HIV- 
infected individuals exhibit an impaired capacity to produce type 1 IFNs in response 
to in vitro stimulation with e.g. HSV, which is thought to reflect both the reduction in 
plasmacytoid DC frequency and an impairment in DC responsiveness.
DCs may become refractory to continuous activation by viral components during 
persistent infections, as is thought to occur during infection with malaria or HIV and 
in LPS-activated DCs which stop producing IL-12 after continuous stimulation with 
LPS (Celia et al. 1997b; Knight et al. 1991; Perry et al. 2005). Defects in DC 
functions may also be induced as a consequence of virus infection of these cells, e.g. 
DCs from chronic HIV and HCV patients have been reported to have a poor T cell 
stimulatory capacity and a population of DCs are thought to be infected with virus in 
each of these infections. Furthermore, depletion of DCs during infection may alter the 
DC-T cell ratio, leading to inappropriate activation of co-stimulatory molecules and 
therefore non-functional activated T cells.
As with DCs, abnormalities in the NK cell numbers, subset composition and/or 
functions have been observed in a number of human persistent infections (Goodier et 
al. 2003; Meier et al. 2005). Notably, although NK cell numbers are reduced during 
chronic HIV infection and the function of these cells is progressively impaired as 
infection progresses (thought to be due in part to alterations in the NK cell subset 
composition and in part to alterations in the relative levels of activating/inhibitory 
receptors on NK cells), the activity of NK cells is actually enhanced during initial 
stages of viral persistence (Meier et al. 2005). The mechanisms underlying this have 
not been elucidated. Defects in the innates response in chronic viral infections may
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promote viral persistence both directly or indirectly due to secondary effects on 
adaptive responses (aspects of which are also impaired in many chronic viral 
infections).
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1.8 Murine Lymphocytic Choriomeningitis Virus (LCMV) infection
1.8.1 LCMV
LCMV belongs to the Arenaviridae family, which consists of a single genus, the 
Arenavirus. 18 species of arenaviruses have been so far identified as belonging to the 
genus; these are listed in Table 1.3. The viruses can be further subdivided into two 
antigenic groups on the basis of serological assays, and as this division also correlates 
with their geographical distribution, the two groups are termed the Old World group 
and the New World group. LCMV is an Old World species and the prototype member 
of the Arenaviridae (Buchmeier et al. 2001).
Arenaviruses are zoonotic and cause chronic infections in rodent species and bats 
indigenous to Europe, Africa, the Americas and perhaps other continents. As the 
natural reservoir of the viruses, infected rodents often do not appear to display overt 
symptoms of disease. However, many of the viruses can be passed on to all other 
mammals including humans, (which are an incidental host in the virus’ replicative 
cycle) usually through exposure to infected rodents and/or their excrement (CDC) 
2005a). In humans, such infections may result in severe, even lethal hemorrhagic 
fevers or meningitis in the infected individual, as noted in the Table 1.3 ((CDC) 
2005a; (CDC) 2005b). Some arenaviruses, such as Lassa and Machupo are 
subsequently able to be spread via human to human contact through direct exposure to 
the blood or excrement of infected patients or even via airborne transmission. 
Treatment with the antiviral drug ribavarin during the early stages of infection has 
shown some success in ameliorating disease ((CDC) 2005a; (CDC) 2004).
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Table 1.3 Old World and New World arenaviruses (adapted from(Buchmeier et al.
2001))
Old World Arenavirus
Virus Host in nature
Geographic
distribution
Disease in humans
Lymphocytic
choriomeningtis
(LCMV)
Mus domesticus 
Mus musculus Europe, Americas
Lymphocytic 
choriomeningitis 
(aseptic meningitis)
Lassa Fever Mastomys species West Africa Lassa fever
Ippy Arvicanthus spp.
Central African 
Republic
-
Mopeia Mastomys natalensis
Mozambique,
Zimbabwe
-
Mobala Praomys
Central African 
Republic
-
New World Arenavirus
Junin Calomys musculinus Argentine pampas
Argentine hemorrhagic 
fever (AHF)
Machupo Calomys callosus Beni region of Bolivia
Bolivian hemorrhagic 
fever (BHF)
Guanarito
Sigmodon alsotni,
Zygodontomys
brevicauda
Venezuela
Venezuelan 
hemorrhagic fever 
(VHF)
Sabia Unknown Brazil
Brazilian hemorrhagic 
fever (VHF)
Whitewater
Arroyo
Neotoma albigula New Mexcico
Acute hemorrhagic 
fever
Tacaribe Unknown (possibly bats) Trinidad -
Amapari
Oryzomys gaeldi, 
Neacomys guianae
Brazil -
Parana Oryzomys buccinatus Paraguay -
Tamiami Sigmodon hispidus United States -
Pichinde Oryzomys albigulans Colombia -
Latino Calomys callosus Bolivia -
Flexel Oryzomys spp Brazil -
Oliveros Bolomys obscurus Argentina -
1.8.2 Characteristics of the LCMV virion and genome
The virus particle is lipid enveloped with a pleomorphic but normally spherical 
structure, with an average diameter of 90 to 110 nm. It is covered with surface 
glycoprotein spikes, enclosing the viral nucleoprotein complex and ribosomes 
acquired from host cells. The name Arenaviridae derives from the ‘sandy’ appearance 
of the virus particle (Bums and Buchmeier 1993). The viral genome consists of RNA 
in two segments of unequal length, totalling -10.6 kb altogether. The genome of 
several strains of LCMV has been sequenced and the S or short RNA has been found 
to be between 3,366 to 3,535 nucleotides in length (Salvato 1989; 1993). The 
sequence of the long or L segment has been sequenced for LCMV as well as Tacaribe 
and Lassa fever viruses and ranges from 7,102 to 7,279 nucleotides. The genes on 
both the S and the L segments are arranged in an ambisense manner, encoding two 
proteins in opposite orientations, separated by an intergenic hairpin, as illustrated in 
Figure 1.4. The S RNA segment encodes the 63 kD nucleoprotein (NP) at the 3’ end 
and the envelope glycoprotein precursor GP-C at the 5’end. GP-C is post- 
translationally cleaved by host proteases to yield two glycoprotein subunits GP-1 (44 
kD) and GP-2 (35 kD). The L RNA segment also contains two genes, the gene for the 
200 kD viral polymerase L protein is located on the 3’ end while the 5’ end contains 
the gene for the Z protein, a small protein (11 kD) with a RING-finger zinc binding 
domain (Comu and de la Torre 2002).
The NP and polymerase genes at the 3’ end of the segments are encoded in the 
conventional negative sense and are therefore expressed through transcription of 
genome-complementary mRNAs. The genes located at the 5’ ends of the S and L 
segments, which encode the GP-C and Z proteins, are encoded in the mRNA sense, 
but they are only expressed through genomic sense mRNAs which are transcribed
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from full length complementary copies of genomic RNAs that function as replicative 
intermediates. On both segments, the 3’ end of the genes have been mapped to the 
intergenic region (IGR) which range from 59-217 nucleotides in length and is 
predicted to form one to three energetically stable, G-C rich, stem-loop (hairpin 
structures) in both the genomic and anti-genomic sense, which may play a role in 
stabilizing the 3’ end of the mRNAs, suggesting structure-dependent transcription 
termination (Figure 1.4) (Borrow and Oldstone 1997). Recent studies have addressed 
the function of the IGR using minigenome analogues encoding reporter genes in an 
ambisense orientation with or without an intergenic region to separate the genes (Lee 
and de la Torre 2002). This work showed that the intergenic region did not affect the 
efficiency of anti-genome replication, but transcription of mRNAs of the reporter 
genes encoded at the 3’end of IGR-deficient minigenomes was hardly detectable, 
suggesting that the intergenic region plays a role in transcription termination for 
enhanced gene expression. Interestingly, this study also revealed a second role of the 
IGR in virus assembly and/or budding, which are required for the efficient 
propagation of LCMV infectivity (Pinschewer et al. 2005).
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GP-C
S RNA 
(3.4 kb) 5’
LA
L RNA 
(7.2 kb) 5’
A
3’
NP
3’
Figure 1.4 The genomic organisation of LCMV
The ambisense coding strategy of the LCMV RNA genome is outlined. GP-C, 
glycoprotein precursor NP, nucleoprotein; L, putative viral polymerase; Z, zinc- 
binding protein (from Borrow and Oldstone, 1997).
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1.8.3 Viral proteins of LCMV
The external surface of the viral envelope is studded with glycoprotein spikes 
composed of glycoprotein subunits GP-1 and GP-2 which are derived from a 
precursor protein GP-C. GP-C contains a 58-amino acid signal peptide sequence that 
is cleaved from the amino terminus before GP-C is transported from the endoplasmic 
reticulum. The protein is glycosylated into GP-1 and GP-2 in the secretory pathway 
between the medial and trans-Golgi network. Cleavage occurs at or near a dibasic 
arginine-arginine motif with the amino-terminal portion of GP-C which becomes GP- 
1 and is mediated by the subtilase SKI-1/S1P (Beyer et al. 2003; Kunz et al. 2003). 
GP-1 contains four to seven potential N-linked glycosylation sites; it is heavily 
glycosylated, with evenly-distributed glycans accounting for about 35% of its total 
mass. GP-2 contains one to four potential N-linked glycosylation sites, all o f which 
may not be occupied. GP-1 and GP-2 stay non-covalently attached until they arrive on 
the virion surface, where the subunits interact and assemble into the glycoprotein 
spike. It is hypothesized that GP-2 adopts the structure of an integral transmembrane 
‘stalk’, with GP-1 forming a club-head spike on the external surface of the virion. It 
was long believed that GP-2 molecules assembled into homotetramers to form the 
stalk; however, recent studies have cast doubt on this hypothesis (Eschli et al. 2006). 
Cryomicroscopy studies clearly distinguished the stalk (presumably GP-2) from the 
spherical head region (presumed to be composed of GP-1). The spikes were 
visualized as single-lobed or double-lobed structures 9.5 nm in height and either 6.7 
nm (single-lobed) or 7.9 nm (double-lobed) in width. Computer modelling alignment 
uncovered a high degree of similarity between GP-2 and other well characterised viral 
transmembrane proteins of the retrovirus and filovirus family, which consisted of 
trimeric subunits. Recent circular dichromism analysis and dynamic light scattering
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experiments performed on GP-2 suggests that GP-2 forms a trimeric intergral 
membrane stalk. Each spike is built of three GP-1/GP-2 heterodimers, where GP-1 
forms the globular head of the spike possibly with some linkage via disulfide bonding. 
In summary, this study concluded that GP was present on the virion surface as a 
trimeric protein, confirming its status as a member of the class I viral fusion protein 
family (Eschli et al. 2006).
The GP-1 subunit of the glycoprotein spike is the virion attachment protein that 
mediates interaction with receptor(s) on the host’s cell surface (Kunz et al. 2003). 
This subunit is also the target for neutralizing antibodies that inhibit receptor binding 
interactions. Four highly variable surface-exposed regions thought to be in close 
proximity to the binding site have been characterized and are believed to aid in 
immunoevasion of neutralizing antibody responses by the virus. The viral 
glycoprotein not only mediates attachment to host cells, but also the fusion of virion 
and host cell membranes required for viral entry into host cells.
NP is the major structural protein of the virion. It is the major protein component of 
nucleocapsids and associates with virion RNA in the form of beadlike structures. NP 
is able to become phosphorylated in the later stages of acute infection and this form 
continues to be expressed during persistent infections in vitro (Fuller-Pace and 
Southern 1988; Oldstone and Buchmeier 1982). In infected cells, full-length NP is 
localized exclusively in the cytoplasm.
The L protein encodes for an RNA-dependent RNA polymerase. It has six 
characteristic sequence motifs conserved among other RNA polymerases of negative- 
strand RNA viruses (Buchmeier et al. 2001). It also contains unique regions 
conserved in the L proteins of ambisense viruses of the Arenavirus and Bunyavirus 
family. The polymerase has been reported to associate with the viral nucleopcapsids
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in order to be active (Pinschewer et al. 2003). The active site of the polymerase was 
recently determined to be on domain III. A series of site-directed mutagenesis studies 
identified conserved residues within the domain that were strictly required for 
polymerase activity (Sanchez and de la Torre 2005).
The Z protein is the smallest protein encoded by the viral genome. It contains a 
RING-finger binding motif and is a zinc-binding protein. The exact function of Z is 
unclear, but it has been detected in both cytoplasm and the nucleus of LCMV-infected 
cells, suggesting it may play a role in DNA transcription/modulation, and it has also 
been found to promote budding of progeny arenavirus virions (Perez et al. 2003; 
Perez et al. 2004). Immunodepletion of Z protein in Tacaribe virus-infected cells 
strongly inhibited viral synthesis of genomic RNA and NP mRNA but it appears to be 
only required during the early stages of infection (Cornu and de la Torre 2002) 
(Jacamo et al. 2003; Lopez et al. 2001).
1.8.4 Viral entry, transcription and translation
Viral entry into host cells is mediated via binding of the virion surface glycoprotein 
GP-1 to host cell receptors, one of which is a-dystroglycan (Cao et al. 1998). a - 
dystroglycan is a highly conserved, peripheral membrane glycoprotein that is 
expressed in almost all cells. Correspondingly, LCMV has a broad in vivo tropism, 
infecting multiple tissues throughout the body of mice, although within individual 
tissues, particular cell types are preferentially targeted for infection (Fazakerley et al. 
1991). Tropism for different cell types may thus depend on the levels of a- 
dystroglycan expressed (Borrow and Oldstone 1997).
While a-dystroglycan has been identified as the predominant attachment protein, the 
observation that a-dystroglycan-deleted cell lines could be infected with LCMV,
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albeit with difficulty, indicates that there are other cellular receptors recognized by the 
virus (Kunz et al. 2004). LCMV isolates differ in their dependence on a-dsytroglycan 
for host cell entry, and correspondingly exhibit some differences in in vitro tropism 
and pathogenicity (Sevilla and de la Torre 2006).
The virion is taken into the cell by viropexis in large-smooth-walled endocytic 
vesicles. A fusion event between virion and endosomal membranes releases the 
contents of the virion into the cytoplasm, initiating the infection and replication 
process. GP-2 may play an integral role in membrane fusion and viral uncoating. 
LCMV fusion is dependent upon a drop in the pH. It is thought that the acidic pH 
environment of the endosome may destabilize the glycoprotein stalk, releasing the 
GP-1 subunit from the spike (Borrow and Oldstone 1994; Di Simone and Buchmeier 
1995; Di Simone et al. 1994). This exposes a previously buried fusion peptide on the 
GP-2 stalk, which inserts into the host membrane. The GP-2 subunit is thought to 
undergo a series of conformational changes to give rise to a fusion pore, facilitating 
transfer of the viral nucleoprotein complex into the cytoplasm, where transcription 
takes place.
The RNA dependent RNA polymerase is thought to posses two distinct methods of 
transcription that generate RNA copies of the LCMV genome for different purposes. 
The transcriptase activity synthesizes capped (Meyer and Southern 1993; Raju et al. 
1990) unencapsidated (Raju et al. 1990) mRNA that will be used as template for 
translation of viral proteins. These molecules posses 3' ends that are heterogenous, 
unpolyadenylated and end within the vicinity of the predicted hairpin in the IGR 
(Meyer and Southern 1994; Tortorici et al. 2001). The replicase function of the 
polymerase directs synthesis of mostly encapsidated (Raju et al. 1990), uncapped full-
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length antigenomic and genomic RNA species, which are used as templates for further 
mRNA transcription and also packaged into new viral particles (Meyer et al. 2002). 
Soluble NP protein is required for RNA replication in order to encapsidate nascent 
viral RNA during replication. Evidence for this comes from observations that full 
length genomic and antogenomic RNA species are found almost exclusively in 
encapsidated form (Raju et al. 1990) and arenavirus replication is dependent on 
ongoing protein synthesis and inhibited by translation inhibitor (Franze-Femandez et 
al. 1987; Salvato et al. 1988), although the addition of exogenous NP restored viral 
replication in the presence of inhibitors (Salvato et al. 1988; Tortorici et al. 2001). 
Transcription and replication levels were also enhanced as levels of NP in the system 
increased, suggesting both processes were highly dependent on NP (Pinschewer et al.
2003).
NP mRNA and protein are the first viral components to accumulate in the infected 
cells (Fuller-Pace and Southern 1988). NP mRNA has been detected as early as 2 
hours post-infection. The L protein can be detected at 12 to 24 hours after infection 
(Fuller-Pace and Southern 1989). Synthesis of GP-C and Z, which are encoded on the 
5’ ends of the genome segments, cannot begin until viral RNA replication starts and 
the full-length replicative intermediate viral-complementary RNAs of S and L is 
available as template for GP-C and Z mRNA transcription. The ambisense coding 
strategy of LCMV thus allows for differential expression of viral mRNAs, temporally 
separating expression of NP and L proteins from GP-C and Z expression.
Host cell enzymes are hijacked to send translated viral proteins to the Golgi for 
appropriate post-translational modifications (Wright et al. 1990). The glycosylated 
envelope glycoproteins are transported to the cell surface where virion assembly 
occurs. The assembly process is poorly understood. Newly synthesized genomic
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RNAs, NP protein and L protein are assembled into nucleopcapsids which also 
incorporate host cell derived ribosomes (Fuller-Pace and Southern 1988; Salvato 
1993). Progeny virions bud from the cell surface using glycoprotein-containing host 
cell membrane as their lipid envelope.
LCMV infection is typically non-cytopathic. Mice can tolerate a high level of LCMV 
replication without showing any major pathological effects (Borrow and Oldstone 
1997) but nonetheless excrete high titres of infectious virus in their urine. For 
example, LCMV-infected guinea pigs may excrete up to 105 pfu/ml of virus in the 
urine. In fact, exposure to excreted LCMV in mouse or hamster urine, cage dust or 
litter is a source of laboratory-acquired LCMV infection (Hinman et al. 1975).
The L polymerase is an RNA-dependent RNA polymerase with low-fidelity. As such, 
the LCMV genome is subject to high rate of mutation. Within an infected host, 
LCMV thus exists as a heterogeneous population or quasispecies that continually 
generates viral variants (Dockter et al. 1996; Sevilla and de la Torre 2006). Under 
selection pressure, for example in certain tissues of organs of the host, viral mutants 
may emerge that have acquired key advantagous mutations. For example, mice that 
have been infected with LCMV Arm from birth often posses variants in the liver and 
lymphoid tissue that contain a mutation that changes amino acid at position 260 in the 
GP-1 subunit from phenylalanine to leucine (Evans et al. 1994; Salvato et al. 1991; 
Villarete et al. 1994). It is believed that this mutation confers on the virus an enhanced 
ability to infect macrophages and dendritic cells as well as other related cells such as 
Kupffer cells in the liver (King et al. 1990; Matloubian et al. 1993; Matloubian et al. 
1990). By contrast, the original strain of LCMV with the phenylalanine at position 
260 predominates in other organs such as the heart and central nervous system. 
Numerous isolates of LCMV have been isolated in such a manner.
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1.8.5 Outcome of LCMV infection of mice
LCMV is a natural pathogen of mice, although it can also infect other mammalian 
species including humans. In mice, LCMV can cause either an acute infection or a 
persistent infection in which the virus may be present for life (Borrow and Oldstone
1997). A number of isolates of LCMV have been characterized, which differ in their 
in vivo pathogenicity. The outcome of an infection depends on both host and viral 
factors, including the age, strain and immunocompetence of the mice infected; and the 
particular LCMV isolate used and dose and route of infection.
Infection of adult immunocompetent mice with a low/moderate dose of most LCMV 
isolates via a peripheral route results in an acute infection, followed by clearance of 
the virus in 10-14 days. Clearance is primarily achieved through perforin-mediated 
lysis of virus-infected cells by CD8+ T cells (Kagi et al. 1994; Leist et al. 1987b; 
Moskophidis et al. 1987b; Walsh et al. 1994b).
However, if the same dose of virus is delivered via the intra-cranial (i.e.) route, there 
is viral replication in the meninges and choroid plexus resulting in targeting of the 
CTL response to these sites. This causes lethal meningitis, which is induced by CTL- 
mediated inflammation and not by viral replication itself (Cole et al. 1972; Gilden et 
al. 1972a; Gilden et al. 1972b).
If mice become infected with LCMV in utero or within 48 hours of birth, LCMV- 
specific T cells are clonally deleted in the thymus as self tolerance is established 
(Pircher et al. 1989). In the absence of an effective LCMV-specific CD8+ T cell 
response, the mice are unable to clear the infection and life-long persistence results. In 
nature, LCMV is maintained by persistent infection of specific species of rodent hosts 
(such as mus musculus and mus domesticus).
98
LCMV is also able to establish a persistent infection in adult mice if they are infected 
under circumstances where viral replication is able to reach high titres in the initial 
stages of infection. This can be achieved by delivery of high doses of virus through the 
systemic i.v. route; by using fast replicating and IFN-resistant LCMV strains such as 
Armstrong Clone 13, WE Docile and Traub; and by infection of 
immunocompromised hosts, such as knock-out mice lacking the type 1 IFN-R 
(Borrow and Oldstone 1997). If there is high level viral replication as the virus specific 
CD8+ T cell response is induced, T cell exhaustion occurs, i.e. virus specific T cells 
are either deleted or rendered non-functional (Moskophidis and Lehmann-Grube 1983; 
1984; Zajac et al. 1998). The mechanism(s) responsible for CTL exhaustion are 
unclear, but it may reflect ‘overstimulation’ of CD8+ T cells during chronic LCMV 
infection causing them to undergo massive expansion (Fuller and Zajac 2003; 
Gallimore et al. 1998; King and Goodboum 1998; Wherry et al. 2003a), which may 
drive them to terminally differentiate and undergo apoptic death. Wherry et al. (2003) 
have proposed that in chronic LCMV infections, activated CD8+ T cells undergo 
distinct stages of CTL ‘exhaustion’, with sequential loss of cytokine production 
leading to deletion or death. This may be a means to control immunopathology to the 
host. A strong correlation between viral load and effector function was also observed 
whereby T cells to highly displayed and/or persisting epitopes were exhausted more 
quickly. The presence of CD4+ T cells helped delay the exhaustion period (Wherry et 
al. 2003a). Another mechanism suggested to contribute to CTL exhaustion is 
inappropriate antigen presentation e.g. antigen presentation by non-professional APCS 
which may prime CD8+ T cells for anergy or deletion (Althage et al. 1992).
Barber et al recently described a novel pathway that may be involved in T cell 
exhaustion (Barber et al. 2006). The receptor programmed death (PD)-l was found to
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be greatly upregulated on exhausted LCMV-specific CD8+ T cells (but not 
functionally competent cells) in persistently-infected mice; furthermore, PD-L1 (also 
called B7-H1), one of the ligands for PD-1, was expressed at very high levels on 
splenocytes ffom persistently-infected mice, especially on virus-infected cells. 
Blockade of the B7-H1-PD-1 pathway by a monoclonal antibody restored CD8+ T cell 
function and reduced viral burden. The authors suggested that the PD-1/PD-L1 axis 
operated under conditions of sustained high levels of antigenic stimulation to reduce T 
cell responsiveness and that the PD-1 inhibitory pathway may have evolved to regulate 
immune-mediated damage during a persistent infection by turning 'off the virus- 
specific T cells.
1.8.6 The host response during acute and persistent LCMV infection
1.8.6.1 Acute LCMV infection
Acute LCMV infection of mice, such as infection with a low dose of LCMV Arm 
delivered i.p. into immunocompetent adult mice, results in stimulation of both innate 
and effector pathways, resulting in clearance of the vims in 7 to 10 days.
1.8.6.1.1 Type 1 IFNs and LCMV
Like infection with most viruses, infection with LCMV very rapidly stimulates 
production of type 1 IFNs. Type 1 IFN mRNA is upregulated in the spleen within 24 
hours of infection (Malmgaard et al. 2002) and levels of type 1 IFN in the serum peak 
at ~2-3 days post-infection (Jacobson et al. 1981). The mechanism of type 1 IFN 
induction by LCMV is still unclear but probably involves activation of the anti-viral 
TLR and/or the intracellular helicase pathways. Analysis of type 1 IFN induction in 
mice lacking IFN-R or STAT-1 production indicated that contrary to other viruses,
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LCMV is a poor direct inducer of type 1 IFN and instead relies on autocrine 
amplification of type 1 IFN induction through the positive feedback loop involving 
signalling via the IFN-R and STAT-1 -mediated transcription, to generate the high 
levels of type 1 IFN observed in serum of infected mice (Malmgaard et al. 2002). The 
predominant cellular source of the serum IFN in LCMV-infected mice are also 
unclear. Whilst plasmacytoid DCs are induced to produce type 1 IFNs very rapidly 
after LCMV infection (Montoya et al. 2005), depletion studies have suggested that 
unlike in other virus infections, they may not constitute the major source of type 1 
IFNs (Dalod et al. 2002). However, an alternative principal IFN-producing cell type 
in LCMV-infected mice has yet to be identified.
Studies carried out using neutralizing antibodies against type 1 IFNs or type 1 IFN 
knock-out mice have shown that type 1 IFNs make a critical contribution to 
controlling the replication of LCMV, in particular, that of strains such as Arm and 
WE Aggressive (Moskophidis et al. 1994; Muller et al. 1992). Typel IFNs likely act 
to combat LCMV infection via a combination of direct effects on viral replication and 
by modulating cellular immunity to ensure the induction of appropriate anti-LCMV 
CD8 T cell effector responses (Ou et al. 2001). Evidence for this is provided by the 
observations that strains that are resistant to the effects of type 1 IFN such as LCMV 
Cl 13, Docile and Traub are the strains capable of establishing a persistent infection in 
vivo (Moskophidis et al. 1994) (illustrating the importance of antiviral effects of type 
1 IFNs); but in addition, persistence of these (and other) LCMV isolates is promoted 
in mice treated with neutralizing antibodies against IFN-a/p or IFN-receptor knock­
out mice (Moskophidis et al. 1994; Ou et al. 2001) (illustrating the importance of 
indirect, immunostimulatory effects of type 1 IFNs in control of LCMV infection).
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1.8.6.1.2 Dendritic cells
DCs are infected by LCMV, with different strains/isolates of LCMV possessing 
varying degrees of tropism for the cells. In general, it has been observed that strains or 
isolates of LCMV that go on to establish a persistent infection preferentially infect 
DC subsets displaying C D llc+ or DEC 205+ expression, with reports suggesting that 
more than 80% of these splenic DCs become infected within the first 20 days by such 
strains. In contrast, infection with a strain of LCMV that is cleared found that the 
virus infected <10% of DCs (Borrow et al. 1995; Sevilla et al. 2000). It has therefore 
been postulated that the increased capacity to infect splenic DCs may be a factor that 
enables certain strains/isolates of LCMV to persist in the host.
Following acute infection with LCMV Arm, dendritic cells from all subsets are 
rapidly activated. As mentioned above, type 1 IFN production is initiated by 
plasmacytoid DCs within 24 hours of infection. Conventional DC subsets upregulate 
expression of MHC class I and class II and adhesion and co-stimulatory molecules 
such as CD40, CD80, CD86, and ICAM-1, produce proinflammatory cytokines, and 
acquire the ability to stimulate LCMV-specific CD8+ T cells (Montoya et al. 2005). 
Endogenous type 1 IFN upregulation was shown to contribute to DC phenotypic 
activation. However, DC functional activation is transient; is rapidly downregulated in 
all DC subsets, and the numbers of C D llchlgh CD8+ and CD4+ DCs in the spleen 
declines as activated cells undergo apoptosis.
1.8.6.1.3 Natural killer cells
NK cells are activated in early LCMV infection as type 1 IFN are produced (Biron et 
al. 1983; Bukowski et al. 1983a; Orange and Biron 1996; Pien and Biron 2000). 
However, experiments carried out using beige mice (which have reduced NK cell
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activity) or in which NK cells were depleted with antibodies to asialo-GMl indicate 
that NK cells do not make a significant contribution to control of LCMV infection in 
vivo. This may be due at least in part to the fact that LCMV infection is not associated 
with activation of high levels of production of IL-12, a cytokine which is required to 
stimulate IFN-y production in NK cells.
1.8.6.1.4 Antiviral humoral response
Antibody responses against LCMV are also generated early in infection, as early as 4 
days post-infection; however, neutralizing antibodies (mainly directed against the 
glycoprotein) are only detected 20-60 days post-infection (Hotchin et al. 1969).The 
reasons for this are not well understood but may be related to depletion of B cells and 
B cell precursors by LCMV. B cell numbers were reported to fall during an acute 
LCMV infection and did not return to normal levels until at least 3 weeks post 
infection (Borrow et al. 2005). The virally-induced suppression was found to be 
dependent on the presence of TNF-a secreted in response to the viral infection. 
Antibodies are not required for clearance of an acute LCMV infection, although they 
do contribute to control of viral replication and can help to prevent/clear persistent 
LCMV infections (Battegay et al. 1993). Importantly, the antibody response induced 
following clearance of an acute LCMV infection also provides protection against re­
infection on subsequent viral exposure (Baldridge and Buchmeier 1992).
1.8.6.1.5 T-lymphocyte Response
T-lymphocytes, specifically the CD8a+ T cell population are absolutely necessary for 
clearance of an acute LCMV infection (Assmann-Wischer et al. 1985; Borrow 1997; 
Fung-Leung et al. 1991; Lehmann-Grube et al. 1988) and are able to mediate viral
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clearance (and therefore effector functions) in the absence of CD4+ T cells or 
expression of MHC Class II (Christensen et al. 1994; Kasaian et al. 1991). However, 
CD4 T cells do contribute to the resolution LCMV infection, as in the absence of 
CD4+ T cells, infection with doses of LCMV that would cause an acute infection in 
immunocompetent adult mice resulted in establishment of a persistent infection 
(Matloubian et al. 1994). CD4+ T cells can combat LCMV replication directly, e.g. 
via secretion of antiviral cytokines such as IFN-y; and also play an important role in 
providing help for the generation and maintenance of CD8+ T cell responses.
The kinetics of virus-specific CD8+ T cell responses correlate well with clearance of 
acute LCMV infection. Effector cells are initially detected at day 4-5 post-infection 
and peak between days 7 and 9 post-infection, which coincides with resolution of the 
infection (Moskophidis et al. 1987a). In the first week after LCMV infection, active T 
cell expansion occurs and there are large increases in the total number of T cells in the 
spleen. By day 8 post-infection, the frequency of LCMV-specific CD8+ T cells in the 
spleen is ~1 in 2 (Murali-Krishna et al. 1998). Expansion is followed by a contraction 
phase with large-scale apoptotic cell death that peaks at day 11 post-infection, after 
the virus is cleared (Razvi and Welsh 1993). The LCMV-specific T cells left are 
maintained as long-lived memory T cells which confer immunity against subsequent 
LCMV infections (Jamieson and Ahmed 1989; Lau et al. 1994; Whitmire et al. 1998). 
CD8+ T cells can combat LCMV infection by either cell contact-dependent lysis of 
virus-infected cells or by production of antiviral cytokines (which does not destroy the 
virally-infected cell). Evidence suggests that clearance by contact-dependent lysis is 
critically important for clearance of an acute infection. In perforin-deficient mice, 
infection with an acute strain of LCMV could not be cleared despite proper T cell 
activation (Clark et al. 1995; Kagi et al. 1994; Walsh et al. 1994a). By contrast, mice
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with non-functional Fas controlled acute LCMV infection with normal kinetics 
indicating that Fas-dependent pathways were probably not critical (Kagi et al. 1994), 
although there is evidence of synergism between FasL and perforin (Rode et al.
2004). However, while perforin is critical for clearance of an acute LCMV infection, 
IFN-y and TNF-a cytokines secreted by effecter T cells are required to control a 
persistent infection where the number of infected cells is much higher (Borrow 1997; 
Guidotti et al. 1999; Suresh et al. 2004).
1.8.6.2 Persistent LCMV infection
As described earlier, mice become persistently infected with LCMV either if  they are 
infected with virus at birth, or if they are subsequently infected under conditions 
where virus replicates to high titres in the early stages of infection, e.g. following 
inoculation of mice with a high titre of an IFN-resistant strain of LCMV such as 
LCMV C113 or LCMV Docile.
In both situations, persistence is associated with a lack of CD8+ T cell control of viral 
replication, but the mechanisms responsible for this differ. When a persistent infection 
is induced by infection of newborn mice, LCMV-specific T cells are clonally deleted 
in the thymus by mechanisms that give rise to tolerization, as the virus is recognized 
as self by the host (Pircher et al. 1991; Pircher et al. 1989). An LCMV-specific T cell 
response is thus not activated. The immune response of these persistently infected 
mice is otherwise functional, and specific T and B cell responses to other antigens are 
not impaired (Tishon and Oldstone 1987). By contrast, when a persistent infection is 
induced in adult immunocompetent mice by infection with high dose of certain 
isolates of LCMV, a virus-specific CD8+T cell response is induced but it is then 
exhausted by functional impairment and physical deletion of LCMV-specific effector
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CD8+ T cells (van der Most et al. 2003; Wherry et al. 2003b). There is also evidence 
that LCMV Cl 13 promotes persistence by subverting the innate arm of immunity.
1.8.7 Immimoevasion strategies of LCMV
As outlined above, the principal mechanisms by which LCMV avoids control of the 
host immune response involve failure to induce a virus-specific CD8+ T cell response 
(as occurs in mice infected at birth with LCMV) and impairment of the function of 
virus-specific T cells (as occurs in wild type adult mice infected with a high dose of a 
persistent LCMV strain/isolate).
Additionally, LCMV may also apply other immunoevasion strategies to resist 
clearance by the host. LCMV isolates have been shown to vary in their susceptibility 
to control by type 1 IFNs, both in vivo and in vitro (Leist et al. 1987a; Moskophidis et 
al. 1994; Ou et al. 2001). Notably, those LCMV isolates that exhibit the greatest type 
1 IFN resistance are those that are able to establish persistent infections on high dose 
inoculation into adult immunocompetent mice, suggesting that this IFN resistance 
may play a key role in vivo. LCMV consists of only 4 viral proteins and viral RNA, so 
at a glance it appears its capacity to interfere with the host’s immune system is 
limited. However, 2 of the 4 proteins encoded, NP and Z, have the potential to 
interfere with host transcription factors. For example, NP is reported to interfere with 
the Pitl transcription factor that regulates growth hormone production in mice 
infected at birth with LCMV (de la Torre and Oldstone 1992). Likewise, NP/Z may 
also be able to modulate the host’s antiviral responses to confer a survival advantage 
upon the virus. Notably, the Z protein interferes with the actions of PML, an ISG, by 
sequestering the protein and preventing it translocating into the nucleus (Borden et al.
1998).
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LCMV persistence may also be promoted by impairment of DC numbers and/or DC 
function. LCMV Cl 13 which is able to cause a persistent infection in adult mice is 
thought to infect DCs more efficiently than LCMV Arm, a closely-related virus 
isolate that is more readily controlled by the host (Borrow et al. 1991; Salvato et al. 
1991; Sevilla et al. 2000). Infection of DCs may target them for destruction by the 
host CD8+ T cell response (Borrow et al. 1995; Odermatt et al. 1991) leading to 
impairment of their functions. Sevilla et al (2004) report that splenic DCs from mice 
with a long-term LCMV Cl 13 infection exhibited reduced surface expression of 
CD40, CD80, CD86 and MHC class I and MHC class II. The total number of splenic 
DCs in persistently infected mice is also reduced (Sevilla et al. 2004), and Hahm et al 
(2005) postulated that the continuous presence of type 1 IFN in the system had 
deleterious effects on DC maturation and expansion, suppressing maturation of 
precursor cells in the bone marrow through a STAT2-dependent pathway (Hahm et al.
2005). Together, these abnormalities in splenic DC in mice persistently infected as 
adults with LCMV may account for observations that these animals (unlike mice 
persistently infected at birth) exhibit an impaired capacity to mount immune 
responses to unrelated antigens/pathogens (Tishon et al. 1993; Odermatt et al. 1991).
In addition to inducing tolerance or exhaustion of LCMV-specific CD8+ T cells, 
LCMV may potentially also evade the T cell response. When mice expressing a TCR 
specific for LCMV were persistently infected with LCMV, viral variants able to 
escape recognition by the transgenic TCR expressing CTL appeared and were 
selected for within the viral quasispecies, resulting in failure of viral clearance 
(Aebischer et al. 1991; Pircher et al. 1990; Puglielli et al. 2001). However, this has 
only been observed in an artifical system using transgenic mice and it is unclear 
whether the virus adopts this strategy to remain in a wild-type host.
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LCMV also possesses strategies for resisting control by the humoural response. In 
acute infection, the production of neutralizing antibodies is relatively delayed 
(Buchmeier et al. 1980; Cemy et al 1988; Bruns et al, 1983; Brundler et al 1996; 
Hangartner 2006) which may help to promote viral persistence in the host. The 
mechanisms involved are not clear but may include LCMV infection of B cells 
producing virus neutralizing antibodies, targeting these cells for destruction by the 
CD8+ T cell response (Battegay et al. 1993; Moskophidis et al. 1992; Planz et al. 
1996) and/or infection associated B cell heamatopoeises (Borrow et al. 2005). Most 
neutralizing antibodies to LCMV are directed towards the GP-1 surface protein. 
During persistent infection, GP-1 expression is downregulated in infected cells, 
possibly as a measure to avoid recognition by the host’s antibody response (Oldstone 
and Buchmeier 1982).
1.8.8 Activation state of the innate system in mice persistently infected with 
LCMV
A persistent LCMV infection is productive, bathing the host with high concentrations 
of viral components. In mice persistently infected with LCMV, there is widespread 
high-level viral replication with continuous production of virus particles. All the 
stimuli to drive activation of the innate responses are thus present. Is the innate 
response correspondingly in a highly activated state?
Early studies that measured type 1 IFN activity during persistent viral infections 
reported different outcomes. Most of the work was conducted on mice which were 
infected at birth, and became persistently infected as a result of delection of LCMV- 
specific T cells. Studies by Bukowski et al (Bukowski et al. 1983b) on 6 month old 
congenitally infected mice reported them to have mid-elevated levels of plasma IFN,
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where they were 4 times above baseline values, but still lower than IFN levels from 
acute LCMV mice. Merrigen et a\ (Merigan et al. 1977) detected continuous 
production of IFN (not distinguished between -a, -(3 or -y) in nude (nu/nu) athymic 
mice persistently infected with LCMV. Some groups reported low levels of IFN-a/p 
and the IFN-stimulated anti-viral molecule 2’5’OAS in the serum of persistently 
infected mice which, when induced with polylC or NDV, produced undetectable or 
reduced levels of serum IFN compared to LCMV-uninfected mice (Holtermann and 
Havel 1970; Bukowski et al 1983; Saron et al. 1982). Conversely, Holtermann and 
Havell (Holtermann and Havell 1970) reported that congenitally infected mice did not 
produce IFN unless they were infected with an unrelated virus. Even then, IFN levels 
were 4-6 fold lower compared to those in non-LCMV infected mice.
Increased NK cytotoxic activity (compared to that of NK cells from uninfected mice), 
was also detected in persistently-infected mice (Bukowski et al. 1983a), which the 
authors attributed to sustained IFN-mediated stimulation of NK cells. The cytotoxic 
activity was intermediate between the low activity of uninfected mice and the high 
activity of acutely infected mice.
Mice persistently infected with LCMV have also been reported to have a reduced 
susceptibility to infection with certain viruses including equine encephalomyelitis 
virus, Rauscher leukemia virus and polyoma virus (as commented upon in (Bukowski 
et al. 1983b) and (Holtermann and Havell 1970)). Whether this is due to the elevated 
activation status of the innate system is unclear.
A recent study by Homann et al (2004) reported activation of DCs and virus-infected 
T cells in mice persistently infected in utero or at birth (Homann et al. 2004). These 
infected cells were also more prone to apoptosis. When infected with an second virus, 
the T-cell response was functional, although the total number of responding T cells
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were reduced, suggesting that persistent LCMV infection from birth did alter the 
functions of the host’s heterologeous immunity.
1.9 Objectives of the research project
Many viruses are able to infect and then persist in their hosts indefinitely. The effect 
such an infection has on the host’s immune response, especially on the innate immune 
response, is still unclear. Firstly, if such viruses impair aspects of the innate responses 
in order to persist in the host, which of the response are affected, and how is this 
impairment mediated?
Secondly, what effect does constant exposure to virus and/or viral components have 
on the host’s innate immune system -  is it perpetually activate, or are responses 
downregulated.
Thirdly, how does the presence of persisting virus affect the ability of the innate 
immune systemt to response to other virus infections?
These are questions that have yet to be properly understood in chronic infections such 
as HTV, HBV or HCV. I planned to use the murine model of persistent LCMV 
infection to address some of these questions. Several factors make LCMV a good 
model virus to study aspects of persistent viral infections. Firstly, LCMV is a natural 
pathogen of mice, making it possible to study infection in a host in which the virus is 
adapted for persistence. Secondly, murine models are amenable to kinetic analysis 
and experimental manipulation. Thirdly, different strains/isolates of LCMV are 
available that cause either acute or persistent infection in mice. Also, unlike other 
viruses that become latent during persistency, persistent infection with LCMV is 
accompanied by high levels of systemic infection, as is observed in human infection 
with HIV, HCV or HBV. In addition, viral mechanisms can also be studied in vitro as
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LCMV readily infects multiple cell lines and is able to establish a non-lytic, persistent 
infection in these cells. Finally, many reagents, e.g. LCMV-specific antibodies, and 
expression plasmids were available in the lab.
The objectives of my project were as follows:
1. To develop assays (i) to enable quantitation of low levels of bioactive type 1 IFN 
(using reporter gene systems) and (ii) to detect, quantify and distinguish between 
various subtypes of type 1 IFN at the mRNA level.
2. To employ the sensitive and specific assays developed above to follow the 
induction of type 1 IFN in serum and spleen during the early and late stages of a 
persistent LCMV infection in vivo, comparing the magnitude and kinetics of the 
response with that observed in an acute LCMV infection.
3. To determine whether there are impairments in type 1 IFN induction during chronic 
LCMV infection by investigating the responsiveness of persistently infected mice to 
TLR stimuli and infection with an unrelated RNA virus.
4. To assess the effects of LCMV infection on the ability of cell lines to produce type 
1 IFNs in response to different in vitro stimuli.
5. To dissect the role of individual LCMV proteins in impairment of type 1 IFN 
induction using cell lines stably transfected with GP, NP or Z.
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CHAPTER 2 
MATERIALS AND METHODS
2.1 Materials
2.1.1 Plasticware and other consumables
Product Catalogue No. Supplier
12-well Flat bottom Plates 3513 Coming Costar, High Wycombe, UK
13 mm Coverslips ML-579-13 Western Lab Suppliers, Aldershot, 
UK
140 mm Nunclon TM Dishes 168381A Life Technologies, Paisley, UK
15 ml Falcon Tubes 352096 Becton Dickinson Labware, NJ, USA
4 8-well Plates 150687 Life Technologies, Paisley, UK
50 ml Falcon Tubes 352070 Becton Dickinson Labware, NJ, USA
6-well Plates 353046 Becton Dickinson Labware, NJ, USA
96-well microtitre 
plate(Luciferase assay)
3917 Coming Costar, High Wycombe, UK
96-well V bottom Plates 3894 Coming Costar, High Wycombe, UK
Bijou Tubes 275/0460/24 BDH Lab Supplies, Poole, UK
Cell Strainers 40 pm 352340 Becton Dickinson Labware, NJ, USA
Cluster Tubes 
(Fluorescence activated cell 
sorter (FACS) tubes)
AB-0672 Abgene, Surrey, UK
Eppendorf Tubes 0.5 ml 96.4625.9.01 Tref Ag, Degersheim, 
Switzerland
Eppendorf Tubes 1.5 ml 96.8160.9.02 Tref Ag, Degersheim, Switzerland
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Product Catalogue No. Supplier
FACS Tubes 5 ml 352054 Becton Dickinson Labware, 
NJ, USA
Finntips 9401-255 Life Sciences, Basingstoke, UK
Flasks T150 90151 Helena Biosciences, Sunderland, UK
Flasks T25 9026 Helena Biosciences, Sunderland, UK
Immulon-II Enzyme-linked 
immunosorbant assay 
(ELISA) Plates
3455 Dynex technologies, Middlesex, UK
Immuno 96-well Nunc 
ELISA Plates (Maxisorp)
439454A Life Technologies, Paisley, UK
LS+ Magnetic activation cell 
sorter (MACS) Columns
130-042-401 Miltenyi Biotech, Bisely, UK
Microcon YM100 42412 Millipore Corp, Bedford, USA
Microscope Slides 406-0184-04 BDH Lab Supplies, Poole, UK
MS+ MACS Columns 130-042-201 Miltenyi Biotech, Bisely, UK
Needle, 18G 1.2x40 mm 1100-250016 Sherwood Medical, Northern Ireland, 
BT53 7AP
Needle, 19G 1.1 x 40 mm 197 Terumo Corp,
Needle, 27G,0.4x20mm Z192384-100EA Terumo Corp
Nunc Cryovial External 
Thread 1.8 ml
375418 Life Technologies, Paisley, UK
Nunc Cryovials Internal 
Thread 1.8 ml
377267 Life Technologies, Paisley, UK
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Product Catalogue No. Supplier
Pasteur Pipettes 475-068
Petri dish, 100x150 mm 
(BM-DC dish)
35-1029 Becton Dickinson Labware, NJ, USA
Petri dish, 3 5x10mm (BM- 
DC dish)
351008 Becton Dickinson Labware, NJ, USA
Pipettes 10 ml 47110 Bibby Sterilin, Stone, UK
Pipettes 25 ml 18327 Bibby Sterilin, Stone, UK
Pipettes 5 ml 40105 Bibby Sterilin, Stone, UK
Plate Sealers EC/005. SPN Camlab Ltd, Cambridge, UK
Slide-A-Lyzer (1000 
MWCO) Dialysis Cassettes
6638122 Pierce & Warriner UK Ltd., Chester, 
UK
Standard Repette Dispenser 
Tips, 2.5 ml
488-007 Jencons Scientific, Leighton Buzzard, 
UK
Sterile Repette Dispenser 
Tips, 5 ml
488-008 Jencons Scientific, Leighton Buzzard, 
UK
Syringes 1, 2, 25, 50 ml X IAH Stores, Compton, UK
Tips lOOOpl GPS1000 Rainin Instruments Co Ltd., Woburn, 
USA
Tips 20pl GPS25 Rainin Instruments Co Ltd, Wobum, 
USA
Tips 200|li1 GPS250 Rainin Instruments Co Ltd., Wobum, 
USA
Universal Tubes 275/0460/04 BDH Lab Supplies, Poole, UK
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Product Catalogue No. Supplier
Ribonuclease (RNase)-ffee 
0.5ml microfuge tubes
12350 Ambion Europe Ltd, Huntingdon, 
Cambridgeshire, UK
RNase-free 1.5ml microfuge 
tubes
12450 Ambion Europe Ltd, Huntingdon, 
Cambridgeshire, UK
30 pi pre-sterilized filter tips RT-20F Rainin Instruments Co Ltd, Wobum, 
USA
lOOOpl pre-sterilized filter 
tips
RT-1000F Rainin Instruments Co Ltd, Wobum, 
USA
200pl pre-sterilized filter tips RT-200F Rainin Instruments Co Ltd, Wobum, 
USA
96-well flat-bottomed plates 3595 Coming Costar, High Wycombe, UK
96-well U-bottomed plates 3799 Coming Costar, High Wycombe, UK
Lab-Tek II Chamber slide, 
sterile, 8 chambers
154534 Nalge Nunc International, Naperville, 
IL, USA
Cell scrapers 353086 Becton Dickinson Labware, NJ, USA
Glasstic®Slide 10 
combination coverslip 
microscope slides
87144 Hycor Biomedical, Garden Grove, 
CA, USA
Millex 0.22pl syringe filter SLGP033RS Millipore, Cork, Ireland.
Eppendorf Combipure 2.5ml 
dispensers
0030.069.447 Eppendorf, Hamburg, Germany
96-well polymerase chain AB0900 Abgene, Surrey, UK
115
Product Catalogue No. Supplier
reaction (PCR) plate
Domed cap strip for PCR 
plate
AB0852 Abgene, Surrey, UK
FACS tube with cell strainer, 
5ml
352235 Becton Dickinson Labware, NJ, USA
Poly-L-lysine coated slides J2800AMNZ Menzel GmbH, Braunschweig, 
Germany
Teflon-coated glass slides 10-3114 Cel-line Associates Inc, Newfield, NJ, 
USA
Coverglass (22x50mm) 406/0188/44 BDH Lab Supplies, Poole, UK
Homogenization tubes 2ml 19201 Qiagen, Crawley, UK
Stainless steel cone balls, 6.0 
mm diameter
22.455.0003C Retsch (U.K) Ltd, Leeds, UK
Tissue moulds M497-12 Simport, Fisher Scientific UK, 
Loughborough, UK
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2.1.2 Tissue Culture Reagents
Product Catalogue No. Supplier
2x Medium 199 21157-029 GibcoBRL, Paisley, UK
Accutase LI 1-007 PAA laboratories, Linz, Austria
Agar:Agar 1.01613 Merck, Darmstadt, Germany
Baby hamster kidney 
(BHK) Medium
GibcoBRL, Paisley, UK
Blasticidin S 
Hydrochloride
150477 ICN Biomedicals GmbH, 
Eschwege, Germany
Collagenase Type III LS004182 Worthington Biochemical Corp. 
Reading, UK
Dubecco’s modified 
Eagles’ medium (DMEM) 
with Glutamax Medium
31955-021 GibcoBRL, Paisley, UK
Effectene Transfection 
reagent
301427 Qiagen Ltd, Crawley, UK
FACS Lysing Solution lOx 349202 Becton Dickinson Labwear, 
UJ, USA
Foetal Calf Serum (FCS) A 15-002 PAA laboratories, Linz, Austria
FuGENE 6 Transfection 
Reagent
1 815 091 Roche Diagnostics Corporation, 
Roche Applied Science, 
Indianapolis, IN, USA
GeneJuice Transfection 
Reagent
70967-3 CN Biosciences, Beeston, UK
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Product Catalogue No. Supplier
Good Foetal Calf Serum 
(GFCS)
10106-169 Invitrogen, Paisley, UK
Iscove’s Modified 
Dulbecco’s Medium 
(IMDM) with Glutamax
31980-022 GibcoBRL, Paisley, UK
Low Endotoxin Foetal 
Bovine Serum (FBS, Lot: 
62K3376)
F9666 Sigma-Aldrich, Poole, UK
Modified Eagles medium 
(MEM) with Glutamax
41090-028 GibcoBRL, Paisley, UK
NycoPrep 1.077 A 1113029 Axis-shield PoC AS, Oslo, Norway
Opti-MEM I Reduced 
Serum Medium
51985-042 GibcoBRL, Paisley, UK
Penicillin and X IAH Media Supplies, Compton,
Streptomycin UK
Polymyxin B sulfate salt P4932 Sigma-Aldrich, Poole, UK
RPMI with Glutamax 72400-.021 GibcoBRL, Paisley, UK
RPMI with Glutamax 72400-.021 GibcoBRL, Paisley, UK
Saline F7124 Baxter Healthcare, Compton
Trypan blue 15250-061 GibcoBRL, Paisley, UK
Trypsin-EDTA 45300-019 GibcoBRL, Paisley, UK
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2.1.3 Chemicals and molecular biology reagents
Product Catalogue No. Supplier
100 bp Deoxyribonucleic acid 
(DNA) Ladder
G210A Promega, Southampton, UK
lkb DNA Ladder G571A Promega, Southampton, UK
250 bp DNA Ladder 10596-013 Invitrogen Life Technologies, 
Paisley, UK
6 -carboxyfluorescein (FAM)- 6 - 
carboxy-N,N,N’,N \- 
tetramethylrhodamine (TAMRA) 
dual-labelled oligonucleotide 
probes
Sigma-Genosys, Haverhill, U K , 
or
Eurogentec, Seraing, Belgium
Acetone 32201 Sigma Aldrich, Poole, UK
Agarose LE Analytical Grade A9539 Sigma Aldrich, Poole, UK
Ammonium Persulphate 161-0700 BioRad Laboratories Ltd, Hemel 
Hempstead, UK
Ampicillin X LAH Media Supplies, Compton, 
UK
Bgl II Invitrogen Life Technologies, 
Paisley, UK
Blue/Orange 6 x Loading Dye G190A Promega, Southampton, UK
Bovine Serum Albumin (BSA) A7030 Sigma Aldrich, Poole, UK
Chloamphenicol acetyl 
transferase (CAT) ELISA kit
1 363 727 Roche Diagnostics
Roche Molecular Biochemicals
Mannheim, Germany
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CpG1826 MWG, Ebersberg, Germany
Crystal violet C3886 Sigma Aldrich, Poole, UK
Cytochrome 5 (Cy5) Ab 
Labelling kit
P A35000 Amersham Biosciences, Little 
Chalfont, UK
Cytokine Bead Array (CBA) 
Mouse Inflammation kit
552364 BD Biosciences, PharMingen, 
Oxford, UK
Deoxyribonuclease I, 
Amplification Grade
18068-015 Invitrogen Life Technologies, 
Paisley, UK
DH5a competent cells 18265-017 Invitrogen Life Technologies, 
Paisley, UK
Dimethyl sulphoxide (DMSO) D2650 Sigma Aldrich, Poole, UK
DNAse I AMPD1 Sigma Aldrich, Poole, UK
EcoRI 15202-013 Invitrogen Life Technologies, 
Paisley, UK
Endofree Plasmid Maxi Kit 12362 Qiagen Ltd, Crawley, UK
Ethanol X IAH Stores, Compton, UK
Ethanol, absolute, molecular 
biology grade
E7023 Sigma Aldrich, Poole, UK
Ethidium Bromide E1510 Sigma Aldrich, Poole, UK
Ethylenediaminetetraacetic acid 
(EDTA)
100935V BDH Lab Supplies, Poole, UK
FAM- Major groove binder 
(MGB) dual-labelled
Applied Biosystems, Warrington, 
UK
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oligonucleotide probes
Fluorescent mounting medium S3023 DakoCytomation, Glostrup, 
Denmark
Formaldehyde 47629 Sigma Aldrich, Poole, UK
Glycerol 101186M BDH Lab Supplies, Poole, UK
Halothane - LAH Supplies, Compton
HEPES buffer 15630-049 GibcoBRL, Paisley, UK
Hindlll 15207-012 Invitrogen Life Technologies, 
Paisley, UK
Hydrochloric acid 30721 Sigma Aldrich, Poole, UK
ImmEdge wax pen H400 Vector Laboratories, 
Peterborough, UK
Isopropanol 59080 Sigma Aldrich, Poole, UK
Lipopolysaccharide (LPS) E.coli 
055.135
L2880 Sigma Aldrich, Poole, UK
Luciferase Assay System El 500 Promega, Southampton, UK
Luria Broth (LB) X IAH Media Supplies, Compton, 
UK
Luria Broth Agar Plates X IAH Media Supplies, Compton, 
UK
Methanol 10158BG BDH Lab Supplies, Poole, UK
Mouse IFN-a ELISA kit 42100-1 PBL Biomedical Laboratories, 131 
Ethel Rd West Suite 6 , Piscataway,
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NJ 08854, USA
Mouse IFN-a/(3 Gift from Dr. 
Agnes Le Bon
Le Bon etal., 2001
Nuclease-free water 9937 Ambion Europe Ltd, Huntingdon, 
Cambridgeshire, UK
OCT Compound 36160 3E BDH Laboratory Supplies, Poole, 
UK
One Shot INVaF’ Competent 
Cells
C2020-03 Invitrogen Life Technologies, 
Paisley, UK
One step revese transcriptase 
(RT) quantitative PCR (qPCR) 
Mastermix
RT-QPRT-032X Eurogentec, Seraing, Belgium
OPD Tablets P9187 Sigma Aldrich, Poole, UK
Paraformaldehyde 2944704L BDH Lab Supplies, Poole, UK
Paraformaldehyde P6148 Sigma Aldrich, Poole, UK
Phosphate Buffer Saline xlO 14200-067 GibcoBRL, Paisley, UK
Polyinosinic acid:Polycytidylic 
acid, sodium salt, double 
stranded (Poly IC)
P0913 Sigma Aldrich, Poole, UK
QIAfilter Plasmid Maxi Kit 12263 Qiagen, Crawley, UK
Qiaprep Miniprep Kit 27104 Qiagen Ltd, Crawley, UK
Qiashredder 79654 Qiagen Ltd, Crawley, UK
R848 Tlrl-r848 AutogenBioclear, Caine, Wiltshire,
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UK
Recombinant Mouse 
granulocyte-macrophage colony 
stimulating factor (GM-CSF)
415-ML R&D Systems, Abingdon, UK
Recombinant murine IFN-a HC 1040b HyCult Biotechnology b.v., Uden, 
The Netherlands
Recombinant murine IFN-(3 HC 1050b HyCult Biotechnology b.v., Uden, 
The Netherlands
RNase-Free DNase Set 79254 Qiagen Ltd, Crawley, UK
RNaseZap 9780-9782 Ambion Europe Ltd, Huntingdon, 
Cambridgeshire, UK
RNeasy Mini Kit 74104 Qiagen Ltd, Crawley, UK
Sequence detection 
oligonucleotide primers
MWG, Ebersberg, Germany
Sodium acetate (anhydrous) S2889 Sigma Aldrich, Poole, UK
Sodium Azide S-8032 Sigma Aldrich, Poole, UK
Sodium Carbonate Anhydrous 102405Y BDH Lab Supplies, Poole, UK
Sodium Chloride 102415K BDH Lab Supplies, Poole, UK
Sodium Dodecyl Sulphate (SDS) 444464T BDH Lab Supplies, Poole, UK
Sodium Hydrogen Carbonate 102475W BDH Lab Supplies, Poole, UK
Sodium Hydroxide 30620 Sigma Aldrich, Poole, UK
Sulphuric Acid 102761C BDH Lab Supplies, Poole, UK
Taqman Universal PCR 4324018 Applied Biosystems, Warrington,
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Mastermix UK
Tris-acetate EDTA (TAE) 25x 0796-1.6L Amresco, Ohio, USA
Tris-hydrochloric acid (Tris- 
HCL)
T3253 Sigma Aldrich, Poole, UK
Triton-X-100 T9284 Sigma Aldrich, Poole, UK
Trizma Base T1503 Sigma Aldrich, Poole, UK
Tween-20 P7949 Sigma Aldrich, Poole, UK
B -mercaptoethanol M7522 Sigma Aldrich, Poole, UK
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2.1.4 Anti-murine antibodies for FACS analysis
Antibody to Clone Isotype Conjugated
to
Working
dilution
Catalogue
no.
Supplier
CD llc HL-3 Armenian 
Hamster IgGl, X
APC1 1 in 1 0 0 553802 BD Biosciences PharMingen, Oxford, UK
CD1 lc (N418) MicroBeads 130-052-001 Miltenyi Biotec, Bisley, UK
CD19 ID3 Rat IgG2a, k Biotin 1 in 1 0 0 553784 BD Biosciences PharMingen, Oxford, UK
CD3e 145-2C11 Armenian 
Hamster IgGl, k
Biotin 1 in 1 0 0 553059 BD Biosciences PharMingen, Oxford, UK
CD4 (L3T4) RM4-5 Rat IgG2a, k FITC" 1 in 1 0 0 553046 BD Biosciences PharMingen, Oxford, UK
CD40 3/23 Rat IgG2a, k RPEj 1 in 1 0 0 553791 BD Biosciences PharMingen, Oxford, UK
CD49b/Pan-NK
cells
DX5 Rat IgM, k Biotin 1 in 1 0 0 553856 BD Biosciences PharMingen, Oxford, UK
1 APC = Allophycocyanin
2 FITC = Fluorescein isothiocyanate
3 RPE = Red phycoerythrin
Antibody to Clone Isotype Conjugated
to
Working
dilution
Catalogue
no.
Supplier
CD54 (adhesion
molecule,
ICAM-1)
3E2 Armenian 
Hamster IgGlK
RPE 1 in 1 0 0 553253 BD Biosciences PharMingen, Oxford, UK
CD80 (B7-1) 16-10A1 Armenian 
Hamster IgG2, k
RPE 1 in 1 0 0 553769 BD Biosciences PharMingen, Oxford, UK
CD8 6  (B7-2) GL1 Rat IgG2a, k RPE 1 in 1 0 0 553692 BD Biosciences PharMingen, Oxford, UK
CD8 a (Ly-2) 53-6.7 Rat IgG2a, k FITC 1 in 1 0 0 553030 BD Biosciences PharMingen, Oxford, UK
CELLection 
Biotin Binder 
Kit
Biotin 115.33 Dynal Biotech ASA, Oslo, Norway
F4/80 Antigen A3-l(F4/80) Rat IgG2b RPE 1 in 1 0 MCA497PE Serotec, Oxford, UK
Fc block 2.4G2 Rat IgG2b, k 1 in 1 0 0 553141 BD Biosciences PharMingen, Oxford, UK
H-2Kd AF6-88.5 Mouse (Balb) 
IgG2a, k
RPE 1 in 1 0 0 553570 BD Biosciences PharMingen, Oxford, UK
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Antibody to Clone Isotype Conjugated
to
Working
dilution
Catalogue
no.
Supplier
I-A/I-E M5/114.15.2 Rat IgG2b, k RPE 1 in 1 0 0 557000 BD Biosciences PharMingen, Oxford, UK
PDCA-1 JF05.1C2.4.1 Rat IgG2b FITC 1 in 1 0 130-091-961 Miltenyi Biotec, Bergisch Gladbach, 
Germany
PDCA-1 JF05.1C2.4.1 Rat IgG2b PE 1 in 1 0 130-091-962 Miltenyi Biotec, Bergisch Gladbach, 
Germany
2.1.5 Isotype-matched control antibodies for FACS analysis
Isotype Clone Conjugated to Working dilution Catalogue no. Supplier
Hamster IgGl G235-2356 APC 1 in 1 0 0 553956 BD Biosciences PharMingen, 
Oxford, UK
Hamster IgGl A 19-3 RPE 1 in 1 0 0 553972 BD Biosciences PharMingen, 
Oxford, UK
Isotype Clone Conjugated to Working dilution Catalogue no. Supplier
Hamster IgG2, k B81-3 RPE 1 in 1 0 0 550085 BD Biosciences PharMingen, 
Oxford, UK
Mouse IgG2a, k G155-178 RPE 1 in 1 0 0 553457 BD Biosciences PharMingen, 
Oxford, UK
Rat IgG 2a, k R35-95 FITC 1 in 1 0 0 553930 BD Biosciences PharMingen, 
Oxford, UK
Rat IgG 2b, k A95-1 FITC 1 in 1 0 0 556923 BD Biosciences PharMingen, 
Oxford, UK
Rat IgG2a, k R35-95 RPE 1 in 1 0 0 554688 BD Biosciences PharMingen, 
Oxford, UK
Rat IgG2b, k A95-1 RPE 1 in 1 0 0 553989 BD Biosciences PharMingen, 
Oxford, UK
2.1.6 Antibodies used in confocal/immunofluorescence Studies
Antibody to Clone Isotype Conjugated
to
Working
dilution
Catalogue
no.
Supplier
Murine-IFN-a F18 Rat IgGl unconjugated 1 in 2 HM1001 HyCult Biotechnology 
b.v., Uden, The 
Netherlands
Murine-PDCA-1 JF05-1C2.4.1 Rat IgG2b biotin 1 in 5 130-091-964 Miltenyi Biotec, Bergisch 
Gladbach, Germany
LCMV NP NP-113 Mouse IgG2a Cy5 1 in 1 0 Hybridoma cells were a 
gift from Dr Michael 
Buchmeier, The Scripps 
Research Institute, La 
Jolla, CA, USA
LCMV Arm 
E350
Antiserum immune 
ascitic fluid
Mouse antibodies unconjugated 1 in 50 VR1271-AF ATCC, LGC Promochem, 
Middlesex, UK
2.1.7 Secondary Conjugates and Dyes
Reagent Isotype Conjugated to Working
dilution
Catalogue
no.
Supplier
Anti-rabbit IgG Affinity isolated goat 
polyclonal
biotin 1 in 1 0 0 0 B 8895 Sigma-Aldrich, Poole, UK
Streptavidin- Alexa 
Fluor 488
Alexa Fluor 488 1 in 2 0 0 0 554060 BD Biosciences PharMingen, Oxford, 
UK
Anti-mouse 
polyvalent Ig 
(IgGl, IgA, IgM)
Affinity isolated goat 
polyclonal
FITC 1 in 2 0 0 F1010 Sigma-Aldrich, Poole, UK
Bo-Pro 1 in 2 0 0 B3587 Molecular Probes, Invitrogen, Paisley, 
UK
Anti-rat IgG (H+L) Affinity purified donkey 
antibodies
Alexa Fluor 488 1 in 1 0 0 A21208 Molecular Probes, Invitrogen, Paisley, 
UK
Anti-mouse-
IgG(H+L)-Alkaline
Affinity purified goat 
antibodies
Alkaline
phosphotase
1 in 1 0 0 0 1031-04 Southern Biotech, Cambridge 
Biosciences, Cambridge, UK
Reagent Isotype Conjugated to Working
dilution
Catalogue
no.
Supplier
Phosphotase (AP)
Streptavidin-AP AP 1 in 1 0 0 0 7100-04 Southern Biotech, Cambridge 
Biosciences, Cambridge, UK
TSA kit (HRP- 
streptavidin and 
AlexaFluor594 
tyramide)
HRP-
Streptavidin & 
AlexaFluor594 
tyramide
1 in 1 0 0 T-20935 Molecular Probes, Invitrogen, Paisley, 
UK
ImmunoPure (A 
Plus) IgG 
Purification kit
Protein A 44679 Pierce, Rockford, IL, USA
AP conjugate 
substrate kit
AP 170-6432 BioRad Laboratories Ltd, Hemel 
Hempstead, UK
2.1.8 Isotypes matched antibodies for confocal/immunofluorescence, control sera and blocking reagents
Isotype Clone Conjugated to Working
dilution
Catalogue
no.
Supplier
Rat IgG2b A95-1 biotin 1 in 5 553987 BD Biosciences PharMingen, Oxford, UK
Rat IgGl R3-34 unconjugated 1 in 2 559072 BD Biosciences PharMingen, Oxford, UK
Mouse IgG2a G155-178 Cy5 1 in 10 555575 BD Biosciences PharMingen, Oxford, UK
Normal rabbit serum unconjugated 1 in 1 0 0 Kind gift from Julie Lewis, Edward Jenner 
Institute, Compton, UK
Normal mouse serum - unconjugated 1 in 1 0 0 X0910 DakoCytomation, Glostrup, Denmark
Mouse on Mouse 
(M.O.M)
Immunodetection kit
90jnl in 
15 ml
PK-2200 Vector Laboratories, Peterborough, UK
2.1.9 Antibodies used in type 1 IFN quantitation assays
Antibody to Clone Isotype Conjugated to Working dilution Catalogue
no.
Supplier
Mouse IFN-a Polyclonal
antibody
Rabbit
polyclonal
unconjugated 1 in 6000 32100-1 PBL Biomedical 
Laboratories, 
Piscataway, NJ, USA
Mouse IFN-(3 Polyclonal
antibody
Rabbit
polyclonal
unconjugated 7 Neutralization 
units per 1U IFN
AB2215 Chemicon International, 
Temecula, CA, USA
Mouse IFN-y F-3 Rat IgG2a unconjugated 0.4pg/ml HM 1002a HyCult Biotechnology 
b.v., Uden, The 
Netherlands
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2.1.10 Plasmids
Plasmid Protein Vector Selection marker Provided by
p(9-29 ISRE) 4tkA(- 
39)lucter
Luciferase pBR322 Ampicillin Dr. Steve Goodboum (St George’s Hospital 
Medical School, University of London, 
London, UK)
pMX-CAT CAT pRSV-CAT Ampicillin Dr. Bryan Charleston (IAH, Compton, UK)
pCDNA-GFP Green fluorescent protein 
(GFP)
pCDNA Ampicillin Dr. Mike Flint (University of Reading, UK)
pCDNA- 6  V5-HisB Blasticidin Ampicillin Invitrogen, Paisley, UK
pCAGGS-GP LCMV-GP pCAGGS Ampicillin All constructs provided by
Dr. Juan Carlos de la Torre (The Scripps
Research Institute, La Jolla, CA, USA)
pCAGGS-NP LCMV-NP pCAGGS Ampicillin
pCAGGS-ZII LCMV-Z pCAGGS Ampicillin
2.1.11 Sequences for Taqman primers and probes
Gene Reference Primers and Probe Sequence
Primer 
dilution *
Baseline and 
Threshold values
IFN-(3
(Karaghiosoff 
et a l .  2003)
Forward : ATGAGTGGTGGTTGCAGGC
Reverse : TGAC CTTT CAAATGCAGTAGATTCA
Probe : FAM-AAGCATCAGAGGCGGACTCTGGGA - TAMRA
1:5 (3-15), 0.05
IFN-ot
(Karaghiosoff 
et al. 2003)
Forward: CTGTGTGATGCAGGAACC 
Reverse: TCACCTCCCAGGCACTGA
Probe : FAM-AGACTCCCTGCTGGCTGTGAGGACA - MGB-NFQ
1:2
(3-24), 0.08
IFN-o(non-o4)
Forward (for a 6,8,7,11):
CACTGTGTTCCTGAGAGAGAAGAAAC
Forward (for 5,2,1,13, pseudogene):
CACTGTGTACCTGAGAGAGAAGAAAC
Reverse: GGAAGACAGGGCTCTCCAGACT
Probe : FAM-CACCTCCCAGGCACAGGGGCT-MGB-NFQ
1:5 (3-18), 0.03
Hypoxanthine 
ribosyl transferase 
HPRT
(Karaghiosoff 
et al. 2003)
Forward: TTGCTCGAGATGTCATGAAGGA 
Reverse: TGAGAGATCATCTCCACCAATAACTT 
Probe : FAM -CTGGAGGGCGTGCAGCGTGA - TAMRA
1:10 (3-15), 0.03
Mx
Forward: GGAATTACCAGGGTGGCTGTAG 
Reverse: TGGATGTATGTCTTGATAAGTCTCTTGA 
Probe : FAM- ACCAGCCTGCAGACATAGGACGCC-TAMRA
1:10
(3-15), 0.03
Gene Reference Primers and Probe Sequence
Primer 
dilution *
Baseline and 
Threshold values
LCMV-NP
Forward: CAGCATCTTCCTGCACCTTGT
Reverse: ATCGGTGTGGCTTTGGACAT
Probe : FAM- AATACCAACACACAGGCACATAAAAGGTGGC-
TAMRA
1 : 1 0 (3-11),0.05
Influenza A
(van Elden 
et al. 2001)
Forward 1: GGACTGCAGCGTAGACGCTT 
Forward 2: CATTCTGTTGTATATGAGGCCCAT 
Reverse : CATCCTGTTGTATATGAGGCCCAT 
Probe : FAM- CTCAGTTATTCTGCTGGTGCACTTGCCA- 
TAMRA
1:2 (3-18),0.01
Sendai Z-NP (Wagner et al. 2003)
Forward: CAGAGGAGCACAGTCTCAGTGTTC
Reverse: TCTCTGAGAGTGCTGCTTATCTGTGT
Probe : FAM- TGCATCATCAGTCACACTTGGGCCTAGTA- 
TAMRA
1:7.5 (3-8), 0.1
’‘'dilution is from stocks of forward and reverse primers at 1 OOpmol//d each.
o\
2.1.12 Viruses
Virus Originally obtained from Working stock grown in Prepared by Titre of 
working stock
LCMV Arm Dr. Michael Oldstone (The Scripps 
Research Institute, La Jolla, CA, USA)
BHK cells Mai Lee Wong 6  x 1 0 7 pfu/ml
LCMV Cl 13 Dr. Michael Oldstone (The Scripps 
Research Institute, La Jolla, CA, USA)
BHK cells Mai Lee Wong 5.6 x 107 pfu/ml
LCMV Docile Dr. Rolf Zinkemagel (Institute for 
Experimental Immunology, University of 
Zurich, Zurich, Switzerland)
BHK cells Lian Ni Lee 1 .2  x 1 0 7 pfu/ml
Influenza A/PR/8/34 Dr. Sam Hou (Edward Jenner Institute, 
Compton, UK)
Allentoic fluid Charles River SPAFAS, 
North Franklin, USA
512 HA 
units/0.05ml
EMCV ATCC virus collection, BHK cells Dr. Mike Riffkin 5x10s pfu/ml
Virus Originally obtained from Working stock grown in Prepared by Titre of 
working stock
LGC Promochem, Middlesex, UK
Sendai Z Dr. John Macauley (IAH, Compton, UK) 1 0 -day old embryonated 
chicken eggs
Dr. John Macauley ~ 1 0 7 p.f.u/ml
HSV-1 Dr. Terry Hill (University of Bristol, 
Bristol, UK)
DM-21 cells Miranda Ashton lxlO 7 p.f.u/ml
2.1.13 Mammalian cell lines
Cell line Catalogue No. Description Supplier
BalbC17 Mouse fibroblast cell line derived from Balb/c mice. 
This cell line was transfected for IFN reporter 
bioassays and infected with LCMV for in vitro chronic 
infection studies
Laboratory stocks, originally obtained from 
ATCC, LGC Promochem, Middlesex, UK
Vero ATCC: CCL-81 An adherent cell line derived from African green 
monkey kidney cells and used in viral plaque assays
Laboratory stocks, originally obtained from 
ATCC, LGC Promochem, Middlesex, UK
u>
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Cell line Catalogue No. Description Supplier
BHK ATCC: C-13 An adherent cell line derived from baby hamster 
kidney cells and used to grow up stocks of LCMV 
Docile virus.
Laboratory stocks, originally obtained from 
ATCC, LGC Promochem, Middlesex, UK
L929 ATCC: CCL-1 Mouse fibroblast cell line used in IFN bioassays Laboratory stocks, originally obtained from 
ATCC LGC Promochem, Middlesex, UK
FSDC Semi-adherent mouse DC line used in chronic LCMV 
experiments
Dr. Peter Beverley, Edward Jenner Institute, 
Compton, UK
D2SC/1 Semi-adherent mouse DC line used in chronic LCMV 
experiments.
Dr. Peter Beverley, Edward Jenner Institute, 
Compton, UK
2.1.14 Mice
Female C57BL/6 mice 8-12 weeks of age supplied by Charles River (Margate, UK) were used for all in vivo experiments. BM-DC were 
generated from C57BL/6 mice obtained from the SPF animal unit (IAH, Compton, UK)
u>
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2.2 Propagation of cell lines
BHK cells were grown in BHK medium supplemented with 10% foetal calf serum 
(FCS), 10% tryptose-phosphate broth and 1 pg/ml (P/S) in a 37°C, 5% CO2 incubator. 
They were subcultured when confluent by washing the monolayer with sterile 0.9% 
saline and adding 0.05% trypsin/0.02% EDTA solution.
Vero cells were grown in RPMI 1640 with 7% FCS and 1 pg/ml P/S and maintained 
in a 37°C, 5% CO2 incubator. They were subcultured as above.
Untransfected BalbC17 cells were grown in Eagle’s MEM supplemented with 7% low 
endotoxin FCS and 1 pg/ml P/S at 37°C in 5% CO2. Stably transfected cells were 
cultured in growth media supplemented with 8  pg/ml blasticidin. Cells were 
subcultured as described above.
L929 cells were grown in DMEM supplemented with 7% FCS and 1 pg/ml P/S at 
37°C, 5% CO2 Cells were subcultured as described above.
FSDC cells were grown in RPMI 1640 medium supplemented with 10% GFCS and 1 
pg/ml P/S at 37°C in 5% CO2. Confluent cells were resuspended into spent media and 
cultered into new flasks with fresh media.
D2SC/1 cells were grown in RPMI 1640 medium supplemented with 10% GFCS and 
1 pg/ml P/S at 37°C, 5% CO2. Confluent cells were subcultured as described for 
FSDC cells.
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2.3 Preparation and assay of viruses
2.3.1 Preparation of working stocks of LCMV Docile
From an aliquot of LCMV Docile (PI) provided by Dr Rolf Zinkemagel (Institute of 
Experimental Immunology, University of Zurich, Switzerland), master stocks (P2) 
and working stocks (P3) were generated. BHK cells were set up in T150 flasks (TRP, 
Trasadingen, Switzerland) flasks at ~5xl 06 cells per flask in a volume of -30 ml of 
complete growth medium and grown at 37°C in a 5% CO2 environment overnight. 
Cells were infected with a master stock of virus at a multiplicity of infection (m.o.i.) 
of 0.1 pfu/cell in 4 ml serum-free media per flask. After a one hour incubation period 
at 37°C/ 5% CO2, 2 0  ml of supplemented complete growth medium was added to 
each flask and the cells were then incubated for a further two days. After this time the 
virus containing supernatant was harvested, and any cell debris removed by 
centrifugation at lOOOg for 20 mins at 4°C Sorvall RT7 Plus (Sorvall, Newtown, 
USA). Aliquots of the resulting vims working stock were then made and stored at - 
80°C. The vims titre of the stock was determined by immunoplaque assay as 
described below.
2.3.2 Plaque assay for titration of LCMV Arm
LCMV Arm and Cl 13 were titrated by plaque assay on Vero cells as described by 
Dutko and Oldstone (Dutko and Oldstone 1983). Briefly, Vero cells were seeded into 
6 -well plates at 3x105 cells per well in 3 ml of growth medium and incubated 
overnight. Virus-containing test samples were serially diluted from 10'2 to 10"8 in 
semm free RPMI 1640. Supernatant was removed then replaced with 500 pi of each 
vims dilution and incubated for 1 hour. Cell monolayers were subsequently overlaid 
with 3 ml agar/199 media per well. Plates were wrapped in foil and incubated in a
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37°C, 5% CO2 incubator for 6  days. Monolayers were then fixed with 8 % 
formaldehyde in PBS for 1 hour and subsequently stained with 0.1% crystal violet to 
visualise the plaques.
2.3.3 Immimoplaque assay for the titration of LCMV Docile
LCMV Docile was titrated on Vero cells as described above except that the 
monolayers were infected for 4 days and the plaques were visualised by 
immunostaining. Plates were fixed with formalin as described above and then fixed 
with 100% methanol for 20 minutes at -20°C. The monolayers were blocked with 
PBS-3%BSA for 1 hour at room temperature, washed with 0.9% saline and probed 
with anti-LCMV antibody (either anti-LCMV ascites VR1271-AF at a 1/50 or 1/100 
dilution or biotin anti-NP monoclonal antibody at 1/12 dilution in PBS-1%BSA, at 
500 pi per well. After 1 hour incubation at room temperature plates were washed and 
bound antibodies detected with either 500 pi anti-mouse-AP conjugate or 
streptavidin-AP (at 1/1000 dilution). Conjugate was incubated for 1 hour at room 
temperature before plaques were detected and visualised with AP substrate. Foci of 
infection appeared to be large, circular and with a defined edge.
2.3.4 Infection of mice with LCMV
Female C57BL/6 mice at 8-12 weeks of age were infected i.v with LCMV Arm at 
5x10s plaque forming units (p.f.u.) diluted in 200 pi serum-free RPMI media or 
LCMV C113 or LCMV Docile at 5xl06 p.f.u. in 200 pi serum-free RPMI media. They 
were housed in Category 3 containment facilities and provided with food and water ad 
labitum. All animal studies were carried out in accordance with UK Home Office 
regulations and were approved by the site ethical review committee.
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2.4 Plasmid preparation
2.4.1 Plasmids for IFN-reporter gene assays
1. p(9-29 ISRE) 4tkA(-39)lucter (also known as pISRE-luc)
The plasmid contains 4 IFN-stimulated response elements (ISRE) linked to the 
luciferase reporter gene (King and Goodboum 1998) and can be used for the detection 
of biologically active IFN-a and -(3.
2. pMX-CAT
This plasmid contains the CAT gene under the control of an IFN-inducible Mx- 
promoter. pMX-CAT was derived from pRSV-CAT by inserting the human Mx- 
promoter region upstream of the CAT gene (Ronni et al. 1998). The MXA promoter is 
induced by IFN-a/(3, with high, sustained expression even after transient exposure to 
type 1 IFNs (Baigent et al. 2002).
3. pcDNA6  V5-HisB (Invitrogen)
The plasmid encodes a blasticidin resistance gene and was co-transfected with the 
IFN responsive constructs to provide a selectable marker for stably transfected cells.
4. pCDNA-GFP
This is a control plasmid that encodes for green fluorescent protein (GFP). It was used 
as a positive control to determine the efficiencies of transfection.
All of these plasmids, apart from plasmid pcDNA-GFP, were transformed into recAV 
competent cells, purified and checked by Julie Lewis.
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Plasmid pCDNA-GFP was transformed into DH5a competent cells, purified and 
checked by Rachel Owen.
2.4.2 Plasmids containing individual LCMV genes
pCAGS-GP, NP and Z encode the full length sequence of the GP, NP and Z proteins 
of LCMV strain Arm 53. The proteins were inserted downstream of a chicken y 
globulin promoter.
2.4.3 Transformation of LCMV plasmids
pCAGS-GP, NP and Z were transformed into DH5a competent cells using a standard 
heat-shock method. 50 pi of competent cells were aliquoted into chilled eppendorf 
tubes. 2 pi of plasmid DNA (18-32 ng DNA) were added to the cells and incubated on 
ice for 30 mins. The cells were given a heat-shock by immersion in a 37°C water-bath 
for 20 seconds, then were placed on ice for 2 mins. 950 pi of Luria Bertani (LB) 
medium was added and incubated for 1 hour at 37°C. 100 pi of the cell mixture was 
plated out on LB agar plates containing 100 pg/ml ampicillin and incubated overnight 
at 37°C in an InnOva 4230 shaker incubator to select for transfected colonies. 5 single 
colonies from each plasmid were selected at random and inoculated into 5 ml LB 
broth cultures containing 100 pg/ml ampicillin and incubated overnight at 37°C in an 
InnOva 4230 incubator with shaking at 225 rpm.
2.4.4 Plasmid purification
Plasmids were purified using a Qiagen Plasmid Miniprep kit according to the 
manufacturer’s instructions. Plasmid DNA was eluted in 50 pi TE buffer (0.5M 
EDTA, 1 ml Tris(hydroxymethyl) aminomethane) in H20  at pH 7.4) and the identity 
of each plasmid was checked by restriction enzyme digest followed by gel
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electrophoresis of the digested products to confirm the presence of the desired 
plasmids.
The following restriction enzymes were used to identify purified plasmids:-
Plasmid Restriction enzyme(s) Expected products
pCAGS-GP Hindlll Single band 6.2kb
pCAGS-NP EcoRI and Bglll 1.6 kb and 4.8kb bands
pCAGS-Z EcoRI Single band 4.9-5kb
1 pi of plasmid DNA was digested for 1 hour at 37°C with the respective restriction 
enzymes and the products resolved by electrophoresis on 1% TAE agarose gels 
containing ethidium bromide (1 pi per 10 ml gel) together with 1 kb Plus and 100 bp 
DNA ladders in Biorad subcell electrophoresis chambers (Biorad Laboratories, Hemel 
Hampstead, UK) and visualised under UV light (Jencons Forest Row, UK).
The colony displaying the highest expression of the relevent plasmid (most intense 
band on the gel) was selected for generation of glycerol stocks. The selected colonies 
were inoculated into 3ml of LB broth cultures containing 100 pg/ml ampicillin and 
incubated for 8 hours at 37°C in an InnOva 4230 incubator (Fischer Scientific, 
Loughborough, UK) with shaking at 225 rpm. Cultures were removed from 
incubation and mixed with 3 ml glycerol. This 1:1 mixture of culture:glycerol was 
aliquoted into cryotubes at 2 ml/tube and stored at -80°C.
2.4.5 Large-scale Preparation of Plasmid DNA
Large-scale preps of the IFN-reporter plasmids p(9-29 ISRE) 4tkA(-39)lucter and 
pMX-CAT, the selection plasmid pcDNA6  V5-HisB, the control plasmid pCDNA- 
GFP and the LCMV plasmids pCAGS-GP, NP and Z were prepared. Frozen glycerol
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stocks were streaked onto LB agar plates containing 100 pg/ml of ampicillin from 
streaking relevant frozen glycerol stocks. A single colony for each plasmid was 
selected and inoculated into 3 ml of LB broth culture containing 100 pg/ml ampicillin 
and this was incubated for 8  hours at 37°C in an InnOva 4230 incubator with shaking 
at 225 rpm. 1ml of culture was then used to inoculate 100 ml of LB broth culture 
containing 100 pg/ml ampicillin and incubated overnight at 37°C in an InnOva 4230 
incubator with shaking at 225 rpm.
Bacterial cells were pelleted from the broth by centrifugation for 15 min at 6000g at 
4°C using a Beckman J-301 (Beckman Coulter, Fullerton, CA, USA) centrifuge. 
Plasmid was purified from the cell pellets using the Endoffee maxiprep purification 
kit, following the manufacturer’s instructions. Precipitated plasmid DNA was 
resuspended in 500-1000 pi of TE buffer. The purity and quantity of each plasmid 
was determined by UV spectroscopy on a GeneQuant pro RNA/DNA calculator 
(Amersham Pharmacia Biotech, Cambridge, UK) by measurement of the absorbance 
at 260 nm and 280 nm. The 260 nm/280 nm ratio for all plasmids was always -1.8, 
indicating a pure DNA prep.
2.5 Measurement of type 1 IFN Protein or Activity
2.5.1 IFN-alpha ELISA
Two methods were employed to determine concentrations of IFN-a protein. The first 
method used a commercially available ELISA specific for murine IFN-a (PBL 
laboratories), according to the manufacturer’s protocol. Briefly, samples were added 
in duplicate to coated 96-well ELISA plates in a volume of lOOpl/well, in parallel 
with known concentrations of IFN-a solution provided with the kit, to construct a 
standard curve. When appropriate, the samples and standards were diluted in dilution
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buffer prior to addition. The plate(s) were sealed and incubated for 1 hour, then 
washed with lx wash buffer. 100 pi of IFN-a antibody solution at working 
concentration was then added to each well and the plate(s) were incubated for 24 
hours at 24°C. Unbound antibody was then removed and the wells were washed again 
with lx wash buffer prior to addition of lOOpl/well of lx  HRP conjugate and 
incubated for 1 hour at 24°C. The plates were washed and then lOOpl/well TMB 
solution was added and allowed to develop for 15 mins in the dark. The reaction was 
stopped with lOOpl stop solution and the absorbance was determined by UV 
spectroscopy at 450nm on a Spectramax 340 plate reader (Molecular Devices, 
Winnersh, UK). A standard curve was constructed using readings from the known 
IFN-a concentrations and sample calculations were performed using the Softmax Pro 
analysis package (Molecular Devices).
Alternatively, IFN-a was quantitated using a laboratory-based protocol. 96-well 
plates were coated with anti-IFN-a monoclonal (Clone F I8 , Hycult) diluted 1/100 in 
coating buffer, 0.1M NHCO3 pH8.4, at lOOpl /well. After an overnight incubation at 
4°C the plates were blocked with 200pl /well PBS-2 %FCS. After a 2 hour incubation 
at room temperature, blocking buffer was removed, then 50pl/well samples or 
recombinant IFN-a at known concentrations, which were either serum or cell 
supernatants diluted in blocking buffer, were added in duplicate and incubated on a 
shaker for 4 hours at room temperature. Samples were aspirated and the plate was 
washed once with washing buffer (PBS-0.5% Tween 20), before addition of lOOpl 
/well polyclonal anti-IFN-a detection antibody diluted 1/9000 in blocking buffer. 
After an overnight incubation at 4°C, the plate was rinsed 4 times with washing buffer 
and biotinylated goat-anti-mouse Ig diluted 1 / 1 0 0 0 0  in blocking buffer was added at 
lOOpl /well for one hour at room temperature. The plate was washed 4 times with
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washing buffer before lOOpl /well streptavidin-HRP was added for 2 hours at room 
temperature. The plate was washed 6 times with washing buffer prior to addition of 
lOOpl /well OPD substrate solution, then allowed to develop for about 10 mins before 
the absorbance was determined by UV spectrometry at 450nm on a Spectramax 340 
plate reader (Molecular Devices, Winnersh, UK). Standard curve was constructed 
using readings from recombinant IFN-a and sample calculations were performed 
using the Softmax Pro analysis package (Molecular Devices).
2.5.2 IFN Bioassay for antiviral activity
Type 1 IFN antiviral activity was assayed using a bioassay based on the method 
original described by Familletti et a\ (Familletti et al. 1981). lOOp.1 of sample was 
added to the first wells of each row of a 96-well plate containing 50pl o f complete 
media in the other wells. Serial 2-fold dilutions were performed across the plate by 
transferring 50pl from well 1 into the next well along the row until the end. A 
standard curve of recombinant IFN-a was set up on the top row of every plate by 
adding 100U of recombinant IFN-a into well 3 of the top row and diluting 2-fold 
across the remainder of the row as for the samples. The first two wells were left as 
positive (no virus) and negative controls (no IFN). If neutralizing anti-IFN- a ,P or y 
antibodies were added the samples would be incubated with the antibody for 30 mins 
at 37°C. A single-cell suspension of L929 cells at a concentration of 2 xlO6 cells/ml 
was made up using supplemented growth media. 50pl of the suspension was added to 
each well, making the final cell concentration lx l0 5 cells/well, and then the plates 
were incubated at 37°C in 5% CO2 overnight. The following day, the medium was 
removed and the cells were rinsed with PBS then infected with 104 p.f.u 
encephalomyocarditis vims (EMCV) in DMEM-0.5% BSA at lOOpl /well. After a 16
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hour incubation in 37°C, 5% CO2, the virus was removed and the wells rinsed with 
PBS, fixed with 8% formalin for 1 hour and stained with 0.1% crystal violet. The first 
well in each sample dilution series that exhibited the 50% cytopathic effect observed 
in the IFN alpha standard was defined as the endpoint and the IFN titre was calculated 
from this by comparison to the standard curve (titres were expressed as U/ml).
2.5.3 Generation of cell lines stably transfected with IFN-responsive reporter 
plasmids and their use in assaying IFN-a/p activity
2.5.3.1 Transfection of reporter gene constructs
Murine BalbC17 cell lines were stably transfected with the plasmids pISRE-luc, pMX- 
CAT. They were plated into 6-well plates and when at 70-80% confluency were 
transfected with Gene Juice Transfection Reagent following the manufacturer’s 
protocol. Briefly, medium was removed and replaced with medium containing 
plasmid DNA mixed with GeneJuice reagent. After an overnight incubation at 37°C 
in 5% CO2, the medium was removed and replaced with fresh growth medium and 
incubated for a further 24-48 hours before reporter gene expression was assesed. 
Reporter plasmids were co-transfected with pcDNA6 V5-HisB at a ratio of 1:1 
respectively. An aliquot of cells were transfected with pCDNA-GFP in parallel using 
the same conditions in order to assess transfection efficiency.
2.5.3.2 Selection of stably transfected cells
Approximately one week after transfection growth medium was supplemented with 
lOpg/ml of Blasticidin S. Resistant colonies were observed and these were maintained 
within the selection media. After further expansion, the resistant colonies were 
trypsinized and pooled together. A bank of cells was frozen down while the rest were
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gradually expanded into 60mm dishes, then T25 and finally T75 culture flasks. Stably 
transfected cells were later cloned by limiting dilution, seeding cells into 96-well 
plates at a concentration of 1.2 cells/well. Single cell colonies were identified. Clones 
were expanded into 24-well plates and tested to identify those giving the best 
response to IFN-a.
2.5.3.3 IFN assay using reporter plasmids
Transfected cells were seeded into either 6-well plates at lx l0 6 cells/well or 2.5x105 
cells/well, 24-well plates at 6xl04 cells/well or 48-well plates at 0.5-2xl04 cells per 
well and the plates were incubated overnight at 37°C in 5% CO2. The medium was 
removed and samples were added in a volume of 1 ml/well for 6-well plates, 
500pl/well for 24 well plates or 250pl/well for 48-well plates. The plates were then 
incubated for 18-24 hours. All assays included a medium only control and IFN-a 
and/or -p standard curves. In other assays polyclonal antibodies against murine IFN- 
a  or IFN-p was included in the assay medium at 100 Neutralizing Units (N.U). All 
variables were assayed in duplicate. Reporter gene expression was quantified as 
described below.
2.5.3.4 Detection of luciferase reporter gene expression
Expression of luciferase was quantitated using a commercially available Luciferase 
Assay System which measures bioluminescence emission catalyzed by luciferase. The 
medium was aspirated from the assay wells and the cells were lysed with 70pi of lysis 
buffer. 35-50pl of lysate was transferred into opaque 94-well microtitre plates and 
50pl luciferase substrate added. Luminescence was quantified on a Wallac Victor2
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1420 multilabel counter (PerkinElmer, Beaconsfield, UK). Results from these assays 
were expressed as counts per minute (cpm).
2.5.3.5 Detection of CAT reporter gene expression
CAT expression was determined using a commercial ELISA kit. Briefly, cells in 
assay wells were washed with cold PBS and lysed with 75pl lysis buffer for 20 mins. 
All the lysate was transferred to individual wells of the CAT-ELISA plate and 
assayed according to the manufacturer’s instructions. Briefly, 96-well plate-sized 
strips precoated with anti-CAT antibody was rehydrated and blocked. Blocking buffer 
was removed and samples were added, diluted in sample buffer. After 4 hour 
incubation at room temperature, the samples were removed, the wells were washed 
and anti-CAT-antibody conjugated to dixogenin (DIG) was added. The readings were 
amplified by detecting bound anti-CAT antibody with anti-DIG antibody conjugated 
to peroxidase (POD). POD substrate was added for colourimetric assay. The 
absorbance of the samples was measured at 405nm read using a Spectra Max 340 
reader (Molecular Devices). Results were analysed with Softmax Pro software 
(Molecular Devices) and expressed as absorbance at 405nm.
2.6 Quantitation of Type 1 IFN mRNA
2.6.1 Introduction
The reverse-transcriptase polymerase chain reaction (RT-PCR) is a method whereby 
existing mRNA templates of a given gene are amplified through in vitro gene 
transcription. The mRNA is first converted into DNA by RNA-dependent reverse 
transcription. On the templates of interest, DNA between two specific oligonucleotide 
primers is amplified by thermocycling in the presence of Taq DNA polymerase and
151
free nucleotides. As the amount of amplified product at the end of the experiment 
correlates with the initial number of templates in the input sample, monitoring product 
formation during the linear phase of amplication enables quantitative analysis of the 
levels of template in a sample. A schematic of the Taqman real-time PCR detection 
principle is shown below. In a Taqman PCR reaction, a Taqman probe, consisting of 
an oligonucleotide labelled with a reporter fluorochrome on one end and a quencher 
dye on the other is designed to specifically recognize an internal sequence within the 
amplified DNA region. In its intact form (A), the net output of fluorescence signal is 
zero as the fluorescence emission on one end will be quenched by the quencher dye. 
This probe will bind to the amplified sequence during the annealing phase. During the 
extension phase of the amplification (B), the 3’-5* nuclease activity of the Taq 
polymerase will degrade the probe as it extends the new DNA chain. The separation 
of the reporter and quencher results in an increase in reporter emission. The amount of 
fluorescence released is directly proportional to the amount of product generated in 
each PCR cycle and can be applied as a quantitative measure of PCR product 
formation.
3'  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 5‘
A F primer Prober R primer
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3 '  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 5 '
    •>
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+  a polymerase activity R primer
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The principle of quantitative Taqman PCR.
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2.6.2 Design of Taqman Primers and probe
Primers and probes that were specific for the detection of murine IFN-(3 and IFN-a4 
and the housekeeping gene HPRT have been published in the literature, optimized and 
used to quantitate IFN-p and IFN-a4 mRNA transcript levels (Karaghiosoff et al. 
2003). Oligonucleotides and Taqman FAM-TAMRA probes for IFN-p, IFN-a4 and 
HPRT were synthesised according to the published sequences, and used in accordance 
to the published experimental condition. The primers and probes for detection of 
murine Mx were designed and optimized by Elizabeth Balman of the Memory Group, 
Edward Jenner Institute, Compton. In order to design Taqman primers and probe that 
could detect all IFN-a subtypes except for IFN-a4, genomic or cDNA sequences of 
murine IFN-a2, 4, 5, 6, 8,9, 11, 12, 13 subtypes and IFN-P were downloaded from the 
GenBank database. The accession number for each sequence is listed in the following 
table:
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Table 2.1 Type 1 IFN genes aligned
Gene
IFN-a family 
IFN-a 2 mRNA 
IFN-a4 mRNA 
IFN-a5 gene 
IFN-a6 gene
IFN-a8 gene, full coding sequence (cds) 
IFN a (1-9) gene, complete cds 
IFN-a 11 precursor gene, complete cds 
IFN-a 12 mRNA, complete cds 
IFN-a 13 mRNA, complete cds 
IFN-P mRNA
Genbank Accession
gi| 194094|gb|M68944.1 |MUSIFN[ 194094] 
gi|6754291 |reflNM_010503.1 ([6754291 
gi|6754293|ref]NM_010504.1|[6754293] 
gi|51546|emb|X01971.1 |MMIFNA5 [51546] 
gi|927431 |emb|X01972.1 |MMIFNA6[927431 ] 
gi|220441 |dbj |D00460.1 |MUSIFNA8 [220441 ] 
gi| 194100|gb|M 13660.1 |MUSIFNA 1 A[ 194100] 
gi|29469012|gb| AY225954.11[29469012 
gi|28628329|gb|AYl 90046.11[28628329] 
gi|28628331 |gb|AY190047.1 j[28628331 ] 
gi|6754303 |reflNM_010510.1) [6754303]
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Multiple sequence alignment was carried out using the ClustalW program (Pearson 
and Lipman 1988) (website: http://www.ebi.ac.uk/clustalw ). Conserved regions of 
IFN-a2, 5, 6, 8, 9, 11, 12 and 13 were identified and downloaded onto the Primer 
Express software program (PE Applied Biosystems, Warrington, UK) and primers 
and probes were designed that recognized the conserved regions and conformed to the 
following constraints:
Primers -  must not have >2 cytoseine (C)/guanine (G) in the last 5 nucleotides (i.e. on 
the
3’ end)
- forward and reverse primers should have equal annealing temperatures 
(Tms) where possible
Probe -  must not start with a G on the 5’ end
- must have more C residues than G residues
- Tm must be 7-10°C higher than the primers
Suitable primers and probes were selected and these were checked by BLAST 
(Altschul et al. 1990) to ensure they were specific for the IFN-a subtypes and did not 
correspond to sequences in the IFN-P gene, other murine genes or LCMV. Primers 
specific for IFN-a4 were checked in a similar manner, with the multiple sequence 
alignment of the IFN-a genes used to ensure the IFN-a4 primers recognised a unique 
region of the IFN-a4 gene and would not cross react with other IFN-a subtypes. The 
specificity of the IFN-p primers and probes were likewise confirmed.
Primer and probe sequences specific for LCMV envelope glycoprotein were also 
designed using the Primer Express Software program in collaboration with Miranda 
Ashton. The reference sequence for LCMV S (reference M20869, gi 1331358) was 
used primers and probes were synthesized that were specific for the GP-C viral
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protein, and did not cross react with murine genes. The sequence of primers and 
probes that detected the Influenza A and Sendai virus were obtained from the 
literature (van Elden et al. 2001; Wagner et al. 2003). See Figure 3.13 in the next 
chapter for the full sequence of all the primers and probes used.
2.6.3 Purification of total RNA from tissue samples
Pieces of spleen were snap frozen in liquid nitrogen at the time of excision and stored 
at -80°C until purification. Tissues were homogenized using dounce (IKA, Fischer 
Scientific, Loughborough, UK) or bead mill (Retsch, Leeds, UK) homogenizers in the 
presence of 300pl of RLT buffer from the Qiagen Rneasy RNA Mini Isolation kit 
supplemented with 1% p-mercaptoethanol per 30mg tissue. Homogenized tissue was 
loaded onto a Qiashredder column and centrifuged to shear the genomic DNA. Total 
RNA was subsequently extracted from the lysate using the animal tissue protocol of 
the Rneasy Mini RNA Isolation kit. Briefly, the lysate was mixed with 70% molecular 
biology grade ethanol and added to the RNA isolation column. Genomic DNA 
contamination was removed by on-column DNase 1 cleanup followed by washes with 
RW and RPE buffers. Total RNA was eluted from the column in 50pl of nuclease- 
free water and the purity and concentration were determined by UV spectroscopy 
(Pharmacia) using an aliquot of total RNA diluted in nuclease-free water and blanked 
with water. The 260nm/280nm ratio was always within the 1.8-2.0 range, indicating 
samples were not contaminated with protein.
2.6.4 Purification of total RNA from cultured cells
For semi-adherent cells grown in 6 or 24 well plates, spent media was removed and 
collected. The monolayer was washed with PBS and the wash buffer also collected.
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The medium and wash buffer was centrifuged at 1500rpm for 5 mins to pellet the 
cells. This was resuspended in 300(il RLT+ 1% P-mercaptoethanol buffer and 
returned to the monolayer. If the semi-adherent cells were cultured in 96-well plates, 
the entire plate was centrifuged at 1500rpm for 5 mins to pellet the cell. Spent media 
was removed and 300 pi RLT+ 1% p-mercaptoethanol buffer was added to the cell 
pellet. If the cells were an adherent monolayer, the spent media was removed and 
300jnl RLT+ 1% p-mercaptoethanol buffer was added directly to the adherent 
monolayer. Lysates were collected and purified using the method used to extract total 
RNA from tissue samples or was stored at -80°C until purification.
2.6.5 Taqman PCR reaction
For initial optimization assays, Taqman qPCR reactions were set up containing 2.5pl 
of lOx Taqman universal Mastermix (proprietry formulation consisting of optimized 
concentrations of AmpliTaqGold DNA Polymerase, AmpErase Uracil-N-glycosylase, 
deoxynucleotides (dNTPs), passive reference dye and buffer components) 10-fold 
serial dilutions (top concentration 0.2pg/pl) of genomic DNA from wild-type 
C57B1/6 mice as template, various concentrations of primers and labelled probes and 
enough nuclease-free water to make up a 25 pi reaction volume in 96-well optical 
reaction plates (ABGene). Samples were run and analyzed on the ABI Prism 7700 
Single Reporter Detection System 1.5 (Applied Biosystems, Warrington, UK) using 
the following cycling conditions:
AmpliTaqGold Activation 10 min 95°C
PCR amplification
1 min. 60°C
Results were analysed as described below.
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2.6.6 Taqman qRT-PCR reaction
Expression levels of a selection of IFNp, IFN-a4 subtype, all IFN-a subtypes and the 
IFN-induced gene, Mx mRNA transcripts were determined. When purified RNA 
could be quantitated by UV spectroscopy, 300-500ng of total RNA was used as 
template for duplicate Taqman real-time qRT-PCR reactions with primers and probes 
detailed in Table 2.11. In some cases, the amount of RNA purified was not sufficient 
for quantitation, e.g. total RNA from CD1 lc+ B220+/' cells sorted from the spleen of 
infected mice and here, the entire sample was divided equally between the qRT-PCRs 
tested. The samples were amplified in lx Reverse-Transcriptase qPCR™ Master Mix 
consisting of dNTPs, HotGoldstar DNA polymerase, 5mM MgCh, stabilizers, ROX 
passive reference dye, 0.25U/pl Euroscript reverse transcriptase and O.lU/pl RNAse 
inhibitor plus respective primers and probes (see Table 2.x for concentrations) in a 
25pi reaction volume. Reactions were set up in 96-well optical reaction plates. 
Samples were run and analyzed on the ABI Prism 7700 Single Reporter Detection 
System 1.5 (Applied Biosystems) using the following cycling conditions:
Initial reverse transcriptase step 30 mins 48°C
Hot GoldStar activation 10min95°C
Taqman qRT-PCR assays were also conducted to determine levels of a selection of 
viruses, including LCMV, Influenza A/PR/8/34 and Sendai. The reactions were set up 
as described for the IFN-a/p Taqman qRT-PCR reactions using similar amplification 
conditions apart from the Influenza A qRT-PCR which was run for 45 cycles instead 
of the usual 40 cycles.
PCR amplification
1 min. 60°C
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2.6.7 Data Analysis
2.6.7.1 Setting the Baselines and Threshold values
The ABI Prism sequence detector monitors amplification of PCR products by 
quantitatively analyzing fluorescence emissions. The reporter dye (FAM) signal is 
measured against the internal reference dye (ROX) signal to normalize for non-PCR 
related fluctuations in the fluorescence in each well to give the normalized reporter 
value Rn at every PCR cycle. The baseline and threshold values must be properly set 
in order to determine when the target amplification is sufficiently above the 
background signal. The level of fluorescence in a well at a given cycle during PCR 
generally corresponds to the amount of target RNA present in the sample at the start. 
However, during early cycles of PCR, prior to significant accumulation of the target 
amplicon, background fluorescence levels can fluctuate as a result of changes in the 
reaction medium. The background signal in all wells during a given number of PCR 
cycles is used to determine the baseline fluorescence across the plate. Usually, the 
baseline flurorescence is the fluorescence generated between PCR cycle 3 and one or 
two cycles before the earliest amplification emerges. When the baseline is set 
correctly, a plot of the linear view of ARn (Rn-background fluorescence) vs PCR cycle 
number will show a flat line at 0.00 ARn between the set baseline cycles followed by 
increasing ARn values in subsequent cycles. If that is not the case, the stop value will 
be re-set until a flat line is generated. The Sequence Detector software sets the 
baseline as the value in PCR cycles 3 to 15. In practice, the default setting is not 
altered if the first reaction emerges after cycle 15 unless a good baseline is not 
generated. The plot is then switched to log view and the threshold value is set 
manually in the region of exponential amplification, i.e. the linear portion of the plot
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that maximises the sensitivity and precision of the assay. The threshold cycle (Ct) 
value reflects the cycle number at which the fluorescence generated within a reaction 
crosses the threshold.
2.6.7.2 Relative quantitation of mRNA expression
To quantitate and compare the relative transcription levels of target mRNAs in 
different samples, the levels were ‘normalised’ to the levels of housekeeping gene 
HPRT in each sample. The difference between the Ct value of the housekeeping gene 
HPRT and the Ct value of the target genes, i.e. IFN-p, IFN-a4, IFN-a(non-a4) and 
Mx, in the same sample was determined (ACt=CthPrt-Cttarget). As expression of the 
housekeeping gene is believed to be constant, higher ACt values thus reflect the 
presence of increased target mRNA in the samples.
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2.7 In vivo responses to LCMV infection
2.7.1 Collection of spleen and blood from LCMV-infected C57B1/6 mice
Mice were infected with LCMV as described in section 2.3.4. Mice were culled at 
timepoints between 6 hours and 6 weeks post infection and blood and spleens were 
collected.
Blood was collected by cardiac puncture and was allowed to clot at room temperature 
for about 1 hour before centrifugation at 6000g for 10 mins. Separated serum was 
removed and stored in aliquots at -80°C before use. Spleens were removed, cut into 
pieces and divided between cryotubes, snap-frozen in liquid nitrogen and stored at 
80°C for subsequent RNA extraction, or immersed in OTC medium in tissue moulds, 
snap frozen in liquid nitrogen or dry ice and then stored at -20°C for subsequent 
cryosectioning.
2.7.2 Isolation and Analysis of murine splenic DC subpopulations
2.7.2.1 Isolation of murine splenic dendritic cells
Spleen DCs were obtained using a variation of the method described by Vremec et al 
(Vremec et al. 1992). 9-10 spleens were pooled from groups of mice at various 
timepoints post-LCMV infection and perfused with 200pl per spleen of DNase 
(325KU/ml):Collagenase (1 mg/ml, type III) diluted in RPMI supplemented with 10% 
GFCS, O.lmM EDTA pH7.2, lOOU/ml polymyxin B and penicillin-streptomycin. 
After a 30 min incubation the spleens were mashed and passed through a 0.45pm 
sieve into a 50ml centrifuge tube containing RPMI-supplemented medium. Cells were 
pelleted by centrifugation and then resuspended in 3ml Nycoprep and overlaid onto 
3ml Nycoprep in a 15ml centrifuge tube for density separation. The tubes were 
centrifuged for 20 mins at 2,000 x g in a Sorval RT7plus centrifuge. All the cells in
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the upper zone were collected and transferred into a fresh 50ml centrifuge tube and 
washed twice with 20ml RPMI supplemented medium. After the second wash, the cell 
pellet was resuspended in RPMI-supplemented medium to a concentration of 1x10
o
cells/ml, and CD llc MACS beads were added at a concentration of lOOpl per 10 
cells. This was incubated for 15 mins on ice, and then the cells were washed with 
20mls supplemented RPMI to remove unbound beads. The cell pellet was 
resuspended in 5 ml supplemented RPMI and passed through an equilibrated CD llc 
MACS bead positive selection LS column placed on a magnet. The column was 
washed twice and then the cells were eluted with supplemented RPMI medium.
2.7.2.2 Analysis of expression of non-DC markers by C D llc+ cells isolated from 
murine spleen
To determine the proportion of C D llc+ cells isolated from the spleens of uninfected 
and infected mice that expressed markers characteristic of non-DC cell lineages, 
isolated CD llc+ cells were co-stained with antibodies to CD llc, MHC Class II and 
either CD3 (a T-cell marker), CD 19 (a B cell marker), CD 14 (a monocyte marker), 
DX5 (expressed by many NK cells) or F4/80 (expressed by most mature 
macrophages). C D llc+ cells were isolated from mouse spleens as described in the 
section above. After another wash, the positively selected cells were blocked with Fc 
block ( I jliI per 106 cells) on ice for lOmins, before cells were pelleted by 
centrifugation to remove unbound FC-block. Cells were resuspended in either 
supplemented RPMI media or FACS buffer (PBS, 2% FCS and 0.1%NaN3) and 
plated into V-bottomed plates at lx l05 cells per well and triple stained with anti- 
C D llc+-APC, anti- MHC Class II-FITC and PE-conjugated anti-CD3, anti-CD19, 
anti-CD3, anti-DX5 or anti-F4/80 antibodies. The cells were incubated with the
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antibodies for 30 mins at 4°C, and then the plate was centrifuged for 5 mins at 200g in 
a Sorval RT7plus centrifuge. Buffer containing excess unbound antibody was 
removed and cells were washed by resuspension in 200pi fresh FACS buffer per well 
followed by centrifugation as before. Cells were then fixed by resuspension in 
FACSFix buffer (PBS with 2% paraformaldehyde). Staining was analyzed on a 
FACSCalibur® (Becton-Dickinson U.K. Ltd. Cowley, Oxford, UK) flow cytometer 
using CellQuest software (Becton Dickinson U.K. Ltd.).
2.7.2.3 Isolation of murine splenic dendritic cell populations for RNA extraction
Dendritic cells were isolated as described above. After enrichment with 
C D llc+ MACS beads, the positively selected cells were stained with CDllc-APC, 
B220-FITC, and PE-conjugated CD3, CD19 and DX5 (0.5pl antibody stock per 106 
cells) for 30 min on ice. Cells were centrifuged for 5 mins at 200g and unbound 
antibody in the supernatant was removed. Fresh buffer was added to wash the cells 
and the resuspended cells were pelleted again by centrifugation. Resuspended cells 
were sorted using a Mo-Flo cell sorter (Cytomation, Fort Collins, Colorado USA), 
isolating C D llc+ B220+ and C D llc+ B220' populations with C D llc+ PE+ cells 
excluded. RNA was extracted from a equal number of cells of each subpopulation in 
every sample in each specific experiment, typically between 2xl04 and 1x105 cells.
2.7.2.4 Analysis of cell surface markers expression on splenic C D llc+ DC 
subpopulations from persistently infected mice
After positive selection as above, C D llc+ cells were resuspended in FACS 
buffer and cells expressing non-DC lineage were depleted. A cocktail of biotinylated 
depletion antibodies were added at a concentration of lp.1 antibody per 106 purified
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cells. Antibodies used for depletion were biotinylated anti-CD3, anti-CD 19 and anti- 
DX5. Cells were incubated with the antibodies for 30 mins at 4°C before excess 
antibody was removed by pelleting the cells by centrifugation for 5 min at 1500rpm 
and removing the unbound antibody-containing supernatant. The cells were washed 
by resuspension in fresh buffer followed by centrifugation at 200g for 5 mins. Spent 
buffer was removed and the cells were resuspended in buffer containing CELLection 
Biotin-Binder streptavidin-conjugated magnetic Dynal beads added at a concentration 
of 250pl beads per 108 cells. Beads and cells were incubated on a rotating incubator 
(Jencons) at 4°C for 20 mins, then excess beads were removed and the cells were 
washed by centrifugation as before. After resuspension in fresh FACS buffer, bound 
CD3+, CD19+, DX5+ cells were depleted by magnetic separation, which was 
performed twice for each sample, leaving unbound cells in the supernatant which 
were washed as before. Depleted cells in FACS buffer were dispensed into 96-well V- 
bottomed plates at a concentration of 1x10s cells per well in lOOpl and stained with 
PE-conjugated antibodies to MHC class I (H-2Kb), MHC class II (I-A/I-E), CD40, 
CD80 (B7.1), CD86 (B7.2) or CD54 (ICAM-1). The cells were co-stained with FITC- 
conjugated anti-PDCA-1 and APC-conjugated anti-CDllc to identify plasmacytoid 
DCs, or with FITC-conjugated anti-CD4 and APC-conjugated anti-CD 1 lc to identify 
CD4+ DCs or alternatively with FITC-conjugated anti-CD8a and APC-conjugated 
anti-CDllc to identify CD8+ DCs. Other cells were also stained with appropriate 
isotype control antibodies. The cells and mAbs were incubated in the dark at 4°C for 
30 mins, then the cells were washed as described previously and resuspended in 
FACSFix buffer. Data was collected on a FACSCalibur® (Becton-Dickinson) flow 
cytometer and analysed using CellQuest software (Becton Dickinson).
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The mean fluorescence intensity (MFI) of surface marker staining on DCs of each 
subset was calculated as the MFI of cells stained with marker-specific mAh minus the 
MFI of cells stained with an isotype-matched control mAb.
2.7.3 Stimulation of C D llc+ DCs with TLR ligands
CD1 lc+ cells isolated from murine spleens as described in section 2.7.2.1 were seeded 
at lx l0 5 cells per well in a 96-well U-bottomed plate in 100pi of medium containing 
one of the following: polylC (lOOpg/ml, lOpg/ml or lpg/ml), R848 (lOOpg/ml, 
lOpg/ml or lpg/ml), CpG (2nmole/ml, 0.2nmole/ml or 0.02nmole/ml) or LPS 
(lOOng/ml, lOng/ml or lng/ml). After 24 hours stimulation at 37°C, the plate was 
centrifuged at 1200rpm for 5 mins and the supernatant collected and stored at -80°C 
prior to analysis of its cytokine content.
2.7.4 Confocal studies on spleen sections from mice acutely or persistently 
infected with LCMV Arm or C113
2.7.4.1 Purification and labelling of mouse anti-NP113 mAb
Hybridoma supernatant from large scale cultures of murine anti-NP113 mAb 
hybridoma cells was prepared by Julie Lewis and stored at -20°C until purification. 
Antibody was purified on a Protein A affinity column following the manufacturer’s 
instructions. The antibody was eluted in amine-containing elution buffer at pH 2.8, 
which was neutralized by the addition of 1M Tris buffer at pH 9. Fractions were 
collected, and the amount of protein in each fraction was determined by carrying out 
UV spectroscopy at 260nm, 280mn and 320nm using the Christian and Warburg 
equation to calculate the protein content. The fractions containing the highest amounts 
of protein were pooled and dialyzed in Slide-A-Lyzer® dialysis cassette with a
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molecular cut-off of 10000 MW against PBS. After buffer exchange, the antibody was 
again quantitated by UV spectroscopy before it was concentrated to a concentration of 
1 mg/ml in PBS on a Microcon-YMIOO centrifugal filter device with a 100 000 MW 
molecular weight cut-off by centrifugation at 14,000g on an Eppendorf 5417R fixed 
rotor centrifuge (Eppendorf, Hamburg, Germany) according to manufacturer’s 
instructions.
lmg of purified antibody was conjugated to Cy-5 using a Cy-5 labelling kit, following 
the manufacturer’s instructions. Briefly, the purified, dialyzed antibody was allowed 
to react with Cy-5 dye to a enable conjugation to the carbohydrate moieties on the Fc 
portion of the antibody. Unbound dye was separated from the labelled antibody by 
size-exclusion column chromatography. Purified, labelled antibody was quantitated 
by uv spectroscopy (concentration at 0.1 pg/ml) and stored at 4 °C.
2.7.4.2 Staining protocol to visualize IFN-a, pDC and LCMV-NP protein on 
spleen sections
Pieces of spleen were embedded in O.C.T compound (<11% Polyvinyl alcohol, <5% 
Carbowax) in plastic tissue moulds and stored at -20°C. Cryosections of 5-8 pm were 
cut on the Leica CM1900 cryostat (Leica Instruments, Nussloch, Germany), 
transferred onto poly-L-lysine slides and fixed with acetone for lOmins at 4°C. The 
sections were rehydrated with PBS and blocked with a 1:1 mix of lx blocking reagent 
from a tyramide signal amplification kit and lx M.O.M. mouse Ig blocking reagent 
(90pl reagent per 2.5ml PBS) for 1 hour at RT. Rat anti-IFN-a diluted 1 in 2 and 
mouse anti-NPl 13-Cy5 diluted 1/10 in M.O.M. diluent (600pl protein concentrate 
solution diluted into 7.5ml PBS) were then added. After incubation for 2 hours at RT, 
slides were washed 3x with PBS for 5 min per wash. Goat anti-rat AlexaFluor 488
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diluted 1/50 was added for 1 hour at room temperature (RT) in a humidified chamber. 
Excess antibody was removed and slides were again washed 3x with PBS and then 
blocked for 30mins with 5% normal rat serum. Biotinylated rat-anti-m-PDCA-1 
diluted 1/5 in tyramide blocking buffer was added and the slides were incubated 
overnight at 4°C. After washing 3x in PBS as before, streptavidin -HRP diluted 1/100 
in tyramide blocking buffer was added and incubated for 1 hour at RT. Slides were 
washed as before then lx tyramide-Alexa Fluor 594 substrate solution was added and 
allowed to react for 7 mins. After washing 3x, with a final 10 min wash in PBS, the 
slides were mounted with one drop of Vectashield fluorescent preservative reagent 
prior to visualization by confocal microscopy. To ensure specificity of labelling, 
sections were stained in parallel with appropriate isotype control antibodies, namely, 
unconjugated rat-IgGl (0.5mg/ml) at 1/5 dilution, biotin-rat-IgG at 1/25 dilution and 
mouse-IgG2a-Cy5 diluted 1/10 (all isotypes from. The results were recorded using 
software for the Leica TCS NT confocal system (Leica, Knowlhill, UK). Staining for 
IFN-a appeared green, LCMV-NP staining appeared blue and pDCA-1 staining 
appeared red.
2.7.5 Analysis of the response of mice persistently infected with LCMV C113 to 
innate stimuli
At 3 weeks post infection, LCMV Cl 13 infected mice and uninfected controls were 
stimulated with intra-peritoneal (i.p) injections of one of the following TLR stimuli in 
200pl PBS: 5pg polylC, 50 nmoles R848, 25 nmoles CpG 1826 or with 800 
haeagglutinin (H.A) units of influenza virus PR8. Mice were culled at timepoints 
between 6 hours and 24 hours post-stimulation and blood and tissues removed as 
described in section 2.7.1. For all experiments, 3 mice per treatment type and 1
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uninfected control were culled at every timepoint from both the LCMV-infected and 
uninfected groups.
2.7.6 Detection of cytokines by cytokine bead array (CBA) assay
A murine inflammation CBA kit was used to measure the levels of IL-6, IL-10, MCP- 
1, IFN-y, TNF-a and IL-12 p70 in the serum of mice exposed to different innate 
stimuli. In CBA assays, capture beads which have discrete fluorescent intensities bind 
to specific cytokines and these cytokines are further detected using PE-conjugated 
mAbs specific to the cytokines.
CBA assays were carried out following the manufacturer’s instructions. Supernatants 
were thawed at 4°C just before the start of the assay. Serial dilutions of the standards 
were prepared in assay diluent to cover concentrations from 20-5000 pg/ml of each 
cytokine measured. Master-mixes of the capture beads were prepared by mixing 6pl 
of each cytokine capture bead per sample to be tested. 3 5 pi of diluted serum (diluted 
between 1:2 and 1:8 in assay diluent to cover the range of cytokines measured) or the 
dilutions of the standards were mixed with 3 5 pi of the capture bead master-mix and 
35pl of the detection reagent containing PE-conjugated anti-mouse cytokine mAbs. 
The mix was incubated for 2 hours at RT in the dark. Samples were washed in 1ml of 
wash buffer and centrifuged at 200g for 5 mins in a Sorvall RT7 centrifuge. The 
supernatant was discarded and beads resuspended in 300pl FACSFix buffer to 
inactivate any LCMV in the sample prior to flow cytometric analysis. Cytokine levels 
were then assessed using a FACSCalibur™ flow cytometer with FASComp software 
(Becton Dickinson) for instrument settings. The data was analysed using CellQuest™ 
software.
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2.8 Analysis of Type 1 IFN production during in vitro persistent LCMV 
infection
2.8.1 Production and infection of murine bone marrow derived-DC (BM-DC)
Hind limbs were collected from C57BL/6 mice and tibia and femurs were dissected 
using forceps and scissors. After removing the flesh, the bones were cleaned by 
spraying with 70% ethanol and placed in complete DC medium (RPMI supplemented 
with 10% (v/v) FCS, lpg/ml P/S, lOOU/ml polymyxin B and 50mM p- 
mercaptoethanol). The ends of the bones were cut off to create a hollow tube. The 
marrow was flushed out of the bones using a 27G needle attached to a syringe 
containing complete medium. This was repeated until all the marrow was removed, 
then the marrow was passed through the syringe to generate a single cell suspension. 
The number of bone marrow precursor cells, which are large, irregular cells, in the 
suspension was counted, and the cell concentration adjusted to 2xl05/ml in complete 
DC medium supplemented with 20ng/ml mouse GM-CSF. The suspension was plated 
into 100x150 mm Petri dishes at 10ml per dish and incubated at 37°C in 5% CO2 for 8 
days to allow bone marrow precursors to differentiate into DCs. At day 3 of culture, 
the dishes were gently swirled and an extra 10ml of complete RPMI medium 
supplemented with 20ng/ml of murine GM-CSF was added into each dish. At day 6, 
10ml of spent medium was removed and centrifuged to pellet the cells therein. The 
cell pellet was resuspended in 10ml of fresh complete RPMI medium, again 
supplemented with 20ng/ml of murine GM-CSF and returned to the dish. Cells were 
harvested at day 8 of culture. The medium was removed and collected in 50ml 
centrifuge tubes, then 5ml of accutase was added to each dish. This was incubated 
briefly in a 37°C 5% CO2 incubater, then the dishes were swirled about to dislodge 
the adherent cells which was transferred to the centrifuge tubes. Fresh accutase was
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added to the dish, the incubation and swirling repeated until all of the adherent cells 
were removed.
Harvested cells were centrifuged and resuspended in fresh media. The yield was 
calculated and the cells divided into 15ml centrifuge tubes at a concentration of 
3.2x107 cells per tube. The cells were pelleted by centrifugation and then infected 
with LCMV Arm or clone 13 at appropriate m.o.i. Virus was diluted in serum-free 
RPMI or PBS to a volume of 0.5-lml, and the tubes were flicked to dislodge the cell 
pellet and mix the cells with the viral suspension. The tubes were incubated in a 37°C, 
5% CO2 incubator for 1 hour to allow viral attachment and entry. Tubes were then 
centrifuged, all the viral suspension removed and the cells were resuspended in fresh 
complete medium and plated out into 35mm x 10mm Petri dishes at 2xl06 cells per 
dish in 1ml complete media supplemented with 20ng/ml GM-CSF.
2.8.2 Generation of cell lines chronically infected with LCMV Arm and C113
MC57, BalbC17, FSDC or D2SC/1 cells or BM-DC were seeded into 6-well plates at 
1.5x10s cells per well or lxlO6 cells/well in 60mm dishes in 1 ml medium and 
incubated overnight. The supernatant was then removed and the cells were infected 
with LCMV Arm or LCMV C113 at a m.o.i of either 0.1, 0.5, 5 or 10 in 500pl serum- 
free medium for 1 hour at 37°C. After the incubation, the virus containing medium 
was removed and the cells were washed with PBS to remove excess virus. Wash 
buffer was removed by centrifugation at 300g for 5 mins. Infected cells were overlaid 
with 3ml growth media and cells and supernatant were sampled at indicated 
timepoints. Cells were transferred into small flasks when they appeared confluent, 
usually at 48 or 72 hours and were then passaged twice a week. Plaque assays (section
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2.3.2) and immunostaining (described in the following section) were performed to 
confirm that the cells were chronically infected with LCMV.
2.8.3 Immunostaining of chronically infected cells
At various timepoints post-infection, cells were harvested and resuspended in PBS at 
a concentration of ~5 x 106 cells/ml. 50pl of the cell suspension was spotted onto 
wells of Teflon slides. The remaining liquid was sucked off after 2-3 mins and slides 
were left to dry under the hood for about 1 hour. Slides were fixed with 100% 
methanol at -20°C for 10 mins and allowed to dry. Fixed cells were rehydrated with 
50pl of PBS-2% BSA for 30 mins. For infected DC cells (FSDC, D2SC/1 or BM- 
DC), Fc-mediated non-specific binding was blocked by treatment with the M.O.M. 
kit. The buffer was then removed, 20pl of anti-LCMV ascites VR164 at a 1/50 
dilution was added and the slides were incubated for 1 hour at 37°C in a humidified 
incubator. Slides were washed by immersion in PBS for 5 min. 20pl of FITC- 
conjugated goat anti-mouse IgG and IgM (H+L) diluted 1/200 was added. After 
incubation for 50 mins at room temperature, the slides were washed by immersion in 
PBS for 3 mins. Bo-Pro diluted 1/200 in blocking buffer was added to visualize the 
nuclei. After 15 min incubation at room temperature, the slides were washed 3x by 
immersion in PBS for 3 mins, with a final immersion for 15 mins. A drop of 
Vectashield was added on to each slide prior to visualization. LCMV infected-cells 
were visualised and the images captured by confocal microscopy (Leica 
Microsystems (UK) Ltd, Milton Keynes, UK). Viral antigen appeared green and the 
nuclei appeared red.
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2.8.4 Generation of stably transfected cells expressing LCMV proteins
2.8.4.1 Transfection of individual LCMV genes into FSDC and D2SC/1
cells
FSDC and D2SC/1 cells were transfected with plasmids encoding individual LCMV 
proteins described in section 2.4.3. Cells were seeded into 6 well plates at lxlO5 cells 
per well. Effectene Transfection Reagent (Qiagen) at the ratios below was used to 
transfect each LCMV plasmid into FSDC or D2SC/1 cells. LCMV plasmids were co­
transfected with pcDNA6 V5-HisB at a ratio of 5:1:
FSDC lpg DNA in 0.5pl vol: 10pi Condensation buffer :10pl Effectene in 1ml
media
D2SC/1 lpg DNA in 0.5pl vol: 8pl Condensation buffer :50pl Effectene in 1ml
media
Cells were incubated in transfection reagent overnight, then this was replaced with 
complete growth medium. After 24 hours incubation in a 37°C, 5% CO2 incubator, 
the medium was replaced with selection medium, which was complete growth 
medium supplemented with lOug/ml blasticidin. Cells were cultured for a week in 
selection medium, during which time cells expressing the blasticidin resistence genes 
survived and multiplied. The survivors were resuspended with accutase and cloned by 
limiting dilution into 96-well plates. Single cell colonies were identified and the cells 
tested for expression of the respective LCMV protein by immunofluorescence.
2.8.4.2 Selection of positive colonies by immunofluorescence
Single-cell colonies which survived in the selection media were expanded from 96- 
well to 24-well plates. Some of the cells transferred onto wells of a Teflon slide and 
fixed and stained for LCMV protein expression using the method described in
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section2.8.3. Colonies that were strongly positive for GP or NP expression were 
selected and subsequently expanded into clonal cell lines. Antibody specific for Z 
protein was not available, and for these cells, blasticidin positive colonies were cloned 
and one clone was selected and used in subsequent experiments.
2.8.5 Stimulation of infected cells with TLR ligands
BalbC17, D2SC/1 or FSDC cells infected with LCMV C113 and their respective 
uninfected controls were seeded at lxl05 cells/well in 100pi of medium. After an 
overnight incubation, supernatant was replaced with media containing the following 
TLR ligands:
PolylC at lOOpg/ml, R848 at 50pg/ml, CpG 1826 at 2nmole/ml or medium only as a 
control. The cells were incubated overnight at 37°C for 24 hours. The plates were then 
centrifuged at 200g for 5 mins, and the supernatant was collected and stored at -80°C 
until tested. Cell pellets were lysed with RLT buffer and RNA isolated using the 
RNeasy Mini kit (or were stored at -80°C until RNA extraction).
2.8.6 Infection of LCMV C113-infected or transfected cells with Sendai or HSV
Uninfected cells and cells infected 80 days previously with LCMV Cl 13 were seeded 
at 1x10s cells per well in U-bottomed 96-well plates. After an overnight incubation, 
cells from one well was resuspended and counted, and cells were infected with Sendai 
virus at 1 or 10 m.o.i. or HSV at an m.o.i. of 5, diluted in PBS. After 1 hour 
incubation at 37°C, the virus was removed and replaced with growth medium. At 4 
and 18 hours post-infection, the plates were centrifuged at 200g for 5 mins in a 
Sorvall RT7 centrifuge and cells and supernatant were collected as described in 
section 2.8.5 and stored at -80°C prior to analysis.
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2.9 Statistical Analysis
Statistical analyses were performed on Minitab Release 14 software (Minitab Ltd, 
Coventry, UK). The significance of differences in the levels of type 1 IFN produced 
by uninfected and persistently infected ex vivo CD11+ DCs upon stimulation with 
TLR ligands was addressed by 1-sample t-test. Analysis of Variance (ANOVA) using 
a general linear model with Tukey’s pairwise comparison was used to determine the 
statistical significance of the following:
1. The difference in the total numbers of DCs in the spleens of uninfected versus 
persistently infected mice
2. The difference in the levels of type 1 IFN induced in uninfected and 
persistently infected mice upon exposure to innate stimuli
3. The difference in the maximal levels of type 1 IFN produced by cultured cell 
lines in response to infection with different RNA viruses or stimulation with 
polylC.
4. The difference in the levels of type 1 IFN produced by uninfected and 
persistently infected cell lines in response to stimulation with TLR ligands
5. The difference in the levels of type 1 mRNA transcript produced by uninfected 
and persistently-infected cell lines upon Sendai or HSV viral infection
6. The difference in the levels of type 1 IFN activity produced by uninfected and 
persistently infected cell lines upon Sendai or HSV viral infection
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CHAPTER 3
DEVELOPMENT OF SENSITIVE ASSAYS FOR THE DETECTION OF 
MURINE TYPE 1 IFNs AT THE PROTEIN AND mRNA LEVELS
3.1 Introduction
Murine type 1 IFNs were first described in 1961 by their resistance to acid wash at pH 
2.0 and their ability to protect L929 cells from infection with EMCV (Hitchcock and 
Porterfield 1961). Methods to detect type 1 IFNs have advanced since then and it now 
possible to visualise type 1 IFN protein in situ and to quantitate type 1 IFN by 
bioactivity, protein concentration or by the relative abundance of type 1 IFN mRNA 
within cells (Deonarain et al. 2000; Lewis 1995; Meager 2002). Some of the methods 
currently in use are discussed below.
The purpose of the series of experiments described in this chapter was to design and 
optimize sensitive means to measure type 1 IFN produced by cultured cells or in 
mouse tissue or serum. Existing methods for quantitation of type 1 IFN activity or 
protein were evaluated for their sensitivity and ease of application on large sample 
numbers. In addition, efforts were made to develop new, more sensitive methods for 
quantitation of type 1 IFNs at the protein and mRNA level. The most appropriate 
assays were then selected for application in subsequent in vivo and in vitro studies.
3.1.1 IFN-a ELISA
A kit to measure murine IFN-a is commercially available from PBL Laboratories, and 
several labs have developed type 1 IFN sandwich ELISAs using commercially 
available anti-murine IFN-a antibodies (Asselin-Paturel et al. 2001; Diebold et al. 
2003). Monoclonal antibodies against IFN-p were not commercially available at the
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time this project was initiated, but an ELISA kit to measure murine IFN-p has since 
been introduced (RnD Systems, Abingdon, UK). Samples, which can be either 
supernatants or serum, are quantitated against a standard curve of known IFN-a 
concentration. While ELISAs are useful in that they provide partial information 
regarding the type of IFN secreted, they are relatively insensitive, with the detection 
limit of commercial IFN-a murine ELISAs reported to be -10 pg/ml (Murine IFN-a 
kit technical notes (2004)).
The commercial IFN-a ELISA purports to recognise IFN-aA,-al, -a4, a5, a6 and a9 
subtypes while the number of subtypes recognized by the laboratory-developed 
sandwich ELISA is unclear. At the start of the project, the PBL ELISA from the kit 
and a laboratory-developed protocol (Diebold et al. 2003) were evaluated, so that their 
limits of sensitivity could be compared to those of other methods.
3.1.2 Antiviral bioassay
The antiviral assay, first developed in 1981 by Familletti et al (Familletti et al. 1981) 
to quantitate human type 1 IFN, is the “gold standard” for measurement of type 1 IFN 
activity. It measures the antiviral bioactivity of IFN-a, IFN-p and to a lesser extent 
IFN-y in a given sample based on their ability to protect a monolayer of cells from 
lysis by vesicular stomatitis virus (VSV) or EMCV. To assay murine type 1 IFN 
activity, L929 cells at a fixed concentration of lxlO5 cells/well are seeded in wells in 
a 96-well plate containing serial dilutions of an IFN standard and the test sample. 
IFNs in the standards and sample signal through the IFN-a/p and y receptors on the 
cell surface to activate the expression of anti-viral genes, and establish an anti-viral 
state within the cells. 24 hours later, the standard and sample are removed and 
replaced with medium containing the lytic viruses VSV or EMCV at a m.o.i of 0.1. If
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an anti-viral state has been achieved, the monolayer will be resistant to infection and 
will appear intact when stained 16 to 24 hours later with crystal violet. The amount of 
type 1 IFN that protects 50% of the monolayer from lysis is defined as 1U of IFN. As 
such, the limit of detection for this assay is 1U of IFN activity. The total amount of 
type 1 IFN in a given sample can then be calculated by multiplying the dilution at 
which there is 1U of IFN in the sample with the dilution factor. In practice, a standard 
curve of known type 1 IFN activity is mn on every plate as reference. The activity of 
type 1 IFN in cell culture supernatant, serum and homogenized tissue samples can be 
assayed using this method.
Although the viral protection bioassay provides a very sensitive indirect measurement 
of type 1 IFN activity, it does not provide any information on protein concentrations. 
Another drawback of this assay is that is does not distinguish between the activity of 
IFN-p or IFN-a unless saturating amounts of IFN-subtype specific neutralizing 
antibodies are added; neither can it give information on the distinct IFN-a subtypes 
present in a sample.
3.1.3 Reporter gene-based bioassays
The expression of antiviral proteins such as Mx is induced by the presence of type 1 
IFNs as their genes contain promoter elements that are recognized by transcription 
factors which are activated via the type 1 IFN signalling cascade initiated by the 
binding of type 1 IFNs to its receptor (Platanias 2005). New cell-based assays to 
quantitate type 1 IFN activity have exploited the specificity of these promoter 
elements by linking them to a promoter-less reporter gene such as luciferase, secreted 
alkaline phosphotase or human growth hormone on an eukaryotic expression plasmid 
(reviewed in (Meager 2002)). These plasmids are transfected into cells, which are
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stimulated with type 1 IFNs. The level of reporter protein that accumulates within the 
cells is proportional to the quantity of the type 1 IFN stimulus in a linear dose- 
response relationship. Such reporter assay systems offer a means to quantitate IFN 
activity in a manner that is more direct and specific than the traditional antiviral 
bioassays, and with a quicker assay time. Reporter assays to measure IFN from 
several species have been described (Canosi et al. 1996; Fray et al. 2001; Hammerling 
et al. 1998; Lleonart et al. 1990), including an assay to quantitate the activity of 
murine IFN-y (Lewis 1995). The sensitivities of reporter gene-based assays varied 
from system to system. Some systems, such as assays established for the detection of 
bovine type 1 IFNs, are reported to respond to as little as of 0.32 U/ml of type 1 IFN 
and posses a dose-dependent range of up to 125 U/ml (Baigent et al. 2002; Fray et al. 
2001), which was more sensitive than the bioassay. However, like the bioassay, 
current assays are not able to distinguish between the activity of IFN-(3 and IFN-a or 
different IFN-a subtypes. One of the aims of the project was to develop a reporter 
gene-based assay to measure type 1 IFNs from murine samples. In 2005 an assay to 
measure type 1 IFN on the basis of percentage of cell expressing the eGFP reporter 
gene was developed (Bollati-Fogolin and Muller 2005). Murine embryonic fibroblast 
(MEF) cells were immortalized from mice genetically engineered to contain Cre- 
recombinase linked to an Mx promoter, and eGFP gene containing a loxP flank stop 
cassette silencer element. Upon stimulation with type 1 IFN, expression of cre- 
recombinase was induced, which when expressed, deleted the loxP silencer element, 
allowing expression of eGFP. This system was reported to have a detection range of 
between 20-300U and 10-500U for IFN-a and IFN-P respectively, which is less 
sensitive than the bioassay; and like the bioassay, current reporter assays are not able 
to distinguish between the activity of IFN-P and IFN-a or different IFN-a subtypes.
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3.1.4 Detection of specific type 1 IFN subtype mRNA by RT-PCR
It would be of interest to be able to dissect the responses of individual subtypes of 
type 1 IFN, as evidence exists that they may be differentially regulated during the 
response to viral infections. This is difficult to perform using bioassays - while it is 
possible to dissect the IFN-p response from the IFN-a by addition of neutralizing 
antibodies, dissecting the individual contributions of the different IFN-a subtypes is 
not yet possible as IFN-a subtype-specific neutralizing antibodies are not available. 
For this purpose, RT-PCR assays have been developed (Deonarain et al. 2000; Fung 
et al. 2004). PCR primers specific for IFN-P, IFN-a4 and all IFN-a subtypes have 
been designed making it possible to measure induction of individual type 1 IFN types 
and subtypes. Such assays are also particularly suited to quantitating type 1 IFN 
responses in cells or tissues, in contrast to bioassays which are useful to measure type 
1 IFN activity in serum or supernatant. Total or mRNA is purified from cells or 
tissues and used as template RNA in PCRs using the specific primer to amplify 
distinctive subtypes. When the template is also tested with a housekeeping control 
PCR, the assay becomes semi-quantitative as the amplified products are 
electrophoresed and detected on an agarose gel and then individual bands quantitated 
by densitometric analysis. An obvious limitation of the RT-PCR assay is that it can 
not measure type 1 IFN levels in serum or supernatant samples. Although RT-PCR 
will not give information on protein concentration or bioactivity, its key advantage 
over the other methods is that it is a fast, direct method that enables dissection of the 
different subtypes of type 1 IFN induced under various conditions in samples that can 
not be readily analysed using cellular or ELISA assays. However as reaction products 
of the RT-PCR assay are only detected at the endpoint of a PCR reaction, they only
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provide qualitative or at best semi-quantitative results regarding the presence and 
levels of various IFN types or subtypes in a given sample.
Real-time quantitative reverse transcription PCR (RT-PCR) is a recent innovation in 
the field of analysis by PCR. In a modification of the conventional PCR assay, 
primers and probes that specifically recognize a region within a given gene of interest 
are designed that can be run under universal thermal cycling conditions. The probe, 
which binds a sequence in between the forward and reverse primers, is degraded 
during the extension phase of the PCR amplification and releases a fluorescent signal; 
the amount of fluorescence released is directly proportional to the amount of product 
generated in each PCR cycle and acts as a quantitative measure of PCR product 
formation. The technology is well-suited for high throughput analysis -  assays are 
conducted in a 96-well plate format and direct monitoring of the fluorescent signal 
during PCR amplification does away with the requirement for post-PCR analysis. 
Since its introduction, assays to measure a whole range of murine and human 
cytokines, chemokines and immune-related factors have been designed (Overbergh et 
al. 1999). Real-time quantitative RT-PCR primers and probes that detect murine IFN- 
P and IFN-a4 had been published soon after the project was initiated (Karaghiosoff et 
al. 2003), and reagents for quantitating distinct human IFN-a subtypes using this 
approach had been developed (Loseke et al. 2003). It was planned to design and 
optimize additional real-time quantitative RT-PCRs assays that recognized either all 
murine IFN-a subtypes or distinct IFN-a subtypes to complement the existing IFN-p 
and IFN-a4 assays, to enable comprehensive analysis of the type 1 IFN response in 
cells or tissues during acute and persistent LCMV infection.
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In summary, at the time of the initiation of this project, a number of systems existed to 
measure type 1 IFN protein levels in biological samples. Each system has its 
strengths, weaknesses and particular utility as summarized in the next table.
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Table 3.1 Summary of aspects of various IFN-a/p quantitation methods
Assay Quantitates Advantages Disadvantages
ELISAs IFN-a protein 
concentration 
IFN-p protein 
concentration
Direct, simple 
Able to distinguish 
IFN-a from IFN-P 
levels
Relatively insensitive 
No ELISAs are 
available for IFN-a 
subtypes
Antiviral
bioassay
IFN-a/p
activity
Very sensitive assay Indirect, relatively 
laborious assay 
Doesn’t distinguish 
between IFN-a and 
IFN-p
Unclear whether all 
subtypes show equal 
activity in this assay
Reporter gene- 
based bioassay
IFN-a/p
activity
Simpler than the 
antiviral bioassay 
Potential for high 
sensitivity
Indirect assay 
Does not distinguish 
between type 1 IFN 
subtypes
Again, unclear if all 
subtypes show equal 
activity in this system
Quantitative
RT-PCR
IFN-a or -p 
mRNA levels
Able to distinguish 
between IFN subtypes 
Very sensitive
Only suitable for use in 
cells/tissues 
mRNA levels may not 
correspond to protein 
or bioactivity levels.
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This chapter describes the steps that were taken to evaluate the existing assays and 
also develop new, potentially more sensitive assays for detection of murine type 1 
IFN bioactivity. The aims were to
1) Perform IFN-a ELISAs and EMCV-based antiviral bioassays in order to 
evaluate the level of sensitivity of each
2) Set up reporter gene-based assays for the detection of murine type 1 IFN 
bioactivity, and compare their performance to that of the IFN-a ELISA and the 
antiviral bioassay
3) Establish quantitative RT-PCR assays for detection of IFN-(3, all IFN-a 
subtypes and selected IFN-a subtypes, and evaluate their performance.
3.2 Quantitation of IFN-a protein levels by IFN-a ELISA
In order to determine the sensitivity with which IFN-a was detect by the 
commercially available IFN-a ELISA, an assay was conducted testing dilutions of a 
series of concentrations of IFN-a that was supplied by the manufacturer. Figure 3.1 A 
depicts a standard curve generated from the known concentrations of recombinant 
IFN-a when the IFN-a sandwich ELISA was conducted according to the steps 
described in section 2.5.1. This ELISA appears to detect IFN-a only when it is in 
concentrations of more than 50-100 pg/ml. The concentrations used in the experiment 
did not achieve saturation, and so range of detection appears to be up to more than 
2000 pg/ml, which was the highest concentration tested.
Next the laboratory-based IFN-a ELISA protocol was run to determine whether this 
provided more sensitive detection of IFN-a. Figure 3.IB shows the standard curve 
generated. This ELISA was able to detect IFN-a only when it was in concentrations of
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Figure 3.1 IFN-a ELISA standard curves generated using the commercially- 
available kit and the lab-developed assay
The sensitivity of IFN-a sandwich ELISAs carried out using the commercially 
available kit (A) or the laboratory-developed protocol (B) were assessed by assaying 
known concentrations of recombinant IFN-a, serially diluted to cover a range from 
0.15 to 2000 pg/ml (A) or 1 to 50000 U/well (B). The ELISA results, which were the 
mean absorbance at 405nm from duplicate wells for the commercial protocol and at 
450nm from triplicate wells for the laboratory-based protocol, were plotted against the 
sample concentration to obtain at standard curve. A representative standard curve for 
each assay generated by the SOFTMax Pro Analysis software is shown.
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100 U/well or more and was able to quantitate up to 50000 U/well. The standard 
curve was expressed as units of activity (U) per ml because homogenous recombinant 
IFN-a from a commercial source was used in this experiment and information was 
only provided on the bioactivity and not the quantity of IFN-a protein in the prep as 
the recombinant IFN-a had been quantitated by bioassay by the manufacturers. The 
IFN-a was stabilised in bovine serum albumin, and as such protein quantitation assays 
could not be applied to measure the levels of IFN-a protein in the prep. ELISAs in 
fact quantitate IFN protein and not activity levels. Neither the commercial nor the 
laboratory-developed ELISAs has been shown to detect all a subtypes and it has been 
reported that certain IFN-a subtypes posseses differing levels of bioactivity to other 
subtype (Forster et al. 1996) although this is still uncertain (van Pesch et al. 2004). As 
an experimental sample would contain a mixture of IFN-a subtype proteins, it would 
not be valid to correlate the protein levels of IFN-a in an experimental sample with 
the level of bioactivity exerted.
An experiment was conducted in collaboration with Maria Montoya (Viral 
Immunology Group, Edward Jenner Institute, Compton) to convert the activity of the 
recombinant IFN-a into protein concentrations. Standards of known activity were 
tested in the commercial ELISA alongside the standard curve of IFN-a protein 
concentration. 35 U/ml of IFN-a from the laboratory-based assay corresponded to 
lpg/ml of IFN-a.
Thus, the sensitivity of the laboratory-based ELISA was -2.8 pg/ml, with a range of 
up to 1428 pg/ml, which indicated the laboratory-based ELISA was more sensitive and 
possibly possessed a wider range of IFN-a subtype detection than the commercially 
available ELISA.
185
3.3 EMCV Antiviral protection bioassay
To evaluate the specificity and sensitivity of the antiviral bioassay, L929 cells were 
treated with 2-fold serial dilutions of recombinant IFN-a, IFN-P or IFN-y in the 
presence or absence of neutralizing anti-IFN-a, -P or -y  antibodies prior to infection 
with EMCV. Figures 3.2 shows images of the results obtained. As anticipated, IFN-a, 
-p and -y protected the L929 monolayer from CPE mediated by EMCV infection. For 
IFN-a and -p  the visual endpoint, which was the transition from a monolayer which 
was completely intact to a monolayer with CPE, occurred when the standards were 
diluted to 2 log2 (3.9)
U/ml. For IFN-y the visual endpoint of the assay occurred at llog2 (2)U/ml. The 
difference between the expected endpoint of lU/ml and observed endpoint of 4 U/ml 
may be the result of differences in the method employed to titrate the IFN, such as the 
use of different viruses (the potency of recombinant IFN-a, IFN-p and IFN-y was 
determined by the manufacturer by viral inhibition bioassay but the virus employed 
was not disclosed), or the sensitivity of the particular strain of L929 cells to the 
EMCV virus or the fact that the standards may have lost some of their activity during 
the freezing and thawing process -  the standards were derived from aliquots of stock 
recombinant IFN-a, -P or -y that had been distributed into small aliquots and stored 
frozen at -20°C prior to use.
Addition of neutralizing antibodies against IFN-a abolished the protection conferred 
by this cytokine, although there was some residual activity observed at the top 
concentrations of 10 log2 (500) and 9 log2 (250)U/ml of IFN-a, despite addition of 
neutralizing antibodies at a ratio of 2 neutralizing units to 1 unit of IFN-a. This 
residual protection was also observed when neutralizing antibodies against IFN-P 
were tested at similar ratios against high concentrations of IFN-p.
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The bioassay was to be used on samples which would contain a mixture of subtypes 
of type 1 IFN. In order to demonstrate the specificity of the neutralizing anti-IFN-a 
and IFN-p antibodies in such samples, the neutralizing antibodies were tested in a 
mixture of recombinant IFN-a and P, combined in a 1:1 ratio starting at a top 
concentration of lOOU/ml (Figure 3.2). When pre-incubated with either neutralizing 
anti-IFN-a or anti-IFN-P polyclonal antibody at a ratio of 2 neutralizing units to 1 U 
of IFN, the endpoint occurred 2 wells (or 4 dilutions) earlier in the presence of 
neutralizing antibody than in wells without neutralizing antibody, indicating that the 
concentrations of bioactive type 1 IFNs the wells with neutralizing antibody had 
halved, consistent with specific neutralization of only one of the two species of IFN in 
the sample.
It was anticipated that the samples tested in the bioassay will contain LCMV, which 
could potentially infect the L929 monolayer. LCMV does not lyse L929 cells as it 
instead establishes a persistent infection in these cells (Bruns et al. 1988; Gessner and 
Lother 1989; Weber et al. 1983); however, it was unclear whether these infected L929 
cells produce type 1 IFNs in response to the infection. Therefore, the capacity of L929 
cells to produce endogenous type 1 IFN following exposure to samples containing 
LCMV vims or residual TLR ligands from in vitro stimulation experiments was 
investigated. Figure 3.3 shows the result of an experiment in which L929 cells were 
treated with serial 2-fold dilutions of LCMV starting at 106 p.f.u./lOOpl media/well. A 
standard curve of 2-fold serial dilutions of recombinant IFN-a (Hycult), with a top 
concentration of 500 U/ml was set up in parallel. Based on the results shown in Figure 
3.3, L929 cells do not produce detectable levels of endogenous type 1 IFN when 
exposed to up to 106 p.f.u./lOOpl media/well of LCMV.
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Figure 3.2 Standard curves of IFN-a, -p and -y +/- neutralising antibodies in an 
EMCV antiviral bioassay
Serial two-fold dilutions of recombinant murine IFNs were prepared, starting from a top 
concentration of 500 U/ml (IFN-a , ~p or -y alone) or 1000 U/ml (IFN-(a + P) combined 1:1, 
marked with an *), and were added, with or without pre-incubation with the indicated 
neutralizing antibodies (mAb), and were added at a ratio of 2 neutralizing units per unit of 
IFN, to rows of L929 cells in 96 well microtitre plates (well 1= highest IFN concentration; 
well 10= lowest IFN concentration). After an overnight incubation the IFN containing 
supernatant was removed and the stimulated L929 cells were infected with EMCV at a m.o.i. 
of 0.1 at for 16-21 hours. The virus was then removed and the monolayer and stained. Wells 
marked *+’ were positive control wells that were not infected with EMCV, and so possessed 
an intact monolayer while the wells marked were negative control wells which did not 
receive IFN treatment prior to EMCV infection, resulting in complete lysis of the monolayer. 
The results shown are representative of findings made in at least 2 independent experiments.
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Figure 3.3 The effect of viable LCMV on the EMCV antiviral protection bioassay
In order to determine whether the presence of live LCMV in test samples would stimulate 
endogenous type 1 production in the test L929 cells and protect them from lysis by 
EMCV, duplicate wells of serial two-fold dilutions of LCMV (starting from a 
concentration of ~107 p.f.u/ml) were mixed with 105 L929 cells/well in 96-well plates. 
Serial two-fold dilutions of recombinant IFN-a, at a top concentration of 250U/ml 
(81og2U/ml) were set up in parallel. After an overnight incubation, the LCMV containing 
supernatant was removed and the cells were infected with EMCV at a m.o.i. of 0.1 for 16 
hours. The following day, the supernatant containing EMCV was discarded and the 
monolayer was fixed and stained. A photograph of the plate is shown.
The titre of LCMV in the relevant wells are shown at the bottom of the plate, expressed as 
logio p.f.u/ml virus. The concentration of IFN-a in the corresponding wells are shown 
above the figure, expressed as U/ml or converted to log2U/ml.
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Figure 3.4 A-D Plasmids employed in the development of IFN-ct/jS reporter gene
assays (figure legend overleaf)
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(A). Map of the IFN-responsive plasmid p(9-27 ISRE)4tkA (-39)Lucter (pISRE-luc) 
showing the insertion of 4x ISRE responsive elements in place of the thymidine 
kinase promoter to control expression of the firefly luciferase gene. (B). Another IFN- 
responsive plasmid pHH-CAT (pMX-CAT) was derived by inserting the human Mx- 
promoter region into the plasmid pRSV-CAT upstream of the CAT gene. As neither 
of the plasmids in (A) and (B) contained a eukaryotic selection marker, they were co­
transfected with the plasmid pcDNA6/V5-HisB (C) which encoded the blasticidin 
selection marker to allow for positive selection of co-transfected cells. The efficiency 
of tranfection during transient transfection assays was monitored by transfecting an 
aliquot of cells with the plasmid pcDNA 3.1/GFP (D) which expresses the 
luminescent GFP protein. The number of cells expressing GFP within a transfected 
population could be enumerated by FACS, which enabled the proportion of the total 
cell population which had taken up the plasmid to be calculated. Plasmid maps 3.4(C) 
and 3.4(D) were obtained from the supplier’s website, www.Invitrogen.com
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L929 were also stimulated with media containing 10 jug/ml polylC, 10 pg/ml R848, 2 
nmol/ml CpG 1826 or 10 pg/ml LPS that had previously been incubated at 37°C for 
24 hours to mimic the conditions of an in-vitro stimulation experiment, and the results 
indicate that the cells were not stimulated to produce endogenous IFN by any residual 
amounts of TLR ligand still present in the supernatant after 24 hours at 37°C (data not 
shown).
The results presented above indicate that the bioassay is a more sensitive assay than 
the IFN-a ELISA (detection limit of ~4 U/ml EFN-a versus -100 U/ml (2.8 pg/ml) by 
the laboratory-based IFN-a ELISA). Nonetheless, the limit of detection of the 
bioassay may not be sensitive enough to detect very low levels of type 1 IFN in 
experimental samples. I therefore decided to develop a reporter gene-based assay 
capable of sensing very low levels of murine type 1 IFNs.
3.4 Development of reporter gene-based assays for sensitive detection of type 
1 IFNs
For quantitation of type 1 IFN activity, reporter gene-based assays were set up where 
cells are transfected with a plasmid containing a reporter gene such as luciferase 
(Figure 3.4 A) or CAT (Figure 3.4 B) under the control of an IFN-responsive 
promoter and type 1 IFN activity is quantitated on the basis of the level of gene 
expression it stimulates in transfected cell. I worked with two reporter plasmids MX- 
CAT or ISRE-luc. The CAT reporter in the MX-CAT plasmid is linked to the 
promoter for the Mx gene, an anti-viral protein upregulated by type 1 IFNs while the 
luciferase gene is controlled by the 4 copies of the core 9-27 ISRE sequence of 
AGGAAATAGAAACTG which was engineered to remove the IFN-y response
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element (King and Goodboum 1994). Stocks of these plasmids were generated as 
described in Section 2.4.5.
Reporter gene-based assays using these plasmids could have several advantages over 
the classical antiviral bioassay: firstly, they represent a more direct method of 
detecting type 1 IFN activity; secondly, they may be more specific as the reporter 
gene is only activated by the presence of type 1 IFN; and finally, they could be more 
sensitive as the signal can be amplified through the presence of multiple copies of the 
plasmid in a single cell.
3.4.1 Setting up a reporter assay system using transiently transfected cells
The most common method of utilizing the ISRE-luc plasmid to quantitate human type 
1 IFN activity is by transiently transfecting the plasmid into human 293 cells and then 
stimulating the transiently transfected cells with experimental samples and known 
quantities of human type 1 IFN to generate a standard curve from which levels of type 
1 IFN in the experimental samples can be determined (Andrejeva et al. 2004; 
Deonarain et al. 2000; Didcock et al. 1999a; b; Poole et al. 2002).
However, certain species of type 1 IFN do not cross recognize other species 
(Bridgman et al. 1988; Proietti et al. 1986). For example, human but not murine type 
1 IFNs are recognized and promote signalling by the type 1 IFN receptor on the 
bovine kidney cell line MDBK (my unpublished observations). As such, in order to 
develop assays for quantitation of murine type 1 IFN activity, I decided to transiently 
transfect the MX-CAT or ISRE-luc plasmids into a murine cell line. The promoter 
sequence of the Mx gene was cloned from murine Mx gene (Lleonart et al. 1990), 
while the ISRE was derived from human sequences, however, pilot experiments using
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transiently transfect cells showed that these would still be recognized by intracellular 
transcription factors in mouse cells (my unpublished observation).
The plasmids ISRE-luc or Mx-CAT were transfected into early passage murine 
BalbC17 cells, an adherent fibroblast cell lines that had previously been shown to give 
the best transfection efficiencies of a panel of murine cell lines evaluated (Guyver 
2001). In order to monitor the efficiency of transfection in each experiment, a well of 
BalbC17 cells were transfected with the GFP plasmid pcDNA-GFP (Figure 3.4D) at 
similar DNA:lipid ratios as used for the reporter gene plasmids. I observed large assay 
to assay variation in the transfection efficiencies which typically ranged from 40% to 
80% as shown in Figure 3.5. More importantly, the transfection process itself 
stimulated a moderately high level of reporter gene expression (which may potentially 
have been due to stimulation of endogenous type 1 production by BalbC17 cells) and 
although the response to exogenously added recombinant IFN-a or IFN-p could be 
observed above this, the increases observed were in consistent and reproducible, 
quantitative IFN-a or IFN-P standard curves could not be generated (Figure 3.6). 
Another drawback was that the assay only worked when the cells were plated out into 
individual wells of 6-well plates and then transfected one at a time, making this 
strategy both costly and impractical for the analysis of large numbers of samples.
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Figure 3.5 The efficiencies of transfection of BalbC17 cells in different experiments
When BalbC17 cells were transfected with a type 1 IFN-responsive plasmid in 6-well plates, a well of cells was transfected in parallel 
with the GFP-reporter plasmid to assess the efficiency of transfection in each experiment. The number of cells expressing GFP at 24 
hours post transfection was determined by FACS analysis, comparing the fluorescence of the transfected cells (shaded histograms) to 
that of non-transfected cells (open histograms). The M 1 marker was set relative to the uninfected cell population. The percentage of 
GFP-transfected cells falling within the M l region is shown beneath each histogram.
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Figure 3.6 Responses of BaIbC17 transiently transfected with the pISRE-luc or pMX-CAT plasmids to recombinant IFN-a or 
IFN-0
BalbC17 cells transiently transfected with the pISRE-luc (Expt 3) or pMX-CAT (Expt 5) plasmids in 6-well plates were stimulated the 
following day with serial dilutions of murine IFN-a or j(3. After an overnight incubation the cells were lysed and expression of the 
respective reporter genes assayed. Lysates from stimulated cells transfected with pISRE-luc (Expt 3) were quantitated using the 
Luciferase Assay system (results expressed as counts per minute, cpm), while a CAT ELISA was used to determine the reporter gene 
levels in stimulated pMX-CAT transfected transfected cells (Expt 5) (results expressed as absorbance values (abs) at 405nm). The 
results obtained have been plotted against the concentration o f IFN used in the stimulation; ‘untrans’ represents the background counts 
or absorbance observed when untransfected cells were assayed and 0 indicates the level of reporter gene expression observed in
voas
transfected cells that were not stimulated with type 1 IFN. The values shown are the mean of triplicate wells, with the 
indicating one standard deviation above the mean.
3.4.2 Generation of cell lines stably transfected with reporter gene constructs 
and analysis of their responsiveness to type 1 IFNs
As quantitating type 1 IFN activity using transiently transfected BalbC17 cells did not 
prove a workable plan, I decided to generate BalbC17 cell lines stably transfected with 
the reporter gene plasmids to obtain more consistent results in a practical manner. 
While the ISRE-luc construct has only been used in transient transfection assays 
(Deonarain et al. 2000; Didcock et al. 1999a; Poole et al. 2002; Young et al. 2001), 
several other groups have developed reporter gene assays utilizing stably transfected 
cell lines to measure human and bovine type 1 IFN (Baigent et al. 2002; Meager 
2002).
As neither of the reporter constructs used here contains a eukaryotic cell selection 
marker, they were co-transfected with a plasmid encoding a blasticidin resistance 
gene (Figure 3.4C) so stably that transfected cells could be selected on the basis of 
resistance to blasticidin by culture in blasticidin supplemented media. Several 
blasticidin-resistent colonies were isolated from each transfection, and these were 
initially pooled together and assayed for quantitative responses to recombinant and 
natural IFN-a and -p. The cells were seeded into 6-well plates, treated overnight with 
a range of IFN-a and -p concentrations and then they were lysed and reporter gene 
expression assayed. Luciferase activity was detected by luminometry while an anti- 
CAT ELISA was used to detect CAT expression in BalbC17 MX-CAT cell lysates. 
Both cell lines gave dose dependent responses to IFN-a and -p, with the limit of 
detection at approximately 10U (data not shown).
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Figure 3.7 Response of BalbCI7 ISRE-luc cells to type 1 IFN as detected in assays 
carried out in plates with wells of differing sizes 
BalbC17 ISRE-luc cells were seeded into 24-, 48- and 96-well plates at cell 
concentrations of 4xl04,2xl04 and 8xl03 cells per well respectively. The following 
day, the cells were stimulated with recombinant murine IFN-a or IFN-/3 protein. After
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a 24 hour incubation, cells were lysed and luciferase production was measured by 
luminescence assay. The results are shown as mean cpm from triplicate wells; the 
error bars indicate one standard deviation (SD) above the mean.
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The initial assay was performed in 6-well plates and I subsequently adapted it to 24- 
well plates and them attempted to scale down the assay format to allow samples to be 
tested in 48- or 96-well plates. Cell concentrations were scaled down from the 6-well 
format by the calculating ratio of the number of cells/surface area. Accordingly, 48- 
well plates were seeded with 2xl04 cells/well in 500pl media while 96-well plates 
(Coming) were seeded with 8xl03 cells/well in lOOp.1 media. The 48-well format 
produced similar quantitative responses to IFN-a or -p  to those observed in the 24- 
well format (Figure 3.7). Attempts to scale the assay down further into 96-well plates 
were not successful, as the levels of luciferase induction obtained in this format were 
minimal and were not quantitative.
3.4.3 Selection of single colonies
The pooled blasticidin resistant cells initially gave reproducible responses to IFNs, 
however with time, the BalbC17 cells appeared to become less responsive to IFN, 
suggesting that a large proportion of the heterogenous cell population had been taken 
over by non-responders. We recovered aliquots of cells frozen at ~4 weeks post 
blasticidin selection and cloned these cells by limiting dilution. Single cell colonies 
were identified, 30 for BalbC17 transfected with ISRE-luciferase (BalbC17 ISRE- 
luciferase) and 64 for BalbC17 transfected with MX-CAT (BalbC17 MX-CAT). These 
were expanded into 24- well plates and tested for their response to 500U/ml of IFN-a, 
Figure 3.8 shows an example of the results from the screening of BalbC17 ISRE- 
luciferase cells and Figure 3.9 an example of results from the screening of BalbC17 
MX-CAT clones. We found that most of the blasticidin resistant cells only contained 
the blasticidin resistence gene without a reporter plasmid. However, a number of 
doubly transfected clones were detected which gave good responses to type 1 IFN
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Figure 3.8 Screening clones of BalbCI7 cells transfected with the ISRE-luc plasmid (BalbC17-ISRE-luc) for responsiveness to 
IFN-a
Single-cell colonies generated by limiting dilution growth of BalbC17 cells transfected with an ISRE-luc plasmid were expanded into 
replicate wells in 48-well plates. When they were about 40% confluent, cells in duplicate wells were stimulated with 500U/ml of 
recombinant IFN-a for 24 hours; other wells of cells were left untreated. Luciferase expression in IFN-treated and untreated wells was 
analysed by luminescence assay and the results are expressed as counts per minute (cpm). Clones were tested in duplicate and the 
error bars indicate one SD above the mean.
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Figure 3.9 Screening clones of BalbC17 cells transfected with plasmid MX-CAT (BalbC17-MX-CAT) for responsiveness to 
IFN -a
Single-cell colonies generated by limiting dilution growth of BalbC17 cells transfected with HH-CAT plasmid were expanded into 
replicate wells in 48-well plates. When they were about 40% confluent, cells in duplicate wells were stimulated with 500U/ml of 
recombinant IFN-a for 24 hours; other wells o f cells were left untreated. The level o f CAT expression in IFN-treated and untreated 
wells was analysed by CAT ELISA and the results are expressed as the absorbance (abs) at 405nm. Clones were tested in duplicate 
and the error bars indicate one SD above the mean.
while maintaining low background levels of reporter gene expression (Figure 
3.8/3.9). As illustrated by example in Figure 3.10, when these clones were expanded 
they retained the ability to respond to IFN-a in a dose dependent fashion. As the 
responding cells were from a clonal lineage, the total number of cells seeded into 48- 
well plates was halved from the number of uncloned parental cells that was previously 
seeded. Reducing the cell concentration from 2xl04 cells/well to lxlO4 cells/well did 
not affect the responses obtained. Importantly, the clones gave a detectable response 
to as little as ~lU/ml of IFN-a or -p, and their responses were more reproducible than 
that of the parental cell lines. This is more sensitive than the visual endpoint of the 
bioassay of -3.9U of IFN-a. Stimulation with recombinant serial 10-fold dilutions of 
recombinant EFN-y confirmed that the ISRE-luc promoter did not respond to IFN-y 
(Figure 3.10). This was also true of the MX-CAT promoter (data not shown).
3.4.4 Analysis of the ability of different anti-IFN antibodies to block murine 
IFN-a and p activity
To enable even more accurate determination of the IFN composition and 
concentration in biological samples, neutralising anti-IFN-a antibodies could be 
added to the samples prior to testing, thus allowing IFN-f3 levels to be quantitated off 
the IFN-|3 standard curve, and vice versa.
Commercially available antibodies against murine IFNs were tested to determine their 
ability to neutralise IFN-a or -p activity in the reporter gene assays (Figure 3.1 IB). As 
shown in Figure 3.11, neutralizing antibodies against IFN-a (Figure 3.11 A) or IFN-p 
(Figure 3.1 IB) were able to block the activity of their respective IFN types when 
added in excess to the culture media.
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Figure 3.10 Response of BalbC17-ISRE-luc clone B2 to recombinant murine IFN- 
a,-/5 and -7
The cells were plated into 48-well plates at a concentration of lx l04cells/well. The 
following day, cells were stimulated with serial dilutions of a) recombinant mouse 
IFN-a! or b) recombinant murine EFN-/3 in 200/d of growth medium. After a 24 hour 
incubation, the cells were lysed and the amount of luciferase reporter expression was 
determined by luminescence assay. The results are expressed as mean counts per 
minute (cpm). The data shown are mean values from duplicate wells; the error bars 
indicate one standard deviation (SD) above the mean.
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Figure 3.11 A) and B) Neutralizing antibodies abrogate the response of BalbC17 
ISRE-luciferase cells to type 1 IFNs (legend on following page)
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BalbC17 ISRE-luciferase clone B2 cells were seeded into 48-well plates at lx l0 4 cells 
/well and incubated overnight. The following day, cells were stimulated with a range 
of concentrations of recombinant IFN-a (A) or IFN-p (B) that had been pre-incubated 
for 30 mins at 37°C either alone or with neutralizing antibody at 7 neutralizing units 
per unit of IFN. After a 24 hour stimulation, the cells were lysed and luciferase 
production measured by luminescence assay. The results are expressed as mean 
counts per minute (cpm). The data shown are mean values from duplicate wells; the 
error bars indicate one standard deviation (SD) above the mean.
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3.4.5 Effects of passaging on the sensitivity of the reporter cells
It was discovered over time that constant passaging of the reporter cells in blasticidin 
supplemented media resulted in higher backgrounds of luciferase and CAT 
expression, leading to the cells losing their sensitivity to type 1 IFN. Figure 3.12 
compares the IFN-a standard curve from BalbC17 ISRE-luciferase at a late passage 
with an identical experiment conducted using early passage cells of the same clone. 
While early passage cells were responsive to at least 2.5U of IFN-a or IFN-P, cells at 
later passage could only respond to >50U of IFN-a or IFN-p, due to the background 
counts increasing by 3-fold. Other people have observed this with other cell lines (Dr 
Steve Goodboum, St George’s Medical School, London, personal communication); it 
is believed to be due to endogenous type 1 IFN production which occurs despite the 
measures taken to ensure the system is free from potential type 1 IFN inducing 
stimuli, which included culturing the cells with polymyxin B in low-endotoxin, 
BVDV-free serum and keeping the cells at log-phase, sub-confluent growth.
The loss of sensitivity in these stably transfected cells as they were passaged rendered 
the reporter assays unreliable. It was therefore decided that they were not suitable for 
measuring the levels of secreted type 1 IFN in experimental samples.
3.5 Real-time PCR detection of different type 1 IFN subtypes and IFN- 
stimulated genes
In parallel with efforts to develop assays to measure secreted type 1 IFN in 
supernatant or serum, optimization of real-time quantitative PCR reactions to detect 
mRNA of IFN-p and specific IFN-a subtypes was conducted. Quantitative PCR 
reactions were designed to allow measurement of levels of expression of IFN-P and
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Figure 3.12 Comparison of the response of early and late passage BalbC17 ISRE- 
luciferase clone B2 cells to IFN-a4
Early passage BalbC17 clone B2 cells (~5 passages after clone was selected and 
expanded) and cells that had been passaged an additional 5 times were seeded at 
lxlO4 cells/well into a 48-well plate. The following day, the cells were stimulated 
with serial dilutions of murine IFN-o4 in 200/d of media. After a 24 hour incubation 
period, cells were washed, lysed and the amount of luciferase was determined by 
luminescence assay. The results shown are the mean counts per minute (cpm) from 
triplicate wells; the error bars indicate one standard deviation (SD) above the mean.
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specific IFN-a subtype trancripts in in vitro cultured cells or tissues from infected vs. 
uninfected animals and also to enable comparison of the level of expression of 
mRNAs for individual subtypes of type 1 IFN induced in a given sample.
The main hurdle in designing primers specific for type 1 IFN subtypes is the 
homology shared across all IFN genes: the murine IFN-p gene shares 25-40% 
homology with the IFN-a genes while the murine IFN-a gene cluster consists of 12 
non-allelic intronless genes which are only 13% divergent from one another (De 
Maeyer and De Maeyer-Guignard 1998), Nonetheless, primers and probes were 
designed or obtained from the literature to detect the following gene(s) IFN-P, all 
IFN-a subtypes except for IFN-a4 (IFN-a(non-a4)), IFN-a4, Mxl and HPRT 
(Karaghiosoff et al. 2003). The location of the forward primer, probe and reverse 
primers specific for IFN-p, IFN-a4 and IFN-a(non-a4) is highlighted in the Clustal W 
alignment of a section of the sequence of IFN-P and selected IFN-a subtypes in 
Figure 3.13. The IFN-a subtypes aligned here represent the entire sequence variation 
observed within that section of sequence in all the subtypes of IFN-a. The sequences 
were confirmed by BLAST to be specific for their respective genes. The EFN-p probe 
was labelled with the fluorescent dyes FAM on the 5’ end and TAMRA on the 3’ end 
while the probes for IFN-a4 and IFN-a(non-a4) were labelled with FAM on the 5’ 
end and TAMRA plus a minor groove binder (MGB) at the 3’ end to provide 
increased sequence specificity (Kutyavin et al. 2000).
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6 6 8 0 3 6 8 | r e f | N M _ 0 0 8 3 3 5 . 1 | ( a 6 )  
2 2 0 4 4 1 | d b j | D O 0 4 6 0 . 1 | M U S I F N A 8  
5 1 5 4 6 | e m b | X 0 1 9 7 1 . 1 | MMI FNA5  
6 7 5 4 2 9 3 | r e f | N M _ 0 1 0 5 0 4 . 1 | ( a 4 )  
6 7 5 4 2 9 1 j r e f j N M _ 0 1 0 5 0 3 . 1 j ( a 2 )  
6 7 5 4 3 0 3 j r e f j N M _ 0 1 0 5 1 0 . 1 | ( b e t a )
6 6 8 0 3 6 8 | r e f | N M _ 0 0 8 3 3 5 . 1 | ( a 6 )  
2 2 0 4 4 1 | d b j | D 0 0 4 6 0 . 1 |MUSIFNA8 
5 1 5 4 6 | e m b | X 0 1 9 7 1 . 1 |MMIFNA5 
6 7 5 4 2 9 3 | r e f | N M _ 0 1 0 5 0 4 . 1 | ( a 4 )  
6 7 5 4 2 9 l j r e f j N M _ 0 1 0 5 0 3 . i l (a2)  
6 75 43 03  r e f  NM 0 1 0 5 1 0 . 1  ( b e t a )
6 6 8 0 3 6 8 | r e f | N M _ 0 0 8 3 3 5 . 1 | ( a 6 )  
2 2 0 4 4 1 | d b j | D O 0 4 6 0 . 1 | M U S I F N A 8  
5 1 5 4 6 | e m b | X 0 1 9 7 1 . 1 | MMI FNA5  
6 7 5 4 2 9 3 | r e f | N M _ 0 1 0 5 0 4 . 1 | ( a 4 )  
6 7 5 4 2 9 1 j r e f j N M _ 0 1 0 5 0 3 . 1 j ( a 2 )  
6 7 5 4 3 0 3 j r e f j N M _ 0 1 0 5 1 0 . 1 j ( b e t a )
AGGCTGTCTGATGCAGCAGGTAGAGATACAGGCACTTCCCCTGACCCAGG 4 7 7  
AGGCTGTCTGATGCAGCAGGTAGAGATACAGGCACTTCCCCTGACCCAGG 9 6 3  
AGCCTGTGTGATGCAACAGGTCGGGGTGCAGGAATCTCCCCTGACCCAGG 1 0 9
AGCCTGTGTGATGCA------------------------------------ GGAACCTCCTCTGACCCAGG 3 9 7
AACCTGTCTGATGCAGCAGGTGGGGGTGCAGGAACCTCCTCTGACCCAGG 4 0 9
AGACAGTACTAGAGGAAAAG------------------- CAAGAGGAAAGATTGACGTGGG 4 0 8
*  *  * *  *  *  * * * *  * *
AAG ACTCC--------- CTGCTGG CTG- -  TGAGGACATACTTCCACAGGATCACT 5 2 1
AAG ACTCC--------CTGCTGG CTG- -TG AG G ACATACTTCCACAGGATCACT 1 0 0
AAG ACTCC--------CTGCTGGCTG -  -  TGAGGAAATACTTCCACAGGATCACT 1 1 3
AAG ACTCC--------CTGCTGGCTG -  -  TGAGGACATACTTCCACAGGATCACT 4 4 1
AAGACGCC--------CTGCTGGCTG -  -  TGAGGAAATATTTCCACAGGATCACT 4 5 3
AGATGTCCTCAACTGCTCTCCACTTGAAGAGCTATTACTGGAGGGTGCAA 4 5 8  
*  * *  * * * * *  *  * * *  * *  * *  *  *  * * *  *
GTGTTCCTGAGAGAGAAGAAACACAGCCCCTGTGCCTGGGAGGTGGTCAG 5 7 1  
GTGTTCCTGAGAGAGAAGAAACACAGCCCCTGTGCCTGGGAGGTGGTCAG 1 0 5  
GTGTACCTGAGAGAGAAGAAACACAGCCCCTGTGCCTGGGAGGTGGTCAG 1 1 8  
GTGTACCTGAGAAAGAAGAAACACAGCCTCTGTGCCTGGGAGGTGATCAG 4 9 1  
GTGTACCTGAGAGAGAAGAAACACAGCCCCTGTGCCTGGGAGGTGGTCAG 5 0 3  
AGGTACCTTAAACTCATGAAGTACAACAGCTACGCCTGGATGGTGGTCCG 5 0 8  
* *  * * *  * *  * * * *  * * *  * * *  * * * * * *  * * * *  * *  *
AGCAGAAGTCTGGAG-AGCCCTGTCTTCCTCAGCCAAGTTGCTGGCAAGA 6 2 0  
AGCAGAAGTCTGGAG- AGCCCTGTCTTCCTCAGCCAAGTTGCTGGCAAGA 1 1 0  
AGCAGAAGTCTGGAG- AGCCCTGTCTTCCTCAGTTAACTTGCTGGCAAGA 1 2 3  
AGCAGAAGTCTGGAG- AGCCCTCTCTTCCTCAACCAACTTGCTGGCAAGA 5 4 0  
AGCAGAAGTCTGGAG- AGCCCTGTCTTCCTCAGTCAACTTGCTGCCAAGA 5 5 2  
AGCAGAGATCTTCAGGAACTTTCTCATCATTCGAAGACTTACCAGAAACT 5 5 8  
* * * * * *  * * *  * *  *  *  *  * *  * *  *  *  * *  *  * *
C T G A A- -  -  TGAGGACGAGTGAGTCCTGAGACCAAGTGTGGAGAG -  ACCTC 6 6 6  
C T G A A- -  -  TGAGGACGAGTGAGTCCTGAGACCAAGTGTGGAGAG -  ACCTC 1 1 5
TTG AG CAAGGAGGAGTGACTCCTGAGACAAAGTGTGGAGAGGACTTT 1 2 8
CTG AG - -  - TGAGGAGAAG- GAGTGA------------------------------------------------------------- 5 6 1
CTGAG TGAAGAGAAG- GAGTGA------------------------------------------------------------- 5 7 3
TCCAAAACTGAAGACCTGTCAGTTGATGCCTCAGAATGAGTGGTGGTTGC 6 0 8  
*  *  * *  *  *  *
CCTGGACTAGAACACTGCACCTGCACTTTATAAG- - C T CCCTTTACAACT 7 1 4  
CCTGGACTAGAACACTGCACCTGCACTTTATAAG- - C TCCCTTTACAACT 1 2 0  
TCTGAACCAGAACACTGCATCT -  CACTTTATAAG ATCTCCTTTAAAAACT 1 3 3
AGGCAACCTTTAAGCATCAGAGGCGGACTCTGGGA- CTGGTAGTGAATCT 657
CTCATTACCTTCA-GTGTGAACACAATCAACCTGCCAAGACGCTGCAGCA 763  
CTCATTACCTTCA- GTGTGAACACAATCAACCTGCCAAGACGCTGCAGCA 124  
CTCATAACTTTCACATATGAGTACAAACAACCTGCACAGATGTTTCAGCA 13 8
ACTGCATTTGAAAGGTCAAAGGAAAACAGAGTTTTTATTAATTTATAAT - 706
Figure 3.13 ClustalW alignment of cDNA or genomic sequences of selected IFN-a subtyp
Figure 3.13 ClustalW alignment of cDNA or genomic sequences of selected IFN-a 
subtypes and IFN-p
Multiple sequence alignment using ClustalW was conducted to identify conserved 
and heterogenous regions within the coding sequences of the genes for IFN-P and 
selected IFN-a subtypes; only the relevant portion of the alignment of the entire 
coding sequence is shown. The column to the left of the alignment identifies the gene 
through its Genbank designation, with the subtype name in brackets at the end of the 
desgination. The IFN-a subtypes aligned here represent all the sequence variation 
within the region shown. The nucleotide position of each of the aligned sequences is 
revealed in the column on the right of the alignment. Asterisks (*) beneath the 
alignment indicate the position is occupied by nucleotides that are conserved in all the 
sequences compared, while a dash (-) within the aligned sequence highlights a 
sequence deletion at that position. This information was applied to design primers 
and probes that were specific for the IFN-a(non-a4) subtypes only. The primer and 
probe sequence recognised by the IFN-a(non-a4) primer set is highlighted in red 
(coloured font = primer sequences, underlined coloured font = probe sequence), while 
the sequence recognised by the IFN-a4 probe/primers is coloured green and the 
region recognised by the IFN-p probe/primer set blue.
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Initial optimization experiments determined the optimal primer concentration for each 
set. Figure 3.14 is an example of the optimization of the primer dilution for the IFN- 
a(non-a4) Taqman PCR; the value of slope of the line is a measure of the efficiency 
of the PCR reaction. The slopes for low dilutions of the primer set should be similar 
with a change in the slope indicating that the primer concentration limited the 
efficiency of the PCR reaction. Here, the minimum appropriate working dilution 
proved to be at 1/10 dilution or lower of the stock concentration. Ultimately, we 
decided to dilute the primers 1/5 of the stock concentration of 100pmol/pl, giving a 
final concentration of 20 pmol per reaction.
All type 1 IFN genes do not contain introns so primers that spanned exon-exon 
boundries could not be designed as a means to exclude genomic contamination. It 
therefore became imperative that all genomic DNA was removed from the samples, 
and this was achieved by an on-column DNAse digestion step during RNA isolation. 
In some samples, a second DNAse digestion step was performed on the aliquot of 
input RNA just before RT-PCR was conducted.
To check that IFN-P and IFN-a4 primer sets do not recognize non-a4 subtypes of 
IFN-a, they were tested against plasmids encoding the IFN-a2, -a5, -a6/8 or -al4 
subtype (provided by Dr. Graeme Frith, Edward Jenner Institute, Compton, UK) in 
real-time PCR assay. As shown in Figure 3.15, positive responses against all the 
plasmids were obtained from the IFN-a(non-a4) primer set. The IFN-a4 primers did 
not recognize any of the non-a4 plasmids, and negative responses were also observed 
with the IFN-P primer set (data not shown). The primers for IFN-a4 and IFN-P were 
obtained from a published source, and the primer and probe sequences for the 
respective genes were confirmed by BLAST search to be specific for only the IFN
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Figure 3.14 Optimization of primer dilutions for quantitative PCR
Working dilutions of primer sets for quantitative PCR were optimized to determine the lowest primer concentration which would not limit the 
efficiency of the PCR reaction. As a representative example, results of the experiment carried out for the optimization of the IFN-c^non-o4)
K>
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♦  1/2.5 y = -3.444x + 26.232 
R2 = 0.9997
■ 1/5 y = -3.375x+26.204 
R2 = 0.9983
1/10 y=-3.397x+26.458 
R2 = 0.9995
•  1/20 y = -3.669x + 28.25 
R2 = 0.9998
primers is shown. PCR reactions were set up on serial 10-fold dilutions of mouse genomic DNA template using forward and reverse primers of 
IFN-a(non-a4) diluted 1/2.5, 1/5, 1/10 and 1/20 from a stock concentration of lOOpmol/jLil . The working concentration of the IFN-o(non-a4) 
probe was fixed at 5pmol/reaction for all the reactions. The Ct value was plotted against the logio concentration of the input template for each 
primer dilution and regression lines calculated for all primer dilutions. The value of the slope of the line is a measure of the efficiency of the 
PCR reaction. The slopes for low dilutions of the primer set should be similar, with a change in the slope indicating the primer concentration 
limited the efficiency of the PCR reaction.
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Figure 3.15 Amplification plot of IFN-a4 and IFN-a(non-a:4) real-time PCR
assays
To confirm the specificity of the IFN-o4 and the IFN-o(non-a4) quantitative PCR 
reactions, IFN-o4 or IFN-o(non-o4) primer sets were tested against 4 distinct 
plasmids encoding the IFN-o:2, -a5, -o6/8 or -al4 subtype. Recognition of a subtype 
by the primer set results in the increase of the reaction’s ARn above the set threshold 
during successive PCR cycles. The threshold was set according to criteria as 
explained in the Methods section 2.x. The threshold indicated is the threshold of the 
IFN-a(non-a4) reaction, which was set at 0.03, with the fluorescence detected during 
cycles 3-15 as the average baseline fluorescence. The threshold for the IFN-a4 
reaction was set at 0.8, with the average fluorescence emissions during cycles 3-22 as 
the baseline. As illustrated above, the PCR reactions set up with the IFN-a(non-o4) 
primers crossed the threshold at cycle -28 and at -35. Using the threshold and 
baselines for the IFN-o4 reaction, the ARn values for all reactions using the IFN-o4 
primer set remained negative.
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subtype they were designed against. I would have liked to have confirmed the 
specificity myself but we were not able to obtain plasmids containing the IFN-a4 or 
IFN-p coding sequence which could also have been used to check that the IFNa(non- 
a4) primer and probe set did not cross-recognize those sequences. Based on BLAST 
sequence analysis conducted on the IFN-a(non-a4) primer sets, the forward and 
reverse primers and probe sequence was specific for the a subtypes only and did not 
recognize the IFN-P gene. The BLAST analysis did not recognize the IFN-a4 gene 
sequence as it contained a single nucleotide substitution in the forward and reverse 
primer binding regions (Figure 3.13). However, the PCR conditions may not have 
been stringent enough to prevent cross-recognition of the IFN-a4 subtype, so it 
remains a possibility that this primer set also recognizes the IFN-a4 subtype.
I next investigated the feasibility of directly comparing the levels of each IFN type 
measured to those of the other IFN types/subtypes. For a valid comparison of the 
levels of different IFN subtypes, the rate or efficiency of the PCR amplification 
process would need to be similar in all the primer sets. In order to determine the 
efficiencies of each primer set, they were tested against wild-type mouse genomic 
DNA which would contain an equal number of copies of the IFN-P and each of the 
IFN-a intronless gene. Taqman real-time PCR assays were conducted for each of the 
primer sets in PCR mastermix with 10-fold dilutions of genomic DNA from wild-type 
C57BL/6 mice (provided by Miranda Ashton, Edward Jenner Institute, Compton) as 
template. The Ct values were determined and plotted against the logio concentration of 
input genomic DNA as template to generate standard curves for each primer set. As 
can be seen in Figure 3.16, the IFN-p and IFN-a (non-a4) primer set have similar 
slope values indicating the PCR reactions are of similar efficiencies. The curves are 
parallel and not superimposed because the IFN-p primer set is specific for the IFN-p
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Figure 3.16 Standard curves for real time PCR analysis of IFN-& IFN-a(non-a4) and IFN-a4 subtypes performed with 10-fold serial 
dilutions of mouse genomic DNA (legend on following page)
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Mouse genomic DNA (from 100 to 0.01 ng per reaction) was used as a template to determine the efficiency of each PCR reaction using 
optimised working dilutions of the primer sets. The cycle number at which the reporter signal first increased above the set threshold (Ct value)
was plotted against the logio concentration of input DNA. The data shown are the mean of results from at least 2 independent experiments.
• • * 2Regression lines were fitted to the data; the equation for each line is shown in the figure, as is the correlation coefficient, R , value. Error bars
indicate one standard deviation above and below the mean.
gene while the IFN-a (non-a4) primers recognizes > 9 IFN-a subtypes (a-1, -2, -5, -6, 
-7, -8, -11, -13 and a psuedogene) and, as such, record lower Ct values at the same 
template concentration as there would be nine times as many IFN-a (non-a4) template 
as there was every IFN-|3 template.
The IFN-a4 primer set has a different slope value indicating that the PCR efficiency is 
not the same as that of the reaction carried out with the other IFN primer sets.
The primers were designed to measure levels of mRNA transcript in two-step reverse- 
transcriptase PCR assays that employed a real-time quantitative RT-PCR mastermix, 
in which input RNA template would be converted into cDNA by reverse transcriptase 
and the cDNA levels subsequently amplified by PCR. To confirm that the efficiencies 
of the primers in the two-step RT-PCR reaction would follow a similar trend to those 
in the one-step PCR assay, the primers were tested on 10-fold serial dilutions of total 
RNA extracted from polylC stimulated BM-DC as polylC is a known inducer of type 
1 IFN. The HPRT and Mxl primer sets, which could not recognize their respective 
genes in genomic DNA as the primers go across exon-exon boundaries, were also 
tested. The Ct values were plotted against the logio concentration of input total RNA. 
As shown by the standard curves generated (Figure 3.17), the two-step RT-PCR 
assays did not have the same efficiency as the one-step PCR assays (Figure 3.16); 
however, the trends observed in efficiencies of the individual primer sets in the RT- 
PCR assays mirrored the results obtained when the primer sets were tested with 
genomic DNA. Again, the IFN-p and IFN-a(non-a4) primer sets had similar slope 
values, while the IFN-a4 RT-PCR gave rise to a different slope value. The HPRT 
primer set had a similar efficiency to that of the IFN-p and IFN-a(non-a4) primers 
while the efficiency of the Mx RT-PCR was slightly different to that of all the other
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Figure 3.17 Standard curves for real-time RT-PCR analysis of IFN-0, IFNa(non-a4) subtypes, IFN-a4, Mx and the housekeeping gene 
HPRT performed with seria lly  diluted RNA from polylC-stimulated BMDCs (legend on following page)
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RNA in quantities ranging from 1000 to lOng per reaction was used as a template for RT-PCR reactions using the primer sets designed to 
recognize HPRT, IFN-/3, IFN-o4, IFN-o(non-a4) subtypes and Mx, each used under optimised conditions for each primer set. The cycle number 
at which the reporter signal first increased above the set threshold (Ct value) was plotted against the logio concentration of input RNA. All real­
time assays were performed in triplicate with the mean of each data point shown. Regression lines were fitted to the data; the equation for each 
line is shown in the figure, as is the correlation coefficient, R2, value.
t o
t o
t o
RT-PCR assays. Although these quantitative RT-PCR assays were suitable for 
comparison of the levels of a given IFN subtype in different samples, they could not 
be used for accurate comparison of levels of different IFN subtypes, e.g. IFN-p and 
IFN-a4 within a sample or between samples.
3.6 Analysis of type 1 IFN levels in FSDC cells after stimulation with viruses 
or polylC
After developing and evaluating new and existing methods to measure type 1 IFN 
mRNA, protein or activity, the most promising methods, namely the real-time 
quantitative RT-PCR and the EMCV antiviral protection bioassay, which measured 
type 1 IFN mRNA and activity respectively, were applied in a pilot experiment to 
verify that the selected, optimized protocols could be successfully employed for 
analysis of type 1 IFN responses in experimental systems.
A DC cell line, FSDC, was stimulated with 50pg/ml of polylC. At 4 and 18 hours post 
stimulation, total RNA was extracted from the cells and levels of type 1 IFN mRNA 
transcripts (IFN-p, IFN-a4 and IFN-a (non-a4)). Figure 3.18A shows the levels of 
each mRNA Type 1 IFN subtype induction was induced measured by real-time PCR 
in samples stimulated with poly IC for different durations while the corresponding 
type 1 IFN activity present in the supernatant of each sample is displayed in (Figure 
3.18B). For the real-time quantitative RT-PCR, the raw data in the form of Ct values 
for the gene of interest was analysed as discussed in section 2.6.62 and the values 
shown in Figure 3.18A are the ACt value which has been normalised against the 
housekeeping gene HPRT. A ACt value that is higher than the ACt value of the 
unstimulated control indicates an increase in the relative levels of the transcript of the 
gene of interest over the control. Type 1 IFN production was induced in response to
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Figure 3.18 A) Quantitation of the levels of IFN-& IFN-a4 and IFN-a(non-a4) mRNA induced in FSDC cells after stimulation with 
polylC
FSDC cells (lx l0 5/well) were stimulated with 50/ng/ml polylC. At 4 and 18 hours post-treatment, stimulated and unstimulated (unstim) cells 
were collected, RNA was extracted and levels of individual type 1 IFN mRNA subtypes were determined by Taqman RT-qPCR (A). The level 
of each target gene was normalised by subtracting the Ct value of the target from the Ct value of the invariant housekeeping gene HPRT of the 
same sample to obtain the ACt value. The results shown are the mean ACt value of each sample from two independent experiments, with the 
error bars indicating one standard deviation (SD) above the mean.
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Figure 3.18 B) Quantitation of supernatant type 1 IFN activity induced in FSDC cultures after stimulation with polylC
FSDC cells (lx l0 5/well) were stimulated with 50^g/ml polylC. At 4 and 18 hours post-treatment, supernatants were collected from stimulated 
and unstimulated (unstim) cells and tested by bioassay to determine the level of type 1 IFN activity present (B). The results are the mean log2 
value from two independent experiments, and the error bars show one standard deviation above the mean.
stimulation of FSDC cells with polylC. Upregulation of type 1 IFN mRNA levels 
was detectable at 4 hours and 18 hours post-stimulation. Levels of IFN-p and IFN-a4 
subtype mRNA had increased over background unstimulated levels by 4 hours post 
polylC treatment. IFN-p mRNA expression remained at the same level at 18 hours 
post-stimulation, whilst mRNA levels had undergone further increase by this time and 
expression of IFN-a(non-a4) subtypes continued to be induced. Type 1 IFN activity 
in the supernatant of polylC stimulated cells had doubled (and increase of 1 log2U/ml) 
compared to the level in unstimulated cell supernatant at 4 hours post-stimulation and 
then increase to 8 fold (31og2U/ml) above the control level by 18 hours post­
stimulation. This experiment thus confirmed that real-time quantitative RT-PCR and 
the bioassay were sensitive enough to enable analysis of the type 1 IFN response in 
this experimental system, and could together provide a picture of the kinetics of 
upregulation of levels of mRNA of different subtypes of type 1 IFN and of production 
of bioactive type 1 IFN.
3.7 DISCUSSION
The aim of these experiments outlined in this chapter was to set up assays that 
could be used to analyse type 1 IFN production during acute and chronic LCMV 
infection. These assays had to be able to detect low levels of type 1 IFN. Existing 
assays that measured type 1 IFN protein or activity were evaluated for their sensitivity 
and utility. In addition, new assays were set up namely reporter gene-based assays for 
quantitation of murine type 1 IFN activity and real time quantitative RT-PCR assays 
for the measurement of distinct type IFN subtypes. Following development and 
evaluation of multiple assay methods, two approaches were chosen for quantitation of 
type 1 IFN mRNA levels and activity in future experimental work. The chosen assays
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were trialed in a pilot experiment to confirm their suitability for evaluation of type 1 
IFN responses and the complementarity of the data obtained using two different 
assays.
A number of systems exist for measurement of type 1 IFN protein levels in biological 
samples (reviewed in (Meager 2002)). Commercial ELISA kits are available that can 
not only measure type 1 IFNs but also distinguish between IFN-a subtypes and IFN- 
p. I found that laboratory and commercially available ELISA kits for quantitation of 
murine IFN-a were reliable but fairly insensitive, with limits of detection of 25 pg/ml 
or 50-100 pg/ml respectively. Furthermore, the IFN-a ELIS As only measure the total 
amount of protein within a sample, and as different interferon subtypes have been 
reported to have different bioactivity, do not provide information on the units of 
biological activity of the IFNs. We did not have a chance to evaluate the IFN-p 
ELISA (RnD systems cat no:42400-l), which was only released in late 2004, which 
was reported by the manufacturers to have a detection range of 15.6-1000 pg/ml.
Cell based assay systems include the classic antiviral protection bioassay system, 
where IFNs are detected by their ability to confer an antiviral state on a susceptible 
fibroblast cell line such as L929 cells and protect it from lysis by a cytopathic virus 
such as EMCV or VSV (Ishitsuka et al. 1977). This is the system upon which a unit of 
IFN activity is defined. In my hands, the EMCV antiviral protection bioassay proved 
to be reliable and to have a reproducible endpoint of ~3.9 or 2 log2 U/ml with a 
recombinant IFN-a standard curve, which is almost 100 times more sensitive than the 
IFN-a ELISA assay. While the bioassay is not able to distinguish between IFN-a, 
IFN-P or IFN-y, nonetheless the activity of IFN-a, IFN-P or IFN-y can be blocked by 
addition of excess subtype-specific neutralising antibody to the samples before they
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are mixed with the cells (Figure 3.2), enabling dissection of the IFN subtypes 
mediating the observed activity.
Some of the experimental samples to be tested would contain IFN-stimulatory 
components such as polylC, CpG, R848 or LCMV. The TLRs expressed by L929 
cells is unclear, so the cells were tested for production of endogenous type 1 IFN 
activity upon exposure to these TLR ligands. The cells were insensitive to all the 
stimuli at the concentrations tested, apart from LPS which in any case was not used as 
a test stimuli, which were the maximum concentrations the samples would contain. 
With LCMV, L929 cells did not exhibit endogenous antiviral protection in the 
presence of up to 106 p.f.u./ml of LCMV C113 (Figure 3.3). It was unlikely that 
LCMV-infected samples would contain more than 106 p.f.u./ml of virus and thus there 
should not be any endogenous antiviral protection by L929 cells in response to either 
virus or residual type 1 IFN stimuli in the experimental samples I planned to go on to 
test.
Another cell based assay system involves the use of cells transfected with reporter 
genes linked to an IFN-responsive promoter (Canosi et al. 1996; Fray et al. 2001; 
Hammerling et al. 1998; Lewis 1995). Like the classic bioassay system, this differs 
from the ELISA system in that it quantitates IFN activity, and it has the advantage 
that this quantitation is based on the level of induction of the reporter gene, which also 
allows signal amplification, enabling these assays to be very sensitive. The use of 
promoters responsive only to IFNs gives the reporter gene assay more specificity than 
the classic bioassay, although until promoters specifically responsive to subtypes of 
type 1 IFN are identified, subtype specific blocking antiserum must still be used to 
dissect the IFN subtypes present in a sample. The reporter gene system method is also 
quicker and easier than the virus inhibition bioassay. The reporter systems I obtained
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were based on two different IFN responsive promoters. The ISRE-luciferase reporter 
(p(9-29 ISRE) 4tkA(-39)lucter, (Figure 3.4A) has 4-human ISRE promoter sequences 
upstream of the luciferase gene (King and Goodboum 1998) while the MX-CAT 
(pHH-CAT, Figure 3.4B) plasmid has the promoter for the human MxA gene linked 
to the gene for CAT. Both promoters respond to both IFN-a and IFN-P and very 
little if at all to IFN-y (Baigent et al. 2002) (Figure 3.10). The MX-CAT system has 
been reported to be able to detect very low levels of human (Ronni et al. 1998) or 
bovine (Baigent et al. 2002) type 1 IFNs. The ISRE-luc plasmid has been mainly used 
in human IFN signalling studies where it has been found to be highly inducible by 
low amounts of IFN (King and Goodboum 1998).
Type 1 IFNs are not strictly species-specific, rather they have a defined host range 
(Bridgman et al. 1988). Existing reporter gene systems which were set up in human or 
bovine systems could not be used to measure murine type 1 IFNs as the IFN-R cell 
surface receptor did not recognize IFN-a/ps from murine species (my unpublished 
observations). The promoter sequences of Mx was derived from mouse Mx protein 
(Lleonart et al. 1990) and the ISRE used, although derived from human genes, would 
nonetheless be recognized by the activated murine transcription factors. As such, I 
decided to transfect the reporter plasmids into a murine cell line, in order to allow the 
murine type 1 IFNs to be recognized by the murine IFN-R and activate the signalling 
pathway, culminating in the expression of the transfected reporter gene. Transient 
transfection assays were initially conducted to determine whether transiently-transfect 
cells would respond to type 1 IFN in a quantitative and reproducible manner.
Previous optimization assays conducted in the laboratory had shown that out of a 
panel of cell lines tested, which included the fibroblast cell lines BalbC17 and MC57 
and the macrophage-like cell lines IC-21 the highest levels of plasmid uptake
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occurred in BalbC17 cells (Guyver 2001). To increase the transfection efficiencies the 
transfection protocol was further refined by extensive testing of a range of 
transfection reagents (FuGene, GeneJuice and Effectene) at different DNA:lipid 
ratios. When the optimised protocol, which used DNA to Effectene at a ratio of 1:15, 
was followed to transfect early passage BalbC17 cells, the efficiency, as measured by 
GFP reporter expression, was between 50-70% (Figure 3.5). Despite these reasonably 
good transfection efficiencies, I did not see quantitative responses to IFN-a or IFN-P 
in these transfected cells. Excessive cell death was observed after transfection, with 
50% of the cells typically dying post transfection, drastically reducing the total 
number of live cells per well, which may have been another one of the factors that 
contributed to the poor responses observed in this assay. In human signalling studies 
that employed the ISRE-luc reporter assay, the plasmid was transiently transfected 
into human 293T cells containing the SV40 T antigen which allows for highly 
efficient uptake of transfected DNA, so there would be consistent luciferase 
production in all the wells of transiently transfected cells in a dose dependent manner. 
However, another, perhaps more significant problem was the high background 
obtained. This was likely the result of endogenous production of type 1 IFN, which 
may have been triggered by the transfection procedure itself, in which cells are often 
incubated overnight with the lupid:DNA mixture in a low serum environment which 
may have induced cellular stresses, or type 1 IFN may have been induced by the 
toxicity of the lipid and the presence of dead and dying cells in the population after 
after transfection. Furthermore, it has been recently reported that type 1 IFN may be 
upregulated in response to the presence of DNA in the cytosol, such as would have 
occurred in the transiently-transfected cells (Stetson and Medzhitov 2006).
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Given the problems I encountered with the transient transfection approach, I decided 
to generate cell lines stably transfected with the ISRE-luciferase and MX-CAT 
constructs in order to simplify the assay and make the results more reproducible. I 
used both constructs because the MX-CAT reporter system in bovine cells had a 
reported sensitivity of 0.32U/ml (Fray et al. 2001) and I hoped it would prove to be 
similarly sensitive in detecting murine type 1 IFNs, but the luciferase reporter system 
appeared to offer advantages in terms of ease, speed and cost of the reporter assay. 
Both plasmids did not have a selectable eukaryotic marker and so they were co­
transfected with a plasmid encoding blasticidin resistance and transfected cells were 
selected based on blasticidin resistance. Initial tests using the pooled blasticidin 
resistant cells showed that quantitative responses against recombinant human and 
murine IFNa and IFN-p could be generated using the ISRE-luc system. However, 
with increasing passages, the BalbC17 ISRE-luciferase cells became less sensitive to 
type 1 IFN, as the background continued increasing, necessitating sub-cloning. 
Although I was able to generate subclones that reproducibly gave a dose-dependent 
response to concentrations of IFN-a and -p between lOU/ml and ~500U/ml (Figure 
3.10), and successfully used these in preliminary experimental work, assays 
conducted using these stably transfected cells suggested they were not as sensitive to 
low type 1 IFN concentration as hoped.
A drawback to the reporter gene-based IFN assays is that the promoters are 
responsive to both IFN-a and IFN-p, hence they do not differentiate the subtypes of 
type 1 IFN present in a given sample. To solve this problem, I attempted to find 
antibodies that would specifically neutralise IFN-a and IFN-P activity, allowing each 
subtype to be assayed in isolation. Neutralizing antibodies against murine IFN-a and
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IFN-|3 were tested and appear to work (Figure 3.11) specifically neutralising the 
activity of the appropriate type 1 IFN subtype.
Although the reporter gene-based assays initially worked reasonably well, I ultimately 
made a decision not to use them because I found they lost their sensitivity to IFN-a 
after several passages in culture. (Figure 3.12). The background luciferase expression 
levels increased, resulting in the cells beoming less sensitive to lower doses of IFN-a. 
Efforts were made to reduce the endogenous background luciferase expression levels, 
for example, background levels generally increased when unstimulated cells became 
confluent, and so the cell numbers were halved from 2xl04 to lxlO4 cells/well in the 
48-well plate format to reduce the chance of the cells becoming confluent and 
maintain the sensitivity of their response to IFN-a. It was not clear what caused the 
increasing background levels. The plasmids may have integrated or been maintained 
episomally. If the plasmids were integrated into genomic DNA, chance integration 
into a transcriptionally active site may have resulted in high, non-specific luciferase 
expression; this has been observed in other laboratories which attempted to generated 
stably-transfected reporter systems using the ISRE-luc vector (S.Goodboum, personal 
communication).
Other reporter gene assays circumvented this problem by utilizing cells which had lost 
their IFN genes e.g. Vero cells, which respond to human but not murine IFN-a/p, or 
by extensive testing of transfected clones for one with the best signal to noise ratio 
such as was conducted when developing transfected Mx-CAT MDBK cells (B. 
Charleston, personal communication). I tested 30 and 64 clones for ISRE-luc and Mx- 
CAT inducible activity respectively and selected the best responders, which worked 
initially before losing their sensitivity over extensive passages. If I had more time, I 
could have tested more clones, but there were other objectives that needed to be met
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and we had set up and evaluated the protocol for the EMCV bioassay in the meantime 
and decided to use this method for analysis of experimental samples. Human cell lines 
which have a targeted disruption of the IFN-locus and are thus unable to produce type 
1 IFN have recently been described (Young et al. 2003) and an analogous system set 
up in murine cells could prove to be a suitable carrier cell line to develop such assays 
in the future.
In future experiments, I felt it would be of interest to dissect the subtypes of type 1 
IFN produced by different cell types/tissues and at different stages of infection, as 
there is increasing evidence that their production is temporally regulated. For 
example, IFN-p and IFN-a4 are thought to be more important than the other -a 
subtypes during the initial stages of infection, and to trigger additional IFN induction 
(Capobianchi et al. 2003; Deonarain et al. 2004). There is also evidence that IFN-a 
subtypes are differentially regulated, with IFN-a2, -a5, -a6 and -a8  reported to be 
specifically upregulated during viral infections (Marie et al. 1998), reviewed in (Levy 
et al. 2003).
As none of the protein/activity-based assays I had established/evaluated had the 
capacity to distinguish subtypes of IFN-a to allow more detailed analysis of the 
kinetics of production of different IFN subtypes, real-time quantitative RT-PCRs were 
thus set up to detect specific IFN subtype transcripts. Conventional RT-PCRs primers 
specific for murine IFN-p and discrete IFN-a subtypes have been designed 
(Deonarain et al. 2000). However, we found these conventional RT-PCRs to be semi 
quantitative and not sensitive (data not shown). Real-time PCR assays which rely on 
the release of fluorescent products during the amplification phase of a PCR reaction to 
measure levels of the transcript of interest have been demonstrated to be sensitive
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than conventional PCR assays and may posses a linear detection range of up to 7 (or 
5) logs.
Real-time quantitative RT-PCR analysis of IFN mRNA also complements the 
bioassay system by enabling detection of IFN responses in samples that can’t be 
tested in the bioassay, e.g. tissue samples.
The major difficulty in designing primers that were specific for a given type 1 IFN 
subtype lay in the fact that they shared close homologies with one another. While the 
IFN-P gene only shared 30-40% homology with the IFN-a subtypes, the 12 IFN-a 
subtypes, whose genes are located in a cluster on chromosome 4, have a homology of 
-80% to one another (De Maeyer and De Maeyer-Guignard 1998). Heterologous 
regions within the genes, which could be used to distinguish the IFN-a subtypes, were 
limited. To compound matters, the real-time RT-PCR assay sets a fixed annealing 
temperature and elongation period for the PCR amplification cycles, so all real-time 
Taqman primers and probes must be designed to be optimal within the set values. 
This is not the case for conventional PCRs, where the annealing temperatures and 
elongation periods are customised to the primers. In addition, primers for real-time 
Taqman RT-PCR assays are subject to many constraints, which are listed in Section 
2.6.1. These were adhered to by the Primer Express software package that was used to 
predict suitable primer-probe sets for the genes. Among the constraints listed for the 
probe sequence are that the number of cytoseine (C) residues must exceed the number 
of guanine (G) residues; furthermore, the primer sequence should not have more than 
2 C/G residues in the last 5 nucleotides at the 3’ end. As the all the IFN-a/p sequences 
are posses GC-rich regions as observed by ClustalW alignment, this severely limited 
the number of heterologous regions of sufficient length that encoded sequences which 
were suitable for the design of real-time RT-PCR primers and probe.
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Taqman primer sets for IFN-p and IFN-a4 had already been described (Karaghiosoff 
et al. 2003); these were re-checked to confirm that they were the optimal primers for 
their respective genes. The IFN-a4 primer set generated a less efficient RT-PCR than 
to the other primer sets. However, I did not change this primer set in favour of more 
efficient alternatives as the forward primer of this set spanned a 15bp deletion within 
the IFN-a4 gene which did not occur in the other IFN-a subtypes, thus ensuring the 
reaction would be specific for IFN-a4 only (Figure 3.14). Ideally discrete primers and 
probes would have been designed for all IFN-a subtypes. However, in the face of the 
severe constraints on primer design, we could only design a primer and probe set that 
recognized a region identical in all the IFN-a subtypes apart from IFN-a4 in order to 
study the induction of these subtypes. Real-time quantitative RT-PCR assays were 
conducted on an ABI-SDS instrument, which also supported assays based on the 
Sybr-Green detection system. While the cyber-green assay could have been applied 
and indeed have since been developed to detect IFN-a/p transcription (Honda et al. 
2005; Sato et al. 2000), we decided to use the Taqman real-time quantitative RT-PCR 
system as there was the extra specificity afforded by the binding of the probe 
sequence. This would potentially reduce the detection of genomic DNA 
contamination, as it lengthened the template that needed to be recognized and was 
thus less likely to bind to fragments of genomic DNA which might still be present 
after DNase treatment. Furthermore, it has been suggested that Sybr-Green PCRs may 
be less sensitive than assays employing the fluorogenic probe (Yin et al. 2001). 
Real-time quantitative RT-PCRs for IFN-p, IFNa-4, IFN-a(non-a4) and Mx were set 
up (Deonarain et al. 2004; Montoya et al. 2002) and optimized (Figures 3.14 to 3.17). 
Type 1 IFN mRNA are low abundant transcripts because until their production is 
stimulated by the presence of infections, there is usually very little type 1 IFN
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produced by a resting cell in vivo. It was therefore crucial that the IFN a/p real time 
PCR assays were not only specific but also sensitive. Several 3’ labelling and 
modifications are available which are designed to improve the specifity and 
sensitivity of the binding of the probe to the PCR amplicon. One of these 
modifications is the attachment of the non-fluorescent minor groove binder (MGB) to 
the 3’ end of the probe. MGB is a non-fluorescent conjugate which forms hyper 
stabilized duplexes with complementary DNA enabling MGB-conjugated probes to 
hybridize with greater sequence specificity than, it is claimed, natural unconjugated 
probes(Afonina et al. 2002; Kutyavin et al. 2000; Letertre et al. 2003). Conventional 
FAM-TAMRA and MGB labelled probes for IFN a4 and nona4 were synthesised and 
compared - we found in our hands that the MGB-labelled IFN-a4 probe had an 
improved the efficiency of its real-time RT-PCR over the unconjugated probe. Probes 
for the IFN-a4 and IFN-a(non-a4) RT-PCR assays were thus synthesised with the 
MGB modification. The MGB-probe and primers were shown to be specific for the 
IFN-a4 subtype as it did not amplify any of the other closely-related a subtypes 
(Figure 3.15).
The reliability of a quantitative real-time RT-PCR assay is dependent upon several 
elements, including the treatment/quality of the input RNA, the intra-assay variation, 
the selection of the housekeeping gene and the normalisation strategies employed. 
The quality of the input total RNA was a key concern throughout the project as the 
interferon genes do not posses introns (De Maeyer and De Maeyer-Guignard 1998) 
and so the primers would not be able to discriminate between RNA transcripts and 
genomic DNA contamination. I attempted to minimize the likelihood of genomic 
DNA contamination by treating all samples with DNase prior to quantitative RT-PCR 
analysis. The intrassay variation was tested by using known concentrations of
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genomic mouse DNA as template and was found to be minimal (unpublished 
observations). Type 1 IFN transcripts are not normally highly abundant in the cells, 
and so the housekeeping gene selected should also be of similar low abundance in 
order to ensure any discrepancies in the amount of input sample is not masked by the 
saturating levels of the housekeeping gene. The HPRT gene was used as the 
housekeeping gene because it was normally present in low levels in cells, and partly 
because it had been previously used as the housekeeping gene in the quantitative 
analysis of IFN-a4 and IFN-p (Karaghiosoff et al. 2003). An ideal housekeeping gene 
should have an invariant rate of expression under any situation, and in this regard, 
HPRT qualifies as its expression does not show much variation under different 
conditions (Loseke et al. 2003). However, it may have been more appropriate use p- 
glucoronidase as a housekeeping gene as it displayed more stable expression, or to use 
a panel of housekeeping genes as control for one another.
There are several ways to normalise the results (in Ct values) of real-time 
quantitative PCR assays. Common methods include running a standard curve of 
plasmid containing a known copy number of the target gene alongside the unknown 
samples, which would express the results as mRNA copy number per sample; or by 
expressing the level of a target gene in a treated sample as the fold difference over the 
level in a control sample (Pfaffl 2001). Quantitation by standard curve analysis did 
not prove practical for the large number of samples involved as a standard curve 
would have to be run on every plate that was tested. Baseline levels of IFN-P and 
IFN-a in uninfected unstimulated control samples were usually very low or non­
existent, and as such I felt it was not valid to express the levels as fold induction over 
either the baseline or an arbitrarily selected sample expressing the gene. I also decided 
that the fairest way to determine the levels of IFN-a and p in the different samples
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would be to analyse expression levels in a fixed amount of sample. As such, all the 
samples were quantitated by UV spectroscopy after RNA extraction the concentration 
of input RNA was fixed at 300ng/well for all samples where possible. In some cases, 
such as during the isolation of mRNA from Mo-Flo sorted dendritic cells, there was 
not enough RNA for quantitation, and there, RNA was extracted from an equal 
number of cells from each subpopulation in every sample in each specific experiment. 
The levels of HPRT were checked to ensure they were similar in all the samples 
tested. Furthermore, the results were presented with minimal manipulation of the raw 
data, which was normalised by subtracting the Ct value of the target gene from the Ct 
value of the housekeeping gene, thus, the larger the difference in the Ct value (ACt), 
the higher the mRNA level of the target gene in the sample.
Having evaluated a range of IFN-a/p-quantitation assays, I selected the EMCV 
antiviral bioassay as the best means to measure secreted bioactive IFN levels and the 
real-time quantitative RT-PCR to measure cellular levels of type 1 IFN mRNA and to 
discriminate between induction of IFN-p, IFN-a4 and the remaining IFN-a subtypes. 
The EMCV antiviral protection bioassay was demonstrated to be sensitive and 
consistent. The main weakness of this assay is that there are other cytokines, e,g. 
TNF-a that may be present in experimental samples and which may exert anti-viral 
effects in this assay (Jacobsen et al. 1989); however, this drawback can be overcome 
using blocking antibodies to demonstrate that antiviral activity in experimental 
samples is indeed mediated by IFN-a/p. Another consideration was that the samples 
would likely contain IFN-inducing stimuli such as LCMV or TLR ligands, which may 
possibly induce endogenous typel IFN infection in the L929 cells. Tests conducted to 
determine the potential of this effect showed that L929 cells do not secrete 
endogenous type 1 IFN in response to LCMV unless it was present at very high titres
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not likely to occur in our samples and did not respond polylC, R848 or CpG DNA 
that would be used as stimuli.
The assays were applied in a pilot experiment to determine whether the data obtained 
by two different methods would concur with each other. A murine DC cell line, FSDC 
(Girolomoni et al. 1995) was stimulated with poly IC, a synthetic ligand of TLR3 
known to induce type 1 IFN production in DCs. Quantitation of type 1 IFN mRNA 
levels at two early timepoints after stimulation indicated that IFN-P and IFN-a4 were 
the subtypes initially most strongly upregulated, with the expression of the other IFN- 
a subtypes only increasing at the later timepoint of 18 hours post stimulation, by 
which time IFN-p expression had reached a plateau. Expression of IFN-a4 continued 
to increase between 4 and 18 hours post stimulation. Low pre-existing levels of all 
type 1 IFN subtypes were detected in unstimulated controls. The EMCV bioassay 
confirmed the presence of low levels of type 1 IFN production by unstimulated cells, 
as the assay detected low type 1 IFN bioactivity of about 3 log2 units/ml in the cell 
supernatant (Figure 3.18B). Results from the EMCV bioassay were also consistent 
with the observations made at the mRNA level, in that a small increase of IFN activity 
was detectable in the supernatant at 4 hours post-stimulation, and higher type 1 IFN 
activity levels were observed by 18 hours post-stimulation. Previous reports indicate 
that upon stimulation/infection, fibroblast cells predominantly secrete IFN-p and IFN- 
a4, which then signals through the IFN-R to upregulate expression of the other IFN-a 
subtypes (Goodboum et al. 2000). These results suggest that type 1 IFNs may be 
induced in a similar manner in these DC cell lines upon polylC stimulation. It has 
been previously reported that infection of D2SC/1 and FSDC with live or inactivated 
vims induced higher levels of IFN-p activity than IFN-a (Eloranta et al. 1997) and our 
data, showing early upregulation of IFN-P which was sustained still sustained 18
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hours post-stimulation does lend support to this observation. The results of the pilot 
experiment indicate that both the assays are reliable and are able to complement each 
other.
These primers have since been used to measure the levels of type 1 IFN mRNA 
induced in response to i.p. infection with LCMV Arm in the spleens of mice 
expressing different isoforms of CD45 or lacking the molecule entirely (Montoya et 
al. 2006). CD45 knock-out mice were found to mount only a partial type 1 IFN 
response against the infection -  while IFN-a4, IFN-a(non-a) and IFN-p transcripts 
were detected in the spleens of these mice post-infection, the levels were lower than 
responses recorded in wild-type mice or transgenic mice that expressed one of the 
isoforms of CD45. Furthermore, the results of the real-time quantitative RT-PCR 
analysis were in agreement with data of the serum type 1 IFN levels, which was 
measured by IFN-a ELISA, which showed that serum IFN-a levels in the infected 
CD45 knock-out mice were also reduced. These, plus observations from other 
experiments does suggest that CD45 is required for normal type 1 IFN responses to 
viral infection.
Since the time my project was initiated, other type 1 IFN quantitation protocols have 
reported, namely a reporter gene-based bioassay utilizing GFP expression (Bollati- 
Fogolin and Muller 2005), while the company Applied Biosystems now offer pre­
designed, pre-optimized Taqman real-time quantitative PCR assays which the 
manufacturers claims is subtype specific, with individual assays for IFN- P and a l, 2, 
4, 5, 6, 7, 9, 12 or 13 subtypes available as inventoried or made-to-order assays 
(Applied Biosystems, product.appliedbiosystems.com). However, the existing issues 
which I encountered during development of the reporter gene-based bioassay and 
real-time quantitative RT-PCR assays have not all been overcome by the reported
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methods. For example, the newly published eGFP bioassay is not very sensitive, as 
the detection range was reported to be between 20-300U and 10-500U for IFN-a and 
IFN-p respectively and it is not able to distinguish between the activity of IFN-P and 
different IFN-a subtypes. The sensitivity and specificity of the commercially available 
Taqman assays was not reported by the manufacturer (indeed, some of the assays 
have yet to be assessed by quality control) and all cannot exclude detection of the 
genomic sequence. Furthermore, no information is provided as to whether the 
readings of the assays could be compared with each other. Nonetheless, given the 
opportunity, it would have been interesting to compare the sensitivity of some of the 
IFN real-time assays I used, especially the IFN-a4 subtype assay, in order to 
determine if the commercially available assay possessed a higher level of 
sensitivity/efficiency than the assay I employed.
3.8 Conclusions
Methods were set up and optimized to allow sensitive, reliable measurement of type 1 
IFN protein and mRNA levels in in vivo and in vitro samples. In addition to 
evaluating established protocols for detection of type 1 IFNs at the protein level such 
as the IFN-a ELISA and the EMCV antiviral bioassay, new assays based on reporter 
gene technology were developed, optimized and tested. Early in development, 
reporter gene based-assays were more sensitive than IFN-a ELISAs, and were equally 
or slightly more sensitive than the bioassay. However, the reporter cells gradually lost 
their sensitivity to type 1 IFN as they were passaged, so this approach could not be 
used as a quantitative assay in future studies. It was thus decided to use the EMCV 
bioassay to determine the levels of bioactive type 1 IFN in the serum or supernatants. 
Real-time quantitative RT-PCR assays were also set up that measured transcript levels
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of IFN-p, IFN-a4 and other IFN-a subtypes to enable information on the mRNA 
levels of different IFN subtypes in tissues and cells to be obtained.
A pilot experiment tracking type 1 IFN induction in a DC cell line after polylC 
stimulation confirmed that both assays were sensitive and robust enough to be used in 
the quantitation of type 1 IFNs in future work.
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CHAPTER 4
CHARACTERIZATION OF TYPE 1 IFN RESPONSES DURING IN  VIVO 
ACUTE AND PERSISTENT VIRAL INFECTIONS
4.1 Introduction
The outcome of a murine LCMV infection in adult, immunocompetent C57BL/6 mice 
is dependent upon the virus strain employed, the dose and the route of inoculation 
(Borrow and Oldstone 1997). For example, adult, immunocompetant mice infected i.p. 
with a low dose (~5 x 105 p.f.u) of the Armstrong strain of LCMV will experience an 
acute infection that is cleared in 7-10 days while i.v. inoculation with a high dose 
(~5xl06 p.f.u) of LCMV C113 or Docile results in a long-term, systemic infection 
with high viral loads. Persistent infection also results when mice are infected at birth 
due to clonal deletion of virus-specific T-cells by mechanisms involved in the 
induction of self-tolerence. There are a number of differences in the host immune 
response in LCMV infections that are cleared and infections that go on to persist 
which may contribute to and/or result from viral persistence (Borrow 1997).
Among the cytokines produced early in infection are type 1 IFNs which both have 
direct anti-viral effects and important immunoregulatory roles in the innate and 
adaptive immune responses. Many studies have reported that infection with acute 
strains of LCMV elicits production of type 1 IFN early in infection (Bukowski et al. 
1983; Jacobson et al. 1981; Leist et al. 1987). Biron et al report that during LCMV 
infection, type 1 IFN production in response to the presence of the virus is not high, 
but this is subsequently amplified through the autocrine amplification via type 1 IFN- 
R and JAK-STAT signalling (Malmgaard et al. 2002). Type 1 IFNs play a key role in 
control of LCMV infection (Moskophidis et al. 1994; Ou et al. 2001). However, it is
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not clear whether this is a consequence of the direct antiviral effects on limiting viral 
replication and/or a result of its direct or indirect effects on LCMV specific T-cell 
expansion. Induction of type 1 IFNs are critical for the proper maturation of LCMV- 
specific T-cells which that are responsible for controlling and ultimately killing the 
virus (Bartholdy et al. 2000; Buchmeier et al. 1980; Havenar-Daughton et al. 2006; 
Ou et al. 2001; Wille et al. 1989). While T-cell exhaustion occurs rapidly in the 
absence of type 1 IFN activity, this could either be a consequence of increased viral 
load thus affecting the T-cell response or impairment of the T-cell activity.
While almost any cell type can produce type 1 IFN in response to a viral infection, 
studies with other viruses (Celia et al. 2000; Dalod et al. 2003; Hochrein et al. 2004; 
Schmidt et al. 2005) have suggested that the majority of type 1 IFN in the serum is 
secreted by plasmacytoid DCs in the spleen. Plasmacytoid DCs do not appear to be 
the predominant source of serum type 1 EFN during acute infection with LCMV as 
mice which were depleted of plasmacytoid DCs produced similar levels of type 1 IFN 
as wild-type mice upon infection with LCMV Arm (Dalod et al. 2002). The cells 
responsible for type 1 IFN upregulation during acute LCMV infection have not been 
comprehensively defined, although our group has previously reported that the CD1 lc+ 
B220+ /B220" DC subsets within the spleen become highly activated and the CD1 lc+ 
B220+ subset produces high transient levels of type 1 IFN upon infection with LCMV 
Arm (Montoya et al. 2005). Nonetheless, it is unclear if the bulk of type 1 IFN is 
produced by infected cells or by uninfected cells that sense the presence of viral 
components. Type 1 IFN production may be triggered by activation of the TLRs on 
cells that recognize viral components such as viral glycoproteins and nucleic acid, in 
which case the cell need not necessarily be infected in order to respond, or by the 
intracytoplasmic helicase pathways that sense viral dsRNA, in which the cells would
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have to be infected by the virus and accumulating replicative intermediates in the 
cytoplasm.
During a persistent infection with LCMV, very high levels of viral stimuli are present 
systemically for extended periods in the host. Little is known about the regulation of 
type 1 IFN production in chronic LCMV infection, although old studies have 
suggested that mice persistently infected at birth with LCMV have reduced levels of 
circulating serum type 1 IFN and produce lower levels of the cytokine when 
stimulated with polylC or Newcastle Disease virus compared to uninfected mice 
(Holtermann and Havell 1970). However, these studies only analysed type 1 IFN 
levels during the chronic stage of infection using mice that were infected at birth with 
LCMV.
In short, the type 1 IFN response during persistent viral infection, the type of cells that 
produce type 1 IFN during persistent viral infection and the functional state of the 
innate immune system during persistent LCMV infection still requires investigation. 
As such, I plan to characterise the type 1 IFN response during persistent LCMV 
infection by employing the more sensitive quantitative real-time RT-PCR assay to 
measure levels of type 1 IFN subtype mRNA in spleen of acute and persistently 
infected mice to determine the levels of induction of individual type 1 IFN subtypes 
over time. The levels of type 1 IFN activity in the spleen will be measured in parallel 
using the EMCV bioassay. Furthermore, the specialised type 1 IFN producing cell, 
the DC population, will also be investigated in order to determine the role that they 
play in type 1 IFN production during acute and persistent LCMV infection. 
Immunostaining of spleen sections from acute and persistently-infected mice will also 
be conducted to gain insight into whether type 1 IFN is predominantly produced by 
uninfected or LCMV-infected cells. Finally, I also intend to use the quantitative real­
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time RT-PCR assays and the EMCV bioassay to analyse the ability of the persistently 
infected mice to respond to exogenous type 1 IFN inducing stimuli in the presence of 
high levels of infectious virus.
4.2 Generation of mice acutely and persistently infected with LCMV
My first goal was to establish an infection regime that would allow the generation of a 
persistent infection in adult, immunocompetent C57B1/6 mice. In C57B1/6 mice 
infected i.v. with LCMV, the virus replicates systemically and infectious virus can be 
detected in the spleen and blood at very early times post infection. Whether or not the 
infection is cleared depends on the infecting virus strain and the dose used (reviewed 
in (Borrow and Oldstone 1997). Mice were infected i.v. with a moderate dose of 
LCMV Arm, a strain that is cleared even when administered i.v. at a high dose to 
adult mice, or with two different LCMV strains previously reported to cause a 
persistent infection in adult mice, LCMV C113 at 5xl06 p.f.u or LCMV Docile, at a 
range of doses from lx l0 6p.f.u 50 5xl06 p.f.u. Virus clearance or persistence was then 
evaluated by bleeding from the tail vein at different times post-infection and 
determining serum viral titres by plaque assay (Arm or Cl 13) or immunoplaque assay 
(Docile).
4.2.1 Serum viral titres in LCMV-infected mice over time
A comparison of the levels of infectious LCMV in the serum after i.v. inoculation 
with three different LCMV strains is shown in Figure 4.1. None of these strains 
caused a lifelong
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Figure 4.1 Kinetic analysis of serum viral titres in mice infected with LCMV 
Arm, C113 or Docile
C57BL/6 mice were infected i.v. with 5xlOsp.f.u LCMV Arm or 5xl06p.f.u LCMV 
Cl 13. At the indicated times post-infection, blood samples were collected from groups 
of three mice infected with each virus, and serum viral titres of individual animals 
were determined by plaque assay on Vero cells. The values shown are the mean 
serum viral titres of each group of mice, expressed as logio plaque forming units 
(p.f.u)/ml serum. The error bars indicate 1 standard deviation above and below the 
mean. The assay detection limit is indicated by the dotted line. BD indicates that virus 
was below the levels of detection at the indicated timepoint. The results are 
representative of findings made in 2 independent experiments.
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persistent infection in adult immunocompetent mice at the doses used here. After 
infection with LCMV Arm, low titres of virus were detected in the serum at very early 
times by day 1 post-infection but this was rapidly controlled, with serum viral titres 
falling below the level of detection of the plaque assay by day 10, entirely in keeping 
with the acute nature of this strain of LCMV. In contrast, gradually increasing levels 
of infectious virus were detected in the serum of mice infected with LCMV Cl 13. 
Serum viral titres peaked at 2 weeks post-infection at ~ lx l0 6 pfu/ml, almost 3 logs 
higher than the maximal levels observed after LCMV Arm infection. Infectious virus 
continued to be detected for a further 4 weeks thereafter. The kinetics of control of 
serum vireamia varied in different animals, typically being achieved between 6-8 
weeks post-infection (data not shown). Serum viral titres in mice infected with 5xl06 
p.f.u of LCMV Docile were similar to those in mice infected with LCMV C113, 
peaking at 2 weeks post-infection and at levels approximately 3 logs higher than the 
peak serum viral titre in mice infected with LCMV Arm, and with virus persisting 8- 
12 weeks before the infection was ultimately cleared by the host. The duration of 
persistence after infection with LCMV Docile was wholly dependent upon the initial 
dose administered, with inoculation of lower doses resulting in earlier clearance of the 
virus from serum (data not shown). As there was little difference between the duration 
of virus persistence in mice infected with LCMV Cl 13 and LCMV Docile, LCMV 
Cl 13 was employed as the persistent strain for experimental work. It was chosen 
because it could be compared against LCMV Arm, with which it shared a virtually 
identical viral sequence aside from a single amino acid substitution in the GP and the 
RNA-dependent polymerase (Salvato 1993). Furthermore, viral titres could be 
determined using conventional plaque assays rather than the cumbersome 
immunoplaque assays required for determining titres of LCMV Docile. In subsequent
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experimental work, a persistent LCMV infection was generated by i.v. inoculation of 
mice with 5xl06 p.f.u. of LCMV C113.
4.2.2 Viral titres in the spleen of LCMV-infected mice over time
Figure 4.2 shows the levels of infectious virus in the spleen during the course of 
infection of mice with LCMV Arm or LCMV C113. Following i.v. infection with 
5x10s p.f.u. of LCMV Arm, infectious virus was detectable in the spleen for 14 days, 
with peak viral titres in the spleen being observed at day 2 post-infection. In contrast, 
the level of infectious virus in the spleen of mice infected with 5xl06 p.f.u of LCMV 
Cl 13 continued to increase until day 4 post-infection and peak splenic viral titres were 
approximately 100 times higher than those in mice acutely infected with LCMV Arm. 
Viral titres in the spleen of the persistently infected mice began to drop between days 
4 and 6 post-infection, but here, a moderately higher viral load was still sustained for 
4 weeks post-infection, with infectious virus falling below detectable levels in the 
spleen by 8 weeks post-infection.
4.3 Analysis of type 1 IFN mRNA levels in the spleen during LCMV Arm and 
LCMV C113 infection
Having established an LCMV strain and dose that could be used to generate 
persistently infected mice (albeit not a lifelong persistent infection), and also analysed 
the infectious viral titres in the serum and tissues during acute and persistent LCMV 
infections, I next examined the host type 1 IFN response over the course of an acute 
infection and one that went on to persist. Mice were infected i.v. with 5x105 p.f.u of 
LCMV Arm, (to generate an acute LCMV infection) or 5xl06 p.f.u of LCMV C113 (to 
generate a persistent LCMV infection), and total
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Figure 4.2 Kinetic analysis of viral titres in the spleen in mice infected with 
LCMV Arm or C113
C57BL/6 mice were infected i.v. with 5xl05 p.f.u LCMV Arm or 5xl06p.f.u LCMV 
C113. At the indicated timepoints post-infection, spleen samples were collected from 
groups of three mice infected with each virus, and spleen viral titres were determined 
by plaque assay on Vero cells. The values shown are the mean spleen viral titres, 
expressed as logio plaque forming units (p.f.u)/gm spleen. The error bars indicate 1 
standard deviation above and below the mean. The assay detection limit is indicated 
by the dotted line. BD indicates that virus was below the levels of detection at the 
indicated timepoint. The results are representative of findings made in 2 independent 
experiments.
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RNA was purified from homogenized pieces of snap-frozen spleen at different times 
post-infection for analysis of type 1 IFN mRNA levels. The levels of IFN-(3, IFN-a4 
and IFN-a(non-a4) mRNA in 300 ng of total RNA were determined by real-time 
quantitative RT-PCR assays, using primer probe sets specific for each type/subtpe of 
IFN listed. Levels of Mx mRNA, a gene whose upregulation is dependent upon 
expression of type 1 IFNs, were also tracked.
4.3.1 Levels of type 1 IFN mRNA in the spleen during acute and persistent 
LCMV infections
IFN-P (Figure 4.3 A) and IFN-a (Figure 4.3 B and C) production was rapidly induced 
upon infection of mice with either LCMV Arm or LCMV Cl 13, with the peak of 
expression occurring at 12-24 hours post-infection in both infections. In mice acutely 
infected with LCMV Arm, type 1 IFN mRNA levels fell sharply after the peak and 
returned close to baseline between days 3 and 7 post-infection (as the infection was 
controlled). The kinetics of the acute-phase type 1 IFN mRNA response in LCMV 
Cl 13-infected mice were very similar to those in mice infected with LCMV Arm, 
although the peak levels of all type 1 IFN mRNAs were slightly higher in the Arm- 
infected mice. Notably, the sharp drop in type 1 IFN mRNA levels that was observed 
in LCMV Arm-infected mice at 48 and 72 hours post-infection also occurred in 
LCMV C113-infected mice, as did the subsequent further decline in type 1 IFN 
mRNA levels from 3-7 days post-infection, despite the fact that viral titres in the 
LCMV Cl 13 mice were increasing over this time-frame (Figure 4.1 and Figure 4.2). 
However, there was a difference in type 1 IFN mRNA levels in mice inoculated with 
LCMV Arm and LCMV Cl 13 at later times post-infection: whereas no IFN-P or IFN- 
a4 mRNA could be
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Figure 4.3 A-D Type 1 IFN and Mx mRNA levels in the spleen during the acute 
and persistent phases of infection of mice with LCMV (figure continued on the 
following page)
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Figure 4.3A-D (continued) Type 1 IFN and Mx mRNA levels in the spleen during 
the acute and persistent phases of infection of mice with LCMV
C57BL/6 mice were infected i.v. with 5x10s p.f.u LCMV Arm or 5xl06 p.f.u LCMV 
C113. At the indicated times post infection, spleen samples were collected from 
groups of three mice infected with each virus or 1-3 uninfected control animal (Unf) 
for extraction of total RNA. The levels of IFN-/3, IFN-o4 and IFN-a(non-Q4) mRNA 
subtypes in the spleen were determined by quantitative real time RT-PCR. The results 
are expressed as ACt, where the level of the target gene in each isolated sample is 
normalized relative to the HPRT housekeeping control. The values shown at each
timepoint represent the mean results obtained in 3 animals tested per group and are
representative of results obtained from 3 independent experiments. The error bars 
indicate 1 standard deviation above and below the mean. n.d. indicates no target 
mRNA was detected in the sample at the timepoint (note that in the IFN-o4 assay, 
only two data points for the Unf group are shown as only two of all of the samples 
tested possessed detectable levels of IFN-o4 mRNA). The mRNA level in uninfected 
spleens (Unf) is indicated by the dotted yellow line, with the shaded area defining 1 
standard deviation above and below the maximum and minimum uninfected values.
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detected in the spleen of LCMV Arm inoculated mice at 3 weeks post-infection, low 
but nonetheless slightly elevated levels of IFN-p and IFN-a4 mRNA were found to be 
present in the spleen of LCMV C113-infected mice.
4.3.2 Levels of Mx mRNA in the spleen during acute and persistent LCMV 
infections
The magnitude and kinetics of Mx mRNA upregulation following infection of mice 
with LCMV Arm and LCMV Cl 13 were very similar. Mx 1 levels increased over the 
first 24 hours of infection, then began to decline, gradually returning to the levels 
observed in uninfected controls beyond day 7 post-infection (Figure 4.3D). In contrast 
to type 1 IFN mRNA levels, Mx mRNA levels in LCMV C113-infected mice were not 
found to be chronically elevated at 3 weeks post-infection.
4.4 Serum levels of type 1 IFN during LCMV Arm or LCMV C113 infection
Serum samples were collected in parallel with spleen tissue to enable measurement of 
systemic levels of type 1 IFN activity during acute and persistent LCMV infections. 
The L929-EMCV protection bioassay was employed to determine total bioactivity of 
type 1 IFN in the serum, with no distinction between IFN types or subtypes.
The kinetics of type 1 IFN production in mice infected with LCMV Arm or Cl 13 were 
found to be very similar (Figure 4.4). In both groups of mice, type 1 IFN production 
was induced very rapidly after infection, with levels of activity in the serum reaching 
a peak within the first 48 hours of infection, well before peak in viral titres were 
reached (Figures 4.1 and 4.2). The peak serum IFN titre in LCMV C113-infected mice 
was slightly (~2-fold less) lower than the maximal level of circulating IFN recorded in
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Figure 4.4 Type 1 IFN levels in the serum over time following infection of mice 
with LCMV Arm or C113
C57BL/6 mice were infected i.v. with 5x10s p.f.u LCMV Arm or 5xl06p.f.u LCMV 
Cl 13. At the indicated times post-infection, blood samples were collected from groups 
of three mice infected with each virus or a single uninfected control mouse (Unf), and 
serum antiviral activity was determined by bioassay. The values shown are the mean 
serum IFN-g^  activity in groups of LCMV infected mice, with the error bars 
indicating 1 standard deviation above and below the mean. The maximal and minimal 
values of the uninfected (Unf) controls are indicated by the shaded area of the graph. 
The data shown are representative of results obtained from 3 independent experiments.
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mice infected with LCMV Arm. Type 1 IFN levels in the serum fell rapidly from day 
3 onwards in both groups of mice, reaching background levels by day 7 or slightly 
later. Interestingly, mice persistently infected with LCMV Cl 13 were not found to 
have elevated levels of type 1 IFN activity in the serum at chronic timepoints (e.g. day 
21), despite the presence of high viral titres in the serum.
4.5 Analysis of splenic DC subsets in persistently infected mice
Analysis of type 1 IFN mRNA from whole spleen tissue suggested that there was little 
difference in the early kinetics of type 1 IFN induction in mice infected with LCMV 
Arm or LCMV Cl 13, and that persistently infected mice continued to express low 
levels of type 1 IFN mRNA throughout the course of the infection. Dendritic cells 
have been identified as important producers of type 1 IFNs during many virus 
infections, with pDCs being implicated as the source of much of the type 1 IFN found 
in serum in a number of infections (although this remains controversial for LCMV 
(Dalod et al. 2002)). Experiments were thus carried out to address changes taking 
place in the number and activation state of spleen DC subsets in LCMV-infected mice, 
and the role they may play in type 1 IFN production during acute and persistent 
LCMV infections.
4.5.1 Identification of splenic DC subsets
To isolate splenic DCs, spleens pooled from a group of 6-10 mice were lysed, then 
low density cells were enriched on a Nycoprep gradient and DCs were isolated by 
positive selection on CD llc Macs columns. DC subsets were identified (and in some 
experiments isolated by Mo-Flo sorting) by staining with C D llc and B220 mAbs to 
distinguish DC subpopulations of the C D llc+ B220+ (plasmacytoid DC) or C D llc+
256
B220' (myeloid or conventional DC) phenotype. In some experiments, plasmacytoid 
DCs within the C D llc+ population were instead identified on the basis of pDCA-1 
expression, which was a newly available marker reported to be specifically expressed 
by plasmacytoid DCs (Krug et al. 2004). Here, plasmacytoid DCs were defined as 
cells with CD1 lc+ pDCA-1+ surface marker expression.
Figure 4.5 shows a typical FACS profile of splenic DC subsets after enrichment and 
CD1 lc+ column purification and staining with anti-CDl lc-APC and anti-B220-FITC. 
The proportion of plasmacytoid DCs, defined by the C D llclow B220+ phenotype, 
comprised ~10-20% of the total C D llc+ population while the conventional DC 
population comprised ~60-80% of the total splenic DC population, as has been 
previously described (Asselin-Paturel et al. 2003). The percentage of CD1 lc+ pDCA- 
1+ cells is about 13% of the total CD1 lc+ population which is similar to the value of 
the CD1 lc+ B220+ subpopulation.
CD llc, which is routinely used as a marker for DC is also expressed on some cell 
types other than DCs in the spleen of normal mice and is upregulated on many non- 
DC cell types when they become activated (Lin et al. 2003). To determine what 
proportion of CD1 lc+cells in the spleen of normal mice express markers identifying 
them as belonging to other cell lineages and how this may change in mice persistently 
infected with LCMV, CD1 lc+ cells were isolated from spleens of uninfected and mice 
infected 3 weeks previously with LCMV Arm or LCMV Cll 13 and were stained with 
anti-MHC-Class II FITC, anti-CDl lc-APC plus one of a panel of markers specific for 
a range of different lymphocyte subsets: CD3 (for T-cells), CD19 (for B-cells), CD14 
(for monocytes), DX5 (for NK cells), F4/80 (for macrophages) and pDCA-1 (for 
plasmacytoid DCs). Figure 4.6 shows the percentage of C D llc+, MHC class IIhlgh 
cells from each group of mice that also expressed the different lineage specific
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Figure 4.5 FACS plots of the gating scheme used to define the plasmacytoid and 
conventional DC subsets in isolated purified splenocytes
An example of the gating scheme used to identify the DC subsets is shown here using 
samples of lymphocytes isolated from pooled spleens from uninfected mice which 
were positively selected for C D llc expression. In some experiments, the isolated 
splenocytes were co-stained with mAbs to C D llc and pDCA-1 to identify the 
plasmacytoid DC population, while in other experiments, the splenocytes were co­
stained with mAbs to C D llc and B220+ to identify the plasmacytoid and 
conventional DC subsets on the basis of B220 expression. Dotplot A shows the 
forward and side scatter profile of the isolated splenocytes, with the R1 gate defining 
the live lymphocyte population. In dotplot B, R2 defines the C D llc+ lymphocytes 
within the R1 region, and in dotplot C, R3 defines the population of CD1 lclow pDCA-
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1+ plasmacytoid DCs that fall within the R2  and R1 region. In experiments where the 
cells were stained with C D llc and B220 antibodies, the plasmacytoid DCs, which 
possessed a CD1 lc low B220+ phenotype, was defined by the R4 gate in dotplot D and 
the conventional DC subset, which possessed a C D llchlgh B220' phenotype was 
defined by the R5 gate.
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Figure 4.6 The percentage of C D llc+ cells from uninfected animals and mice 
infected 3 weeks previously with LCMV which co-express non-DC markers
CD1 lc+ lymphocytes isolated by positive selection from pooled spleens of uninfected 
mice and LCMV-infected mice at 3 weeks post-infection with LCMV Arm or LCMV 
Cl 13 were stained with PE-conjugated mAbs to a range of lineage-specific markers, 
namely CD3 (T-cells), CD 19 (B-cells), CD 14 (monocytes), DX5 (NK cells) and 
F4/80 (macrophages). Cells were co-stained with CD 1 lc-APC and MHC-class II- 
FITC. The % of CD1 lc+, MHC-class II high cells expressing each non-DC marker is 
shown.
25-i
20-
8
O)
.E 15-
c
E
4 -1coo
£
DX5 F4/80CD3 CD19 CD14
260
markers. There were more non-DC C D llc+ MHC class IIhlgh cells in cell populations 
derived from the spleens of LCMV-infected mice: almost 40% CD1 lc+ cells from the 
spleens of mice persistently infected with LCMV had a non-DC phenotype. This is 
likely due to chronic activation of the immune system due to the continual presence of 
the virus systemically. B-cells made up the largest population of contaminating cells, 
comprising -16-20% of Class IIhlgh, C D llc+ cells in both the LCMV Arm and C113- 
infected mice. In LCMV C113-infected mice, a large percentage, 12.6% of C D llc+ 
MHC class IIhlgh cells were T-cells that had also upregulated CD llc. Monocytes, 
macrophages and NK cells were also present as contaminants but constituted a 
smaller percentage of the total C D llc+ MHC class IIhlgh population within both 
LCMV Arm and C113-infected mice. In light of this observation, in subsequent 
experiments in which DCs were enriched from persistently-infected animals, PE- 
conjugated CD3, CD19, F4/80 and DX5 antibodies were routinely included in order 
to enable exclusion of these contaminating cell types from the DC populations being 
analysed or sorted.
4.5.2 Changes in the numbers of plasmacytoid DCs and conventional DCs in 
the spleen over time following infection of mice with LCMV
In order to investigate whether the kinetic changes in type 1 IFN mRNA/activity 
levels observed in the spleen and serum following infection of mice with LCMV were 
associated with alterations in DC subset composition, the total number of 
plasmacytoid DCs and conventional DCs present in the spleen was determined in a 
series of timepoints after LCMV Arm or LCMV Cl 13 infection. CD1 lc+ cells isolated 
from spleens pooled from infected and uninfected mice were stained with antibodies 
to CD1 lc, B220 and pDCA-1 to allow identification of the DC subsets as well as a
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Figure 4.7 Numbers of C D llc+ pDCA-l+ and C D llc+ B220‘ cells in the spleen 
during the course of an acute or persistent LCMV infection
C D llc+ cells were isolated by positive selection from the spleens of groups of 10-20 
mice infected with LCMV Arm or LCMV Cl 13 at the indicated times post-infection. 
The isolated cells were stained with anti-CDl lc-APC, B220-FITC or pDCA-1-PE 
and the total number of C D llc+ pDCA-1+ and C D llc+ B220" cells per spleen was 
calculated The percentage of plasmacytoid DCs (B220+, C D llc low) and 
conventional DCs (B220\ C D llc high) in this fraction were determined by FACS 
analysis.. The values shown are the mean cell numbers obtained in 2-6 independent 
experiments, with the error bars indicating 1 standard error above the mean.
cocktail of PE-conjugated non-DC lineage markers (listed above), to exclude 
contaminating cells. Plasmacytoid DCs were identified as C D llc+ pDCA-l+ cells 
wihile conventional DCs were defined as C D llc+ B220’ cells. Figure 4.7 shows the 
number of plasmacytoid DCs and conventional DCs in the spleen of mice infected 
with LCMV Arm or LCMV Cl 13 at different timepoints up to 3 weeks post-infection. 
The number of C D llc+ pDCA-1+ DCs did not change appreciably during the first 
week following infection with LCMV Arm as previously observed in a study of mice 
infected i.p with LCMV Arm (Montoya et al. 2005). However, by 3 weeks post­
infection, the number of C D llc+ pDCA-l+ cells in the spleen was markedly reduced 
compared to total splenic CD1 lc+ pDCA-1+ DCs in uninfected mice. LCMV causes a 
profound depletion of bone marrow cells and this may be the reason for the fall in the 
numbers. Both bone marrow and splenic B-cell numbers for example, drop following 
i.p. infection of mice with LCMV Arm and do not recover until 3 weeks post­
infection (Borrow et al. 2005). As has been observed in mice infected i.p with 
LCMV Arm, the number of conventional (CD1 lc+ B220') DCs in the spleen begin to 
decline within a day of infection of mice with LCMV Arm and was markedly reduced 
compared to conventional DC numbers in uninfected mice by day 2 post-infection. 
The number of CD1 lc+ B220* cells present in the spleen on day 7 post-infection was 
slightly higher than in uninfected animals. This coincides with the peak of the 
expansion of activated T-cells (Moskophidis et al. 1987) which may also have 
upregulated C D llc+ as demonstrated in Figure 4.6. Anti-CD3 antibodies were added 
to the prep in order to exclude the contaminated T-cells, but it could be possible that 
the depletion was not complete due to the large numbers of activated T-cells at this 
timepoint (up to 43% of total splenocytes may be C D llc+ CD8+ T-cells (Lin et al. 
2003)), and so there is a likelihood that a proportion of the CD1 lc+ B220' cells in the
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LCMV Arm samples are actually activated T-cells and not conventional DCs. By 3 
weeks post-infection, the number of CD1 lc+ B220’ cells in the spleen had returned to 
normal. Again, the activated T-cell population may offer a possible explanation for 
this observation as expansion of the activated T-cell subset is followed by an 
apoptotic-mediated contraction phase that peaks about day 11 post-infection leading 
to a reduction in the T-cell numbers (Razvi and Welsh 1993). Thus the lower numbers 
of C D llc+ B220' at 3 weeks post-infection may actually reflect the true number of 
conventional DCs in the spleens of LCMV Arm-infected mice during the later 
timepoints of infection.
A similar trend was observed with the C D llc+ B220' DC subset after LCMV Cl 13- 
infection. The number of C D llc+ B220' DCs in the spleens of mice infected with 
LCMV Cl 13 dropped markedly by day 2 post-infection, increased somewhat by day 7 
post-infection and was again depressed at 3 weeks post-infection. One possible 
explanation for this observation may be that changes in the number of conventional 
DCs are being obscured by an increase in the number of non-DC contaminating the 
CD1 lc+ B220' population on day 7 and 3 weeks post infection as may have occurred 
in the LCMV Arm -infected samples at similar timepoints. However, the number of 
contaminating activated T-cells may be lower than that in LCMV Arm -infected mice 
because of the abortive T-cell response induced in LCMV Cl 13-infected mice, which 
results in lower numbers of activated CD1 lc+ T-cells being present in the spleen.
The splenic CD1 lc pDCA-1+ subset is less likely to be contaminated by non-DC cell 
types as they have been defined by a pDCA-1 marker specific for plasmacytoid DCs. 
The numbers of the CD1 lc+ pDCA-1+ population in the spleens of LCMV Arm mice 
did not change appreciably within the first 24 hours post-infection (Figure 4.7) and 
remained fairly stable over the first week post-infection, and were only depressed at 3
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weeks post-infection. In contrast, there was a more rapid and profound decrease in the 
numbers of splenic plasmacytoid DCs of mice infected with LCMV Cl 13, with the 
numbers being reduced relative to those in uninfected mice by day 2 post-infection, 
and remaining severely depressed at 3 weeks post-infection.
These results suggest that there were profound changes in the splenic DC numbers of 
mice following infection with LCMV Arm or LCMV Cl 13. Notably, mice persistently 
infected with LCMV Cl 13 experienced a sharp reduction in the numbers of 
plasmacytoid and conventional DCs present in the spleen. I would have liked to have 
conducted statistical analysis on the values (ANOVA General Linear Modal followed 
by Tukey’s pairwise comparison) to determined whether the difference between the 
total splenic numbers in uninfected and LCMV-infected mice infected 3 weeks 
previously was significantly different; however, I did not posses enough experimental 
replicates to do so.
4.5.3 Analysis of the activation status of DC subsets in persistently infected 
mice
To enable the phenotype activation status of the low numbers of plasmacytoid DCs 
and conventional DCs that were present in the spleen of mice persistently infected 
with LCMV Cl 13 to be addressed, C D llc+ cells were enriched from the spleens of 
groups of uninfected mice and mice infected 3 weeks previously with LCMV Cl 13, 
then a depletion step was carried out using biotinylated antibodies to appropriate 
lineage-specific markers to remove T cells, B cells and NK cells from the C D llc+ 
population. Depleted cells were subsequently stained with streptavidin PE to 
determine whether all the contaminating subsets had been removed. Figure 4.8 shows 
the results obtained in a typical experiment. Here, undepleted and depleted CD1 lc+
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Figure 4.8 The percentage of C D llc+ cells of different subsets from mice infected 
3 weeks previously with LCMV C113 that co-express non-DC markers after 
negative selection
CD1 lc+ lymphocytes isolated by positive selection from pooled spleens of uninfected 
(Unf) mice and mice infected 3 weeks previously with LCMV Cl 13 were depleted of 
C D llc+ cells expressing non-DC markers by staining with biotinylated mAbs to 
lineage-specific markers, CD3, CD 19 and DX-5, followed by depletion using 
streptavidin conjugated Dynalbeads. The proportion of cells co-expressing non-DC 
lineage markers which remained after depletion was determined by FACS analysis. 
Aliquots of the purified cells were stained with streptavidin-PE and the mAbs CD1 lc- 
APC plus one of the following FITC-conjugated DC subset markers: pDCA-1, CD4 
or CD8. The percentage of contaminating cells within each DC subset (CD1 lc+, DC- 
marked, PE+) cells, expressed as a percentage of all C D llc+, DC-marked cells is 
shown in the upper right quadrant of each dotplot. The results shown are 
representative of observations made in two independent experiments.
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cells were stained with antibodies to C D llc and either pDCA-1, CD4 or CD8a, in 
addition to the panel of lineage specific markers, so that C D llc+ pDCA-1+, C D llc+ 
CD8a+ and C D llc+ CD4+ DC subsets could be identified, and the proportion of 
contaminating cells in each subset evaluated. The level of contamination of C D llc+ 
pDCA-l+, C D llc+ CD8a+ and C D llc+ CD4+ populations from stained uninfected 
mice was relatively low, while there was more contaminating cells in the C D llc+ 
population from LCMV C113-infected mice, a subset of the PE+ cells were also 
positive for mPDCA-1 or CD4, indicating that the C D llc+ pDCA-1+ and 
C D llc+CD4+ subsets contained some contaminating non-DC cells, but the 
contamination was not as great as that observed in the CD1 lc+ CD8a+ subset, where a 
high proportion of PE-positive cells were present in the CD1 lc+ CD8a+ subset which 
meant that this subset was heavily contaminated with non-DC cells (likely activated 
CD8+ T-cells).
Experiments were then carried out in which C D llc+ cells were isolated from the 
spleens of groups of uninfected or LCMV-C113-infected mice, depleted of non-DCs 
by the method described above, and co-stained with antibodies to C D llc and either 
CD4, CD8 or pDCA-1 together with antibodies to the following phenotypic markers: 
MHC class I, MHC class II, CD86, CD80, CD40 and ICAM-1. The mean 
fluorescence intensities of the expression of the activation markers on DCs of each 
subset in uninfected and infected mice were compared (Figure 4.9). Expression of 
most of the markers examined was upregulated on CD1 lc+ mpDCA-1+ and CD1 lc+ 
CD4+ DC subsets, from mice infected 3 weeks previously with LCMV Cl 13, 
indicating these DCs were present in a heightened activation state. While C D llc+ 
pDCA-1+ DCs from infected mice had upregulated MHC and co-stimulatory markers, 
the level of activation marker expression on these cells was lower than that on the
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Figure 4.9 Phenotypic analysis of spleen DC subsets from mice persistently 
infected with LCMV C113
C D llc+ cells were purified from the spleens of groups of 6-10 uninfected mice and 
mice infected 3 weeks previously with 5xl06 p.f.u. of LCMV C113. Purified cells 
were depleted of non-DC cells and then stained to allow identification of the indicated 
spleen DC subsets and co-stained with mAbs against adhesion, co-stimulatory and 
MHC molecules. The results shown here are the relative level of expression (mean 
fluorescence intensity (MFI)) of ICAM-1, CD40, CD80, CD86, MHC class I and 
MHC class II, as indicated, on each DC subset. The results shown are representative 
of findings made in two independent experiments.
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C D llc+ CD4+ subset, in line with observations made in previous studies where 
plasmacytoid DCs have been shown to exhibit activation-associated phenotypic 
changes during acute viral infections (Dalod et al. 2003; Montoya et al. 2005) but was 
not induced to express as high a level of MHC and co-stimulatory molecules as 
conventional DCs. Notably, an elevation in surface expression of MHC class I, MHC 
class II, CD80, CD40 and ICAM-1 was not observed in the C D llc+ CD8a+ 
population from mice persistently infected with LCMV C113. However, given that 
>76% of the cells within this population were non-DC cell types, no conclusions can 
be drawn about the activation state of C D llc+ CD8a+ population from mice 
persistently infected with LCMV C113. In summary, these observations indicate that 
at least some of the DC subsets from the spleens of animals persistently infected with 
LCMV Cl 13 were activated to express elevated levels of MHC and co-stimulatory 
molecules upregulating expression of activation-associated markers in response to 
continual presence of high viral load.
4.6 Characterization of type 1 IFN production by DC subsets during acute 
and persistent phases of LCMV infection
Previous studies from experiments carried out using total splenic tissue and serum 
showed that there was not high level of type 1 IFN production during persistent 
LCMV infection but nonetheless indicated that elevated levels of IFN-p and IFN-a4 
were present in the spleen and serum of chronically infected animals. To gain insight 
into the roles of plasmacytoid DCs and conventional DCs in type 1 IFN production 
during the early and late phases of LCMV infection, a kinetic analysis of type 1 IFN 
mRNA levels in plasmacytoid DCs and conventional DCs isolated from the spleens of 
LCMV-infected mice was carried out. Pooled spleens from uninfected and mice
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infected with LCMV Arm or LCMV Cl 13 were lysed, then C D llc+ cells were 
positively selected and sorted by Mo-Flo into two subsets, C D llc+ B220+ 
(plasmacytoid DC) or C D llc+ B220' (conventional DC) populations. When samples 
from later timepoints (day 7 and 3 weeks) were processed, the CD1 lc+ cells were co­
stained with a cocktail of antibodies to T-cells, B-cells, macrophage and NK-cell 
markers so that cells of these lineages that had upregulated CD1 lc could be excluded 
from the sort. The number of cells of each sorted DC subset was determined and total 
RNA was extracted from an equal number of cells of each subset. The levels of IFN-P, 
IFN-a 4 and IFN-a (non-a 4) and Mx mRNA in each sample were then determined by 
quantitative real time Taqman RT-PCR. As shown in Figure 4.10 A, B, and C, type 1 
IFN transcripts were strongly upregulated in the C D llc+ B220+ plasmacytoid DC 
subset within 12 hours of infection of mice with LCMV Arm or LCMV Cl 13, and 
also some type 1 IFN mRNA upregulation was recorded in the C D llc+ B220‘ 
conventional DC population, although not as marked an increase as occurred in 
plasmacytoid DCs. Type 1 IFN mRNA levels in plasmacytoid DCs were at their 
maximum at 12 hours post-infection, declining by day 1 post-infection and returning 
to baseline between days 2 and day 7 post-infection. The kinetics of type 1 IFN 
mRNA upregulation in the conventional DC population was somewhat slower, 
reaching their maximum on day 1 post-infection and then declining again between 
days 2 and 7 post-infection. There was no appreciable difference in type 1 IFN 
mRNA upregulation in plasmacytoid DCs/ conventional DCs in the acute phase of 
infection with LCMV Arm or LCMV C113. In mice infected with LCMV Arm, IFN-p 
and IFN-a4 mRNA levels in both plasmacytoid DCs and conventional DCs were 
below the limit of detection by 3 weeks post-infection, but during the persistent phase 
of infection, only the CD1 lc+ B220+ plasmacytoid DC subset continued to secrete a
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Figure 4.10 Type 1 IFN and Mx mRNA levels in plasmacytoid DC and 
conventional DC subsets during the acute and persistent phases of LCMV 
infection (figure continued on the following page)
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Figure 4.10 (continued) Type 1 IFN and Mx levels in plasmacytoid DC and 
conventional DC subsets during the acute and persistent phases of LCMV 
infection
Plasmacytoid DCs (B220+, C D llc low) and conventional DCs (B220\ CD llc high) 
were isolated from the spleens of groups of 10-20 mice infected with LCMV Arm or 
LCMV C113, and levels of EFN-ft a-4, o(non-Qf4) subtypes and Mx mRNAs within 
these DC subpopulations were assessed by quantitative real-time RT-PCR. The results 
are expressed as ACt, where the level of the target gene in each isolated subset is 
normalized relative to the HPRT housekeeping control. The results shown are 
representative of values obtained in at least 2 independent experiments conducted for 
each timepoint. Pooled spleens from uninfected mice were analysed in parallel at 
every timepoint, and the level at 0 hr post infection reflects the maximal ACt value 
detected in the uninfected controls from these multiple experiments. The IFN-o4 
mRNA levels in DC subpopulations isolated from uninfected control mice were 
below the limit of detection, (n.d indicates that no mRNA was detected).
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low level of IFN-p mRNA (albeit at a level below that observed in this DC subset in 
uninfected mice). Notably, IFN-p mRNA levels in total splenic tissue of persistently 
infected mice were higher than those in the spleen of the uninfected mice (Figure 4.3), 
suggesting that a cell type other than pDCs or cDCs may constitute the main source of 
type 1 IFN production in mice persistently infected with LCMV C113. The elevation 
of Mx mRNA levels in LCMV Arm and LCMV Cl 13 infected mice occurred between 
12- 24 hours post-infection (Figure 4.10 D) consistent with it being an IFN-responsive 
gene, the kinetics of upregulation of which would be expected to be delayed relative 
to those of type 1 IFN mRNA upregulation. As observed for type 1 IFN subtypes, 
maximal Mx expression occurred in the acute phase of infection with LCMV Arm or 
LCMV Cl 13 and Mx mRNA levels returned to baseline by day 7 post-infection, 
remaining low during the persistent phase of LCMV infection.
4.6.1 Analysis of LCMV RNA levels in plasmacytoid and conventional DC 
populations from LCMV-infected mice
An important inducer of type 1 IFN production in cells is viral RNA; most cells are 
able to respond to the presence of viral RNA in the cytoplasm while DC subsets have 
the ability to detect the presence of viral nucleic acids in their external environment 
via expression of TLR 3/7 or 9. To gain insight into the levels of LCMV RNA 
associated with DC subsets (due to association of virion nucleic acids with these cells), 
real-time Taqman quantitative RT-PCR analysis was conducted on RNA extracted 
from plasmacytoid and conventional DC subsets isolated from the spleens of mice at 
different times following infection with LCMV Arm or LCMV C113, using primers 
that detected genome-sense LCMV NP RNA. As shown in Figure 4.11, similar levels 
of LCMV RNA were found to be associated with plasmacytoid DCs (CD1 lc+ B220+)
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Figure 4.11 Levels of LCMV RNA in splenic plasmacytoid DC and conventional 
DC subsets of LCMV-infected mice during acute and chronic phases of LCMV 
infection
Plasmacytoid DCs (B220+, C D llc low) and conventional DCs (B220', CD 11c high) 
were isolated from the spleens of groups of 10-20 mice infected with LCMV Arm or 
LCMV Cl 13 and the level of genome-sense LCMV NP RNA within these DC 
subpopulations was assessed by quantitative real-time RT-PCR. The results are 
expressed as ACt, where the level of the target gene in each isolated subset is 
normalized relative to the HPRT housekeeping control. The results shown are 
representative of values obtained in at least 2 independent experiments conducted for 
each timepoint. n.d indicates the level in the sample was below the limit of detection.
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and conventional DCs (CD llc+ B220‘) cell subsets from mice infected with LCMV 
Arm and LCMV Cl 13 on day 1 post-infection. In the LCMV Arm-infected mice, DC- 
associated viral RNA levels had declined slightly by day 7 post infection and was 
below the limit of detection by 3 weeks post-infection. By contrast, high levels of 
viral RNA were associated with DC subsets isolated from LCMV C113-infected mice 
on day 7 and 3 weeks post-infection (although the levels present at the later 
timepoints were slightly lower than those present on day 7). From these experiments, 
it can be concluded that type 1 IFN production was induced very rapidly in 
plasmacytoid DCs, and with somewhat slower kinetics in conventional DCs following 
infection of mice with LCMV Arm or LCMV Cl 13; however, high levels of type 1 
IFN mRNA expression in these DC subsets was not sustained but was quickly 
downregulated, and remained low/undetectable in mice persistently infected with 
LCMV C113, despite constant exposure of these cells to viral LCMV RNA which was 
found to be associated with both DC subsets.
4.7 Confocal staining of spleen sections from acute and persistently infected 
mice
As stated above, type 1 IFN can be triggered in response to a cell becoming infected, 
or can be triggered by specialised cell subsets, including plasmacytoid DCs, that are 
able to detect the presence of pathogen components in their environment. To gain 
insight into whether type 1 IFN was predominantly produced by infected or 
uninfected cells in LCMV-infected mice, sections of spleen from mice infected with 
LCMV Arm or LCMV Cl 13 were co-stained with antibodies to IFN-a and LCMV-NP. 
The sections were also co-stained with the plasmacytoid-specific antibody pDCA-1, 
to enable the level of infection of plasmacytoid DCs in LCMV-infected mice and the
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Figure 4.12 (continued) Immunofluorescent staining to identify IFN-a producing cells, LCMV-infected cells and plasmacytoid DCs in the 
spleens of LCMV-infected mice during the acute and persistent phases of infection
Cryosections from the spleens of uninfected mice and mice infected with LCMV Arm or Cl 13 12 hours or 4 weeks previously were fixed and serially 
stained with the mAbs IFN-a-FITC, LCMV-NP-Cy5 and mpDCA-1 -biotin followed by streptavidin-Tyr-Alexa 594 to enable identification of IFN-a 
producing cells (green), LCMV-infected cells (blue) and plasmacytoid DCs (red). Overlapping of IFN-a and plasmacytoid DCs staining produces a 
yellow overlay, IFN-a and LCMV-NP113 co-staining results in a pale blue colour, LCMV-NP113 and plasmacytoid DC co-localisation results in a
NP113 pDCA-1 IFN-a O verlay
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Figure 4.12 Imm unofluorescent staining to identify IFN-a producing cells, LCMV-infected cells and plasmacytoid DCs in the spleens of 
LCMV-infected mice during the acute and persistent phases of infection (figure continued on the following page)
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a white colour, as shown in the colour key. Appropriate isotype-matched control reagents were also tested. Images were captured at lOx 
magnification.
number of plasmacytoid producing IFN-a at different stages of the infection to be 
determined in parallel.
Spleens were excised, flash frozen and cryosectioned into 5pm sections and stained 
with IFN-a-FITC (green), LCMV-NP113-Cy5 (blue) and pDCA-1-biotin, followed 
by streptavidin-HRP and Tyr-594 substrate (red) to visualize IFN-a-producing, 
LCMV-infected and pDC cells in the spleen respectively. Staining of sections from 
uninfected mice revealed that plasmacytoid DCs were present in concentric patterns 
consistent with their reported location in the marginal zone (Figure 4.12). Staining of 
sections taken from the spleen of LCMV Arm and LCMV C113-infected mice at 12 
hours post-infection indicated that pDCA-1 expression had been upregulated on the 
pDC surface by this time, possibly indicative of plasmacytoid DC activation. This was 
particularly evident in the mice infected with LCMV Arm but was also observed in 
LCMV Cl 13-infected mice (although this is not obvious in the section shown in 
Figure 4.12). Further evidence of plasmacytoid DC activation at the timepoint in mice 
infected with both LCMV Arm and LCMV Cl 13 is shown in Figure 4.13, which 
illustrates FACS analysis profiles of the forward and side scatter of isolated CD1 lc+ 
pDCA-1+ DCs from uninfected and infected mice: the cells from both groups of 
infected mice are enlarged and have increased in granularity. Many LCMV-infected 
cells were found to be present around the splenic marginal zones at 12 hours 
following infection of mice with LCMV Arm or LCMV C113. Notably a huge 
proportion of these appeared to be plasmacytoid DCs, as evidenced by co-localisation 
of NP113 and pDCA-1 staining in the overlay (magenta). IFN-a producing cells were 
also observed around the splenic marginal zones. Some of these were cell types other 
than plasmacytoid DCs which were not infected LCMV (green in the overlaid image) 
- but there was also evidence of type 1 IFN production by plasmacytoid DCs despite
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Figure 4.13 The morphology of C D llc+ pDCA-l+ cells from mice infected with 
LCMV
The forward and side scatter patterns of C D llc+ pDCA-1+ cells from uninfected or 
infected animals are shown. Groups of 6-10 mice were infected with LCMV Arm or 
LCMV C113 as previously described. At 24 hours post-infection, C D llc+ pDCA-l+ 
cells from the spleen were isolated, stained and analysed by FACS. CD1 lc+ pDCA-l+ 
cells were defined from the total cell population and the scatter profile of the gated 
cells were compared to determine whether infection with LCMV activates and alters 
the morphology of splenic C D llc+ pDCA-1+ cells. The results shown are 
representative of two experiments performed.
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the fact that many of these cells were infected (cells co-staining for pDCA-1, IFN-a 
and LCMV-NP appear white in the images). At 4 weeks after infection of mice with 
LCMV C113, the numbers of plasmacytoid DCs present in the spleen was reduced. A 
proportion of these plasmacytoid DCs were infected with LCMV (magenta in the 
overlaid image). The number of IFN-a -producing cells was also reduced, but 
nonetheless some cells were producing IFN-a at this timepoint. Some of the IFN-a 
producing cells did not appear to be plasmacytoid DCs, but there were some which 
were plasmacytoid DCs. There was also very little co-localisation of IFN-a and 
NP113 staining, indicating that the majority of IFN-a producing cells were not 
infected with LCMV. However, a low number of LCMV Cl 13-infected IFN-a 
producing pDCA-1+ plasmacytoid DC (white in the overlaid image) were observed in 
the spleen at this time.
There are some caveats to this analysis, firstly, NP is a virion structural protein, and 
hence the presence of NP may not necessarily be indicative of infection but may be 
the result of bound or endocytosed virions. However, given the widespread nature and 
intensity of cytoplasmic NP113 staining observed and the relatively small quantities 
of NP present within a virion, it is more likely that the NP113 staining seen in these 
experiments is reflective of LCMV infection of the NP positive cells. Secondly, NP 
expression may not have reached detectable levels in newly infected cells, hence it is 
possible that a higher proportion of plasmacytoid DCs and/or IFN-a producing cells 
may have been infected with virus than were detected in this experiment Thirdly, as 
the IFN-a monoclonal antibody used here only recognizes the IFN-a subtypes, these 
experiments do not provide any information on IFN-|3 production. Furthermore, 
because both the anti-IFN-a and the pDCA-1 antibodies were both rat monoclonals, 
the antibodies had to be applied in a step-wise manner, beginning with the anti-IFN-a
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mAb and then the anti-rat-FITC, followed by the biotinylated anti-PDCA-1 and 
finally streptavidin-Tyr and the anti-NP-113 Cy5. Therefore, it can not be ruled out 
that steric hindrance from the anti-IFN-a or pDCA-1 antibodies may have prevented 
attachment of subsequent antibodies to the same cell. And finally, these experiments 
do not provide any information on the identity of the other IFN-a producing cells. 
Nonetheless, these experiments provide an insight into the cellular sources of type 1 
IFN production in LCMV-infected mice, suggesting that in both the acute and chronic 
phases of infection, IFN-a is produced by uninfected cells that are not plasmacytoid 
DCs, and by a subset of plasmacytoid DCs, a subset of which appear to be infected.
4.8 Type 1 IFN production in persistently infected mice in response to 
exogenous stimulation with innate stimuli
Previous experiments showed that there is very little type 1 IFN expression in the 
spleen and serum of persistently infected mice, despite the presence of ongoing 
replication. To determine whether mice persistently infected with LCMV retained the 
capacity to respond to exogenous type 1 IFN-inducing stimuli, uninfected and LCMV 
C113-infected mice were inoculated i.p with ligands for TLR3 (polylC) TLR7 (R848), 
TLR9 (CpG 1826 DNA) or with influenza PR8 which would activate TLR7 and/or 
the intracellular infection sensing pathway (Diebold et al. 2004; Prakash et al. 2005), 
and type 1 IFN and Mx mRNA levels in the spleen and type 1 IFN activity in the 
serum monitered at a series of timepoints thereafter.
4.8.1 PolylC stimulation
In both uninfected mice and LCMV C113-infected mice, inoculation of the TLR3 
ligand polylC induced upregulation of all type 1 IFN mRNA subtypes in the spleen,
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Figure 4.14 Type 1 IFN mRNA induction and serum type 1 IFN levels in persistently infected mice following inoculation with polylC
IFN-/?, IFN-a4, IFN-g: (non-o4) subtype and Mx mRNA levels in the spleens of uninfected mice and mice persistently infected with LCMV Cl 13 
were assessed by real-time quantitative RT-PCR at the indicated timepoints after i.p. injection of 5pg of the TLR3 ligand polylC. The results
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have been normalized against the house-keeping gene HPRT by calculating the ACt (Cthprt -  Cttarget) values. In cases where no target transcript 
was detected (e.g IFN-o4 in the uninfected 0 hour sample) a Ct value of -14.35 was set, this being the smallest ACt value for the quantity of 
template RNA used. Samples were tested in duplicate; values shown are the mean of the mean ACt values from a total of 6 mice per group for 
the 0 hour timepoint and 9 mice per group at subsequent timepoints, with the error bars depicting one standard error above the mean. Blood 
samples were also collected from all animals and the levels of type 1 IFN activity in the serum were measured by EMCV antiviral bioassay. The 
values shown are the mean of all the mice analysed at each timepoint (6 per group at time 0 and 9 per group at subsequent timepoints), with the 
error bars indicating one standard error above the mean.
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with maximal type 1 IFN mRNA levels being reached by 6 hours post-infection and 
levels remaining elevated at 24 hours post-stimulation (Figure 4.14). The levels of 
bioactive type 1 IFN present in the serum mirrored this finding. There was no 
appreciable difference in the levels of type 1 IFN mRNA in the spleen or activity 
present in the blood of uninfected and LCMV C113-infected mice at 6, 12 or 24 hours 
post-stimulation. However, the uninfected mice upregulated type 1 IFN production to 
a greater extent than the infected animals as the baseline levels of IFN-p, -a4, -a (non- 
a4) transcripts were low or undetectable in the spleen of uninfected mice, while 
infected spleens contained pre-existing elevated levels of all the type 1 IFN-subtypes 
and low levels of type 1 IFN activity could be detected in the serum of LCMV Cl 13- 
infected but not uninfected mice prior to inoculation of polylC. Notably, Mx mRNA 
levels in the spleen of uninfected mice were found to be appreciably higher than those 
in infected mice at up to 24 hours post-stimulation possibly due to the greater increase 
in type 1 IFN production that occurred in the uninfected animals.
4.8.2 R848 stimulation
Inoculation of the TLR7 ligand R848 induced a very similar type 1 IFN expression in 
the spleen and blood of uninfected and infected mice (Figure 4.15). Notably, there 
was no appreciable difference in the levels of type 1 IFN mRNA present in the spleen 
or of type 1 IFN activity present in the serum of uninfected and infected mice at 6, 12 
or 24 hours following R848 inoculation. However, as with polylC, the extent of 
upregulation of type 1 IFN mRNA/activity was lower in infected than in uninfected 
mice, as the infected mice had pre-existing levels of type 1 IFN mRNA/activity. In 
association with this, Mx mRNA levels in the spleen of uninfected mice were again 
significantly higher than those in infected mice at 24 hours post-stimulation.
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Figure 4.15 Type 1 IFN mRNA induction and serum type 1 IFN levels in persistently infected mice following inoculation with R848
IFN-/3, IFN-o4, IFN-a (non-a4) subtype and Mx mRNA levels in the spleens of uninfected mice and mice persistently infected with LCMV Cl 13 
were assessed by real-time quantitative RT-PCR at the indicated timepoints after i.p injection of 25nmoles of the TLR7 ligand R848. The results
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have been normalized against the house-keeping gene HPRT by calculating the ACt (Cthprt -  Cttarget) values. In cases where no target transcript 
was detected (e.g IFN-o4 in the uninfected 0 hour sample) a Ct value of -14.35 was set, this being the smallest ACt value for the quantity of 
template RNA used. Samples were tested in duplicate; values shown are the mean of the mean ACt values from a total of 6 mice per group for 
the 0 hour timepoint and 9 mice per group at subsequent timepoints, with the error bars depicting one standard error above the mean. Blood 
samples were also collected from all animals and the levels of type 1 IFN activity in the serum were measured by EMCV antiviral bioassay. The 
values shown are the mean of all the mice analysed at each timepoint (6 per group at time 0 and 9 per group at subsequent timepoints), with the 
error bars indicating one standard error above the mean.
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4.8.3 CpG 1826 DNA stimulation
Inoculation of the TLR9 ligand CpG 1826 DNA induced a type 1 IFN response in 
both uninfected and infected mice that was similar to that induced by polylC and 
R848, but was of slightly lower magnitude (Figure 4.16). Once again, however, there 
was no significant difference in spleen type 1 IFN mRNA levels or serum IFN activity 
in infected and uninfected mice at the 6, 12 or 24 hour timepoints, although the extent 
of upregulation was smaller in LCMV-infected mice which had already low pre­
existing levels of type 1 IFN than in uninfected animals.
4.8.3 Influenza PR8 stimulation
Intraperitoneal inoculation of influenza virus into mice introduces the virus into the 
peritoneal cavity, from which some systemic spread of virions occur. When influenza 
virus PR8 is introduced to mice via this route, viral entry into cells and a single round 
of replication can occur, but not subsequent spread of viral infection as virion 
infectivity is
dependent on the activity of host proteases that are not expressed systemically (Kido 
et al. 1999). The presence of infection could be detected via a range of receptors, 
including TLRs and intracellular pathways for stimulation of type 1 IFN production. 
Uninfected mice generated a large type 1 IFN response following inoculation of 
influenza virus (Figure 4.17). Peak type 1 IFN mRNA levels in the spleen and activity 
levels in the blood which were reached at 6-12 hours post-infection (slightly later than 
following inoculation of synthetic TLR ligands), were higher than those reached in 
mice inculated with TLR ligands and levels still remained high at 24 hours post- 
inculation. Notably however, there was only a slight upregulation of type 1 IFN 
mRNA expression in the spleen of LCMV C113-infected mice following inoculation
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Figure 4.16 Type 1 IFN mRNA induction and serum type 1 IFN levels in persistently infected mice following inoculation with CpG 1826
DNA (legend on the following page)
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IFN-/3, IFN-q4, IFN-a (non-a4) subtype and Mx mRNA levels in the spleens of uninfected mice and mice persistently infected with LCMV Cl 13 
were assessed by real-time quantitative RT-PCR at the indicated timepoints after i.p. injection of 20nmoles of the TLR9 ligand CpG 1826 DNA. 
The results have been normalized against the house-keeping gene HPRT by calculating the ACt (Cthprt -  Cttarget) values. In cases where no target 
transcript was detected (e.g IFN-o4 in the uninfected 0 hour sample) a Ct value of -14.35 was set, this being the smallest ACt value for the 
quantity of template RNA used. Samples were tested in duplicate; values shown are the mean of the mean ACt values from a total of 6 mice per 
group for the 0 hour timepoint and 9 mice per group at subsequent timepoints, with the error bars depicting one standard error above the mean. 
Blood samples were also collected from all animals and the levels of type 1 IFN activity in the serum were measured by EMCV antiviral 
bioassay. The values shown are the mean of all the mice analysed at each timepoint (6 per group at time 0 and 9 per group at subsequent 
timepoints), with the error bars indicating one standard error above the mean.
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Figure 4.17 Type 1 IFN mRNA induction and serum type 1 IFN levels in persistently infected mice following inoculation with influenza 
virus strain PR8 (legend on the following page)
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IFN-/3, IFN-q4, IFN-q; (non-o4) subtype and Mx mRNA levels in the spleens of uninfected mice and mice persistently infected with LCMV Cl 13 
were assessed by real-time quantitative RT-PCR at the indicated timepoints after i.p injection of 800 HA units of the innate stimuli influenza 
strain PR8. The results have been normalized against the house-keeping gene HPRT by calculating the ACt (Cthprt -  Cttarget) values. In cases 
where no target transcript was detected (e.g IFN-o4 in the uninfected 0 hour sample) a Ct value of -14.35 was set, this being the smallest ACt 
value for the quantity of template RNA used. Samples were tested in duplicate; values shown are the mean of the mean ACt values from a total 
of 6 mice per group for the 0 hour timepoint and 9 mice per group at subsequent timepoints, with the error bars depicting one standard error 
above the mean. Blood samples were also collected from all animals and the levels of type 1 IFN activity in the serum were measured by EMCV 
antiviral bioassay. The values shown are the mean of all the mice analysed at each timepoint (6 per group at time 0 and 9 per group at 
subsequent timepoints), with the error bars indicating one standard error above the mean
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Figure 4.18 Levels of influenza virus RNA in spleens of uninfected and LCMV 
C113-infected mice following inoculation with influenza strain PR8
Uninfected (Unf) and LCMV C113-infected mice (at 3 weeks post-infection) were
injected i.p. with 800 HA units of influenza virus strain PR8. At the indicated 
timepoints, 3 mice per group were sacrificed and their spleens removed for analysis. 
The level of influenza virus RNA that was in the spleen was determined by 
quantitative real-time RT-PCR using primers specific for the influenza A RNA 
genome. The results are expressed as ACt, i.e, the level of influenza virus RNA has 
been normalized relative to the housekeeping gene HPRT. Each point on the chart 
represents the influenza ACt value of a single mouse. The results from 3 independent 
experiments using 3 mice per group per timepoint are depicted. No influenza virus
293
RNA was detected in the spleens of uninfected or Cl 13-mice that were not inoculated 
with influenza virus.
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with influenza vims and semm levels of type 1 IFN activity in these mice were 
appreciably lower than those in uninfected mice at all post-inculation timepoints. Mx 
levels in LCMV Cl 13 infected mice also remained unchanged over time, in contrast to 
the strong Mx upregulation in uninfected controls. Influenza viral RNA was detected 
from total RNA preps of the spleen by quantitative Taqman qRT-PCR. Higher levels 
of influenza PR8 transcripts were present in the total RNA of uninfected spleen when 
compared with the levels detected in LCMV Cl 13 infected splenic cells.
Persistently infected mice may have a pre-existing anti-viral state that makes them 
resistant to subsequent viral infection. To investigate whether the poor type 1 IFN 
induction observed following i.p. inoculation of influenza PR8 into LCMV Cl 13- 
infected mice was associated with failure of influenza vims to infect the spleen of 
these animals, the levels of influenza viral RNA in the spleen of uninfected and 
LCMV Cl 13-infected animals were determined at different times post-infection. 
Analysis by real time quantitative RT-PCR indicated that influenza PR8 genomic 
material could be detected in the spleen of LCMV C113-infected mice (Figure 4.18), 
although the levels present were lower than those observed in uninfected mice at all 
timepoints tested. The PCR primers here would have detected both input influenza 
vims RNA and genomic-sense RNA generated in infected cells. The relatively low 
influenza vims RNA levels observed in the spleen of LCMV Cl 13-infected mice may 
thus have reflected reduced virion trapping in the spleen and/or impaired viral 
replication in the spleen of these animals. This likely contributed to the low type 1 
IFN response in these animals.
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4.9 The level of inflammatory cytokines in persistently infected mice after 
stimulation with innate stimuli
Viral infection and innate stimuli induce production of many other cytokines in 
addition to type 1 IFNs. To gain insight into the effect of a persistent LCMV infection 
on the levels and pattern of production of other cytokines elicited following i.p. 
inoculation of polylC, CpG 1826 DNA, R848 or influenza PR8, blood collected from 
uninfected and persistently infected mice at 6 hours post-stimulation and serum levels 
of the inflammatory cytokines IL-12p70, TNF-a and IFN-y as well as IL-10, IL-6 and 
the chemotactic factor MCP-1 were measured by CBA assay. Initial experiments 
measured the levels at 6, 12 and 24 hours post-stimulation, but the 6 hour timepoint 
was selected as it was the timepoint with the highest level of upregulation.
The results obtained are shown in Figure 4.19. Prior to stimulation, only low or 
undetectable amounts of all the factors were present in the serum of both uninfected 
and LCMV C113-infected mice. Administration of polylC, R848 and influenza to 
uninfected mice induced very little or no production of IL-12, IFN-y or TNF-a at 6 
hours post-inoculation, although a moderate elevation in serum levels of all 3 
cytokines was observed following i.p. inoculation of CpG1826 DNA. Notably mice 
that were persistently infected with LCMV produced lower amounts of bioactive IL- 
12p70 and IFN-y upon CpG 1826 DNA inoculation than their uninfected counterparts; 
but they produced higher levels of TNF-a. Administration of polylC and R848 into 
persistently infected mice also induced an upregulation of TNF-a levels in the serum, 
which was not observed in uninfected animals inoculated with these TLR ligands.
TLR ligands also elicited production of higher levels of IL-10 and IL-6 in LCMV- 
infected mice than were induced in uninfected animals.
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Figure 4.19 Levels of inflammatory cytokines induced in uninfected mice and 
mice persistently infected with LCMV C113 in response to TLR stimuli or 
influenza virus
Uninfected mice and mice persistently infected with LCMV Cl 13 (at 3 weeks post­
infection) were inoculated with 5/zg polylC, 20nmoles CpG 1826, 25nmoles R848 or
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800HA units influenza virus strain PR8, all delivered i.p. in 200|il PBS. Serum was 
collected at 6 hours post-stimulation and the levels of IL-12, IFN-y TNF-a, IL-10, IL- 
6 and MCP-1 induced in response to different TLR stimuli were measured by 
cytokine bead assay. The values shown are the mean of results from 3 independent 
experiments, comprising a total of 3-9 mice per group for each treatment. The error 
bars indicate one standard error above the mean.
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PolylC, R848 and CpG DNA all stimulated an increase in serum IL-6 levels in 
uninfected animals, and CpG DNA and to a lesser extent R848 also elicited 
production of very low levels of IL-10. These responses were all enhanced in LCMV 
C113-infected mice. I.p injection of influenza PR8 did not induce upregulation of IL6 
or IL-10 in the serum of either groups of mice at the 6 hour timepoint.
In summary, there were qualitative differences in the pattern of cytokine production 
elicited by the TLR ligands in uninfected and persistently infected mice. Interestingly, 
the cytokine profile of persistently infected mice appeared to be skewed towards 
expression of TNF-a, IL-6 and IL-10 while production of IL-12 and IFN-y was 
reduced.
4.10 Confocal staining of spleen sections of persistently infected mice after 
inoculation of innate stimuli
It was unclear which cells in the spleen were secreting type 1 IFN in response to 
stimulation with polylC, CpG 1826 DNA, R848 or influenza PR8. In uninfected mice, 
splenic pDCs are reported to express high levels of TLR7 and TLR9 and produce 
large amounts of type 1 IFN in response to these stimuli, while other DC subsets, 
principally the CD8a+ DC subset are better adapted to recognize and respond to TLR3 
ligands (Schulz et al. 2005). To investigate the role of plasmacytoid DCs versus other 
cell types in type 1 IFN production in response to different TLR stimuli in mice 
persistently infected with LCMV and to determine the contribution made by LCMV 
infected and uninfected cells to type 1 IFN production, uninfected and mice 
persistently infected mice inoculated for 6 hours previously with innate stimuli were 
subjected to immunohistochemical analysis as described in section 2.1.1.2 to visualize
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pDCA-1 plasmacytoid DCs (red), IFN-a expressing cells (green) and LCMV-infected 
cells (blue). Figure 4.20 shows images in which all three colours have been overlaid.
In uninfected mice, multiple IFN-a producing cells were observed in the spleen of 
animals given each of the innate stimuli. In CpG, R848 and influenza-inoculated 
animals, many (although not all) of the IFN-a producing cells appeared to be 
plasmacytoid DCs (yellow or bright green). Not all plasmacytoid DCs were producing 
IFN-a at this timepoint. By contrast, the majority of IFN-a producing cells in polylC- 
stimulated mice were not plasmacytoid DCs, but were cells around the outside of the 
marginal zone. These observations are consistent with published reports that 
plasmacytoid DCs express high levels of TLR7 (a receptor for R848 and influenza 
viral RNA) and TLR9 (a ligand for CpG), whilst other DC subsets, including CD8a+ 
DCs, which are located around the marginal zone in the resting spleen express high 
levels of TLR3 (which recognize polylC) (Edwards et al. 2003).
As observed in previous experiments (Figure 4.12), reduced numbers of plasmacytoid 
DCs were present in the spleen of mice persistently infected with LCMV C113. A 
proportion of these plasmacytoid DCs were infected with LCMV Cl 13 (magenta), but 
not all infected cells were plasmacytoid DCs. Inoculation of polylC, R848, CpG and 
influenza virus into LCMV Cl 13-infected mice resulted in an increase in the number 
of IFN-a producing cells in the spleen, although the increase was less marked than 
that observed in uninfected mice, consistent with the results of type 1 IFN mRNA 
analysis in Figures 4.14 -  4.17. As in uninfected mice, the majority of cells induced to 
produce IFN-a following inoculation
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Figure 4.20 Immunofluorescent staining to identify IFN-a producing cells, LCMV- 
infected cells and plasmacytoid DCs in spleens from  mice persistently infected with 
LCMV C113 after inoculation of innate stimuli (legend on following page)
Cryosections from the spleens of uninfected mice and mice infected LCMV Cl 13 (at 3 
weeks post-infection) and stimulated for 6 hours with 5 [xg polylC, 20 nmoles 
CpG1826 DNA, 25 nmoles R848 or 600 HA units of influenza PR8 were fixed and 
serially stained with the mAbs IFN-Of-FITC, LCMV-NP-Cy5 and pDCA-1-biotin 
followed by streptavidin-Tyr-Alexa 594 to enable identification of IFN-a producing 
cells (green), LCMV-infected cells (blue) and plasmacytoid DCs (red). Overlapping 
of IFN-a and plasmacytoid DCs staining produces a yellow overlay, IFN-a and 
LCMV-NP113 co-staining results in a pale blue colur, LCMV-NP113 and 
plasmacytoid DC co-localisation results a magenta overlay, while an overlay of IFN-a, 
LCMV-NP113 and plasmacytoid DC stainings result in a white colour, as shown 
below. Appropriate isotype-matched control reagents were also tested. Images were 
captured at lOx magnification.
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of polylC into Cl 13-infected mice were not plasmacytoid DCs, whereas at least a 
proportion of the cells responding to R848, CpG DNA and influenza virus inoculation 
by production of type 1 IFN were plasmacytoid DCs (yellow) or infected 
plasmacytoid DCs (white).
In summary, these results confirm the ability of mice persistently infected with 
LCMV to upregulate type 1 IFN production in response to inoculation of ligands for 
TLR 3, 7 and 9, and (less efficiently) influenza virus. Further more, they show that 
despite the fact that a proportion of plasmacytoid DCs in persistently infected mice 
are infected with LCMV, plasmacytiod DCs in these animals still participate in the 
type 1 IFN response elicited by TLR 7/9 ligands; and furthermore suggest that 
LCMV-infected plasmacytoid DCs retain the capacity to produce type 1 IFN in 
response to exogenous stimuli. Notably however, there was no evidence of type 1 IFN 
production by LCMV-infected cells other than plasmacytoid DCs at the timepoint 
(which would have appeared pale blue in the overlaid image).
4.11 Levels of type 1 IFN produced by ex-vivo C D llc+ DCs after stimulation 
with TLR ligands
Results in Figure 4.14-4.17 and Figure 4.20 indicated that the extent to which type 1 
IFN production was upregulated in response to TLR ligands in persistently infected 
mice was lower than that in uninfected mice. DCs play a key role in type 1 IFN 
production in response to inoculation of TLR ligands (Asselin-Paturel et al. 2001; 
Diebold et al. 2003) and DC numbers in persistently infected mice were reduced 
(Figure 4.7 and 4.20), suggesting that the impairment in mice persistently infected 
with LCMV Cl 13 may be in part due to a reduction in the number of responding cells. 
To investigate whether there was also an impairment in the ability of those DC
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present in persistently infected mice to respond to TLR stimuli by production of type 
1 IFN, CD1 lc+ DCs were isolated from the spleens of uninfected or mice persistently 
infected with LCMV Cl 13 by positive selection followed by depletion of 
contaminating C D llc+ lymphocytes as previously described. Isolated, depleted ex 
vivo DCs were stimulated with polylC, R848 or CpG 1826 DNA and type 1 IFN 
activity in the supernatant was analysed after an overnight incubation (Figure 4.21). 
C D llc+ DCs from persistently infected mice were found to produce type 1 IFN in 
response to all the TLR stimuli tested, although the levels produced by these cells 
were reduced compared to DCs from uninfected mice. Statisical analysis using the 
one-sample t-test showed a significant difference between levels of type 1 IFN in 
uninfected and LCMV-infected mice after inoculation with polylC (p=0.03), R848 
(p=0.05) and CpG DNA (p=0.03).
It was unclear whether the reduced type 1 IFN levels in the supernatant of TLR 
stimulated DCs from persistently-infected mice reflected a reduced capacity of these 
cells to respond to TLR ligation by type 1 IFN production and or reduced survival of 
these cells, which were shown to be phenotypically activated (Figure 4.8) in vitro. 
However, this result demonstrates that CD1 lc+ DCs from LCMV Cl 13-infected mice 
still retained the capacity to respond to the presence of external TLR stimuli.
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Figure 4.21 Levels of type 1 IFN produced by C D llc+ DCs after ex vivo 
stimulation with TLR stimuli
C D llc+ DCs isolated by positive selection and depletion of contaminating C D llc+ 
lymphocytes from uninfected mice and mice infected with LCMV Cl 13 3 weeks 
previously were seeded into 96-well plates at a concentration of 5x105 cells/well in a 
lOOpl volume and stimulated O/N with the following TLR ligands: polylC at 
lOpg/well, R848 at lpg/well and CpG 2216 at 0.02nmol/well. Supernatant was 
collected after an overnight incubation in a 37°C, 5% CO2 incubator and the level of 
type 1 IFN activity was measured by antiviral bioassay. The results shown are 
representative of findings made in 3 independent experiments that used cells pooled 
from 3-10 mice per group. Statistical analysis using a one sample T-test showed a 
significant difference (p<0.05) between the levels of type 1 IFN activity induced by 
DCs from uninfected and C113-infected mice in response to stimulation with all the 
TLR ligands tested.
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4.12 Summary of results and conclusions
A model of persistent LCMV infection was set up by i.v. inoculation of a high dose of 
LCMV Cl 13 into adult immunocompetent C57BL/6 mice in which infectious virus 
could be detected in the blood for at least 6 weeks post-infection.
Analysis of type 1 IFN activity in the blood and of levels of mRNA of individual IFN- 
a/{3 subtypes in the spleen following infection with LCMV Arm or LCMV Cl 13 
indicated that in mice infected with either virus, mRNA of all subtypes of type 1 IFN 
was rapidly but transiently upregulated in the spleen; reaching maximal expression by 
24 hours post-infection and then swiftly returning close to baseline levels by 72 hours 
post-infection. In LCMV Cl 13 infected mice, very low levels of IFN-p and IFN-a4 
mRNA continued to be produced in the spleen for at least 3 weeks post-infection in 
the context of viral persistence and ongoing high levels of viral replication. Levels of 
type 1 IFN activity in the blood followed a similar kinetic.
Investigation into the numbers and activation state of splenic DC subsets during 
persistent LCMV infection revealed that, the majority of the DCs in the spleen of 
persistently infected mice expressed elevated levels of MHC and co-stimulatory 
molecules suggesting that they were in a heightened state of activation. Notably, the 
number of DCs of both plasmacytoid and conventional subtypes present in the spleens 
of persistently infected mice were reduced compared to DC numbers in the spleens of 
uninfected animals, suggesting that in the context of persistent LCMV infection, the 
development or maturation of precursor DC was impaired and/or the lifespan of DCs 
was decreased (or possibly mature DCs were migrating out of the spleen to other 
sites). Expression of mRNAs of different subtypes of IFN-a/p was measured in 
plasmacytoid and conventional DC subsets at sequential timepoints after infection of 
mice with LCMV Arm or LCMV C113. In both infections, plasmacytoid DCs were
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initially found to produce much higher levels of type 1 IFN on a per cell basis than 
conventional DCs, although the latter DC subset did contribute to type 1 IFN 
production. As observed in whole spleen tissue , type 1 IFN mRNA expression was 
very quickly downregulated in both DC subsets. In mice persistently infected with 
LCMV Cl 13, mRNA levels were low/undetectable in both DC subsets.
The low splenic type 1 IFN mRNA levels and systemic levels of type 1 IFN in mice 
persistently infected with LCMV may be due in part to the low number of DCs 
present in the spleen and in addition, the downregulation of type 1 IFN production by 
DC populations remaining in the spleen may also be of importance. Infection- 
associated changes in the number and/or IFN-producing capacity of non-DC subsets 
could also be involved.
Confocal studies that visualized IFN-a, pDCA-1 from plasmacytoid DCs and LCMV- 
infected cells in spleen sections from mice infected with LCMV Arm or LCMV Cl 13 
early and late times post infection confirmed and extended these observations.
During the early stages of acute infection of mice with LCMV Arm or LCMV Cl 13 
splenic plasmacytoid DCs appeared activated, and some of these cells were found to 
be producing IFN-a, although they were not the only cells that did so. Interestingly, a 
high population of splenic DC appeared to be infected with LCMV Arm or LCMV 
C113.
In mice persistently infected with LCMV Cl 13, plasmacytoid DC numbers in the 
spleen were found to be reduced. A proportion of these cells were infected with 
LCMV, however not all plasmacytoids DCs appeared to be infected and infection of 
other cell types was also observed. Low numbers of IFN-a producing cells were 
present in the spleen of persistently infected mice. Some (but not all) of the IFN-
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producing cells were plasmacytoid DCs, and small numbers of LCMV-infected 
plasmacytoid DCs producing IFN-a were observed.
These studies did not aim to address the principle cellular source of type 1 IFN 
production in LCMV-infected mice. It remains possible that this is a non-DC cell type. 
Infection associated changes in the number and/or IFN-producing capacity play an 
important role in downregulation of systemic type 1 IFN levels both after the burst of 
IFN production at the acute infection and during persistent infection of mice with 
LCMV Cl 13. However, results reported in this chapter demonstrate that type 1 IFN 
production is strongly upregulated in plasmacytoid DCs (and to a lesser extent 
conventional DCs) in the spleen very early in the acute phase of infection of mice 
with LCMV; and that plasmacytoid DCs are among the cell types that continue to 
produce small amounts of type 1 IFN in mice persistently infect with LCMV C113. 
The low splenic type 1 IFN mRNA levels in the spleens of mice persistently infected 
with LCMV may be due in part to the number of DCs present in the spleen of these 
animals being decreased relative to the numbers present in uninfected mice, but low 
type 1 IFN production by the DC remaining in the spleen could also be a contributing 
factor. Evidence of infection of DCs by LCMV was obtained and this may be 
involved in impairment of type 1 IFN production.
Experiments carried out to address the ability of mice persistently infected with 
LCMV to produce type 1 IFN in response to inoculation of synthetic ligands for a 
selection of virally-important TLRs revealed that these stimuli did elicit upregulation 
of type 1 IFN mRNA and protein production in mice persistently infected with 
LCMV, although the upregulation observed was lower than that seen in uninfected 
mice. Lower levels of IL-12 and IFN-y were also produced in persistently infected 
mice, although production of other cytokines was evaluated. Ex-vivo stimulation of
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purified C D llc+ splenic DCs from persistently infected mice with TLR ligands 
provided further evidence that these cells could respond (albeit less well than their 
uninfected counterparts) to TLR stimuli by IFN-a/p production. In contrast, when 
mice were injected i.p. with live influenza PR8, they produced much less type 1 IFN 
than uninfected mice. Interpretation of this observation was complicated by the fact 
that although influenza viral RNA was detected in the spleen of both groups of mice, 
levels were higher in the uninfected mice suggesting they may have experienced a 
heavier burden of infection. Nonetheless, it is tempting to speculate that the ability of 
LCMV-infected mice to respond to infection with RNA virus by production of type 1 
IFN is impaired A possible explanation for those results is that persistent LCMV 
infection may impair the RNA helicase-mediated intracellular innate viral recognition 
pathway while leaving the TLR-mediated type 1 IFN induction pathway intact.
The following chapter (5) described in vitro experimental work that was carried out to 
gain more insight into type 1 IFN production by LCMV-infected cells or mechanisms 
that may underlie impairments in their responsiveness.
Results from Chapter 3 and Chapter 4 are then discussed together in Chapter 5.
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CHAPTER 5
ANALYSIS OF THE MECHANISMS INVOLVED IN THE DOWNREGULATION 
OF TYPE 1 IFN PRODUCTION DURING PERSISTENT LCMV C113
INFECTION
5.1 Introduction
Observations from in vivo experiments indicated that there was only a very low level of 
ongoing type 1 IFN production in mice persistently infected with LCMV, despite the 
presence of high levels of infection in the host. Persistently-infected animals retained the 
capacity to upregulate type 1 IFN in response to exogenous TLR stimuli, as type 1 IFNs 
and other cytokines were produced following i.p. inoculation of TLR3, 7 and 9 ligands. 
However, their capcity to upregulate type 1 IFN production via intracellular pathways 
triggered by RNA virus replication was less clear. There may be several reasons why type 
1 IFNs are not continuously produced at higher levels in mice persistently infected with 
LCMV C113. Although there are large numbers of infected cells in these animals, the level 
of infectious virus they secrte may be relatively low and their turnover may be slow 
resulting in the levels of TLR ligands (e.g. ssRNA, ds replicative RNA and possibly viral 
glycoproteins) available for TLR stimulation being relatively low. It is also possible that 
host cells may be de-sensitised to TLR stimuli that are constitutively present, but retain 
the capacity to respond to a rapid elevation in the level of TLR ligands in their 
environment. The reduction in splenic plasmacytoid DC and conventional DC numbers in 
mice persistently infected with LCMV may also play a role. Coupled with this, there may 
be defect(s) in the pathway(s) for recognition of intracellular RNA virus replication and/or 
upregulation of type 1 IFN production in response to this in cells infected with LCMV.
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These defects could be specific to the intracellular RNA recognition response pathway so 
that infected cells are still able to recognize and respond to external innate stimuli 
(accounting for the observation of some LCMV-infected IFN-a producing cells- 
principally plasmacytoid DCs -  in persistently infected mice). The defects in this pathway 
could be induced by the virus as a strategy for avoiding control by the host immune 
response or may instead constitute a host response to limit immunopathology mediated 
damage mediated by high levels of type 1 IFN and other inflammatory cytokines in the 
system.
Efforts to use in vivo studies to address mechanism(s) that may be involved in impairment 
of type 1 IFN production during LCMV infection are hampered by the complexity of the 
in vivo system. There are multiple heterogenous cell-types present which differ in their 
capacity to produce type 1 IFNs and pathways for triggering of IFN production. The cell 
types producing type 1 IFNs in LCMV-infected mice and how these parameters change 
over time are all incompletely understood. Further, the extent to which different cell types 
are infected by LCMV, and the changes taking place in numbers and proportions of cell 
subsets over the course of infection are difficult to discern. In addition, the levels and 
relative proportions of type 1 IFN-inducing stimuli present are hard to quantify. In this 
chapter, I thus used in vitro systems to study the effects of LCMV infection on the ability 
of homogenous cell populations to produce type 1 IFNs in response to different IFN- 
inducing stimuli.
Many strains of LCMV have been reported to infect primary cells in vitro. Infection of 
most cell types is largely non-cytopathic, and the cells typically grow normally following 
infection, exhibiting a generation time and cloning efficiency identical to that of 
uninfected cells (Staneck et al. 1972). Importantly, once cells are infected with LCMV in 
vitro, the infection persists in the culture over time. All cells are infected with virus, as
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demonstrated by immunofluorescence staining for LCMV proteins in cultures of cells 
infected for long periods, although the level of infectious virus released into the 
supernatant is often relatively low, which has been associated with downregulation of 
expression of the viral glycoproteins in persistently-infected cells (Fuller-Pace and 
Southern 1988).
Cell lines persistently infected with LCMV provide an excellent in vitro system for 
analysing the effects of LCMV infection on the ability of cells to produce type 1 IFNs, 
and addressing the mechanisms involved in dysregulation of IFN production. Using this 
approach, the response of a single cell type with a defined TLR ligand response profile to 
different IFN-inducing stimuli can be analysed, and the effects of persistent LCMV 
infection on the type 1 IFN response addressed using a population of cells, all of which 
are infected with virus. I thus planned to persistently infect different types of cell lines 
(fibroblast and dendritic cells) with LCMV, and compare the ability of uninfected and 
infected cells to produce type 1 IFNs in response to stimulation via TLRs and the 
intracytoplasmic helicase-dependent pathways for detection of RNA virus replication. If 
LCMV infection was found to impair the ability of cells to produce type 1 IFNs in 
response to any of these stimuli, a further objective was to investigate the role of different 
LCMV proteins in mediating this effect by generating cell lines stably transfected with 
individual LCMV proteins (GP, NP or Z) and examining whether they showed a similar 
defect in type 1 IFN production.
5.2 Analysis of the type 1 IFN response induced following acute infection of BM- 
DCs with LCMV
BM-DCs are primary cells matured from bone marrow precursor cells by GM-CSF that 
have a number of properties in common with conventional DCs subsets found in the
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spleen (Boonstra et al. 2003) and have been previously reported to produce type 1 IFN 
when infected with HSV virus (Hochrein et al. 2004). Prior to carrying out experiments 
with long-term cell lines, an initial in vitro experiment was thus carried out using BM- 
DCs, to analyse the levels of type 1 IFN mRNA and activity induced when a population of 
cells are acutely infected with LCMV.
5.2.1 Infectious viral titres
BM-DCs were prepared as described in Section 2.8.1. The cells were cultured in the 
presence of polymyxin B in order to limit the possibility that type 1 IFN was induced by 
endotoxin contamination. Following a 6-day differentiation period, BM-DCs were 
infected with LCMV Arm or LCMV C113 at m.o.i. of 5. This high m.o.i. was selected to 
try to achieve initial infection of the vast majority of cells, so that the response of cells to 
infection could be studied. The morphology of the cells was found to alter following 
infection: they displayed characteristics of activated DC, such as increasing in size, 
acquiring dendrites and migrating into suspension. While LCMV usually causes a non- 
cytopathic infection, cells infected with LCMV Cl 13 seemed to be dying shortly after 
exposure to the virus. It was not clear whether this was a direct result of infection with 
LCMV as even under non-infectious circumstances, BM-DC cells have a very short 
lifespan that is reduced following activation. Notably, BM-DCs infected with LCMV Arm 
seemed to survive better than those infected with LCMV C113. Cl 13 is reported to infect 
C D llc+ cells more efficiently than LCMV Arm (Sevilla et al. 2000), hence reduced 
survival of LCMV C113-infected cultures could be a reflection of larger numbers of cells 
becoming infected and apoptosing as a result of infection and/or associated activation. 
Kinetic analysis of the levels of infectious virus secreted in the supernatant after an 
infection with a high dose of LCMV Arm or Cl 13 is shown in Figure 5.1. By 24 hours
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post-infection, the infectious titre of LCMV in the supernatant of the LCMV d i s ­
infected cells was a log higher than that in the LCMV Arm-infected cells.
5.2.2 Analysis of levels of type 1 IFN and Mx mRNA by Taqman qRT-PCR
Having determined that the cells were infected with LCMV, the type 1 IFN response to 
the presence of the infection was measured by real-time Taqman qRT-PCR over time 
post-infection. As depicted in Figure 5.2, quantitative real time RT-PCR analysis of total 
RNA purified from the infected/polylC stimulated BM-DCs over time showed that 
although IFN-a mRNA levels remained fairly stable over time in uninfected cells, higher 
levels of IFN-(3 were detected at the first timepoint analysed (6 hours) than at late 
timepoints, suggesting that manipulation of the BM-DCs (such as harvesting and plating 
out) may have itself induced an upregulation of type 1 IFN production. This has been 
observed before: simply pipetting GM-CSF matured BM-DCs into fresh plates may 
activate the cells (Gallucci et al. 1999). In polylC stimulated BM-DCs, there was strong 
upregulation in the levels of IFN-|3 and IFN-a subtypes at 6 hours post-infection, 
substantially greater than that observed in untreated cells; this was followed by a slow 
decline in the mRNA of all subtypes of IFN, reacing baseline levels between 48 and 72 
hours post-stimulation. By contrast, there was a much less dramatic increase in type 1 IFN 
production in cells infected with LCMV. In Arm-infected cells, the levels peaked at ~12 
hours post-infection, the relatively delayed kinetics (relative to polylC-stimulated cells) 
possibly reflecting infection of cells and accumulation of viral components over time. 
However, maximal type 1 IFN mRNA levels in LCMV C113-infected cells were recorded 
at 6 hours post-infection -  this could be a consequence of high levels of apoptosis that
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Figure 5.1 Kinetic analysis of the levels of infectious virus in the supernatant of BM- 
DCs infected with LCMV Arm or C113
BM-DCs were infected at an m.o.i. of 5 with either LCMV Arm or Cl 13 and plated out at 
2xl06cells into 60 mm dishes. Supernatant was collected from single wells at the 
indicated timepoints. Infectious viral titres were determined by viral plaque assay and are 
expressed as plaque forming units per ml of supernatant (p.f.u/ml). The dotted line 
indicates the limit of sensitivity for this assay, which was lx l0 2 p.f.u/ml. The results 
shown are representative of three independent experiments.
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Figure 5.2 IFN-ft IFN-a*4, IFN-a(non-a4) and Mx mRNA levels in BM-DC after 
stimulation with polylC or infection with LCMV Arm or C113 (figure continued on 
following page)
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Figure 5.2 (continued) IFN-/5, IFN-os4, IFN-or(non-a4) and Mx mRNA levels in BM- 
DC after stimulation with polylC or infection with LCMV Arm or C113
BM-DCs were infected with LCMV Arm or Cl 13 at a multiplicity of infection (m.o.i.) of 
5 and then plated out into 60 mm dishes at 2xl06 cells per ml/dish. As a positive control, 
BM-DCs were stimulated in parallel with 50 /ig/ml polylC. At the indicated timepoints, 
media was removed, the cells were lysed and total RNA was extracted and IFN-/3, IFN- 
o4, IFN-a(non-G4) and Mx mRNA levels were measured by quantitative real-time 
Taqman RT-PCR. 200ng of total RNA from each sample was used as a template for each 
Taqman RT-PCR; and each RT-PCR was conducted in duplicate. The mean level of 
mRNA for each gene was then normalised against the level of mRNA of the 
housekeeping control gene HPRT to obtain the ACt value. N.d. indicates no detectable 
expression of the target at that timepoint. In uninfected control cells, expression of IFN- 
cA was only detected at 12 hours and 72 hours post-treatment. The yellow shading 
represents the minimum and maximal mRNA levels recorded in the uninfected controls 
during the course of the experiment. The results are representative of findings made in 2 
independent experiments.
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occurred in the cultures or it may have reflected differences in the level of initial 
infection/subsequent replication of LCMV Arm and LCMV Cl 13 in the BM-DCs. 
Consistent with the low-level elevation, expression of the IFN-responsive gene Mx in 
LCMV Cl 13 and LCMV Arm did not really increase over the course of the infection to 
levels that were above the fluctuations observed in the uninfected cells. In contrast, Mx 
levels in polylC stimulated cultures were slightly elevated above those in uninfected cells 
at 6 hours post-stimulation and, remained above the fluctuating baseline for 24 hours after 
the cells were stimulated.
5.2.3 Analysis of type 1 IFN activity in the supernatant
The levels of type 1 IFN activity observed in the supernatant over time, shown in Figure 
5.3, fits very well with the results of the mRNA analysis. The supernatant was collected at 
the same time as the cells were harvested for RNA extraction and so the levels represent 
the level of type 1 IFN that had accumulated in the supernatant by each timepoint. Type 1 
IFN activity was detected in the supernatant of uninfected cells at the first timepoints 
analysed, but levels were not sustained over time. Stimulation with polylC induced a 
marked elevation in supernatant type 1 IFN activity which peaked at 12 hours post­
stimulation and remained elevated throughout the course of the experiment. There was a 
modest elevation in type 1 IFN activity in the supernatant of LCMV Arm and Cl 13 
infected cultures which peaked at 24 hours post-infection before falling to baseline in the 
next 24 hours. The level of activity induced by LCMV Arm and LCMV Cl 13 infection 
was similar, although IFN levels in the supernatant of LCMV Arm-infected cells were 
sustained for slightly longer than those in the supernatant of cells infected with LCMV 
Cl 13. The results here were largely in agreement with data obtained from real-time 
Taqman quantitative RT-PCR, with the delay in the peak activity recorded at 12-24 hours
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Figure 5.3 Type 1 IFN activity in the supernatant of BM-DC cultures after infection 
with LCMV or stimulation with polylC
BM-DC at 2xl06 cells in 60 mm dishes were infected at a m.o.i. of 10 with LCMV Arm 
or LCMV Cl 13 or stimulated with 50 pg/ml polylC. Supernatant was collected from 
different wells at the timepoints indicated and type 1 IFN activity was measured by 
bioassay. IFN activity was quantitated by comparison with a recombinant IFN-a standard 
curve; the results shown are expressed in log2 units/ml (U/ml). The results shown are 
representative of 2 independent experiments.
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post-infection as opposed to 6 hours post-infection for the mRNA transcripts, probably 
reflecting the time lag between transcription and translation of the transcripts.
In summary, infection of murine BM-DC with LCMV Arm or LCMV Cl 13 resulted in 
induction of only a very transient low-level type 1 IFN response. Whether this was due to 
poor in vitro survival of infected cells and/or reflected a capacity of the virus to impair 
type 1 IFN induction in the cells it infects was not clear. Further experiments were thus 
conducted using cell lines in which a long-term persistent LCMV infection could be 
generated.
5.3 Analysis of type 1 IFN production following LCMV infection of the fibroblast 
cell line BalbC17 and DC cell lines D2SC/1 and FSDC 
5.3.1 Infectious viral titres
BM-DC do not survive for long in culture, maturing and undergoing apoptosis once they 
become infected, which renders them unsuitable for long term analysis of the effects of 
persistent LCMV infection on the type 1 IFN response. I thus carried out further 
experiments using an immortalized fibroblast cell line, BalbC17, which was adherent and 
known to be susceptible to infection by LCMV; and two DC lines, D2SC/1 and FSDC 
which had previously been shown to produce measurable levels of type 1 IFN upon 
infection infection with Sendai, another virus with an RNA genome (Eloranta et al. 1997). 
The DC lines were semi-adherent, and it was not clear how readily they would be infected 
by LCMV. Initial experiments were thus carried out in which BalbC17, D2SC/1 and FSDC 
cells were infected with low or high doses of LCMV Cl 13 and the proportion of infected 
cells and virus release into the supernatant analysed by immunofluorescent staining and 
viral plaque assays respectively.
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Immunofluorescent staining of the three cell lines with LCMV-specific antibodies 
showed that 24 hours following infection with LCMV Cl 13 at a high m.o.i., viral antigens 
could be detected in the vast majority of cells, indicating that they were heavily infected 
with virus (Figure 5.4). When infected at a m.o.i. of 0.1, viral antigens could be detected 
at 24 hours in -20% of BalbC17 cells and -45-55% of cells of DC lineage, indicative of a 
higher initial level of infection and/or greater viral production or faster spread in the latter 
cells. However, by 48 hours post-infection, in BalbC17, D2SC/1 and FSDC cultures, the 
vast majority of cells were all heavily infected with LCMV. Viral plaque assays on cell 
supernatants confirmed that all three cell lines had been infected with LCMV and 
produced infectious virus particles following infection (Figure 5.4). The magnitude of 
kinetics of infectious virus production in BalbC17 cells and the two DC cell lines differed 
slightly with peak viral titres in BalbC17 cell supernatant being higher than those in the 
supernatant of the DC cell lines and being reached somewhat later (2-3 rather than 1-2 
days post-infection). In all three cell lines, infection at low m.o.i. produced higher peak 
viral titres than infection at high m.o.i., with viral titres also peaking more rapidly after 
infection at the higher m.o.i. Infection of all three cell lines with LCMV Cl 13 at either low 
or high m.o.i. resulted in long-term virus persistence with continued production of 
infectious virus into the cell supernatant (Figure 5.5). Immunofluorescent staining of 
persistently infected cells (Figure 5.6) confirmed expression of the LCMV-NP protein in 
the vast majority of cells, indicating that the entire population was infected.
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Figure 5.4 Expression of LCMV proteins in BalbC17, D2SC/1 and FSDC cells over 
time following infection with LCMV C113 at low and high m.o.i. (figure continued on 
following pages)
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Figure 5.4 (continued) Expression of LCMV proteins in BalbC17, D2SC/1 and FSDC 
cells over time following infection with LCMV C113 at low and high m.o.i. (figure 
continued on following pages)
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Figure 5.4 (continued) Expression of LCMV proteins in BalbC17, D2SC/1 and FSDC 
cells over time following infection with LCMV C113 at low and high m.o.i.
A fibroblast cell line, BalbC17 and two DC cell lines, D2SC/1 and FSDC, were infected at 
low (0.1) and high (10) m.o.i.s with LCMV C113. Infected cells were either plated out on 
Lab-Tek chamber slides (BalbC17) or spotted onto wells on a Teflon slide (D2SC/1 and 
FSDC). At the indicated times post-infection, cells were fixed, and the proportion of cells 
infected with LCMV was determined by staining with ascitic fluid containing LCMV-
324
specific antibodies (VR164) at a 1/50 dilution followed by anti-mouse Ig-FITC (green). 
Cell nuclei were stained with Bo-Pro (red). The percentage of infected cells in each 
sample was determined by counting the proportion of cells stained with the LCMV- 
specific antibody in at least 3 fields. The results shown here are pictures of representative 
fields visualised at lOx magnification, and are representative of findings made in 2 
independent experiments.
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Figure 5.5 Kinetic analysis of the levels of infectious virus in the supernatant of 
BalbC17, D2SC/1 and FSDC cells infected with low or high doses of LCMV C113
BalbC17, D2SC/1 and FSDC cells were infected at an m.o.i. of 0.1 or 10 with LCMV 
Cl 13 and were seeded out into 6-well dishes at lxlO6 cells per well in a 1 ml volume. 
Supernatant was collected from single wells at the indicated timepoints. Infectious viral
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titres were determined by viral plaque assay and are expressed as plaque forming units 
per ml of supernatant (p.f.u/ml). The dotted line indicates the limit of sensitivity for this 
assay, which was 1x10 p.f.u/ml. The results shown are representative of 2 independent 
experiments.
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Figure 5.6 Immunofluorescent staining for LCMV NP in BalbC17, D2SC/1 and 
FSDC cells persistently infected with LCMV C113
Cells which were persistently infected with LCMV Cl 13 were spotted onto Teflon slides, 
fixed and stained with monoclonal antibody NP113 (that recognizes the LCMV NP 
protein) followed by anti-mouse IgG-FITC (green). Cell nuclei were stained with Bo-Pro 
(red). The percentage of infected cells in each sample was determined by counting the 
proportion of cells stained with the LCMV-specific antibody in at least 3 fields. The 
results shown here are pictures of representative fields visualised at lOx magnification, 
and are representative of findings made in 2-4 independent experiments.
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5.3.2 mRNA and activity of Type 1 IFN in persistent LCMV infection
Figure 5.7 shows the results of analysis of type 1 IFN mRNA transcripts in BalbC17, 
D2SC/1 and FSDC cells at different times following infection with LCMV C113. Type 1 
IFN mRNA levels in uninfected cells were found to fluctuate over time in all three cell 
lines possibly reflecting a response to manipulation/medium change during passage 
and/or changes in the degree of confluence of cells. LCMV infection was associated with 
very little type 1 IFN mRNA above the background range, with a transient low-level 
increase in IFN-(3 and IFN-a4 transcripts being observed in BalbC17 cells 1-2 days post­
infection, and little response being detected in the DC cell lines. In all three cell lines, 
type 1 IFN mRNA levels in persistently-infected cells did not differ appreciably from 
those observed in uninfected cells. These observations were supported by analysis of type 
1 IFN activity in the supernatant shown in Figure 5.8. Fluctuating (but fairly low) levels 
of type 1 IFN were detected in the supernatant of uninfected cells over time, and it was 
very difficult to distinguish any infection-associated upregulation in supernatant type 1 
IFN levels above this backround in any of the cell lines tested. In both fibroblast and DC 
cell lines, it thus appeared that infection with LCMV induced low to negligible levels of 
type 1 IFN production.
5.4 Levels of Type 1 IFN induced by different viral infections or polylC
As shown in Figures 5.7 and 5.8, LCMV infection of BalbC17, D2SC/1 or FSDC cells was 
associated with little type 1 IFN induction. In order to determine whether this was due to 
abnormalities in these cell lines which were immortalized in order to be amenable to 
culture and may have potentially lost the ability to recognize/respond to infectious stimuli 
by production of type 1 IFN, or reflected a specific failure to upregulate type 1 IFN 
production upon infection with LCMV, possibly dues to virus-induced impairment of
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Figure 5.7 Levels of IFN-& IFN-o4 and IFN-a(non-a4) mRNA in BalbC17, D2SC/1 
and FSDC cells after infection at low or high m.o.i. with LCMV C113 (figure 
continued on following pages)
330
B) D2SC/1
IFN-(3 Uninfected
CM 3  0.1 
CM 3  10
O) -€■
-10-
- 12-
-14-
-16-
- 18-
- 20-
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Days post-infection
IFN-a4
_  - 10* 
©
P  -12-re
r  -14-
o 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Days post-infection
IFN -a(non-a4)
i  *  tor-io - u /
<  * 1 2 * \  
-14- I
-16 1 i
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Days post-infection
Figure 5.7 (continued) Levels of IFN-/S, IFN-a4 and IFN-a(non-Q!4) mRNA in 
BalbC17, D2SC/1 and FSDC cells after infection at low or high m.o.i. with LCMV
Cl 13 (figure continued on following pages)
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Figure 5.7 (continued) Levels of IFN-/S, IFN-a4 and IFN-a(non-a4) mRNA in 
BalbC17, D2SC/1 and FSDC cells after infection at low or high m.o.i. with LCMV 
C113
BalbC17, D2SC/1 or FSDC cells were infected with LCMV C113 at a multiplicity of 
infection (m.o.i.) of 0.1 or 5 and then seeded into 6-well dishes at lxlO6 cells/ml per well
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in a 1 ml volume. At the indicated timepoints, medium was removed, the cells were lysed 
and total RNA was extracted and IFN-p, IFN-a4, IFN-a(non-a4) and Mx mRNA levels 
were measured by quantitative real-time Taqman RT-PCR. 200ng of total RNA from 
each sample was used as template for each Taqman RT-PCR; and each RT-PCR was 
conducted in duplicate. The mean level of mRNA for each gene was then normalised 
against the level of mRNA of the housekeeping control gene HPRT to obtain the ACt 
value. There was no detectable expression of IFN-a4 transcripts in uninfected control 
cells at timepoints past 6 hours or in the infected cells after day 3 post-infection. The 
shaded area indicates the range of IFN mRNA levels observed in uninfected, 
unstimulated controls over the experimental timecourse. The results are representative of 
findings made in 3 independent experiments conducted.
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Figure 5.8 Type 1 IFN activity in the supernatant of BalbC17, D2SC/1 or FSDC cells 
after infection at high or low m.o.i. with LCMV C113
A fibroblast cell line, BalbC17, and two DC cell lines, FSDC and D2SC/1, were plated out 
at lxlO6 cells in a 1 ml volume into 60mm dishes or 6-well plates and were infected at 
low (0.1) or high (5/10) m.o.i. with LCMV C113. Supernatant was collected from 
individual wells at the timepoints indicated and the level of type 1 IFN activity was
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measured by bioassay. IFN activity was quantitated by comparison with a recombinant 
IFN-a standard curve; the results are expressed in log2 units/ml (U/ml). The yellow 
shading indicates the range of maximal and minimal type 1 IFN activity recorded in the 
supernatant of the uninfected control during the course of the experiment. The results 
shown are representative of findings made in 3 independent experiments.
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pathway(s) for type 1 IFN induction in uninfected cells.Uninfected BalbC17, D2SC/1 and 
FSDC cells were infected with other viruses, (the RNA virus, Sendai, and the DNA virus 
herpes simplex virus (HSV), both of which are reported to be strong inducers of type 1 
IFN in vitro) at a high m.o.i. (10 and 5 respectively), or were stimulated with polylC, and 
cellular RNA and culture supernatants were collected for quantitation of type 1 IFN 
mRNA/activity levels. Figure 5.9 shows the mean of the maximal levels of type 1 IFN 
mRNA subtypes produced during multiple experiments in BalbC17 and FSDC cells upon 
infection/stimulation with Sendai, HSV or polylC together with the levels induced by 
LCMV infection. The levels shown are expressed as the mean AACt (ACt 
infected/stimulated -  ACt uninfected control) values. The AACt value of each subtype in 
the sample was calculated by subtracting the maximal ACt value obtained in the infected 
or stimulated cells from the maximal level (i.e. highest ACt-value) of each subtype 
recorded in the unstimulated uninfected cells from the corresponding experiment.
In BalbC17 cells, infection with a high m.o.i. of LCMV stimulated a strong IFN-p 
response above the background and low to modest responses of the IFN-a subtypes. Even 
so, these levels were lower than the responses (especially the IFN-a response) induced 
upon infection with high doses (m.o.i. of 10 and 5 respectively) of Sendai or HSV. PolylC 
stimulation of BalbC17 cells generated type 1 IFN responses that were broadly similar to 
the levels induced after LCMV infection.
In FSDC cells, infection with a high m.o.i. (10) of LCMV induced low to modest levels of 
IFN-P, IFN-a4 and other IFN-a subtypes above the background. In contrast, infection with 
high m.o.i. of Sendai and HSV generated much higher levels of all type 1 IFN subtypes 
measured, as compared to the levels induced upon infection with LCMV. Stimulation with 
polylC induced responses of IFN-p, IFN-a4 that were largely equivalent to the levels
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Figure 5.9 Maximal expression of IFN-& IFN-a4 and IFN-a(non-a4) mRNA 
subtypes in BalbC17 and FSDC cells in response to viral infection or polylC 
stimulation
A fibroblast cell line, BalbC17 and a DC cell lines FSDC were seeded into 6-well plates at 
lx l0 6cells/well in 1 ml volume, or into 96-well plates at lx l05cells/well in 100fi\ volume, 
and were infected with either LCMV Cl 13 at a m.o.i. of 10, another RNA virus, Sendai, at 
a m.o.i. of 10; a DNA virus, HSV at a m.o.i. of 5 or were stimulated with 50/ig/ml of the
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TLR 3 ligand polylC. At a series of timepoints thereafter, RNA was extracted from the 
cells and IFN-|3, IFN-a4 and IFN-a(non-a4) mRNA levels were measured by quantitative 
Taqman RT-PCR. The results were normalised against the Ct values of the housekeeping 
gene HPRT, to obtain the ACt values. The maximal level of upregulation, within the first 
24 hours, of each subtype transcript in response to infection/stimulation was determined 
by subtracting the maximal ACt value of each subtype recorded in uninfected cells from 
the maximal ACt value for each subtype after infection/stimulation to obtain the AA Ct 
value. The mean difference (i.e the mean A A Ct value) of the type 1 IFN subtype 
measured after infection/stimulation from 2-3 independent experiments is plotted on the 
y-axis. The error bars indicate the standard error of the mean.
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induced upon infection with high m.o.i. of LCMV but very low levels of other IFN-a 
subtypes were upregulated.
It thus appears that BalbC17 and FSDC cells are able to strongly upregulate type 1 IFN 
when infected by RNA or DNA viruses. However, infection with high m.o.i. of LCMV 
did not induce as strong a type 1 IFN response in BalbC17 fibroblast and FSDC DC cells 
as generated during high dose infection of Sendai or HSV.
These results were reinforced by results from analysis of IFN activity levels in cell 
supernatant collected in parallel (Figure 5.10). In BalbC17 cells, infection with HSV and 
Sendai viruses induced secretion of high levels of type 1 IFN (-1024 or ~210 U/ml), while 
polylC did not induce significant type 1 IFN production, likely because of a lack of TLR3 
expression in this fibroblast cell line. Infection with LCMV Cl 13 did induce some type 1 
IFN production, but the peak levels of IFN activity in the supernatant of LCMV-infected 
cells were much lower than those induced following infection with Sendai virus or HSV. 
The difference in the levels of type 1 IFN induced after LCMV versus HSV or Sendai 
infection was even more marked in the DC cell lines, where the peak levels in the 
supernatant of LCMV infected cells were not significantly higher than those present in the 
supernatant of uninfected cells. Unlike BalbC17 cells, the DC cell lines did also produce 
moderate amounts of type 1 IFN in response to stimulation with polylC. Together, these 
results indicated that BalbC17, D2SC/1 and FSDC cells were capable of producing 
relatively high levels of type 1 IFN in response to infection with viruses including Sendai 
and HSV, suggesting that the comparatively weak type 1 IFN response observed 
following infection of these cells by LCMV may reflect a virus-induced block in type 1 
IFN upregulation in infected cells.
339
BalbCI7
Unst LCMV Sendai HSV PolylC
D2SC/1
Unst LCMV Sendai HSV PolylC
FSDC
-  <1 a  12-
o  11 
>* 10-
S i  7- 
z  3 e-
4-
8 .
■ I I .
Unst LCMV Sendai HSV PolylC
Figure 5.10 Maximal levels of supernatant type 1 IFN activity induced following 
stimulation of BalbC17, D2SC/1 or FSDC cells with polylC or infection with 
different viruses (figure legend on the following page)
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A fibroblast cell line, BalbC17 and two DC cell lines, FSDC and D2SC/1 were seeded 
into 60mm dishes or 6-well plates at 106 cells/well in 1 ml volume, and were infected 
with either LCMV (at high (10) m.o.i); Sendai, another RNA virus, at a m.o.i. of 10; 
HSV, a DNA virus, at a m.o.i. of 5; or stimulated with 50ug/ml of the TLR 3 ligand 
polylC. At a series of timepoints thereafter, RNA was extracted from the cells and type 1 
IFN activity was measured by bioassay. The values shown are the peak levels of type 1 
IFN activity (in log2 units (U)/ml) in cell supernatants within 24 hours after the cells were 
infected/stimulated as assessed by bioassay. Type 1 IFN activity was quantitated against a 
standard curve of recombinant IFN-a.
The results shown are the mean of the maximal levels from at least 2 independent 
experiments; error bars indicate 1 SD above the mean. The significance of the difference 
in the levels of type 1 IFN activity induced by viral infection with LCMV, Sendai or HSV 
or stimulation with polylC was compared against the uninfected, unstimulated (Unst) 
baseline using the ANOVA general linear model followed by Tukey’s simultaneous test. 
Infection/stimulation that induced a statistically significant increase in type 1 IFN activity 
over the unstimulated control (p<0.05) is marked with an asterisk (*).
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5.5 Levels of type 1 IFN induced in LCMV-infected BalbC17, D2SC/1 and FSDC 
cells after infection with Sendai virus or HSV
Further experiments were carried out to address whether cells infected with LCMV also 
were able to produce type 1 IFNs in response to infection with viruses shown in Figure 
5.9/5.10 to elicit type 1 IFN production in uninfected cells. BalbC17, D2SC/1 and FSDC 
cells which were persistently infected with LCMV were infected with a second virus, 
either Sendai or HSV and the levels of type 1 IFN induced by the second infection 
measured and compared to the levels secreted by previously uninfected cells upon 
infection with Sendai/HSV. Total cellular RNA and culture supernatants were collected at 
4 and 8 hours post-infection and type 1 IFN mRNA levels and activity were quantitated as 
in previous experiments. Figure 5.11 shows the levels of the type 1 IFN in uninfected and 
persistently LCMV infected FSDC cells 4 hours after infection with Sendai virus or HSV. 
As previously observed, uninfected cells responded to infection with of Sendai virus or 
HSV by upregulating expression of IFN-P, IFN-a4 and other IFN-a subtypes, with 
infection by HSV eliciting a stronger response than infection with high or low m.o.i. of 
Sendai. In cells persistently-infected with LCMV, infection with HSV also induced a 
strong upregulation of all type 1 IFN subtypes, although the levels produced were slightly 
lower than those made by similarly exposed uninfected cells. However, when 
persistently-infected cells were infected with Sendai vims at low or high m.o.i., although 
there was some upregulation of all subtypes of type 1 IFN, the levels produced were 
significantly lower at 18 hours post-infection than those made by Sendai-infected control 
cells. In line with this, levels of Mx mRNA were upregulated in both uninfected and 
persistently infected cells upon infection with HSV. Uninfected cells also upregulated Mx 
when infected with low or high doses of Sendai vims Mx mRNA levels in persistently 
infected cells did not increase when these cells were infected with Sendai vims.
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Figure 5.11 Type 1 IFN and Mx mRNA upregulation in FSDC cells persistently 
infected with LCMV in response to Sendai or HSV infection
Uninfected FSDC cells and FSDC cells infected >80 days previously with LCMV C113 
were infected with Sendai virus at a m.o.i of 1 or 10 or with herpes simplex virus (HSV) 
at a m.o.i of 5. Control cells were LCMV C113-infected or uninfected cells that were not 
super-infected with any other virus (unstim). At 4 hours post-infection, cells were lysed in 
RLT buffer for mRNA isolation and type 1 IFN/Mx mRNA levels were determined by 
quantitative Taqman RT-PCR. The Ct value of each type 1 IFN/Mx gene was normalised 
by subtraction from the Ct value of the housekeeping gene HPRT; the normalised level 
for each gene is displayed as a ACt value while n.d. indicates target mRNA was not 
detected in the sample. The results shown are representative of observations made in 2 
independent experiments with FSDC cells and a further 2 independent experiments 
conducted on BalbC17 cells. The difference in the levels of type 1 IFN mRNA subtype 
induced by Sendai or HSV infection in uninfected or cells persistently infected with 
LCMV Cl 13 was compared using the ANOVA general linear model followed by Tukey’s 
simultaneous test. Infections that induced a statistically significant difference (p<0.05) in
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the level of type 1 IFN subtype in uninfected versus persistently infected cells are marked 
with an asterisk (*).
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These observations at the transcript level were backed up by results of analysis of type 1 
IFN activity in the supernatant of cells at 18 hours post-infection (Figure 5.12). In 
uninfected cells, high levels of type 1 IFN activity were produced in response to infection 
with Sendai or HSV (~2n U/ml), indicating that both viruses stimulated strong type 1 IFN 
responses. However, whereas the levels of type 1 IFN secreted by uninfected and LCMV- 
infected cells upon infection with HSV, a DNA virus, were similar, the levels of type 1 
IFN detected in the supernatant of persistently infected cells infected with low or high 
doses of Sendai, an RNA virus, were significantly lower than those produced by 
uninfected control cells in response to infection with this vims (p=0.0013, as determined 
by the ANOVA general linear model). These results indicated that the persistently 
infected cells had not lost their capacity to respond to an infection with the DNA vims 
HSV by production of type 1 IFN, but suggested that their ability to respond to infection 
by an RNA vims, Sendai may be impaired. Similar observations were also made in 
experiments carried out using the fibroblast cell line BalbC17 (data not shown).
To exclude the possibility that the persistently infected cells had a pre-existing antiviral 
state and so were resistant to a further infection with Sendai, real-time Taqman PCR 
assays were used to quantify Sendai vims RNA NP transcripts in uninfected and 
persistently-infected cells at different timepoints following infection with Sendai vims. 
The results obtained (Figure 5.13) indicated that both uninfected and LCMV-infected cells 
were infected equally well by Sendai vims. Equivalent levels of Sendai vims NP RNA 
were detected in both cell populations at 4 hours post-infection and had increased to a 
similar extent by 18 hours post-infection, indicative of viral replication occurring in a 
parallel fashion in both control and LCMV C113-infected cells.
345
1 1 - 
r r  10* 
^ 9H 
3  8- 
O) 7- 
£  6- 
Z  5- 
-  4
•  3
>  3 H 1
u
Uninfected  
CM 3
0J  1 1 1------------
Unstim Sendai 1 Sendai 10 HSV 5
Figure 5.12 Type 1 IFN activity detected in the supernatant of uninfected FSDC and 
FSDC cells persistently infected with LCMV following infection with Sendai virus or 
HSV
FSDC cells infected >80 days previously with LCMV Cl 13 were infected with Sendai 
virus at a m.o.i. of 1 or 10 or herpes simplex virus (HSV) at an m.o.i. of 5. Control cells 
were LCMV Cl 13 infected or uninfected cells that were not super-infected with any other 
virus (unstim). At 18 hours post-infection, supernatants were collected and the level of 
type 1 IFN activity they contained was measured by antiviral EMCV bioassay. The 
results are expressed as log2 units of IFN activity per ml (log2 U/ml). The results shown 
are representative of observations made in 2 independent experiments with FSDC cells 
and a further 2 independent experiments conducted on BalbC17 cells. Statistical analysis 
using ANOVA general linear model to compare the levels of type 1 IFN induced after 
uninfected or persistently infected cells were exposed to Sendai or HSV suggested that 
there was a statistically significant difference in the level of type 1 IFN produced by 
uninfected and persistently infected cells following infection with a low or high m.o.i. of 
Sendai virus (p<0.05), indicated by an asterisk (*), but not after infection with HSV.
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Figure 5.13 Sendai virus RNA levels in control and LCMV C113-persistently 
infected FSDC cells 4 and 18 hours after infection with Sendai virus
Uninfected FSDC cells and FSDC cells infected >80 days previously with LCMV Cl 13 
were infected with Sendai virus at a m.o.i. of 1 or 10. Total RNA was extracted at 4 and 
18 hours post-Sendai infection and Sendai virus mRNA levels were determined by 
quantitative Taqman RT-PCR. The level of Sendai viral transcript detected in each 
sample was normalized against the housekeeping gene HPRT which was analysed in 
parallel, and the values are expressed as ACt. The results shown are representative of 
findings made in two independent experiments.
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Together, there results indicated that cells persistently-infected with LCMV Cl 13 had an 
impaired capacity to respond to infection with Sendai virus protein by upregulation of 
type 1 IFN production, but were capable of mounting a normal type 1 IFN response when 
infected with HSV. This suggested that LCMV (itself an RNA virus) may selectively 
impair pathway(s) for type 1 IFN induction in response to RNA virus infected in the cells 
it infects, leaving pathway(s) for recognition/response to DNA viruses. Based on these 
assays, it was evident that uninfected and LCMV-infected FSDC cells were infected with 
Sendai virus at equivalent levels and the levels of intracellular Sendai virus in all cases 
increased at 18 hours post-infection which was indicative of viral entry and replication, 
leaving pathways for recognition of/response to DNA virus infection intact.
5.6 Type 1 IFN activity in the supernatant of persistently infected cells after 
stimulation with synthetic TLR ligands
There are several ways in which cells can senses the presence of viral RNA, including 
through TLR3 or TLR7, which recognize double stranded or single stranded RNA, 
respectively, and via a cytoplasmic pathway initiated by activation of helicases such as 
RIG-1 or MDA5 (Kato et al. 2006). To assess the ability of cells persistently infected with 
LCMV Cl 13 to respond to TLR stimuli, infected cells were stimulated with polylC, R848 
or CpG1826 and the level of type 1 IFN production was analysed. Initial experiments, the 
results of which are shown in Figure 5.14 revealed that when uninfected, the DC lines 
were responsive to polylC, LPS, R848 and CpG, producing moderate to high levels of 
type 1 IFN in response to all these stimuli. As can be seen in Figure 5.15, there was no 
difference in the level of type 1 IFN induced by the synthetic TLR ligands in uninfected 
and persistently infected DC. The data in Figure 5.15 show that the TLR 3, 7 and 9 
stimulated pathways for type 1 IFN induction were not impaired in cells persistently
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Figure 5.14 Type 1 IFN production by D2SC/1 and FSDC cells in response to 
stimulation with different TLR ligands
Two DC cell lines, D2SC/1 and FSDC, were seeded into 96-well plates at lxlO5 
cells/well in lOOpl of media and stimulated with polylC at 100jig/ml, LPS at 10pg/ml, 
R848 at lOpg/ml or CpG 1826 at 0.2nmol/ml (the TLR stimulated by each ligand is 
indicated). Supernatants were harvested the following day and the levels of type 1 IFN 
produced evaluated by bioassay. A standard curve of recombinant IFN-o: was set up in 
parallel. The results shown are the levels of type 1 IFN, expressed as log2 units/ml (U/ml).
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The results are the mean of values obtained from 2-4 independent experiments, with one 
standard error above the mean depicted by the error bars.
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Figure 5.15 Type 1 IFN production in response to TLR stimuli by DC cell lines 
persistently infected with LCMV
D2SC/1 or FSDC cells infected >30 days previously with LCMV Cl 13 were plated out at 
lxlO5 cells/well into 24-well plates and stimulated overnight with the following TLR 
ligands: polylC (lOOgg/ml), R848 (50pg/ml) or CpG 2216 (2nmol/ml). The supernatant 
was collected and type 1 IFN activity was measured by bioassay. A standard curve of 
two-fold serial dilutions of recombinant IFN-a was set up in parallel to quantitate type 1 
IFN activity in the samples. The results are expressed as log2 units/ml (U/ml) of type 1 
IFN activity and are representative of findings made in two independent experiments. 
Statistical analysis using ANOVA general linear model suggests that there was no 
significant difference in the level of type 1 IFN activity induced by the various TLR 
ligands in uninfected and LCMV Cl 13 persistently-infected cells (p>0.05).
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infected with LCMV, suggesting that the impairment in RNA virus infection-induced 
type 1 IFN production may be due to blocking of pathways triggered by activation of 
cytoplasmic RNA helicases such as RIG-I or MDA5.
5.7 Generation of cell lines stably-transfected with the individual LCMV GP, NP 
or Z viral proteins
The results of previous experiments revealed that infection with LCMV interferes with the 
ability of the cell to produce high levels of type 1 IFN in response to RNA virus 
infections. Other RNA viruses, such as HCV and BVDV have been reported to impair 
type 1 IFN production by expressing cytoplasmic viral proteins that interact with and 
block the activity of transcription factors essential for production of type 1 IFN (Baigent et 
al. 2002; Foy et al. 2005). My next series of experiments sought to investigate whether 
one of the viral proteins expressed by LCMV similarly interfered with the type 1 IFN 
induction pathway to block or reduce type 1 IFN production. DC cell lines were stably 
transfected with plasmids encoding individual LCMV proteins, and the effects of 
expression of each protein on the ability of the cells to produce type 1 IFNs in response to 
infection with Sendai virus was investigated.
Plasmids containing single genes of the LCMV genome, encoding the glycoprotein GP, 
nucleoprotein NP or the Z protein respectively, were transfected into FSDC or D2SC/1 
cells. The cells, in 6-well plates, were co-transfected with the LCMV plasmid and the 
plasmid pcDNA-V5-HisB which encodes a protein that confers resistance to blasticidin. 
The LCMV and pcDNA-V5-HisB plasmids were mixed at a ratio of 5:1 prior to 
transfection in order to increase the chance that a cell that internalized the blasticidin 
resistance plasmid would also co-intemalize the LCMV plasmid. Transfected cells were 
then grown in media containing blasticidin in order to select for cells which had
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successfully internalized and expressed the plasmids. The colonies of blasticidin-resistant 
cells were pooled, and plated out into 96-well plates using limiting dilution at a 
concentration of 1 cell per well in order to generate single-celled clones of the transfected 
cells. Following expansion, selected clones co-transfected with each of the LCMV 
plasmids were screened for expression of the LCMV protein in the cells, which were 
confirmed by immunofluorescent staining. For cells transfected with the GP, GP 
expression was detected using the anti-LCMV ascitic fluid VR134, followed by an anti­
mouse Ig-FITC conjugate. Expression of the LCMV NP protein in the NP-plasmid 
transfected clones was detected using the anti-NP-specific monoclonal antibody (mAb) 
NP-113 conjugated to Cy5. Unfortunately, no antibodies were available for detection of 
the LCMV Z protein. However, given that the high proportion of the GP- and NP- 
transfected clones that were found to express the relevant proteins, (9/10 GP-transfected 
clones and 9/11 NP-transfected clones), made it worthwhile to proceed with further 
experiments on a randomly selected Z-transfected clone to test in parallel with the GP- 
and NP-expressing clones. One clone from each transfected plasmid was selected and 
expanded in blasticidin-supplemented growth medium. Prior to experimental use, the 
selected clones were tested again by immunofluorescent staining to confirm that they were 
still expressing the relevant viral proteins. Representative examples of confocal 
microscopy images from an immunoflurescence assay conducted on the GP and NP- 
expressing cell lines are shown in Figure 5.16. No fluorescence was observed when cells 
transfected with the blasticidin-resistence plasmid only were stained with VR-134 ascitic 
fluid whereas cells transfected with the LCMV GP fluoresced. Further, when cell lines 
transfected with the LCMV NP and GP were stained with the mAb NP113, fluorescent 
cells were only observed in the cell line expressing the NP protein, and not GP.
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Figure 5.16 Staining of transfected D2SC/1 and FSDC to verify expression of the LCMV GP or NP
D2SC/1 and FSDC cells which were stably transfected with expression vectors encoding the GP or NP proteins of LCMV were stained with 
either VR-134, followed by anti-mouse Ig-FITC (green) to detect the GP proteins or NP113-Cy5 mAb (blue) which recognized the NP protein,
in order to confirm the expression of the individual viral proteins. Cells transfected with blasticidin vector only (BL) were stained as a negative 
control for VR-134 and the stably GP-transfected cell line was used as a negative control for NP-113 staining. Images shown here were 
photographed at lOOx magnification and are representative of results obtained from 2 independent experiments.
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5.8 Type 1 IFN production by stably-transfected cells in response to infection 
with Sendai virus or HSV
Untransfected cells and cell lines stably transfected with the blasticidin resistance plasmid 
only or this plasmid and LCMV GP, NP or Z-encoding plasmids were plated into 96-well 
plates and infected with Sendai virus at a m.o.i. of 1 or 10 or HSV at a m.o.i. of 5, and the 
type 1 IFN response induced in was measured. The levels of type 1 IFN mRNA induced in 
the uninfected and transfected cells were measured by real-time quantitative RT-PCR and 
the results are shown in Figure 5.17. As expected, type 1 IFN mRNA was upregulated in 
both cell lines when untransfected, after infection with both viruses. Notably, the level of 
type 1 IFN mRNA induced following infection in cell lines expressing individual LCMV 
proteins was not any lower than that induced in the untransfected cells or cells transfected 
with the blasticidin resistance plasmid only in response to infection. Bioassay analysis of 
type 1 IFN activity in culture supernatants, as shown in Figure 5.18, revealed similar 
results, i.e. all the infected cells produced type 1 IFN after infection, there was no 
difference in the levels secreted by untransfected cells, cells transfected with the 
blasticidin-resistance plasmid only or any of the cell lines transfected with plasmids 
encoding individual LCMV proteins.
These preliminary experiments do not provide any evidence to suggest that individual 
LCMV proteins impair intracellular pathways involved in upregulation of type 1 IFN 
production in response to RNA virus infection. However, these results must be interpreted 
with caution. As explained above, it was not possible to verily expression of the LCMV Z 
protein in transfected cells -  hence this protein may not have been produced. Despite the 
fact that GP and NP were shown to be expressed in transfected cells, it is possible that the 
levels of protein produced, their intracellular location and/or their processing may have 
differed from that in LCMV-infected cells.
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Figure 5.17 Levels of type 1 IFN mRNA induced in LCMV-protein-transfected 
FSDC cells upon infection with Sendai virus or HSV
FSDC cells stably transfected with LCMV GP, NP or Z proteins or an empty plasmid 
(BL) and untransfected FSDC cells (untrans) were infected with Sendai virus at high (10)
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or low (1) m.o.i. and HSV at a m.o.i. of 5. Total RNA was extracted from infected and 
uninfected (uninf) cells at 4 hours post-infection and levels of individual type 1 IFN 
mRNA subtypes were measured by quantitative Taqman RT-PCR. The Ct value of each 
type 1 EFN gene was normalised by subtraction from the Ct value of the housekeeping 
gene HPRT; the normalised level of mRNA for each gene is displayed as a ACt value 
while n.d. indicates target mRNA was not detected in the sample. The results shown are 
representative of findings made in two independent experiments.
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Figure 5.18 Levels of type 1 IFN activity produced by FSDC cell lines expressing 
LCMV proteins in response to Sendai virus or HSV infection
Plasmids encoding the GP, NP or Z proteins of LCMV or an empty plasmid (BL) were 
stably transfected into FSDC cells. These cell lines and untransfected (Untrans) cells were 
infected with Sendai virus at low (1) or high (10) m.o.i. or with HSV at a high m.o.i. (5) 
and the levels of type 1 IFN produced and released into the supernatant after infection 
were measured by EMCV bioassay. A standard curve of recombinant IFN-a was set up in 
parallel. The results shown are the levels of type 1 IFN, expressed as log2 units/ml (U/ml), 
present in the supernatant at 4 and 18 hours after infection and are representative of 
results obtained in 2 independent experiments.
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The level and pattern of NP staining in NP-transfected cells (Figure 5.16) appeared fairly 
similar to that typically observed in LCMV-infected cells. In contrast, the pattern of GP 
staining in GP-transfected cells looked somewhat different to that of LCMV-infected 
cells, with the latter showing much more evidence of surface GP-expression (see e.g., 
Figure 5.4). This could reflect abnormal processing/maturation/transport of the GP-C 
precursor protein in the transfected cells. Differences in the levels, processing and/or 
location of the LCMV proteins in transfected and infected cells may have impacted on 
their ability to block type 1 IFN induction in the former cells. It is also possible that co­
expression of two or more LCMV proteins (GP, NP, Z and/or L) in a cell may be required 
for impairment of type 1 IFN induction, and/or of protein expression in the context of 
infection itself (e.g. the presence of viral nucleic acids and/or infection-associated 
alterations in host cell functions). In summary, these experiments do not exclude a role for 
the LCMV GP, NP and/or Z proteins in impairment of type 1 IFN induction in infected 
cells.
5.9 Summary and Conclusion
LCMV has been reported to be able to infect most mammalian cell types. In agreement 
with this I found that LCMV Cl 13 was able to infect bone-marrow derived DCs, the 
fibroblasts cell line BalbC17 and the DC cell lines D2SC/1 and FSDC, establishing a 
productive infection with release of infectious progeny virus into the supernatant in each 
case. In the immortalized cell lines BalbC17, D2SC/1 and FSDC, the infection persisted 
long-term, with release of infectious vims being observed for at least 27 days post­
infection and the presence of LCMV proteins in the cells being demonstrated by 
immunofluorescent staining at >80 days post-infection.
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In BM-DCs, infection with LCMV Arm or LCMV Cl 13 induced upregulation of IFN-a4, 
IFN-p and other IFN-a subtype mRNA within the first 6 hours of infection. IFN-a4 and 
IFN-p mRNA continued to be expressed above baseline levels for up to 48 hour post 
infection. Some increase was also observed in type 1 IFN activity in the supernatant 
during the first 24 hours post-infection. However, the upregulation of type 1 IFN 
production observed was very modest when compared to the levels induced by the 
synthetic TLR3 ligand polylC which stimulated much higher and more sustained 
upregulation of type 1 IFN mRNA and activity.
In line with this observation, LCMV infection of immortalized fibroblast and dendritic 
cell lines also induced very little upregulation of type 1 IFN production, with type 1 IFN 
mRNA levels in cells and activity in the supernatant being scarcely elevated above the 
baseline levels observed in uninfected cells throughout the experiment. Extensive 
fluctuation of type 1 IFN levels was observed in uninfected cells as they were cultured. 
Nonetheless, when compared to the levels of type 1 IFN induced in similar cell lines after 
infection with other viruses, LCMV still appeared to be a poor stimulator of type 1 IFN 
induction.
In order to determine if pathway(s) for type 1 IFN induction were impaired in LCMV 
infection-infected cells, immortalized cells persistently infected with LCMV Cl 13 were 
infected with a second virus, either the RNA virus Sendai or the DNA virus HSV and the 
type 1 IFN response induced was evaluated. The results obtained suggested that there was 
impairment in type 1 IFN production in response to RNA virus infection in the 
persistently infected cells as lower levels of type 1 IFN were produced after Sendai virus 
infection of LCMV-infected cells than were produced after Sendai virus infection of 
uninfected cells, despite the fact that Sendai virus appeared to infect and replicate in both 
cell types equally well (as judged by analysis of Sendai virus RNA transcript levels over
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time). By contrast, a similar impairment was not observed in the ability of persistently- 
infected cells to produce type 1 IFN in response to infection with HSV, suggesting that 
there may be a specific impairment of pathways involved in the recognition of and/or 
response to RNA virus infection in LCMV-infected cells.
When persistently-infected cells were stimulated with synthetic TLR stimuli polylC, 
CpG 1826 DNA or R848, there was no difference in the level of type 1 IFN activity 
induced in the LCMV-infected and uninfected control cells, indicating that the TLR- 
triggered pathways for type 1 IFN induction were still intact in the LCMV infected cells. 
This suggested that the impairment in the ability of LCMV-infected cells to produce type 
1 IFN in response to RNA virus infection may be due to blocking of pathways triggered 
by activation of cytoplasmic helicases such as RIG-I and MDA5. To gain insight into 
whether one of the LCMV proteins was responsible for the partial impairment of type 1 
IFN induction, cell lines stably transfected with plasmids encoding individual LCMV 
proteins (GP, NP or Z) were generated and their ability to upregulate type 1 IFN 
production in response to infection with Sendai virus was investigated. These cell lines 
were not found to exhibit a defect in production following infection with Sendai virus. 
These results did not provide evidence to support a role for the isolated, individual LCMV 
GP, NP or Z proteins in impairment of type 1 IFN induction in LCMV-infected cells; 
however further work would be required before such a role could be excluded.
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CHAPTER 6 
DISCUSSION
Available evidence suggests that most acute viral infections trigger a rapid and short­
lived type 1 IFN response. Notably, this often starts to be downregulated before viral 
titres in the host have reached their peak (Biron and Sen 2001). Further, as reviewed 
in the introduction, persistent viral infections where there are high levels of ongoing 
viral replication are typically not observed to be associated with long term high level 
upregulation of type 1 IFN production. Instead, there may be low-level type 1 IFN 
production, a lack of type 1 IFN upregulation, or suppression of type 1 IFN induction 
(Anthony et al. 2004; Duan et al. 2004).
A number of mechanisms may contribute to downregulation of the acute-phase type 1 
IFN response, and/or suppression of type 1 IFN production in the context of chronic 
viral replication. Many viruses have evolved strategies for impairing pathways 
involved in upregulation of expression of type 1 IFNs (and/or IFN-stimulated viral 
genes) as a means to prolong their survival in the host. As reviewed in the 
introduction (see Figure 1.1 and 1.2), type 1 IFN may be blocked at the level of 
pathogen component recognition, by sequesteration of ligands which may trigger type 
1 IFN induction, e.g. dsRNA (Talon et al. 2000); the signaling pathway involved in 
IFN gene regulation may be targeted, e.g. HCV impairs the MAVS adaptor protein 
(Foy et al. 2005); type 1 IFN binding to its receptor may be impaired or signaling 
through the IFN-R may be affected, e.g. through interference with the JAK/STAT 
signaling pathway (Didcock et al. 1999). Restriction of type 1 IFN production in acute 
or chronic viral infections may thus reflect a virus-induced block.
Virus infections may also reduce type 1 IFN production via detrimental effects on the 
generation, survival and/or functions of key IFN-producing cells such as plasmacytoid
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DCs. Viruses that infect plasmacytoid DCs (e.g. HIV-1) may have direct effects on 
the survival/functions of this important IFN-producing cell type (Flano et al. 2005; 
Pollara et al. 2005). However, virus infections may also impact on plasmacytoid DC 
numbers more indirectly, via effects on pathways controlling their 
generation/survival, e.g. persistent expression of type 1 IFN during chronic LCMV 
Cl 13 infection has been reported to suppress the maturation of DC precursors in the 
spleen (Hahm et al. 2005).
In addition, the host possesses homeostatic mechanisms for downregulation of type 1 
IFN production, because inappropriate expression of type 1 IFN may have pathogenic 
effects e.g. some of the pathology observed in mice neonatally challenged with 
LCMV is reported to result from the toxic effects of excessive type 1 IFN induced in 
response to LCMV infection (Gresser et al. 1978; Riviere et al. 1977). As discussed in 
the introduction, expression of type 1 IFN is typically followed by appropriate 
activation of ISGs as well as repression of further IFN activity and expression, e.g by 
upregulation of IRF-4 or receptor internalization and degradation. However, little is 
known as to whether these homeostatic mechanisms continue operating during long­
term productive viral infections.
In summary, the relative contribution of different mechanisms to the regulation of 
type 1 IFN production in acute and persistent viral infections remains poorly 
understood.
In this project, I aimed to characterize the type 1 IFN response in the acute and 
chronic phases of infection of mice with a natural murine pathogen, LCMV, and to 
analyse the ability of the virus to modulate type 1 IFN production in the cells it 
infects.
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LCMV isolates differ in their ability to establish persistent infections in adult 
immunocompetent C57BL/6 mice, e.g. LCMV Arm typically causes an acute 
infection which is controlled in 7-14 days while the LCMV Docile and LCMV Cl 13 
causes a persistent infection if it is delivered systemically, via the i.v. route at high 
doses (e.g. of about 106 p.f.u). Infection is non-cytopathic; and the virus quickly 
replicates to high viral titres in many organs and infectious virus is secreted for 
extended periods (Borrow and Oldstone 1997). Initial experiments tested strains of 
LCMV available in the laboratory to determine whether they were able to cause a 
long-lived infection (>4 weeks) in adult immunocompetant C57BL/6 mice. While two 
of the LCMV isolates available to me, namely LCMV Cl 13 and LCMV Docile, had 
been previously reported to establish persistent infections in wild-type adult C57BL/6 
mice, the working stocks employed here had been passaged several times in tissue 
culture, which may have affected the in vivo virulence of the strains. A pilot 
experiment was thus conducted to determine how long the newly-generated working 
stocks persisted in vivo. Future experiments aimed to investigate the innate immune 
response in a background of persistent LCMV infection, and so it was imperative that 
the mice remained infected for longer than 3 weeks in order to allow “exhaustion” of 
the adaptive T-cell response to occur and chronic infection to be established.
LCMV Cl 13 and LCMV Docile were both found to persist in wild-type adult 
C57BL/6 mice for a period of >4 weeks; however LCMV C113 was eventually 
selected for experimental use because it possessed a sequence that was almost 
identical to a LCMV strain available in the laboratory, which causes an acute 
infection, namely LCMV Arm. The genome of both LCMV Arm and LCMV Cl 13 
have been sequenced and found to differ by only 2 amino acids, resulting in a 
phenylalanine to leucine substitution at position 260 in GP-1 and lysine to glutamine
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at position 1079 in the viral polymerase of LCMV Cl 13 (Matloubian et al. 1993; 
Matloubian et al. 1990; Salvato et al. 1988)( Salvato et al Virology, 1988 164, 517). 
The use of closely-matched viral isolates is preferable as it facilitates comparative 
analysis of results.
Experiments were then conducted to follow the type 1 IFN responses in mice infected 
with LCMV Arm or LCMV C113. Type 1 IFN levels were assessed by measurement 
of transcript abundance in the spleen and anti-viral activity in the serum. Both 
methods indicated that in mice infected with LCMV Arm, which causes an acute 
infection, type 1 IFN production reached maximal levels by 12-24 hours post­
infection. Upregulation of IFN-(3, IFN-a4 and IFN-a(non-a4) mRNA and activity 
reached maximal levels within 24 hours after LCMV infection, and then fell by 72 
hours post-infection before dropping to baseline/undetectable levels between days 7 to 
21 when the infection was resolved. Thus, during acute infection, type 1 IFN 
induction in the spleen and blood was transient and occurred very quickly post­
infection. Viral plaque assays performed on the same samples show that in mice 
infected with LCMV Arm, the type 1 IFN response declined before viral replication 
reached its peak, which occurred at ~72 hours post-infection. Investigations in mice 
infected with LCMV C113, which is able to establish a persistent infection showed 
that type 1 IFN was induced with similar kinetics of induction after infection with 
LCMV Arm. The magnitude of the peak type 1 IFN response induced in the spleen 
and blood of Cl 13-infected mice was marginally lower than that in Arm-infected 
animals, but was not reduced to a statistically significant extent. Again, type 1 IFN 
responses in LCMV Cl 13-infection peaked before the peak in viral replication, 
although the viral titres in these mice rapidly reached higher titres than recorded in 
mice infected with LCMV Arm. It was unclear whether the increased viral replication
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observed in LCMV C113-infected mice was assisted by the slight reduction in the 
magnitude of the type 1 IFN response (although it should be noted that persistent 
strains of LCMV are typically more resistant to the effects of type 1 IFN), or whether 
increased viral titres were in fact responsible for the reduction in the levels of type 1 
IFN, which would indicate an LCMV-mediated impairment of host type 1 IFN 
production. Such an impairment could in turn impact upon the quality of the antiviral 
state induced in the host.
Apart from upregulating ISGs involved in establishing an antiviral state in the host 
during the early stages of infection, type 1 IFNs are also responsible for the 
maturation of cytotoxic T-cells needed for viral clearance. Resolution of LCMV 
infection requires production of IFN-y cytokine and/or perforin-mediated killing of 
infected host cells. It is possible that the early shutdown of type 1 IFN production may 
lead to suboptimal priming of the CD8 T-cells resulting in a T-cell response which is 
able to contain and clear LCMV Arm infection but may not be sufficient to control 
the faster-replicating LCMV Cl 13 strain. The reduction of circulating type 1 IFN in a 
productive, persistent infection has been reported to occur in other viral infections, 
including HIV, HCV and HBV, where it may be a factor promoting persistence of the 
infection (Anthony et al. 2004; Duan et al. 2004; Murakami et al. 2004; Siegal 2003). 
Viral titres in the spleens of mice infected with LCMV Arm fell beyond the limit of 
detection by 3 weeks post-infection, as the acute infection was resolved. Following 
viral clearance, IFN-p and IFN-a mRNA transcripts in the spleen declined to baseline 
levels. By contrast, in the spleens of mice infected with LCMV C113, viral titres 
remained elevated at 3 weeks post-infection, but only low levels of type 1 IFN 
continued to be produced, (detected at the mRNA level). Confocal studies also 
confirmed this observation, as small numbers of IFN-a producing cells were
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visualized in sections of LCMV Cl 13-infected spleens. Previous studies, mainly 
carried out in mice infected at birth with LCMV also reported conflicting results: low 
but nonetheless elevated levels of IFN activity were reported in the plasma by some 
groups (Bukowski et al. 1983; Saron et al. 1982) whilst other reports did not find 
elevated levels of IFN in these animals (Holtermann, 1970; Wagner and Snyder, 
1962; Traub and Resting, 1963). The differing results of these studies possibly reflect 
the intermittent but low responses I observed in my experiments.
The identity of the cells which secrete type 1 IFN during infection with LCMV is still 
unclear. In acute LCMV Arm infection, it was reported that in contrast to other viral 
infections, plasmacytoid DCs are not the major producers of systemic type 1 IFN 
(Dalod et al. 2003). Depletion of splenic DCs with the DC antibody GR-1 did not 
alter the serum levels of type 1 IFN produced in response to LCMV. However, several 
labs have reported that GR-1 antibody does not completely deplete DCs in vivo 
(Asselin-Paturel et al. 2003; Belz et al. 2005). Studies conducted in our lab have 
found that acute infection with LCMV Arm does induce upregulation of type 1 IFN 
mRNA in CD1 lc+ B220+ plasmacytoid DCs, and also (to a much lower extent) in the 
CD1 lc+ B220' conventional DC subset (Montoya et al. 2005).
My analysis of IFN-a/p mRNA levels in purified plasmacytoid and conventional DC 
subsets conducted on LCMV Arm or LCMV Cl 13-infected mice confirmed the latter 
observations. Infection with LCMV Arm rapidly induced IFN-a/p production in 
splenic DCs, with plasmacytoid DCs upregulating IFN-a/p expression to a much 
higher extent than conventional DCs. Expression of type 1 IFN in plasmacytoid DCs 
also peaked earlier than in the conventional DC subset. Similar responses were 
recorded in plasmacytoid and conventional DC subsets isolated from the spleens of 
mice infected with LCMV C113. This was confirmed by immunofluorescent staining
368
of spleen sections taken shortly after infection from LCMV Arm and LCMV Cl 13- 
infected mice, which showed some IFN-a production in plasmacytoid DCs. However, 
many of the IFN-a-secreting cells within the marginal zone area did not appear to be 
plasmacytoid DCs and it was not clear what the other IFN-a producing cells were. NK 
cells and macrophages as well as conventional DCs have been shown to upregulate 
type 1 IFN during viral infections, and repeating immunofluorescent staining of 
LCMV-infected spleen sections using mAbs specific for these cell types may be one 
way to identify the nature of these IFN-a producing cells. Alternatively, intracellular 
staining assays could be performed on splenocytes from infected mice, co-staining the 
cells with mAbs against IFN-a and markers for different lymphocyte populations, and 
the IFN-a producing cell type identified by FACs analysis.
Nonetheless, it is apparent that plasmacytoid DCs and to a lesser extent conventional 
DCs do contribute to the rising levels of type 1 IFN during the early phase of 
persistent LCMV infection. While the extent of upregulation of IFN-a/(3 in 
conventional DCs may not be equivalent to upregulation in plasmacytoid DCs on a 
per-cell basis, there are lOx more conventional DCs in the spleen, so as a total 
population, these cells probably make some contribution to the level of type 1 IFN in 
the system. Experiments that measure the type 1 IFN levels in LCMV-infected mice 
depleted of splenic DC subsets using other newly isolated plasmacytoid DC-specific 
antibodies such as mpDCA-1 may help resolve the uncertainty surrounding the 
relative contributions of plasmacytoid DCs, conventional DCs and other cell types to 
production of serum type 1 IFNs in LCMV-infected mice.
As previously observed in the spleen and the serum, type 1 IFN expression in 
plasmacytoid and conventional DCs isolated from LCMV C113-infected mice was 
low or undetectable during the later stages of infection. Immunofluorescent staining
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of spleen sections from mice infected with LCMV Cl 13 for 4 weeks showed 
widespread LCMV infection in the spleen but only low IFN-a production. IFN was 
produced by uninfected and a minority of infected cells, including principally 
plasmacytoid DCs (Figure 4.12). Importantly, there was little evidence of IFN-a 
production by infected cells other than plasmacytoid DCs. It thus appeared that the 
majority of infected splenocytes are unresponsive to the presence of LCMV viral 
components which would normally promote induction of type 1 IFNs. One 
explanation for this observation could be that infection with LCMV Cl 13 may have 
mechanisms for impairing type 1 IFN production in the cells it infects.
The majority of cells, including fibroblast and conventional DC cells utilize the 
intracytoplasmic RIG-1, MDA5 and MAVS helicases to detect the presence of 
intracellular infection. By contrast plasmacytoid DCs possess multiple mechanisms 
for type 1 IFN induction: in addition to the RIG-I helicase intracytoplasmic pathway 
above, plasmacytoid DCs also use TLRs on the cell surface or in endosomes to sense 
extracellular or engulfed material (Haller et al. 2006; Kawai and Akira 2006). 
Conventional DCs also express TLR3 in the endocytic compartment which allows 
them to sense viral and other dsRNA molecules. The fact that the small number of 
infected cells in LCMV-infected mice that were observed to be producing type 1 IFN 
were plasmacytoid DCs suggests that LCMV may potentially impair type 1 IFN 
production via the intracellular helicase pathways used for detection of infection in 
the majority of infected cells, but may potentially leave plasmacytoid DC-specific 
type 1 IFN induction mechanisms intact.
Consistent with this, experiments in which BM-DCs and in vitro cell lines were 
infected with LCMV Arm or LCMV Cl 13 revealed very poor induction of type 1 IFN. 
Fibroblast, BalbC17 and DC cell lines, FSDC and D2SC/1, were infected as I wanted
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to reflect the different cell types present in vivo. The DC cell lines were derived from 
spleens (D2SC/l)(Lutz et al. 1994) or dendritic cell precursors from fetal mouse skin 
(FSDC) (Girolomoni et al. 1995) and are reported to display DC phenotype that is 
more akin to conventional DCs than plasmacytoid DCs, as evidenced by stronger type 
1 IFN responses to polylC than R848 or CpG stimulation (Figure 5.14). D2SC/1 and 
FSDC have also been previously reported to upregulate detectable levels of type 1 
IFN in response to an RNA virus, Sendai (Eloranta et al. 1997). It would have been of 
interest to conduct parallel experiments with a plasmacytoid-like cell line, but 
unfortunately no suitable cell lines were available.
A confounding factor in these experiments was that, unlike in in vivo tissue or 
primary cells where the background levels of type 1 IFN were non-existent or 
negligible (0-30U/ml), baseline levels of type 1 IFN in the supernatants of uninfected 
control cells fluctuated to varying degrees depending upon the cell line tested. 
Backgrounds in the supernatants of BalbC17 and DC cells fluctuated wildly from 0 to 
125U/ml. Efforts to minimize the fluctuations, including culturing cells in low 
endotoxin serum, addition of polymyxin B to the culture medium, or making sure the 
cultures were not overgrown, did not overcome the fluctuation. This phenomenon has 
been previously described and is believed to be due to contact or growth-mediated 
stimulation (Hannigan and Williams 1986). While an upregulation of type 1 IFN was 
recorded immediately after LCMV infection in all the cell lines, it was difficult to be 
certain that the upregulation was virus-specific. The hallmark of type 1 IFN 
expression is a strong upregulation in response to viral infection, which was indeed 
observed when the same cells were infected with HSV or Sendai, where the maximal 
levels of type 1 IFN in the supernatant were clearly above the levels of the fluctuating 
background. However LCMV infection stimulated production of type 1 IFN activity
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which was about 2-4-fold less than the other viral infections and barely above the 
background.
All in all, LCMV was able to infect all the cell lines tested, releasing infectious 
virions into the supernatant and generated a persistent infection with production of 
LCMV viral proteins in cells during the course of the persistent infection. 
Nonetheless, the type 1 IFN response to the infection was of a lower magnitude than 
the response seen in other viral infections. In agreement with in vivo observations, 
type 1 IFN production was not sustained beyond the first 3 days of infection even 
though virus continued to be produced at high titres. The presence of the high viral 
load did not induce any additional bursts of type 1 IFN production. While it may be 
possible that no further type 1 IFN was produced because viral components in the cell 
were sequestered away from the innate-sensing receptors present in the cytoplasm 
(e.g. RIG-I), or on the external cell surface or in intracellular organelles (e.g. TLRs), 
these results in in vitro systems also suggest the likelihood that there may be some 
impairment in the ability of infected host cells to recognize viral components and 
respond with production of the antiviral cytokine type 1 IFN.
As outlined above, most cells in the body detect the presence of an intracellular viral 
infection via the RIG-I helicase pathway that senses viral dsRNA (Haller et al. 2006; 
Kato et al. 2005), activating the TBKl/IKKe kinase complex to phosphorylate IRF-3 
(Mori et al. 2004; Paz et al. 2006), enabling nuclear translocation of phosphorylated 
IRF3 and subsequent activation of IFN-P and IFN-a4 mRNA transcription (which 
starts off autocrine amplification of IFN-a/p cytokines and other interferon stimulated 
antiviral genes (as shown in Figure 6.1). Any block in this pathway would 
downregulate type 1 IFN production in these cells. However, a similar impairment 
would not completely block IFN-a/p induction in infected plasmacytoid DCs, as these
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Figure 6.1 Pathways that may be involved in the transcriptional activation of type 1 IFN gene expression following virus infection
Overview of the signalling pathways leading to type 1 IFN production so far described are explained. The putative block along the RIG-I 
signalling pathway is indicated. Abbreviations are explained in the text (adapted from Kawai and Akira, 2006).
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cells are also able to upregulate type 1 IFN expression via the TLR pathway, which 
relies on the activation of IRF7 and NF-k{3 for type 1 IFN induction (Akira et al. 
2006; Fitzgerald et al. 2003; Honda et al. 2005a; Honda et al. 2005b). Conventional 
DCs also possess a limited ability to upregulate type 1 IFN in this manner through 
expression of TLR3. A consequence of this redundancy is that conventional DCs and 
plasmacytoid DCs do not have to be infected to produce type 1 IFNs but can respond 
to inactivated viral particles or parts of dead cells provided they are taken up into the 
endocytic compartment. LCMV may impair the response of the cells to the presence 
of plasmacytoid DCs to endocytosed viral components triggered through TLRs.
In line with this in vivo and in vitro experiments addressing the response to 
persistently infected mice or cells to different innate stimuli suggested that infection 
with LCMV may induce a partial impairment of type 1 IFN induction. In order to 
determine whether persistently infected mice retained the capacity to recognize 
different innate stimuli and respond with type 1 IFN activation, mice infected with 
LCMV Cl 13 3 weeks previously were inoculated with a range of innate stimuli and 
the level of activation of type 1 IFN production was assessed. Upon stimulation with 
synthetic ligands for TLR3, TLR7 or TLR9, namely polylC, R848 or CpG 1826 DNA 
respectively, type 1 IFN levels were upregulated in the spleen and in the serum of 
persistently-infected mice with similar kinetics as to induction in stimulated 
uninfected animals. Type 1 IFN was also induced to comparable levels in uninfected 
and persistently-infected animals, but a difference was observed in the extent of 
upregulation, with a higher extent of upregulation recorded in the uninfected mice, but 
this may have been because the increase was from very low baseline levels. This may 
also indicate that there is a threshold concentration that is tolerated by the host before
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a downregulation or expression plateau is enforced, perhaps as a tactic to avoid the 
toxic side effects of excessive levels of type 1 IFN (Pfau et al. 1983; Riviere et al. 
1980).
The only marked difference in the response of uninfected and LCMV infected mice 
occurred when influenza PR8 was used as a stimulus. Influenza PR8, a live virus, was 
delivered i.p. so as to reduce the potential for complication of interpretation of results 
by differences in replication/spread of infection in uninfected and persistently- 
infected mice. In vivo, influenza replication is limited to epithelial cells of the upper 
and lower respiratory tract which express the protease necessary for viral activation 
(Rott et al. 1995). Therefore, administration of live influenza virus into the 
intraperitoneal cavity will result in attachment and entry of the virus into peritoneal 
cells, followed by replication but no release of new progeny virus. Infection with 
influenza virus has been reported to induce serum type 1 IFN production (Wabuke- 
Bunoti et al. 1986). Type 1 IFN may be produced, possibly in a RIG-I/MDA5- 
dependent manner, by cells responding to vims entry and replication, or may be 
produced by uninfected cells such as plasmacytoid DCs or other cell types responding 
to components of the vims such as ss or ds viral RNA, HA or other viral 
glycoproteins. Notably, influenza NS1 has been shown in in vitro studies to reduce 
type 1 IFN production and PKR activity in influenza-infected cells by sequestering 
dsRNA synthesized during viral replication. However, type 1 IFN production has still 
been observed in influenza-infected BM-DCs and human and mouse plasmacytoid 
DCs, where TLR7 is activated by viral ssRNA (Diebold et al. 2004; Krug et al. 2004; 
Lund et al. 2004).
When persistently infected mice were injected i.p with influenza vims, IFN-a and 
IFN-P mRNA in the spleen were upregulated as was the level of type 1 IFN activity in
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the serum. The response was detectable as early as 6 hours post-stimulation and was 
sustained for at least 24 hours post-stimulation. However, the level of type 1 IFN 
activity induced in the serum of the mice was lower than the activity induced in 
uninfected mice administered with influenza in parallel. Further, mRNA levels of 
IFN-J3, -a4 and other a subtypes were slightly lower in LCMV C113-infected mice and 
the IFN-stimulated gene Mx was upregulated to a much lower extent than in 
influenza-treated uninfected controls.
There may be several explanations for the reduced levels of type 1 IFN induced in 
persistently infected mice following inoculation with influenza virus. Firstly, the 
presence of LCMV Cl 13 virus in the persistently-infected mice may have generated 
an ongoing antiviral state in the animals, making them more resistant to subsequent 
infection by influenza. Indeed, the spleens at 6, 12 and 24 hours post-stimulation did 
contain less influenza mRNA transcript than uninfected stimulated mice (Figure 4.15) 
when measured by Taqman quantitative RT-PCR. There may not thus have been as 
high level of viral components present to stimulate the cells, leading to a weaker 
systemic type 1 IFN response. Another cause of low type 1 IFN production may stem 
from the reduction in splenic DC numbers in the persistently-infected mice, because 
plasmacytoid dendritic cells represent a source of systemic type 1 IFN during 
influenza infections (Bruno et al. 2001; Diebold et al. 2004; O'Keeffe et al. 2002). In 
support of this, confocal images of influenza-stimulated spleen sections in uninfected 
mice showed a high frequency of co-localisation between IFN-a and mPDCA-l+ cells 
(yellow cells) whilst a lower frequency of similar co-localisation was observed in the 
spleens of persistently-infected mice.
A third alternative explanation for the lower response is that the pathways responsible 
for type 1 IFN induction in response to influenza may be impaired in mice persistently
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infected with LCMV C113. As reviewed above, these may include TLR-dependent 
pathways or intracellular helicase-dependent pathways. Stimulation of uninfected and 
persistently-infected mice with TLR ligands induced good type 1 IFN responses, so it 
might have been expected that a good response would also be induced to TLR ligands 
generated during influenza infection. However, it could be that prolonged exposure to 
high levels of LCMV viral components may have tolerised pathogen-responsive cells 
to further stimulation. The response observed following inoculation of synthetic TLR 
ligands could be a result of the high dose of ligand that was administered. By contrast, 
the levels of influenza PR8 was injected i.p. was low and the levels of stimuli 
generated during influenza infection may be lower than the levels of TLR ligands 
administered. Thus, it remains a possibility that cells in LCMV-infected mice may be 
tolerised to low doses of stimuli, leading the response to ligands in influenza PR8 to 
be impaired. In addition, the intracytoplasmic helicase pathway may be impaired in 
LCMV-infected cells, reducing the capacity of infected animals to respond to 
influenza infection via this mechanism.
Furthermore, it was found that ex vivo CD llc+ DCs isolated from persistently- 
infected mice, which would consist of plasmacytoid and conventional DCs, still 
retained the capacity to produce type 1 IFN in response to high doses of exogenously 
added synthetic TLR ligands in culture, which again suggests that activation of type 1 
IFN production via TLR 3, TLR7 and TLR9 pathways was functional (although it 
would have been of interest to examine the response to lower doses of TLR ligands 
too. However, this observation also suggests that should there be any impairment in 
the response to viral components in vivo and in vitro it would likely be in the 
intracellular sensing pathway.
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Experiments on LCMV-infected DC and fibroblast cell lines also lend weight to this 
theory of infection associate impairment of IFN production through selected 
pathways. In a population of homogenous cells with either a DC (D2SC/1 and FSDC) 
or fibroblast (BalbC17) phenotype, where >95% of cells were infected with LCMV, 
productive infection with another RNA vims, Sendai, which is dependent upon the 
RIG-I helicase pathway to upregulate type 1 IFN resulted in induction of reduced 
levels of IFN-a/p (Melchjorsen et al. 2005). In contrast, infection with HSV resulted 
in induction with HSV in induction of similar levels of type 1 IFN to those induced in 
uninfected cells (indicating the TLR 9 (Krug et al. 2004) and/or DNA sensing 
intracytoplasmic pathways (Stetson and Medzhitov 2006) are intact), and stimulation 
of LCMV C113-infected D2SC/1 and FSDC cells with synthetic TLR ligands also 
resulted in induction of an equivalent response to that observed in uninfected cells, 
strengthening the hypothesis that only the intracellular dsRNA-sensing pathway may 
be impaired.
On the basis of the data from in vivo and in vitro experiments, it is thus plausible that 
LCMV may be inhibiting the intracytoplasmic helicase pathway. Helicases such as 
RIG-I are responsible for production of type 1 IFNs by infected cells in response to 
RNA vimses, so it is not unexpected that if viral component(s) mediate impairment of 
IFN production in infected cells they would target the RIG-I or related induction 
pathway(s). Inactivation of the helicase pathway in LCMV-infected cells would offer 
a logical solution to all the observations discussed so far. Firstly, as depicted in Figure 
6.1 (which depicts the same type 1 IFN induction pathways as outlined in Figure 1.1), 
impairment of RIG-I, IPS-1 or TBKl/IKKe would leave other arms of the type 1 IFN 
induction pathway (IRF-3, TRAF6, NFk(3 etc) intact and ready for use by the 
TLR3/7/9 system, offering an explanation as to why I saw type 1 IFN produced when
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infected mice/cells were exposed to TLR ligands (or HSV which is known to signal 
via TLR9).
The increase observed in serum levels of other inflammatory cytokines following 
inoculation of persistently-infected mice with TLR ligands can also be explained on 
the basis of selective impairment of activation of the innate response pathway. TNF-a 
and IL-6 can be upregulated by the presence of intracellular viral RNA activating 
TLR3/TLR7 and the adaptors TRAF6, NFk(3 and IRF5 (Figure 6.1) (Kawai and 
Akira 2006). Increases in the levels of TNF-a and IL-6 upon stimulation with TLR 
ligands would be anticipated if NFicp and TRAF6 are not affected by LCMV 
infection.
Is has also been proposed that an LCMV infection may dysregulate the JAK/STAT 
pathway by activating STAT2 and encouraging formation of STAT2:STAT2 
homodimers not only in DCs but in all infected cells (Hahm et al. 2005). While the 
actual mechanism has not been clarified, if true, this would have the effect of 
disrupting the JAK/STAT pathway e.g. by reducing the amount of free STAT2 
available to create STAT1:STAT2 heterodimers. Inhibitors of JAK/STAT not only 
suppress the production of anti-viral proteins but also the expression of RIG-I, 
MDA5, IPS-1, MAVS, IRF-3 and IRF-7 as they are all IFN-inducible proteins, and as 
a consequence, production of the ‘second wave’ IFNs is reduced, acting against the 
IFN-activating effect of viral dsRNA molecules which progressively accumulate in 
the cytoplasm (Haller et al. 2006). It is interesting to note that while the type 1 IFN 
mRNA levels were upregulated in a similar manner in the spleens of uninfected and 
persistently-infected mice after stimulation with synthetic TLR stimuli, Mx mRNA 
levels were consistently lower in stimulated persistently-infected spleens. Mx
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expression is regulated by type 1 IFNs through activation of the JAK-STAT pathway. 
Low upregulation of Mx may reflect a defect in this pathway.
I investigated the possibility that components of LCMV may be impairing the type 1 
IFN response. Viral proteins of LCMV have been implicated in impairment of other 
cellular functions, e.g. the NP protein interferes with the growth hormone 
transactivator factor GHF1 (Pitl) to dysregulate transcription of growth hormone (de 
la Torre and Oldstone 1992). The Z protein was reported to interact with certain host 
cell translation factors (Campbell Dwyer et al. 2000) and also pro-myelocytic protein 
(PML) -  an oncoprotein induced by and involved in type 1 IFN responses. Binding of 
the Z protein to PML leads to redistribution of PML to the cytoplasm and inhibition 
of apoptosis; deregulation of host cell apoptotic mechanisms may help the virus to 
establish persistence (Chelbi-Alix et al. 1998; Lavau et al. 1995). Additionally, the Z 
protein which is reported to interact with the viral RNA polymerase, contains a zinc 
finger DNA binding motif which may interfere with the activity of other nucleic-acid 
binding proteins such as helicases or transcription factors.
Investigations were conducted in in vitro cell cultures. Plasmids containing individual 
proteins of LCMV, namely GP, NP or Z were stably transfected into DC cell lines as 
initial attempts to conduct experiments in transiently-transfected cells were not 
successful due to non-specific upregulation of type 1 IFN. I was not able to obtain a 
plasmid containing the L polymerase protein and so it was not tested. However, when 
these stably-transfected cells were infected with Sendai or HSV, there was no 
difference between the levels of type 1 IFN produced in the cells expressing GP, NP 
or Z and the levels of type 1 IFN induced in cells expressing blasticidin only or which 
were not transfected, suggesting that none of the proteins impaired type 1 IFN 
induction. Nonetheless, this result does not conclusively prove that the LCMV virus
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or the viral proteins of LCMV does not mediate impairment of type 1 IFN induction. 
There may be several reasons why LCMV-induced IFN inhibition may not have been 
reproduced in the cell lines I generated expressing individual LCMV proteins: firstly, 
during a persistent viral infection, large concentrations of viral antigens accumulate in 
the infected cell, as confirmed by immunfluorescent staining of persistently infected 
cells (Figure 5.6). The stably-transfected cell lines did not express the transfected 
proteins at similar levels (see Figure 5.16), hence the concentration of the viral protein 
may not have been high enough for it to exert its inhibitory effects. In the case of the 
Z protein, I was not able to confirm expression of the protein as I lacked a specific 
anti-Z antibody. Alternative methods could have been employed to detect the 
presence of Z, perhaps by detecting the presence of Z mRNA by RT-PCR using Z- 
specific primers, but this would not give any information on the conformation, 
abundance and location of the Z protein in the stably transfected cells. Furthermore, 
although expression of GP and NP were confirmed by immunofluorescence, I was 
unable to determine the location/distribution of the proteins in the cell, which may 
have been altered through being expressed from an artificial plasmid construct. 
Secondly, viral proteins may not be the inhibitory factor; if the intracellular pathway 
is blocked, it is likely that helicases are targeted and inhibition may be the result of an 
interation between helicases and viral RNA. Thirdly, the inhibitory effects may 
require the synergistic effects of a combination of viral proteins and possibly viral 
RNA e.g. it is hypothesized that the ligand for TLR7 is ssRNA complexed to 
nucleoprotein (Diebold et al. 2004). One possibility is that a similar ssRNA-viral 
protein complex expressed by LCMV could potentially attach to and block TLR7 
activation. Indeed synthetic siRNAs of —21-30 kb designed with 5’ overhang 
structures on the ends efficiently block the activity of RIG-I (Marques et al. 2006).
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Given more time, I would have liked to have been able to dissect the interactions 
between LCMV and components of the intracellular or type 1 IFN pathway. If the 
virus was downregulating components of the intracytoplasmic pathways, the levels of 
these factors in persistently infected cells could be analysed by FACS or quantitative 
real-time RT-PCR. Any evidence of in situ LCMV viral protein interaction with IRFs 
or helicases could be visualized by immunfluorescence while footprinting/Westem 
blot assays could be conducted on persistently infected cells to determine if viral 
RNA interacts with helicases or TLRs. Alternatively, Western blot assays could be 
run to determine if there was interaction between viral proteins and STAT proteins 
and check whether any of the viral proteins interfered with STAT phosphorylation. 
Infection of high dose LCMV in cell lines does not induce much type 1 IFN, 
presumably because in this situation, almost all the cells are infected and thus the 
entire population is impaired its ability to produce type 1 IFN via intracellular 
helicase pathways. GMCSF-matured BMDCs were found to produce some type 1 IFN 
in the first 24 hours after LCMV infection (Figure 5.2 & 5.3). These consist of cells 
with a conventional DC-like phenotype with TLR 2, 3, 4, 5, 6 and 9 expression (Datta 
et al. 2003; Lutz et al. 2000) in addition to the inracytoplasmic pathway (Melchjorsen 
et al. 2005). The type 1 IFN they produced may have been stimulated via TLR 
pathways. The DC cell lines D2SC/1 and FSDC also posses TLR3/7/9 expression as 
evidenced by their responsiveness to polylC, R848 and CpG 1826 DNA (Figure 
5.14); however, the modest levels of type 1 IFN activity induced by R848 in these cell 
lines indicate that they may express only low levels of TLR7. Impairment of the 
intracellular pathway by LCMV coupled with low TLR 7 expression on D2SC/1 and 
FSDC, may explain why very little type 1 IFN upregulation was observed in these 
cells following infection with LCMV.
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In vivo, infection with acute and persistent strains/isolates of LCMV does stimulate, 
albeit for a short period, production of high levels of type 1 IFN. If LCMV impairs 
type 1 IFN production via helicase-dependent pathways in infected cells, it is likely 
that during the early or acute phase of infection, the bulk of the type 1 IFN produced 
is from uninfected cells such as plasmacytoid and conventional splenic DCs able to 
sense and respond the presence of viral components via PRRs such as TLRs, 
Although high levels of type 1 IFN are produced in the acute phase of LCMV 
infection, the response is rapidly downregulated; and there are only low levels of type 
1 IFN production during the persistent phase of infection, as evidenced by analysis of 
spleen and serum levels of IFN-a/p mRNA and bioactivity in LCMV C113-infected 
mice at 3 weeks post-infection. There are a number of possible explanations for the 
downregulation of type 1 IFN production in early LCMV infection and the almost 
complete lack of type 1 IFN production in mice persistently infected with LCMV in 
spite of the systemic presence of infectious virus. As mentioned before, plasmacytoid 
and conventional DCs possess redundant pathways for type 1 IFN production, and so 
should be able to produce type 1 IFN even if they are infected. However, analysis of 
splenic DC subsets revealed that the number of conventional DCs, and subsequently 
plasmacytoid DCs is reduced following the acute phase of LCMV infection, and that 
during persistent LCMV infection the numbers of splenic CD1 lc+ B220' and CD1 lc+ 
mpDCA-l+ or B220+ DC cells were appreciably reduced. Confocal experiments using 
mpDCA-1 antibody confirmed the observation in situ, with a low frequency of 
pDCA-l+ DCs being observed in spleen sections from LCMV Cl 13-infected mice. 
The reduction in plasmacytoid DC numbers may be due in part to maturation into 
other DC subtypes, as as plasmacytoid DCs are able to become myeloid DCs upon
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LCMV infection (Zuniga et al. 2004). However, there is also a dramatic overall 
reduction in splenic DC numbers in mice persistently-infected with LCMV.
Montoya et al (Montoya et al. 2002) showed that the drop in conventional DC 
numbers during acute infection with LCMV Arm was due to apoptosis (evidenced by 
Annexin V staining) of activated conventional DCs. Depletion of matured DCs by 
apoptotic mechanisms, may be accompanied by a defect in replacement of DCs from 
bone marrow precursors, resulting in a permanent depression of splenic DC numbers 
during the persistent stage of infection. It has been previously reported that there are 
profound alterations in hematopoietic functions in LCMV-infected mice, including 
suppression of pluripotent stem cells, granulocyte-macrophage progenitors, 
prothymocytes and erythroid progenitors (Bro-Jorgensen 1978; Bro-Jorgensen and 
Knudtzon 1977) and depletion of bone marrow lineage B cells (Borrow et al. 2005). A 
variety of mechanisms have been proposed to contribute to the abnormalities in 
hematopoietic functions observed during acute and chronic LCMV infection, 
including LCMV infection of bone marrow precursors, and infection-associated 
production of cytokines including IFN-a/p and TNF (Binder et al. 1997; Binder et al. 
1998). The reduction in splenic DC numbers may be a consequence of infection of the 
CD11+ precursor cells in the spleen which would, during normal steady state 
conditions, mature into conventional DCs (Naik et al. 2006). Additionally, it has been 
speculated that continuous type 1 IFN production in response to persistent LCMV 
Cl 13 infection suppresses the development of bone marrow precursor cells into DCs 
via a yet undefined STAT2-dependent pathway (Hahm et al. 2005).
In addition to the numbers of plasmacytoid and conventional DCs in the spleen of 
mice persistently-infected with LCMV being reduced, there is also very little type 1 
IFN from the remaining cells as the levels of IFN-a/p mRNA in the few DCs present
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in the spleen of persistently-infected mice were also low/undetectable. IFN-|3, a-4 and 
non-a4 mRNA levels in plasmacytoid DCs and conventional DCs over the course of a 
persistent LCMV Cl 13 infection demonstrated the same trend of early peak followed 
by a swift fall as was seen in the whole spleen (Figure 4.8). Plasmacytoid DCs appear 
to make a larger and more sustained contribution of type 1 IFN production during the 
early stages of infection than conventional DCs, although conventional DCs also 
upregulate type 1 IFN expression. There may be two reasons for this: first, 
plasmacytoid DCs are specialized type 1 IFN producing cells, second, plasmacytoid 
DCs, by virtue of TLR7 expression, can respond to ssRNA and LCMV, being a single­
stranded RNA virus may be a stronger inducer of TLR7-mediated type 1 IFN 
production. By contrast, conventional DCs express TLR3 and are adapted to produce 
type 1 IFNs following endocytosis of dsRNA. Whilst dsRNA generated in infected 
cells during the LCMV replication process likely stimulates production of type 1 IFN 
by conventional DCs, this may accumulate with relatively delayed kinetics and 
possibly to lower levels than ss RNA.
Nonetheless, there is evidence that while these DCs may not respond to the presence 
of LCMV infection, they are able to produce type 1 IFN in response to synthetic TLR 
stimuli and also to live vims. Ex vivo CD llc+ DCs from persistently-infected mice 
were still able to produce type 1 IFN when stimulated with polylC, R848, or CpG 
(Figure 4.21) and IFN-a-producing infected plasmacytoid DCs were visible in spleen 
sections of infected mice after inoculation with R848, CpG or influenza PR8 (Figure 
4.20). The question then arises as to why these cells were not producing type 1 IFN 
in vivo in response to the presence of high viral components, which could have also 
activated similar TLR. One possibility, as mentioned earlier, is that the continual 
presence of viral components may have tolerised the infected cells to a certain level of
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innate stimuli, perhaps by downregulating expression of their innate sensing PRRs, as 
a measure to limit type 1 IFN-mediated immunopathology. Thus these cells may only 
be able to respond to high doses of a stimulus, such as those I used in my 
experiments: the levels of polylC, R848 or CpG 1826 DNA added into the culture of 
ex vivo C D llc+ DCs may be many times higher than physiological levels (Figure 
4.18). By comparison, the levels of viral components available in the host to trigger 
TLRs may be relatively low. Alternatively, it is also possible that while high levels of 
infectious virus are present in LCMV-infected mice, the viral components that would 
activate TLRs, such as LCMV nucleic acid (ds and ssRNA) may be largely 
sequestered in infected cells, and not available to bind to TLRs.
I also analysed the activation status DCs from persistently-infected mice in order 
determine whether downregulation of type 1 IFN induction was accompanied by other 
changes in the activation state of these infected DCs. LCMV Cl 13 is known to infect 
C D llc+ DCs (Salvato et al. 1991; Sevilla et al. 2000). Previous studies have 
suggested that LCMV C113 infection of adult wild-type C57BL/6 mice prevented DC 
maturation, as the DCs exhibited reduced expression of co-stimulatory molecules, 
leading to immunosuppression of the host and ineffective clearance of the virus 
(Sevilla et al. 2003; Sevilla et al. 2004). However, in these studies, DCs subsets from 
persistently-infected mice were defined on the basis of CD1 lc+ and CD8a+ expression 
from a preparation of whole spleen splenocytes treated with EDTA to disrupt T-cell- 
DC complexes. While CD llc expression is routinely used as a marker for splenic 
dendritic cell populations, it is a P2 intergrin with critical importance for the 
development of functional immune responses in its own right. NK cells are also 
known to be CD llc+ while CD llc expression on T cells has been detected in a 
population of intestinal intraepithelial lymphocytes (Huleatt and Lefrancois 1995) and
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crucially, on activated LCMV-specific CD8+ T cells following systemic LCMV 
infection (Lin et al. 2003). The validity of the conclusions of the studies carried out by 
Sevilla et al is thus questionable as it was likely that the reduced expression of co­
stimulatory markers observed may be the result of a dilution effect stemming from 
observations made of a DC population that was contaminated with C D llc+ CD8a+ 
activated T-cells (which do not express co-stimulatory molecules).
Initial FACS analysis conducted on pooled lymphocytes from mice infected 3 weeks 
previously with LCMV Cl 13 which were enriched on a Nycodenz column and 
positively selected for CD1 lc expression confirmed the presence of a large proportion 
of cells that were CD1 lc+ but expressing non-DC markers in the preparation. A large 
proportion of contaminating cells appeared to be T-cells, as expected. Some of the 
contaminants were B-cells, which are another population reported to express low 
levels of CD llc, but is increased on the surface of B cells from B-cell chronic 
lymphocytic leukemia (B-CLL) sufferers (D'Arena et al. 2001). While DCs 
demonstrate plasticity and have been reported to upregulate other markers, including 
F4/80 (Ruedl et al. 1996) following activation, no reports could be found of DCs 
upregulating CD3, CD 19 or DX5. A negative selection cocktail consisting of CD3, 
CD 19, DX5 and F4/80 was thus employed to remove CD llc+ non-DC cells. The 
antibodies were biotinylated and streptavidin-conjugated Dynal beads were 
subsequently used to remove the contaminating cells. Using this approach, I found 
that after depletion, there were still CD1 lc+ cells that expressed CD3, CD 19 or DX5. 
A small proportion of these cell were also pDCA-1 or CD4 positive, although many 
more CD1 lc+ CD8+ cells (most likely activated T-cells) were present (Figure 4.7). As 
such, only a minority of the C D llc+ non-DC cells remaining in the prep would be
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included in the gated C D llc+ pDCA-l+ or C D llc+ CD4+ populations, but the 
majority of the cells in the CD1 lc+ CD8a+ population would likely be non-DCs. 
Levels of co-stimulatory markers on purified CD4+ and mpDCA-l+ DC subsets were 
found to be enhanced over levels in uninfected DCs (Figure 4.8), consistent with a 
mature phenotype. Levels of ICAM-1, CD40, CD80, CD86 and MHC Class I were 
upregulated in pDCA-l+ DCs and CD4+ DC subsets of mice at 3 weeks post­
infection. In agreement with previous reports (Martin et al. 2002; Montoya et al. 
2005), the pDCA-l+ subset expressed lower levels of co-stimulatory molecules than 
conventional DC subsets, consistent with these cells playing a more minor role as a 
APCs (as they are believed to be predominantly specialized type 1 IFN producers). 
Therefore, there does not appear to be a defect in 2 of the DC subsets studied. The 
results are in line with observations of Homann et al (2004) who studied the activation 
status of DCs in mice that were persistently-infected at birth with LCMV and found 
the DCs in these mice to be activated (Homann et al. 2004). These observations 
suggest that persistent LCMV infection, regardless of the viral strain involved, and 
whether infection is established by T-cell exhaustion in adult mice or tolerance at 
birth, is associated with activation of pDCA-l+ and CD4+ DCs.
Surface expression of co-stimulatory molecules on the CD8a+ DC subset, apart from 
CD86, appear to be reduced as assessed by mean fluorescent intensity (MFI); 
however, this may not reflect the true MFI levels of CD8a+ DCs as it is probable that 
the population contained a high level of non-DC CD8a+ cells, most likely T-cells, 
which would have reduced the overall per-cell MFI levels. Thus persistently-infected 
CD8a+ DC may be expressing higher levels of co-stimulatory molecules than 
measured here. Future experiments employing 6-colour FACS analysis to allow 
staining with a larger panel of phenotypic markers, e.g CD3 staining in conjunction
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with CD8a marker to exclude T-cells in order to definitively isolate the CD8a DC 
subset, should resolve this uncertainty.
It is unclear what the consequences of chronic DC activation in LCMV-infected mice 
may be. The presence of activated DCs may help to drive exhaustion of LCMV- 
specific CD8 cytotoxic T cells, promoting viral persistence. Activated DCs an also be 
tolerogenic; e.g. DC matured in the presence of TNF which are able to stimulate CD8 
T-cell proliferation, but these cells are swiftly deleted leading ultimately to tolerance 
(Albert et al. 2001). Wilson et al reported that when DCs were preactivated with CpG, 
LPS or poly IC and then infected with HSV, no HSV specficic T-cell proliferation was 
recorded as the DCs were not able to present HSV (Wilson et al. 2006) likewise the 
continual presence of LCMV viral components may be mimicking the effects of pre­
treatment with TLR ligands, and may impair DC presentation of LCMV antigens to T 
cells.
Experiments investigating the primary response as well as the generation and 
maintenance of memory responses in these persistently-infected mice to unrelated 
protein antigens (e.g. CGG/OVA) delivered with or without different adjuvants (e.g. 
using tetramer staining to follow T cell responses and in vivo CTL or ELISPOT 
assays to measure T-cell functions) may help provide answers as to the true activation 
status and functional capacity of the DCs in mice persistently-infected with LCMV.
In addition, had I more time, it would have been interesting to determine the 
activation status of other innate cells such as NK cells during persistent infection 
comparing their activity to that of cells from uninfected and acutely-infected animals. 
IFN-y expression was barely detectable in the serum of persistently-infected mice. 
This may be a reflection of the non-functional LCMV-specific CTL immunity, but 
may also suggest that NK cell functions are not chronically activated in mice
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persistently-infected with LCMV, as NK cells represent another important source of 
IFN-y. However, previous studies have shown that NK cells in mice persistently- 
infected with LCMV at birth are more activated than NK cells in uninfected mice 
(Bukowski et al. 1983).
Yet another explanation for the downregulation of type 1 IFN production in 
persistently infected animals may be that it is a host-mediated mechanism to prevent 
the immunopathological effects stemming from high levels of systemic type 1 IFN. 
The presence of excessive levels of type 1 IFN for prolonged periods may impact on 
both the immune system as well as general functions, as described in the introduction. 
After an initial first and second wave of upregulation and amplification of type 1 IFN 
and IFN-stimulated anti-viral cytokines, a third wave of gene transcription is activated 
that produces inhibitors of type 1 IFN. It may be possible that persistent stimulation 
induces production of these inhibitors.
In summary, during the acute phase of an LCMV infection, type 1 IFN is probably 
mainly induced through the TLR pathway (with cell types including plasmacytoid DCs 
and conventional DCs detecting ssRNA through TLR7 or the viral GP through an 
unidentified PRR). It is unlikely that high levels of the type 1 IFN are produced by 
infected cells through the helicase pathway, as data from this study suggests this 
pathway may be impaired. The type 1 IFN produced induces an antiviral state in 
uninfected cells, upregulates antiviral proteins and also activates the immune system to 
control viral spread. However, type 1 IFN-resistant strains/isolates of LCMV such as 
LCMV Cl 13 are able to combat these measures, and are thus able to spread at a faster 
rate, outstripping control by the host T cell response. As infection progresses, the type 
1 IFN response is downregulated, perhaps in part as a result of viral impairment and 
possibly also due to DC “tolerance” and DC loss, and also that homeostatic
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mechanisms that limit type 1 IFN production and associated immunopathological 
damage. The activation and subsequent loss and/or tolerance of DCs may have effects 
on the host’s CTL response which is first stimulated and then becomes exhausted in 
the presence of high viral titres (possibly through a PD-1 dependent mechanism 
(Barber et al. 2006; Fuller and Zajac 2003; Moskophidis et al. 1993; Zajac et al. 1998), 
enabling the virus to persist in the host.
During persistent LCMV infection, little if any type 1 IFN is likely induced through 
the helicase pathway, but there is a low level of IFN-produced by cell types including 
plasmacytoid DCs, probably via TLR pathways. However a reduced number of DCs is 
present in the host is likely as a consequence of LCMV infection-associated activation 
and enhanced DC turnover associated with impaired replenishments of DCs from the 
bone marrow. The low numbers of splenic DCs remaining in mice persistently- 
infected with LCMV are nonetheless activated and express co-stimulatory molecules. 
There is some ongoing production of type 1 IFN by these cells, and in response to 
stimulation with TLR ligands, they are able to upregulate production of type 1 IFN. 
These cells may thus participate in defence against secondary infections; although the 
reduced numbers of these cells present, coupled with the impairment in type 1 IFN 
production through helicase-dependent pathways may result in defective control of 
other infections, in particular RNA virus infections.
At the time of preparation of this report, a paper was published which demonstrated 
that impairment of type 1 IFN production during LCMV infection was caused by the 
LCMV NP protein preventing translocation of IRF3 (Martinez-Sobrido et al. 2006). 
Using an in vitro system, the authors showed that type 1 IFN induction was blocked 
only at the level of induction, through impairment of IRF3 and not at the level of 
signaling (i.e. the JAK/STAT pathway). The results of this paper fit very well the
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findings of this study, which predicted that an impairment was likely to occur along 
the RIG-I helicase pathway, which is dependent on the activation of IRF3 to induce 
transcription of IFN-a/|3 genes (Figure 6.1), unlike the TLR pathway which is able to 
utilize alternative transcription factors, namely IRF7 and NF-kB, to upregulate IFN- 
a/p expression.
As LCMV is a natural pathogen of mice, the model of persistent infection analysed 
here may provide a good reflection of what occurs in during other virus infections. The 
findings made in this study may thus contribute to increasing our current 
understanding of the state of the innate immune system during human persistent viral 
infections of clinical relevance.
The observation that splenic DC numbers are reduced during persistent LCMV 
infection is similar to observations made in some chronic human infections. During 
chronic HIV infection, the number of plasmacytoid DCs is reduced (Donaghy et al. 
2004; Schmidt et al. 2006; Soumelis et al. 2001). This may be due in part to direct 
infection by the virus, but it also may be due to impaired haemopoietic mechanisms 
analogous to the situation in persistent LCMV infection. Like LCMV, HCV is able to 
block type 1 IFN production in the cells it infects, These observations I made in the 
LCMV model suggest that infected cells may still be able to produce type 1 IFN, if the 
correct type 1 IFN induction pathway is stimulated.
It is important to unravel the mechanisms by which type 1 IFN production is impaired 
in chronic viral infections because this information may help direct the design of more 
effective therapies. For example, if impairment occurs only at the IFN induction step, 
then administration of type 1 IFN may be helpful in stimulating cells to establish an 
antiviral state. Such therapies are already used to treat HCV and HBV infections, 
where it is known that the virus-induced impairment occurs at the level of type 1 IFN
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induction (Bertoletti and Gehring 2006; Murakami et al. 2004; Tsubouchi et al. 2004). 
However, such therapies would not be useful in situations where the block occurs in 
the JAK/STAT pathway.
Studies like this also give insight into the consequences of impairment of type 1 IFN 
production for therapeutic vaccination. If for example, a chronic viral infection such as 
HCV, establishes a persistent infection by impairing the RIG-I pathway, then 
vaccination using a live viral vector may not be effective as live viruses would 
normally stimulate production of type 1 IFN (which has important adjuvant properties 
(Le Bon et al. 2003; Le Bon et al. 2001)), via the RIG-I pathway. The choice of 
adjuvants could be adjusted, e.g. use of a TLR ligand such polylC or R848 in 
conjuction with the vaccine may be a better strategy than use of a live viral vector 
alone. Additionally, if an antiviral state is established in patients with a chronic viral 
infection, as was observed in chronic LCMV infection, a live viral vector, which relies 
on replication in the host for effective results, may not be the best strategy to use. The 
LCMV model of persistent infection could be used to test out these vaccine strategies 
for use in infections where the RNA helicase pathways are impaired.
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